	
(	O
5.3	O
)	O
*	O
High	B
blood	I
pressure	I
:	O
Do	O
not	O
prescribe	O
Natazia	O
for	O
women	O
with	O
uncontrolled	O
hypertension	O
or	O
hypertension	O
with	O
vascular	O
disease	O
.	O
	
fFatal	O
bleed	B
:	O
Adjudicated	O
major	O
bleed	B
as	O
defined	O
above	O
with	O
investigator	O
reported	O
fatal	B
outcome	O
and	O
adjudicated	O
death	B
with	O
primary	O
cause	O
from	O
bleeding	B
.	O
	
XIAFLEX	O
was	O
not	O
associated	O
with	O
shortening	B
of	I
penile	I
length	I
in	O
clinical	O
trials	O
in	O
the	O
treatment	O
of	O
Peyronie	O
's	O
disease	O
.	O
	
Myocardial	B
ischemia	I
or	O
myocardial	B
infarction	I
led	O
to	O
death	B
in	O
3	O
patients	O
in	O
the	O
placebo	O
arms	O
and	O
2	O
deaths	B
in	O
the	O
ZYTIGA	O
arms	O
.	O
	
Increased	B
levels	I
of	I
thyroid	I
stimulating	I
hormone	I
(	O
TSH	O
)	O
were	O
observed	O
in	O
57	O
%	O
of	O
patients	O
receiving	O
COMETRIQ	O
after	O
the	O
first	O
dose	O
compared	O
to	O
19	O
%	O
of	O
patients	O
receiving	O
placebo	O
(	O
regardless	O
of	O
baseline	O
value	O
)	O
.	O
	
The	O
decrease	B
in	I
serum	I
potassium	I
is	O
usually	O
transient	O
,	O
not	O
requiring	O
supplementation	O
.	O
	
The	O
adverse	O
reactions	O
reported	O
in	O
more	O
than	O
one	O
subject	O
within	O
the	O
studies	O
are	O
shown	O
in	O
Table	O
2	O
.	O
	
The	O
placebo-adjusted	O
change	O
at	O
the	O
distal	O
forearm	O
for	O
patients	O
randomized	O
to	O
INVOKANA	O
100	O
mg	O
was	O
0	O
%	O
.	O
	
(	O
5.4	O
)	O
*	O
Skin	B
Reactions	I
:	O
Discontinue	O
for	O
severe	O
skin	O
reactions	O
.	O
	
Allopurinol	O
has	O
also	O
been	O
used	O
during	O
the	O
beginning	O
of	O
TREANDA	O
therapy	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
RISK	O
OF	O
ANAPHYLAXIS	B
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
Most	O
patients	O
(	O
87	O
%	O
)	O
were	O
less	O
than	O
65	O
years	O
of	O
age	O
;	O
58.4	O
%	O
were	O
women	O
.	O
	
The	O
incidence	O
of	O
GI	B
events	I
was	O
higher	O
early	O
in	O
the	O
course	O
of	O
treatment	O
(	O
primarily	O
in	O
month	O
1	O
)	O
and	O
usually	O
decreased	O
over	O
time	O
in	O
patients	O
treated	O
with	O
TECFIDERA	O
compared	O
with	O
placebo	O
.	O
	
Serious	O
adverse	O
events	O
were	O
reported	O
in	O
58	O
patients	O
(	O
34	O
%	O
)	O
treated	O
with	O
XALKORI	O
.	O
	
If	O
this	O
drug	O
is	O
used	O
during	O
pregnancy	O
,	O
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
this	O
drug	O
,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
.	O
	
The	O
increased	O
risk	O
of	O
asthma-related	O
death	B
is	O
considered	O
a	O
class	O
effect	O
of	O
the	O
long-acting	O
beta	O
2	O
-adrenergic	O
agonists	O
,	O
including	O
ARCAPTA	O
NEOHALER	O
.	O
	
Transient	O
increases	B
in	I
pain	I
were	O
commonly	O
observed	O
on	O
the	O
day	O
of	O
treatment	O
in	O
patients	O
treated	O
with	O
Qutenza	O
.	O
	
Dose	O
should	O
be	O
reduced	O
for	O
patients	O
with	O
mild	O
(	O
total	O
bilirubin	O
>	O
1	O
to	O
<	O
=	O
1.5	O
*	O
ULN	O
or	O
AST	O
>	O
1.5	O
*	O
ULN	O
)	O
and	O
moderate	O
(	O
total	O
bilirubin	O
>	O
1.5	O
to	O
<	O
=	O
3.0	O
*	O
ULN	O
and	O
any	O
AST	O
)	O
hepatic	O
impairment	O
,	O
based	O
on	O
tolerability	O
data	O
in	O
these	O
patients	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
and	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.7	O
)	O
]	O
.	O
	
However	O
,	O
some	O
patients	O
may	O
require	O
treatment	O
with	O
SAPHRIS	O
despite	O
the	O
presence	O
of	O
the	O
syndrome	O
.	O
	
The	O
incidence	O
of	O
opportunistic	B
infections	I
was	O
similar	O
to	O
that	O
reported	O
with	O
placebo	O
.	O
	
(	O
2.4	O
,	O
5.2	O
)	O
*	O
Hepatic	B
Toxicity	I
:	O
Monitor	O
liver	O
enzymes	O
at	O
least	O
monthly	O
for	O
the	O
first	O
three	O
months	O
and	O
as	O
needed	O
.	O
	
Therefore	O
,	O
the	O
combination	O
of	O
TNF-blockers	O
including	O
SIMPONI	O
ARIA	O
and	O
abatacept	O
is	O
not	O
recommended	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.2	O
)	O
]	O
.	O
	
Monotherapy	O
in	O
Adult	O
Patients	O
with	O
Bipolar	O
Mania	O
:	O
The	O
following	O
findings	O
are	O
based	O
on	O
the	O
short-term	O
placebo-controlled	O
trials	O
for	O
bipolar	O
mania	O
(	O
a	O
pool	O
of	O
two	O
3-week	O
flexible-dose	O
trials	O
)	O
in	O
which	O
sublingual	O
SAPHRIS	O
was	O
administered	O
in	O
doses	O
of	O
5	O
mg	O
or	O
10	O
mg	O
twice	O
daily	O
.	O
	
Among	O
those	O
17	O
subjects	O
,	O
10	O
subjects	O
developed	O
neutralizing	O
antibodies	O
.	O
	
Adjust	O
total	O
fluid	O
intake	O
as	O
clinically	O
appropriate	O
in	O
patients	O
with	O
baseline	O
cardiac	O
failure	O
or	O
who	O
are	O
at	O
risk	O
for	O
cardiac	O
failure	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
There	O
have	O
been	O
post-marketing	O
reports	O
of	O
serious	O
breathing	B
difficulties	I
,	O
including	O
respiratory	B
failure	I
.	O
	
Before	O
using	O
OTEZLA	O
in	O
patients	O
with	O
a	O
history	O
of	O
depression	O
and/or	O
suicidal	O
thoughts	O
or	O
behavior	O
prescribers	O
should	O
carefully	O
weigh	O
the	O
risks	O
and	O
benefits	O
of	O
treatment	O
with	O
OTEZLA	O
in	O
such	O
patients	O
.	O
	
The	O
clinical	O
relevance	O
of	O
the	O
presence	O
of	O
anti-belimumab	O
antibodies	O
is	O
not	O
known	O
.	O
	
Renal	B
impairment	I
(	O
including	O
the	O
terms	O
renal	B
impairment	I
,	O
renal	B
failure	I
,	O
and	O
renal	B
failure	I
acute	I
)	O
led	O
to	O
discontinuation	O
of	O
treatment	O
in	O
5/1015	O
(	O
0.5	O
%	O
)	O
subjects	O
receiving	O
ZERBAXA	O
and	O
none	O
in	O
the	O
comparator	O
arms	O
.	O
	
Immediate	O
gentle	O
pressure	O
at	O
the	O
injection	O
site	O
can	O
limit	O
that	O
risk	O
.	O
	
In	O
some	O
cases	O
the	O
elevations	B
in	I
transaminases	I
were	O
consistent	O
with	O
immune	B
reconstitution	I
syndrome	I
or	O
hepatitis	B
B	I
reactivation	I
particularly	O
in	O
the	O
setting	O
where	O
anti-hepatitis	O
therapy	O
was	O
withdrawn	O
.	O
	
Fifty	O
percent	O
(	O
50	O
%	O
)	O
of	O
the	O
population	O
was	O
male	O
and	O
72	O
%	O
were	O
Caucasian	O
,	O
12	O
%	O
were	O
Asian	O
,	O
and	O
5	O
%	O
were	O
Black	O
or	O
African	O
American	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
POST-TRANSPLANT	B
LYMPHOPROLIFERATIVE	I
DISORDER	I
,	O
OTHER	O
MALIGNANCIES	B
,	O
AND	O
SERIOUS	O
INFECTIONS	B
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
Symptoms	O
associated	O
with	O
these	O
reactions	O
have	O
included	O
chest	B
discomfort	I
,	O
flushing	B
,	O
pharyngeal	B
edema	I
,	O
pruritus	B
,	O
rhinorrhea	B
,	O
sneezing	B
,	O
nasal	B
congestion	I
,	O
throat	B
irritation	I
,	O
urticaria	B
,	O
wheezing	B
,	O
and	O
hypotension	B
.	O
	
Apprise	O
women	O
of	O
potential	O
harm	O
to	O
the	O
fetus	O
.	O
	
Primary	O
prophylaxis	O
with	O
G-CSF	O
should	O
be	O
considered	O
in	O
patients	O
with	O
high-risk	O
clinical	O
features	O
.	O
	
Some	O
of	O
these	O
abnormalities	O
were	O
considered	O
potentially	O
clinically	O
significant	O
.	O
	
At	O
the	O
end	O
of	O
treatment	O
,	O
0.6	O
%	O
,	O
2.7	O
%	O
,	O
and	O
3.5	O
%	O
of	O
patients	O
with	O
hematocrits	O
initially	O
within	O
the	O
reference	O
range	O
had	O
values	O
above	O
the	O
upper	O
limit	O
of	O
the	O
reference	O
range	O
with	O
placebo	O
,	O
JARDIANCE	O
10	O
mg	O
,	O
and	O
JARDIANCE	O
25	O
mg	O
,	O
respectively	O
.	O
	
(	O
5.1	O
)	O
*	O
Infections	B
:	O
Increased	O
risk	O
of	O
infections	B
,	O
some	O
fatal	B
.	O
	
There	O
is	O
insufficient	O
information	O
to	O
characterize	O
the	O
risks	O
of	O
resumption	O
of	O
XALKORI	O
in	O
patients	O
with	O
a	O
severe	O
visual	O
loss	O
;	O
a	O
decision	O
to	O
resume	O
XALKORI	O
should	O
consider	O
the	O
potential	O
benefits	O
to	O
the	O
patient	O
.	O
	
If	O
pulmonary	O
toxicity	O
is	O
confirmed	O
,	O
MULTAQ	O
should	O
be	O
discontinued	O
.	O
	
Monitor	O
patients	O
closely	O
during	O
and	O
after	O
administration	O
of	O
Gadavist	O
(	O
5.2	O
)	O
5.1	O
Nephrogenic	O
Systemic	O
Fibrosis	O
Gadolinium-based	O
contrast	O
agents	O
(	O
GBCAs	O
)	O
increase	O
the	O
risk	O
for	O
nephrogenic	B
systemic	I
fibrosis	I
(	O
NSF	B
)	O
among	O
patients	O
with	O
impaired	O
elimination	O
of	O
the	O
drugs	O
.	O
	
There	O
were	O
no	O
reported	O
thromboembolic	B
events	I
in	O
the	O
patients	O
treated	O
with	O
EYLEA	O
in	O
the	O
first	O
six	O
months	O
of	O
the	O
RVO	O
studies	O
.	O
	
Follow	O
the	O
dose	O
adjustment	O
guidelines	O
to	O
achieve	O
and	O
maintain	O
target	O
platelet	O
counts	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
,	O
2.2	O
,	O
2.3	O
)	O
]	O
.	O
	
Neither	O
clinical	O
studies	O
nor	O
epidemiologic	O
studies	O
conducted	O
to	O
date	O
have	O
shown	O
an	O
association	O
between	O
chronic	O
administration	O
of	O
this	O
class	O
of	O
drugs	O
and	O
tumorigenesis	B
in	O
humans	O
,	O
but	O
the	O
available	O
evidence	O
is	O
too	O
limited	O
to	O
be	O
conclusive	O
.	O
	
In	O
Trial	O
2	O
,	O
13	O
%	O
of	O
patients	O
receiving	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
experienced	O
adverse	O
reactions	O
resulting	O
in	O
permanent	O
discontinuation	O
of	O
trial	O
medication	O
(	O
s	O
)	O
.	O
	
In	O
this	O
trial	O
,	O
use	O
of	O
ESAs	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
thromboembolic	O
events	O
including	O
pulmonary	O
embolism	O
,	O
acute	O
myocardial	O
infarction	O
,	O
cerebrovascular	O
accident	O
,	O
and	O
deep	O
vein	O
thrombosis	O
compared	O
to	O
ribavirin	O
dose	O
reduction	O
alone	O
.	O
	
Decreases	O
in	O
neutrophil	O
counts	O
may	O
require	O
dose	O
reduction	O
or	O
discontinuation	O
of	O
peginterferon	O
alfa	O
and	O
ribavirin	O
.	O
	
Eight	O
of	O
12	O
patients	O
treated	O
with	O
DALVANCE	O
and	O
one	O
comparator	O
patient	O
had	O
underlying	O
conditions	O
which	O
could	O
affect	O
liver	O
enzymes	O
,	O
including	O
chronic	O
viral	O
hepatitis	O
and	O
a	O
history	O
of	O
alcohol	O
abuse	O
.	O
	
For	O
current	O
full	O
prescribing	O
information	O
,	O
please	O
visit	O
www.pfizer.com	O
.	O
	
At	O
these	O
doses	O
,	O
SAPHRIS	O
was	O
associated	O
with	O
increases	B
in	I
QTc	I
interval	I
ranging	O
from	O
2	O
to	O
5	O
msec	O
compared	O
to	O
placebo	O
.	O
	
Consider	O
the	O
risks	O
and	O
benefits	O
of	O
treatment	O
with	O
SIMPONI	O
ARIA	O
prior	O
to	O
initiating	O
therapy	O
in	O
patients	O
with	O
chronic	O
or	O
recurrent	O
infection	O
.	O
	
If	O
ELIQUIS	O
is	O
discontinued	O
for	O
a	O
reason	O
other	O
than	O
pathological	O
bleeding	O
or	O
completion	O
of	O
a	O
course	O
of	O
therapy	O
,	O
consider	O
coverage	O
with	O
another	O
anticoagulant	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.4	O
)	O
andClinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
*	O
Monitor	O
all	O
patients	O
for	O
active	O
TB	O
during	O
treatment	O
,	O
even	O
if	O
initial	O
latent	O
TB	O
test	O
is	O
negative	O
(	O
5.1	O
)	O
.	O
	
*	O
Anaphylaxis	B
and	O
infusion	B
reactions	I
:	O
If	O
an	O
infusion	O
reaction	O
occurs	O
,	O
interrupt	O
the	O
infusion	O
.	O
	
A	O
total	O
of	O
2757	O
subjects	O
with	O
hyperuricemia	O
and	O
gout	O
were	O
treated	O
with	O
ULORIC	O
40	O
mg	O
or	O
80	O
mg	O
daily	O
in	O
clinical	O
studies	O
.	O
	
Other	O
Risk	O
Factors	O
Other	O
known	O
risk	O
factors	O
for	O
PTLD	O
include	O
cytomegalovirus	O
(	O
CMV	O
)	O
infection	O
and	O
T-cell-depleting	O
therapy	O
.	O
	
(	O
5.12	O
,	O
8.1	O
)	O
5.1	O
Non-infectious	O
Pneumonitis	O
Non-infectious	B
pneumonitis	I
is	O
a	O
class	O
effect	O
of	O
rapamycin	O
derivatives	O
,	O
including	O
AFINITOR	O
.	O
	
The	O
risk	O
of	O
hypoglycemia	B
is	O
increased	O
when	O
JARDIANCE	O
is	O
used	O
in	O
combination	O
with	O
insulin	O
secretagogues	O
(	O
e.g.	O
,	O
sulfonylurea	O
)	O
or	O
insulin	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
JEVTANA	O
is	O
contraindicated	O
in	O
patients	O
with	O
neutrophils	O
<	O
=	O
1,500/mm	O
3	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
The	O
overall	O
safety	O
profile	O
of	O
Neuraceq	O
is	O
based	O
on	O
data	O
from	O
978	O
administrations	O
of	O
Neuraceq	O
to	O
872	O
subjects	O
and	O
12	O
subjects	O
who	O
received	O
vehicle	O
only	O
.	O
	
Table	O
8	O
compares	O
the	O
incidence	O
of	O
adverse	O
reactions	O
reported	O
with	O
an	O
incidence	O
of	O
>	O
=	O
10	O
%	O
for	O
patients	O
receiving	O
AFINITOR	O
and	O
occurring	O
more	O
frequently	O
with	O
AFINITOR	O
than	O
with	O
placebo	O
.	O
	
No	O
Grade	O
4	O
laboratory	O
abnormalities	O
were	O
reported	O
.	O
	
At	O
baseline	O
the	O
population	O
had	O
diabetes	O
for	O
an	O
average	O
of	O
7.3	O
years	O
,	O
had	O
a	O
mean	O
HbA1C	O
of	O
8.0	O
%	O
and	O
20	O
%	O
had	O
established	O
microvascular	O
complications	O
of	O
diabetes	O
.	O
	
FANAPT	O
is	O
not	O
approved	O
for	O
use	O
in	O
patients	O
with	O
dementia-related	O
psychosis	O
.	O
	
c	O
Includes	O
pneumonitis	B
,	O
interstitial	B
lung	I
disease	I
,	O
lung	B
infiltration	I
,	O
pulmonary	B
alveolar	I
hemorrhage	I
,	O
pulmonary	B
toxicity	I
,	O
and	O
alveolitis	B
.	O
	
Table	O
3	O
:	O
Monitored	O
Adverse	O
Reactions	O
-	O
Pruritus	B
,	O
Erythema	B
,	O
Pyoderma	B
and	O
Ocular	B
Irritation	I
with	O
Onset	O
After	O
Treatment	O
Signs/Symptoms	O
ULESFIA	O
(	O
r	O
)	O
Lotion	O
Vehicle	O
Pruritus	B
12	O
%	O
(	O
14/116	O
)	O
4	O
%	O
(	O
3/67	O
)	O
Erythema	B
10	O
%	O
(	O
32/309	O
)	O
9	O
%	O
(	O
19/217	O
)	O
Pyoderma	B
7	O
%	O
(	O
22/308	O
)	O
4	O
%	O
(	O
10/230	O
)	O
Ocular	B
irritation	I
6	O
%	O
(	O
26/428	O
)	O
1	O
%	O
(	O
3/313	O
)	O
Other	O
less	O
common	O
reactions	O
(	O
less	O
than	O
1	O
%	O
but	O
more	O
than	O
0.1	O
%	O
)	O
were	O
,	O
in	O
decreasing	O
order	O
of	O
incidence	O
:	O
application	B
site	I
dryness	I
,	O
application	B
site	I
excoriation	I
,	O
paraesthesia	B
,	O
application	B
site	I
dermatitis	I
,	O
excoriation	B
,	O
thermal	B
burn	I
,	O
dandruff	B
,	O
erythema	B
,	O
rash	B
,	O
and	O
skin	B
exfoliation	I
.	O
	
Elevating	O
the	O
head	O
of	O
the	O
bed	O
lessens	O
the	O
risk	O
of	O
supine	O
hypertension	O
,	O
and	O
blood	O
pressure	O
should	O
be	O
measured	O
in	O
this	O
position	O
.	O
	
In	O
clinical	O
trials	O
,	O
subjects	O
who	O
received	O
a	O
higher	O
dose	O
of	O
DYSPORT	O
(	O
r	O
)	O
had	O
an	O
increased	O
incidence	O
of	O
eyelid	B
ptosis	I
.	O
	
Therefore	O
,	O
prescribers	O
should	O
exercise	O
caution	O
when	O
considering	O
resumption	O
of	O
TNF-blockers	O
in	O
this	O
situation	O
and	O
monitor	O
patients	O
closely	O
.	O
	
age	O
>	O
60	O
years	O
,	O
hypertension	O
,	O
diabetes	O
)	O
,	O
estimate	O
the	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
through	O
laboratory	O
testing	O
(	O
5.1	O
)	O
.	O
	
An	O
additional	O
51	O
subjects	O
from	O
a	O
separate	O
repeat	O
dose	O
study	O
were	O
tested	O
for	O
the	O
presence	O
of	O
neutralizing	O
antibodies	O
only	O
.	O
	
This	O
risk	O
was	O
greater	O
in	O
patients	O
with	O
a	O
baseline	O
reduced	O
estimated	O
creatinine	O
clearance	O
(	O
calculated	O
using	O
Cockcroft	O
and	O
Gault	O
equation	O
)	O
.	O
	
The	O
Study	O
2	O
population	O
included	O
patients	O
with	O
a	O
median	O
age	O
of	O
7	O
years	O
(	O
1	O
to	O
17	O
years	O
)	O
;	O
63	O
%	O
were	O
male	O
,	O
27	O
%	O
were	O
Hispanic	O
or	O
Latino	O
,	O
83	O
%	O
were	O
White	O
,	O
3	O
%	O
were	O
Black/African	O
American	O
,	O
7	O
%	O
were	O
Asian	O
,	O
and	O
7	O
%	O
were	O
other	O
(	O
American	O
Indian	O
,	O
Alaska	O
Native	O
or	O
Indian	O
)	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
7	O
15	O
13	O
13	O
Psychiatric	O
disorders	O
Insomnia	B
13	O
16	O
15	O
15	O
Vascular	O
disorders	O
Hypertension	B
2	O
2	O
3	O
2	O
Dose-Related	O
Adverse	O
Reactions	O
:	O
In	O
the	O
short	O
term	O
schizophrenia	O
trials	O
the	O
incidence	O
of	O
akathisia	B
appeared	O
to	O
be	O
dose-related	O
(	O
seeTable	O
8	O
)	O
.	O
	
The	O
nadir	O
in	O
serum	O
calcium	O
level	O
occurs	O
at	O
approximately	O
day	O
10	O
after	O
Prolia	O
dosing	O
in	O
subjects	O
with	O
normal	O
renal	O
function	O
.	O
	
Females	O
of	O
childbearing	O
potential	O
should	O
be	O
advised	O
to	O
avoid	O
becoming	O
pregnant	O
during	O
treatment	O
with	O
JEVTANA	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
Four	O
percent	O
(	O
4	O
%	O
)	O
of	O
patients	O
treated	O
with	O
TECFIDERA	O
and	O
less	O
than	O
1	O
%	O
of	O
placebo	O
patients	O
discontinued	O
due	O
to	O
gastrointestinal	B
events	I
.	O
	
Adverse	O
reactions	O
leading	O
to	O
dose	O
reduction	O
occurred	O
in	O
14	O
%	O
of	O
patients	O
.	O
	
Local	B
skin	I
reactions	I
were	O
assessed	O
within	O
the	O
selected	O
treatment	O
area	O
and	O
graded	O
by	O
the	O
investigator	O
on	O
a	O
scale	O
of	O
0	O
to	O
4	O
.	O
	
INVOKANA	O
can	O
increase	O
the	O
risk	O
of	O
hypoglycemia	B
when	O
combined	O
with	O
insulin	O
or	O
an	O
insulin	O
secretagogue	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
In	O
short-term	O
,	O
placebo-controlled	O
bipolar	O
mania	O
trials	O
,	O
the	O
proportion	O
of	O
patients	O
with	O
total	B
cholesterol	I
elevations	I
>	O
=240	O
mg/dL	O
(	O
at	O
Endpoint	O
)	O
was	O
8.7	O
%	O
for	O
SAPHRIS-treated	O
patients	O
versus	O
8.6	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
If	O
intolerable	O
symptoms	O
occur	O
following	O
a	O
decrease	O
in	O
the	O
dose	O
or	O
upon	O
discontinuation	O
of	O
treatment	O
,	O
then	O
resuming	O
the	O
previously	O
prescribed	O
dose	O
may	O
be	O
considered	O
.	O
	
Signs	O
or	O
symptoms	O
that	O
may	O
reflect	O
serious	O
injury	O
to	O
the	O
injected	O
finger/hand	O
should	O
be	O
promptly	O
evaluated	O
because	O
surgical	O
intervention	O
may	O
be	O
required	O
.	O
	
5.3	O
Skin	O
Discoloration	O
POTIGA	O
can	O
cause	O
skin	B
discoloration	I
.	O
	
Table	O
6	O
:	O
Change	O
in	O
Body	O
Weight	O
FANAPT	O
FANAPT	O
Placebo	O
10-16	O
mg/day	O
20-24	O
mg/day	O
n=576	O
n=481	O
n=391	O
Weight	O
(	O
kg	O
)	O
Change	O
from	O
Baseline	O
-0.1	O
2.0	O
2.7	O
Weight	O
Gain	O
>	O
=7	O
%	O
increase	O
from	O
Baseline	O
4	O
%	O
12	O
%	O
18	O
%	O
5.6	O
Seizures	O
In	O
short-term	O
placebo-controlled	O
trials	O
(	O
4-	O
to	O
6-weeks	O
)	O
,	O
seizures	B
occurred	O
in	O
0.1	O
%	O
(	O
1/1344	O
)	O
of	O
patients	O
treated	O
with	O
FANAPT	O
compared	O
to	O
0.3	O
%	O
(	O
2/587	O
)	O
on	O
placebo	O
.	O
	
Controlled	O
Study	O
The	O
data	O
in	O
Tables	O
1	O
and	O
2	O
below	O
reflect	O
exposure	O
of	O
229	O
EGFR-TKI	O
naive	O
GILOTRIF-treated	O
patients	O
with	O
EGFR	O
mutation-positive	O
,	O
metastatic	O
,	O
non-squamous	O
,	O
NSCLC	O
enrolled	O
in	O
a	O
randomized	O
,	O
multicenter	O
,	O
open-label	O
trial	O
(	O
Study	O
1	O
)	O
.	O
	
5.10	O
Interstitial	O
Lung	O
Disease	O
and	O
Eosinophilic	O
Pneumonia	O
Interstitial	B
lung	I
disease	I
and	O
eosinophilic	B
pneumonia	I
associated	O
with	O
venlafaxine	O
(	O
the	O
parent	O
drug	O
of	O
PRISTIQ	O
)	O
therapy	O
have	O
been	O
rarely	O
reported	O
.	O
	
Given	O
these	O
considerations	O
,	O
FANAPT	O
should	O
be	O
prescribed	O
in	O
a	O
manner	O
that	O
is	O
most	O
likely	O
to	O
minimize	O
the	O
occurrence	O
of	O
tardive	O
dyskinesia	O
.	O
	
Percentage	O
(	O
%	O
)	O
of	O
Patientsa	O
YERVOY3	O
mg/kgn=131	O
YERVOY3	O
mg/kg+gp100n=380	O
gp100n=132	O
System	O
Organ	O
Class/Preferred	O
Term	O
AnyGrade	O
Grade3-5	O
AnyGrade	O
Grade3-5	O
AnyGrade	O
Grade3-5	O
Gastrointestinal	O
Disorders	O
Diarrhea	B
32	O
5	O
37	O
4	O
20	O
1	O
Colitis	B
8	O
5	O
5	O
3	O
2	O
0	O
Skin	O
and	O
Subcutaneous	O
Tissue	O
Disorders	O
Pruritus	B
31	O
0	O
21	O
<	O
1	O
11	O
0	O
Rash	B
29	O
2	O
25	O
2	O
8	O
0	O
General	O
Disorders	O
and	O
Administration	O
Site	O
Conditions	O
Fatigue	B
41	O
7	O
34	O
5	O
31	O
3	O
Table	O
2	O
presents	O
the	O
per-patient	O
incidence	O
of	O
severe	O
,	O
life-threatening	O
,	O
or	O
fatal	B
immune-mediated	B
adverse	I
reactions	I
from	O
Study	O
1	O
.	O
	
a	O
mass	O
in	O
the	O
neck	O
,	O
dysphagia	O
,	O
dyspnea	O
,	O
persistent	O
hoarseness	O
)	O
.	O
	
Table	O
4	O
:	O
Laboratory	O
Abnormalities	O
in	O
>	O
15	O
%	O
of	O
Patients	O
in	O
the	O
ZYTIGA	O
Arm	O
of	O
Study	O
2	O
Abiraterone	O
(	O
N=542	O
)	O
Placebo	O
(	O
N=540	O
)	O
Laboratory	O
Abnormality	O
Grade	O
1-4	O
%	O
Grade	O
3-4	O
%	O
Grade	O
1-4	O
%	O
Grade	O
3-4	O
%	O
Hematology	O
Lymphopenia	B
38.2	O
8.7	O
31.7	O
7.4	O
Chemistry	O
Hyperglycemia	B
56.6	O
6.5	O
50.9	O
5.2	O
High	B
ALT	I
41.9	O
6.1	O
29.1	O
0.7	O
High	B
AST	I
37.3	O
3.1	O
28.7	O
1.1	O
Hypernatremia	B
32.8	O
0.4	O
25.0	O
0.2	O
Hypokalemia	B
17.2	O
2.8	O
10.2	O
1.7	O
Cardiovascular	O
Adverse	O
Reactions	O
:	O
In	O
the	O
combined	O
data	O
for	O
studies	O
1	O
and	O
2	O
,	O
cardiac	B
failure	I
occurred	O
more	O
commonly	O
in	O
patients	O
treated	O
with	O
ZYTIGA	O
compared	O
to	O
patients	O
on	O
the	O
placebo	O
arm	O
(	O
2.1	O
%	O
versus	O
0.7	O
%	O
)	O
.	O
	
Use	O
of	O
COCs	O
also	O
increases	O
the	O
risk	O
of	O
arterial	B
thromboses	I
such	O
as	O
strokes	B
and	O
myocardial	B
infarctions	I
,	O
especially	O
in	O
women	O
with	O
other	O
risk	O
factors	O
for	O
these	O
events	O
.	O
	
The	O
possibility	O
of	O
more	O
extensive	O
systemic	O
involvement	O
has	O
not	O
been	O
excluded	O
.	O
	
Neutropenia	B
may	O
precede	O
the	O
development	O
of	O
agranulocytosis	B
.	O
	
There	O
was	O
no	O
fatal	B
pneumonia	B
in	O
subjects	O
receiving	O
vilanterol	O
or	O
fluticasone	O
furoate/vilanterol	O
50	O
mcg/25	O
mcg	O
.	O
	
(	O
6.1	O
)	O
EXCERPT	O
:	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
GlaxoSmithKline	O
at	O
1-888-825-5249	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
After	O
the	O
fourth	O
injection	O
of	O
XIAFLEX	O
,	O
every	O
XIAFLEX-treated	O
patient	O
developed	O
high	O
titers	O
of	O
antibodies	O
to	O
both	O
AUX-I	O
and	O
AUX-II	O
.	O
	
General	O
disorders	O
and	O
administration	O
site	O
conditions	O
:	O
chills	B
,	O
pyrexia	B
,	O
edema	B
peripheral	I
,	O
multi-organ	B
failure	I
.	O
	
The	O
median	O
duration	O
of	O
exposure	O
was	O
118	O
days	O
for	O
patients	O
receiving	O
HALAVEN	O
and	O
63	O
days	O
for	O
patients	O
receiving	O
control	O
therapy	O
.	O
	
In	O
patients	O
who	O
do	O
require	O
chronic	O
treatment	O
,	O
the	O
smallest	O
dose	O
and	O
the	O
shortest	O
duration	O
of	O
treatment	O
producing	O
a	O
satisfactory	O
clinical	O
response	O
should	O
be	O
sought	O
.	O
	
In	O
the	O
placebo-controlled	O
studies	O
,	O
a	O
total	O
of	O
485	O
patients	O
with	O
Parkinson	O
's	O
disease	O
,	O
multiple	O
system	O
atrophy	O
,	O
pure	O
autonomic	O
failure	O
,	O
dopamine	O
beta-hydroxylase	O
deficiency	O
,	O
or	O
non-diabetic	O
autonomic	O
neuropathy	O
were	O
randomized	O
and	O
treated	O
,	O
245	O
with	O
NORTHERA	O
and	O
240	O
with	O
placebo	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Persistence	B
of	I
sinus	I
tachycardia	I
(	O
reported	O
at	O
more	O
than	O
2	O
visits	O
)	O
was	O
reported	O
in	O
0.2	O
%	O
,	O
0.4	O
%	O
and	O
1.6	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
,	O
TRULICITY	O
0.75	O
mg	O
and	O
TRULICITY	O
1.5	O
mg	O
,	O
respectively	O
.	O
	
5.6	O
Severe	O
Gastrointestinal	O
Disease	O
Use	O
of	O
TRULICITY	O
may	O
be	O
associated	O
with	O
gastrointestinal	B
adverse	I
reactions	I
,	O
sometimes	O
severe	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
All	O
patients	O
treated	O
with	O
Vimizim	O
2	O
mg/kg	O
once	O
per	O
week	O
in	O
the	O
placebo-controlled	O
trial	O
developed	O
anti-drug	O
antibodies	O
by	O
Week	O
4	O
.	O
	
Hypersensitivity	O
Reactions	O
In	O
a	O
pooled	O
analysis	O
,	O
the	O
overall	O
incidence	O
of	O
hypersensitivity	B
reactions	I
was	O
0.6	O
%	O
with	O
NESINA	O
25	O
mg	O
compared	O
to	O
0.8	O
%	O
with	O
all	O
comparators	O
.	O
	
In	O
the	O
MS	O
placebo	O
controlled	O
trials	O
,	O
mean	O
lymphocyte	B
counts	I
decreased	I
by	O
approximately	O
30	O
%	O
during	O
the	O
first	O
year	O
of	O
treatment	O
with	O
TECFIDERA	O
and	O
then	O
remained	O
stable	O
.	O
	
Closely	O
observe	O
patients	O
during	O
and	O
after	O
Vimizim	O
administration	O
and	O
be	O
prepared	O
to	O
manage	O
anaphylaxis	O
.	O
	
In	O
individual	O
clinical	O
trials	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
,	O
episodes	O
of	O
hypoglycemia	B
occurred	O
at	O
a	O
higher	O
rate	O
when	O
INVOKANA	O
was	O
co-administered	O
with	O
insulin	O
or	O
sulfonylureas	O
(	O
Table	O
4	O
)	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
*	O
A	O
28-week	O
,	O
placebo-controlled	O
US	O
study	O
comparing	O
the	O
safety	O
of	O
another	O
long-acting	O
beta	O
2	O
-adrenergic	O
agonist	O
(	O
salmeterol	O
)	O
with	O
placebo	O
,	O
each	O
added	O
to	O
usual	O
asthma	O
therapy	O
,	O
showed	O
an	O
increase	O
in	O
asthma-related	O
deaths	B
in	O
patients	O
receiving	O
salmeterol	O
(	O
13/13,176	O
in	O
patients	O
treated	O
with	O
salmeterol	O
vs.	O
3/13,179	O
in	O
patients	O
treated	O
with	O
placebo	O
;	O
RR	O
4.37	O
,	O
95	O
%	O
CI	O
1.25	O
,	O
15.34	O
)	O
.	O
	
Cases	O
of	O
Stevens-Johnson	B
syndrome	I
(	O
SJS	B
)	O
and	O
TEN	B
,	O
some	O
fatal	B
,	O
have	O
been	O
reported	O
when	O
TREANDA	O
was	O
administered	O
concomitantly	O
with	O
allopurinol	O
and	O
other	O
medications	O
known	O
to	O
cause	O
these	O
syndromes	O
.	O
	
Of	O
these	O
patients	O
,	O
352	O
pediatric	O
patients	O
were	O
treated	O
with	O
SAPHRIS	O
for	O
at	O
least	O
180	O
days	O
and	O
58	O
pediatric	O
patients	O
treated	O
with	O
SAPHRIS	O
had	O
at	O
least	O
1	O
year	O
of	O
exposure	O
.	O
	
In	O
clinical	O
trials	O
(	O
Studies	O
1	O
,	O
2	O
,	O
and	O
3	O
)	O
,	O
a	O
total	O
of	O
1212	O
patients	O
with	O
relapsing	O
forms	O
of	O
multiple	O
sclerosis	O
received	O
GILENYA	O
0.5	O
mg	O
.	O
	
Across	O
controlled	O
and	O
uncontrolled	O
trials	O
in	O
patients	O
receiving	O
adjunctive	O
therapy	O
for	O
partial-onset	O
seizures	O
,	O
1195	O
patients	O
received	O
APTIOM	O
,	O
of	O
whom	O
586	O
were	O
treated	O
for	O
longer	O
than	O
6	O
months	O
and	O
462	O
for	O
longer	O
than	O
12	O
months	O
.	O
	
5.2	O
QT	O
Prolongation	O
In	O
an	O
open-label	O
QTc	O
study	O
in	O
patients	O
with	O
schizophrenia	O
or	O
schizoaffective	O
disorder	O
(	O
n=160	O
)	O
,	O
FANAPT	O
was	O
associated	O
with	O
QTc	B
prolongation	I
of	O
9	O
msec	O
at	O
an	O
iloperidone	O
dose	O
of	O
12	O
mg	O
twice	O
daily	O
.	O
	
No	O
Grade	O
3	O
or	O
4	O
ADRs	O
were	O
reported	O
.	O
	
(	O
5.5	O
)	O
Metabolic	B
Changes	I
:	O
Atypical	O
antipsychotic	O
drugs	O
have	O
been	O
associated	O
with	O
metabolic	O
changes	O
that	O
may	O
increase	O
cerebrovascular	B
risk	I
.	O
	
Patients	O
taking	O
HORIZANT	O
should	O
not	O
drive	O
until	O
they	O
have	O
gained	O
sufficient	O
experience	O
to	O
assess	O
whether	O
HORIZANT	O
impairs	O
their	O
ability	O
to	O
drive	O
.	O
	
Kyprolis	O
can	O
cause	O
increased	B
serum	I
transaminases	I
.	O
	
Table	O
6	O
:	O
Adverse	O
Reactions	O
Reported	O
in	O
at	O
Least	O
10	O
%	O
of	O
Patients	O
with	O
RCC	O
and	O
at	O
a	O
Higher	O
Rate	O
in	O
the	O
AFINITOR	O
Arm	O
than	O
in	O
the	O
Placebo	O
Arm	O
Grading	O
according	O
to	O
CTCAE	O
Version	O
3.0	O
a	O
Stomatitis	B
(	O
including	O
aphthous	B
stomatitis	I
)	O
,	O
and	O
tongue	B
ulceration	I
.	O
	
Subjects	O
received	O
1	O
inhalation	O
once	O
daily	O
of	O
the	O
following	O
:	O
BREO	O
ELLIPTA	O
100/25	O
,	O
BREO	O
ELLIPTA	O
200/25	O
,	O
fluticasone	O
furoate/vilanterol	O
50	O
mcg/25	O
mcg	O
,	O
fluticasone	O
furoate	O
100	O
mcg	O
,	O
fluticasone	O
furoate	O
200	O
mcg	O
,	O
vilanterol	O
25	O
mcg	O
,	O
or	O
placebo	O
.	O
	
Serious	O
adverse	O
reactions	O
related	O
to	O
asthma	B
exacerbation	I
were	O
reported	O
for	O
2	O
patients	O
in	O
the	O
indacaterol	O
300	O
mcg	O
group	O
,	O
3	O
patients	O
in	O
the	O
indacaterol	O
600	O
mcg	O
group	O
,	O
and	O
no	O
patients	O
in	O
the	O
salmeterol	O
active	O
control	O
group	O
.	O
	
Some	O
IgG-positive	O
patients	O
in	O
clinical	O
trials	O
who	O
were	O
retrospectively	O
evaluated	O
for	O
the	O
presence	O
of	O
inhibitory	O
antibodies	O
tested	O
positive	O
for	O
inhibition	O
of	O
enzyme	O
activity	O
and/or	O
uptake	O
in	O
in	O
vitro	O
assays	O
.	O
	
[	O
See	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
EXCERPT	O
:	O
WARNING	O
:	O
INCREASED	O
MORTALITY	B
IN	O
ELDERLY	O
PATIENTS	O
WITH	O
DEMENTIA-RELATED	O
PSYCHOSIS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
For	O
the	O
subgroup	O
of	O
187	O
patients	O
treated	O
with	O
subcutaneous	O
KALBITOR	O
,	O
5	O
patients	O
(	O
3	O
%	O
)	O
experienced	O
anaphylaxis	B
.	O
	
KALBITOR	O
should	O
not	O
be	O
administered	O
to	O
any	O
patients	O
with	O
known	O
clinical	O
hypersensitivity	O
to	O
KALBITOR	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
(	O
5.1	O
)	O
*	O
Eye	B
irritation	I
:	O
Avoid	O
eye	O
exposure	O
.	O
	
Lipids	O
Elevations	B
in	I
fasting	I
serum	I
total	I
cholesterol	I
occurred	O
in	O
the	O
controlled	O
studies	O
.	O
	
Monitor	O
renal	O
function	O
periodically	O
.	O
	
5.2	O
Infusion-Related	O
Reactions	O
DALVANCE	O
is	O
administered	O
via	O
intravenous	O
infusion	O
,	O
using	O
a	O
total	O
infusion	O
time	O
of	O
30	O
minutes	O
to	O
minimize	O
the	O
risk	O
of	O
infusion-related	O
reactions	O
.	O
	
During	O
the	O
initial	O
phase	O
of	O
combination	O
antiretroviral	O
treatment	O
,	O
patients	O
whose	O
immune	O
system	O
responds	O
may	O
develop	O
an	O
inflammatory	O
response	O
to	O
indolent	O
or	O
residual	B
opportunistic	I
infections	I
[	O
such	O
as	O
Mycobacterium	B
avium	I
infection	I
,	O
cytomegalovirus	B
,	O
Pneumocystis	B
jirovecii	I
pneumonia	I
(	O
PCP	B
)	O
,	O
or	O
tuberculosis	B
]	O
,	O
which	O
may	O
necessitate	O
further	O
evaluation	O
and	O
treatment	O
.	O
	
Invasive	O
Fungal	O
Infections	O
For	O
patients	O
who	O
reside	O
or	O
travel	O
in	O
regions	O
where	O
mycoses	O
are	O
endemic	O
,	O
invasive	O
fungal	O
infection	O
should	O
be	O
suspected	O
if	O
they	O
develop	O
a	O
serious	O
systemic	O
illness	O
.	O
	
*	O
Discontinue	O
SIMPONI	O
ARIA	O
if	O
a	O
patient	O
develops	O
a	O
serious	O
infection	O
or	O
sepsis	O
(	O
5.1	O
)	O
.	O
	
5.7	O
Hypokalemia	O
and	O
Hypomagnesemia	O
with	O
Potassium-Depleting	O
Diuretics	O
Hypokalemia	B
or	O
hypomagnesemia	B
may	O
occur	O
with	O
concomitant	O
administration	O
of	O
potassium-depleting	O
diuretics	O
.	O
	
Antigen	O
and	O
antibody	O
testing	O
for	O
histoplasmosis	O
may	O
be	O
negative	O
in	O
some	O
patients	O
with	O
active	O
infection	O
.	O
	
Do	O
not	O
give	O
DUAVEE	O
to	O
other	O
people	O
,	O
even	O
if	O
they	O
have	O
the	O
same	O
symptoms	O
you	O
have	O
.	O
	
Other	O
important	O
serious	O
adverse	O
reactions	O
reported	O
include	O
PML	B
,	O
Stevens-Johnson	B
syndrome	I
,	O
and	O
tumor	B
lysis	I
syndrome	I
.	O
	
In	O
a	O
3-week	O
,	O
bipolar	O
mania	O
pediatric	O
trial	O
,	O
syncope	B
was	O
reported	O
in	O
1	O
%	O
(	O
1/104	O
)	O
of	O
patients	O
treated	O
with	O
SAPHRIS	O
2.5	O
mg	O
twice	O
daily	O
,	O
1	O
%	O
(	O
1/99	O
)	O
of	O
patients	O
treated	O
with	O
SAPHRIS	O
5	O
mg	O
twice	O
daily	O
,	O
and	O
0	O
%	O
(	O
0/99	O
)	O
for	O
patients	O
treated	O
with	O
SAPHRIS	O
10	O
mg	O
twice	O
daily	O
compared	O
to	O
0	O
%	O
(	O
0/101	O
)	O
for	O
patients	O
treated	O
with	O
placebo	O
.	O
	
MALIGNANCY	O
Lymphoma	B
and	O
other	O
malignancies	B
,	O
some	O
fatal	B
,	O
have	O
been	O
reported	O
in	O
children	O
and	O
adolescent	O
patients	O
treated	O
with	O
TNF	O
blockers	O
,	O
of	O
which	O
CIMZIA	O
is	O
a	O
member	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
What	O
can	O
I	O
do	O
to	O
lower	O
my	O
chances	O
of	O
a	O
serious	O
side	O
effect	O
with	O
DUAVEE	O
?	O
	
Prescribers	O
and	O
patients	O
should	O
be	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
prostatic	O
hyperplasia	O
or	O
bladder-neck	O
obstruction	O
(	O
e.g.	O
,	O
difficulty	O
passing	O
urine	O
,	O
painful	O
urination	O
)	O
.	O
	
Treat	O
patients	O
with	O
rehydration	O
,	O
anti-diarrheal	O
or	O
anti-emetic	O
medications	O
as	O
needed	O
.	O
	
The	O
transfusion	O
rate	O
was	O
4	O
%	O
in	O
subjects	O
randomized	O
to	O
receive	O
ribavirin	O
dose	O
reduction	O
and	O
2	O
%	O
in	O
subjects	O
randomized	O
to	O
receive	O
ESA	O
.	O
	
If	O
peginterferon	O
alfa	O
and	O
ribavirin	O
are	O
permanently	O
discontinued	O
,	O
then	O
VICTRELIS	O
must	O
also	O
be	O
discontinued	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
Empiric	O
anti-fungal	O
therapy	O
should	O
be	O
considered	O
in	O
patients	O
at	O
risk	O
for	O
invasive	O
fungal	O
infections	O
who	O
develop	O
severe	O
systemic	O
illness	O
.	O
	
Stop	O
SIMPONI	O
ARIA	O
if	O
new	O
or	O
worsening	O
symptoms	O
occur	O
(	O
5.3	O
)	O
.	O
	
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
described	O
below	O
and	O
elsewhere	O
in	O
the	O
labeling	O
:	O
*	O
Anaphylaxis	O
and	O
hypersensitivity	O
reactions	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
(	O
5.1	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Nephrogenic	B
Systemic	I
Fibrosis	I
has	O
occurred	O
in	O
patients	O
with	O
impaired	O
elimination	O
of	O
GBCAs	O
.	O
	
Consider	O
the	O
potential	O
for	O
drug	O
interactions	O
prior	O
to	O
and	O
during	O
STRIBILD	O
therapy	O
;	O
review	O
concomitant	O
medications	O
during	O
STRIBILD	O
therapy	O
;	O
and	O
monitor	O
for	O
the	O
adverse	O
reactions	O
associated	O
with	O
the	O
concomitant	O
drugs	O
.	O
	
5.8	O
Immune	O
Reconstitution	O
Syndrome	O
Immune	B
reconstitution	I
syndrome	I
has	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
combination	O
antiretroviral	O
therapy	O
,	O
including	O
STRIBILD	O
.	O
	
In	O
one	O
case	O
,	O
insufficient	O
information	O
was	O
obtained	O
to	O
establish	O
or	O
refute	O
a	O
drug-related	O
causality	O
.	O
	
(	O
A	O
)	O
PREMATURE	O
DISCONTINUATION	O
OF	O
ELIQUIS	O
INCREASES	O
THE	O
RISK	O
OF	O
THROMBOTIC	B
EVENTS	I
:	O
Premature	O
discontinuation	O
of	O
any	O
oral	O
anticoagulant	O
,	O
including	O
ELIQUIS	O
,	O
increases	O
the	O
risk	O
of	O
thrombotic	B
events	I
.	O
	
Severe	O
hypersensitivity	B
reactions	I
require	O
immediate	O
discontinuation	O
of	O
the	O
JEVTANA	O
infusion	O
and	O
administration	O
of	O
appropriate	O
therapy	O
.	O
	
5.1	O
Peripheral	O
Neuropathy	O
ADCETRIS	O
treatment	O
causes	O
a	O
peripheral	B
neuropathy	I
.	O
	
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
associated	O
with	O
ILARIS	O
treatment	O
in	O
the	O
CAPS	O
patients	O
were	O
nasopharyngitis	B
,	O
diarrhea	B
,	O
influenza	B
,	O
headache	B
,	O
and	O
nausea	B
.	O
	
Cytomegalovirus	O
and	O
pneumocystis	O
prophylaxis	O
are	O
recommended	O
after	O
transplantation	O
.	O
	
No	O
additional	O
postmarketing	O
adverse	O
reactions	O
specific	O
for	O
emtricitabine	O
have	O
been	O
identified	O
.	O
	
Table	O
5	O
lists	O
adverse	O
reactions	O
occurring	O
in	O
1	O
%	O
or	O
greater	O
of	O
patients	O
receiving	O
ZERBAXA	O
in	O
Phase	O
3	O
clinical	O
trials	O
.	O
	
The	O
observed	O
incidence	O
of	O
antibody	O
positivity	O
in	O
an	O
assay	O
is	O
highly	O
dependent	O
on	O
several	O
factors	O
,	O
including	O
assay	O
sensitivity	O
and	O
specificity	O
,	O
assay	O
methodology	O
,	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
Patients	O
or	O
caregivers	O
should	O
be	O
advised	O
to	O
seek	O
immediate	O
medical	O
care	O
if	O
swallowing	O
,	O
speech	O
,	O
or	O
respiratory	O
disorders	O
occur	O
.	O
	
Clinical	O
manifestations	O
include	O
hyperpyrexia	B
,	O
muscle	B
rigidity	I
,	O
altered	B
mental	I
status	I
(	O
including	O
catatonic	B
signs	I
)	O
and	O
evidence	O
of	O
autonomic	B
instability	I
(	O
irregular	B
pulse	I
,	O
tachycardia	B
,	O
diaphoresis	B
,	O
and	O
cardiac	B
dysrhythmia	I
)	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
associated	O
with	O
discontinuation	O
in	O
patients	O
treated	O
with	O
SAPHRIS	O
(	O
rates	O
at	O
least	O
1	O
%	O
and	O
at	O
least	O
twice	O
the	O
placebo	O
rate	O
)	O
were	O
anxiety	B
(	O
1.1	O
%	O
)	O
and	O
oral	B
hypoesthesia	I
(	O
1.1	O
%	O
)	O
compared	O
to	O
placebo	O
(	O
0	O
%	O
)	O
.	O
	
Patients	O
in	O
the	O
XALKORI	O
arm	O
(	O
n=172	O
)	O
received	O
XALKORI	O
250	O
mg	O
orally	O
twice	O
daily	O
until	O
documented	O
disease	O
progression	O
,	O
intolerance	O
to	O
therapy	O
,	O
or	O
the	O
investigator	O
determined	O
that	O
the	O
patient	O
was	O
no	O
longer	O
experiencing	O
clinical	O
benefit	O
.	O
	
Mean	O
changes	B
(	I
percent	I
changes	I
)	I
from	I
baseline	I
in	I
LDL-C	I
relative	O
to	O
placebo	O
were	O
4.4	O
mg/dL	O
(	O
4.5	O
%	O
)	O
and	O
8.2	O
mg/dL	O
(	O
8.0	O
%	O
)	O
with	O
INVOKANA	O
100	O
mg	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
.	O
	
The	O
relationship	O
to	O
TREANDA	O
can	O
not	O
be	O
determined	O
.	O
	
Across	O
the	O
340	O
patients	O
who	O
were	O
treated	O
in	O
Study	O
1	O
,	O
the	O
median	O
age	O
was	O
53	O
years	O
;	O
16	O
%	O
of	O
patients	O
were	O
older	O
than	O
65	O
years	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
Hypersensitivity	B
reactions	O
,	O
including	O
anaphylaxis	B
,	O
have	O
occurred	O
in	O
patients	O
treated	O
with	O
KALBITOR	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Anti-drug	O
antibody	O
titers	O
were	O
sustained	O
or	O
increased	O
for	O
the	O
duration	O
of	O
Vimizim	O
treatment	O
.	O
	
*	O
Cytopenias	B
:	O
Check	O
complete	O
blood	O
counts	O
monthly	O
(	O
5.3	O
)	O
.	O
	
A	O
grade	O
of	O
0	O
represented	O
no	O
reaction	O
present	O
in	O
the	O
treated	O
area	O
,	O
and	O
a	O
grade	O
of	O
4	O
indicated	O
a	O
marked	O
and	O
severe	O
skin	O
reaction	O
that	O
extended	O
beyond	O
the	O
treated	O
area	O
.	O
	
Severe	O
penile	B
hematoma	I
was	O
also	O
reported	O
as	O
an	O
adverse	O
reaction	O
in	O
39	O
of	O
1044	O
(	O
3.7	O
%	O
)	O
XIAFLEX-treated	O
patients	O
(	O
5.2	O
)	O
.	O
	
While	O
these	O
events	O
are	O
generally	O
self-limiting	O
,	O
there	O
have	O
been	O
reports	O
of	O
serious	O
discontinuation	O
symptoms	O
.	O
	
Cases	O
of	O
skin	B
laceration	I
requiring	O
skin	O
graft	O
after	O
finger	O
extension	O
procedures	O
have	O
been	O
reported	O
post-marketing	O
.	O
	
Table	O
1	O
:	O
Selected	O
Adverse	O
Reactions	O
in	O
Study	O
1	O
a	O
Incidences	O
presented	O
in	O
this	O
table	O
are	O
based	O
on	O
reports	O
of	O
adverse	O
events	O
regardless	O
of	O
causality	O
.	O
	
However	O
,	O
the	O
development	O
of	O
neutralizing	O
antibodies	O
may	O
be	O
underreported	O
due	O
to	O
lack	O
of	O
assay	O
sensitivity	O
.	O
	
The	O
population	O
in	O
these	O
studies	O
was	O
48	O
%	O
white	O
,	O
13	O
%	O
African/African	O
American	O
,	O
7	O
%	O
Asian	O
,	O
and	O
29	O
%	O
Hispanic/Latino	O
.	O
	
b	O
Includes	O
the	O
terms	O
injection	B
site	I
haemorrhage	I
,	O
injection	B
site	I
irritation	I
,	O
and	O
injection	B
site	I
pain	I
.	O
	
As	O
appropriate	O
,	O
administer	O
prophylactic	O
antibiotics	O
and	O
employ	O
surveillance	O
testing	O
during	O
treatment	O
with	O
BLINCYTO	O
.	O
	
In	O
those	O
diseases	O
causing	O
thinning	O
of	O
the	O
cornea	O
or	O
sclera	O
,	O
perforations	B
have	O
been	O
known	O
to	O
occur	O
with	O
the	O
use	O
of	O
topical	O
steroids	O
.	O
	
TRULICITY	O
has	O
not	O
been	O
evaluated	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
pancreatitis	O
.	O
	
Table	O
2	O
reports	O
the	O
most	O
common	O
adverse	O
reactions	O
occurring	O
in	O
at	O
least	O
10	O
%	O
of	O
patients	O
in	O
either	O
group	O
.	O
	
Most	O
adverse	B
reactions	I
were	I
local	I
events	I
of	I
the	I
penis	I
and	O
the	O
majority	O
of	O
these	O
events	O
were	O
of	O
mild	O
or	O
moderate	O
severity	O
,	O
and	O
most	O
(	O
79	O
%	O
)	O
resolved	O
within	O
14	O
days	O
of	O
the	O
injection	O
.	O
	
In	O
the	O
Dupuytren	O
's	O
contracture	O
clinical	O
studies	O
(	O
Studies	O
1	O
and	O
2	O
)	O
,	O
at	O
30	O
days	O
post	O
the	O
first	O
injection	O
of	O
XIAFLEX	O
0.58	O
mg	O
,	O
92	O
%	O
of	O
patients	O
had	O
antibodies	O
against	O
AUX-I	O
detected	O
and	O
86	O
%	O
of	O
patients	O
had	O
antibodies	O
against	O
AUX-II	O
detected	O
.	O
	
Clinical	O
correlation	O
,	O
including	O
histopathological	O
evaluation	O
of	O
the	O
suspected	O
recurrence	O
site	O
,	O
is	O
essential	O
to	O
proper	O
use	O
of	O
the	O
PET	O
imaging	O
information	O
.	O
	
Monitor	O
fasting	O
glucose	O
prior	O
to	O
treatment	O
and	O
periodically	O
thereafter	O
as	O
clinically	O
indicated	O
.	O
	
Interrupt	O
and	O
then	O
reduce	O
or	O
discontinue	O
Zydelig	O
.	O
	
Serum	O
chemistry	O
abnormalities	O
ALT	B
increased	I
73	O
(	O
50	O
)	O
20	O
(	O
14	O
)	O
7	O
(	O
5	O
)	O
AST	B
increased	I
60	O
(	O
41	O
)	O
12	O
(	O
8	O
)	O
6	O
(	O
4	O
)	O
Hematology	O
abnormalities	O
neutrophils	B
decreased	I
78	O
(	O
53	O
)	O
20	O
(	O
14	O
)	O
16	O
(	O
11	O
)	O
hemoglobin	B
decreased	I
41	O
(	O
28	O
)	O
3	O
(	O
2	O
)	O
0	O
platelets	B
decreased	I
38	O
(	O
26	O
)	O
4	O
(	O
3	O
)	O
5	O
(	O
3	O
)	O
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
FATAL	B
AND	O
SERIOUS	O
TOXICITIES	B
,	O
SEVERE	O
DIARRHEA	B
,	O
COLITIS	B
,	O
PNEUMONITIS	B
,	O
and	O
INTESTINAL	B
PERFORATION	I
WARNING	O
:	O
FATAL	B
AND	O
SERIOUS	O
TOXICITIES	B
,	O
SEVERE	O
DIARRHEA	B
,	O
COLITIS	B
,	O
PNEUMONITIS	B
,	O
and	O
INTESTINAL	B
PERFORATION	I
*	O
Fatal	B
and/or	O
serious	O
hepatotoxicity	B
occurred	O
in	O
14	O
%	O
of	O
Zydelig-treated	O
patients	O
.	O
	
An	O
analyses	O
of	O
adjudicated	O
events	O
revealed	O
5	O
cases	O
of	O
confirmed	O
pancreatitis	B
in	O
patients	O
exposed	O
to	O
TRULICITY	O
(	O
1.4	O
cases	O
per	O
1000	O
patient	O
years	O
)	O
versus	O
1	O
case	O
in	O
non-incretin	O
comparators	O
(	O
0.88	O
cases	O
per	O
1000	O
patient	O
years	O
)	O
.	O
	
Delayed	O
AdreView	O
clearance	O
may	O
also	O
reduce	O
the	O
target	O
to	O
background	O
ratios	O
and	O
decrease	O
the	O
quality	O
of	O
scintigraphic	O
images	O
.	O
	
Brentuximab	O
vedotin	O
caused	O
embryo-fetal	B
toxicities	I
,	O
including	O
significantly	O
decreased	B
embryo	I
viability	I
and	O
fetal	B
malformations	I
,	O
in	O
animals	O
at	O
maternal	O
exposures	O
that	O
were	O
similar	O
to	O
human	O
exposures	O
at	O
the	O
recommended	O
doses	O
for	O
patients	O
with	O
classical	O
HL	O
and	O
sALCL	O
.	O
	
Delay	O
administration	O
of	O
HALAVEN	O
and	O
reduce	O
subsequent	O
doses	O
in	O
patients	O
who	O
experience	O
febrile	O
neutropenia	O
or	O
Grade	O
4	O
neutropenia	O
lasting	O
longer	O
than	O
7	O
days	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
How	O
the	O
dose	O
,	O
route	O
,	O
and	O
duration	O
of	O
corticosteroid	O
administration	O
affect	O
the	O
risk	O
of	O
developing	O
a	O
disseminated	O
infection	O
is	O
not	O
known	O
.	O
	
Consider	O
an	O
alternate	O
contraceptive	O
method	O
for	O
women	O
with	O
uncontrolled	O
dyslipidemia	O
.	O
	
Therefore	O
,	O
XIAFLEX	O
should	O
be	O
injected	O
only	O
into	O
the	O
collagen	O
cord	O
with	O
a	O
MP	O
or	O
PIP	O
joint	O
contracture	O
,	O
and	O
care	O
should	O
be	O
taken	O
to	O
avoid	O
injecting	O
into	O
tendons	O
,	O
nerves	O
,	O
blood	O
vessels	O
,	O
or	O
other	O
collagen-containing	O
structures	O
of	O
the	O
hand	O
.	O
	
Subsequently	O
,	O
the	O
physician	O
may	O
continue	O
decreasing	O
the	O
dose	O
,	O
but	O
at	O
a	O
more	O
gradual	O
rate	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.4	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Discontinue	O
COMETRIQ	O
for	O
hypertensive	O
crisis	O
.	O
	
On	O
electrocardiograms	O
,	O
a	O
PR	B
interval	I
increase	I
to	O
at	O
least	O
220	O
milliseconds	O
was	O
observed	O
in	O
0.7	O
%	O
,	O
2.5	O
%	O
and	O
3.2	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
,	O
TRULICITY	O
0.75	O
mg	O
and	O
TRULICITY	O
1.5	O
mg	O
,	O
respectively	O
.	O
	
This	O
assay	O
has	O
substantial	O
limitations	O
in	O
detecting	O
anti-ipilimumab	O
antibodies	O
in	O
the	O
presence	O
of	O
ipilimumab	O
.	O
	
Pool	O
of	O
Placebo-Controlled	O
Trials	O
The	O
data	O
in	O
Table	O
1	O
are	O
derived	O
from	O
4	O
placebo-controlled	O
trials	O
.	O
	
FULYZAQ	O
is	O
not	O
indicated	O
for	O
the	O
treatment	O
of	O
infectious	O
diarrhea	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
the	O
incidence	O
of	O
antibodies	O
to	O
belatacept	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
Patients	O
in	O
the	O
study	O
received	O
a	O
median	O
of	O
4	O
doses	O
(	O
range	O
:	O
1-4	O
doses	O
)	O
.	O
	
Signs	O
and	O
symptoms	O
have	O
included	O
difficulty	B
breathing	I
,	O
urticaria	B
,	O
and	O
swelling	B
of	I
the	I
throat	I
.	O
	
Table	O
5	O
:	O
Change	O
in	O
Body	O
Weight	O
in	O
Adult	O
Patients	O
from	O
Baseline	O
N*	O
=	O
Number	O
of	O
subjects	O
who	O
had	O
assessments	O
at	O
both	O
Baseline	O
and	O
Endpoint	O
.	O
	
Monitor	O
for	O
signs	O
and	O
symptoms	O
after	O
initiating	O
therapy	O
.	O
	
In	O
the	O
pooled	O
analysis	O
of	O
8	O
controlled	O
trials	O
,	O
phimosis	B
was	O
reported	O
in	O
0.3	O
%	O
of	O
uncircumcised	O
male	O
patients	O
treated	O
with	O
INVOKANA	O
and	O
0.2	O
%	O
required	O
circumcision	O
to	O
treat	O
the	O
phimosis	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
Female	B
patients	I
who	I
developed	I
genital	I
mycotic	I
infections	I
on	O
INVOKANA	O
were	O
more	O
likely	O
to	O
experience	O
recurrence	O
and	O
require	O
treatment	O
with	O
oral	O
or	O
topical	O
antifungal	O
agents	O
and	O
anti-microbial	O
agents	O
.	O
	
Discontinue	O
SIRTURO	O
if	O
significant	O
ventricular	O
arrhythmia	O
or	O
QTcF	O
interval	O
>	O
500	O
ms	O
develops	O
.	O
	
There	O
is	O
a	O
risk	O
for	O
transmission	O
of	O
Creutzfeldt-Jakob	B
disease	I
(	O
CJD	B
)	O
however	O
,	O
no	O
cases	O
of	O
transmission	O
of	O
viral	B
diseases	I
or	O
CJD	B
have	O
ever	O
been	O
identified	O
for	O
albumin	O
(	O
5.6	O
)	O
5.1	O
Lack	O
of	O
Interchangeability	O
between	O
Botulinum	O
Toxin	O
Products	O
The	O
potency	O
Units	O
of	O
DYSPORT	O
(	O
r	O
)	O
are	O
specific	O
to	O
the	O
preparation	O
and	O
assay	O
method	O
utilized	O
.	O
	
and	O
untreated	O
or	O
inadequately	O
treated	O
extrapyramidal	O
signs	O
and	O
symptoms	O
(	O
EPS	O
)	O
.	O
	
The	O
other	O
patient	O
developed	O
probable	O
PML	B
after	O
taking	O
GILENYA	O
for	O
approximately	O
4	O
years	O
.	O
	
The	O
early	O
diagnosis	O
of	O
this	O
condition	O
is	O
important	O
for	O
the	O
appropriate	O
management	O
of	O
these	O
patients	O
.	O
	
If	O
an	O
anaphylactic	O
reaction	O
to	O
ZERBAXA	O
occurs	O
,	O
discontinue	O
the	O
drug	O
and	O
institute	O
appropriate	O
therapy	O
.	O
	
Delayed-onset	O
reactions	O
,	O
defined	O
as	O
adverse	O
reactions	O
occurring	O
2	O
-	O
48	O
hours	O
after	O
completion	O
of	O
alglucosidase	O
alfa	O
infusion	O
,	O
that	O
were	O
observed	O
in	O
>	O
=	O
3	O
%	O
more	O
patients	O
in	O
the	O
alglucosidase	O
alfa-treated	O
group	O
compared	O
to	O
patients	O
in	O
the	O
placebo-treated	O
group	O
in	O
the	O
controlled	O
trial	O
,	O
included	O
hyperhidrosis	B
.	O
	
The	O
events	O
were	O
reported	O
in	O
less	O
than	O
1	O
%	O
of	O
subjects	O
receiving	O
TIVICAY	O
in	O
Phase	O
3	O
clinical	O
trials	O
.	O
	
The	O
causes	O
of	O
death	B
varied	O
and	O
included	O
complications	B
of	I
infection	I
,	O
surgery	O
and	O
underlying	O
conditions	O
.	O
	
The	O
average	O
age	O
was	O
53	O
years	O
(	O
range	O
from	O
0.1	O
to	O
97	O
years	O
)	O
.	O
	
Hypokalemia	O
(	O
and/or	O
hypomagnesemia	O
)	O
may	O
increase	O
the	O
risk	O
of	O
QT	O
prolongation	O
and	O
arrhythmia	O
.	O
	
Withhold	O
trametinib	O
if	O
RPED	O
is	O
diagnosed	O
.	O
	
Mortality	B
related	O
to	O
diarrhea	B
has	O
been	O
reported	O
.	O
	
Physicians	O
prescribing	O
DIFICID	O
to	O
patients	O
with	O
a	O
known	O
macrolide	O
allergy	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
of	O
hypersensitivity	O
reactions	O
.	O
	
(	O
5.3	O
)	O
*	O
Use	O
in	O
children	O
:	O
ULESFIA	O
(	O
r	O
)	O
Lotion	O
should	O
only	O
be	O
used	O
on	O
children	O
under	O
the	O
direct	O
supervision	O
of	O
an	O
adult	O
.	O
	
*	O
Hematologic	B
toxicities	I
:	O
Monitor	O
complete	O
blood	O
counts	O
prior	O
to	O
each	O
dose	O
of	O
ADCETRIS	O
.	O
	
5.6	O
Rebound	O
Hypertension	O
Patients	O
who	O
receive	O
prolonged	O
Cleviprex	O
infusions	O
and	O
are	O
not	O
transitioned	O
to	O
other	O
antihypertensive	O
therapies	O
should	O
be	O
monitored	O
for	O
the	O
possibility	O
of	O
rebound	O
hypertension	O
for	O
at	O
least	O
8	O
hours	O
after	O
the	O
infusion	O
is	O
stopped	O
.	O
	
The	O
most	O
frequently	O
reported	O
adverse	O
drug	O
reactions	O
were	O
infections	B
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rate	O
observed	O
in	O
clinical	O
practice	O
.	O
	
Development	O
of	O
cardiomyopathy	B
resolved	O
in	O
all	O
five	O
patients	O
following	O
dose	O
reduction	O
(	O
4/55	O
)	O
and/or	O
dose	O
interruption	O
(	O
1/55	O
)	O
.	O
	
Discontinue	O
SAPHRIS	O
in	O
patients	O
with	O
severe	O
neutropenia	O
(	O
absolute	O
neutrophil	O
count	O
<	O
1000/mm	O
3	O
)	O
and	O
follow	O
their	O
WBC	O
until	O
recovery	O
.	O
	
For	O
patients	O
at	O
risk	O
for	O
chronically	O
reduced	O
renal	O
function	O
(	O
for	O
example	O
,	O
age	O
>	O
60	O
years	O
,	O
hypertension	O
or	O
diabetes	O
)	O
,	O
estimate	O
the	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
through	O
laboratory	O
testing	O
.	O
	
Refer	O
to	O
the	O
prescribing	O
information	O
for	O
ribavirin	O
and	O
peginterferon	O
alfa	O
for	O
guidelines	O
for	O
discontinuation	O
of	O
therapy	O
based	O
on	O
laboratory	O
parameters	O
.	O
	
Abdominal	O
pain	O
and	O
tenderness	O
,	O
fever	O
,	O
persistent	O
constipation	O
,	O
diarrhea	O
,	O
with	O
or	O
without	O
neutropenia	O
,	O
may	O
be	O
early	O
manifestations	O
of	O
serious	O
gastrointestinal	O
toxicity	O
and	O
should	O
be	O
evaluated	O
and	O
treated	O
promptly	O
.	O
	
Table	O
2	O
:	O
Adverse	O
Reactions	O
Reported	O
by	O
Greater	O
Than	O
or	O
Equal	O
to	O
2	O
%	O
of	O
Patients	O
Treated	O
With	O
STENDRA	O
in	O
an	O
Open-Label	O
Extension	O
Trial	O
Adverse	O
Reaction	O
STENDRA	O
(	O
N	O
=	O
711	O
)	O
Headache	B
5.6	O
%	O
Flushing	B
3.5	O
%	O
Nasopharyngitis	B
3.4	O
%	O
Nasal	B
congestion	I
2.1	O
%	O
Adverse	O
reactions	O
reported	O
by	O
greater	O
than	O
or	O
equal	O
to	O
1	O
%	O
,	O
but	O
less	O
than	O
2	O
%	O
of	O
patients	O
in	O
the	O
open-label	O
extension	O
study	O
included	O
:	O
upper	B
respiratory	I
infection	I
(	O
URI	B
)	O
,	O
influenza	B
,	O
sinusitis	B
,	O
bronchitis	B
,	O
dizziness	B
,	O
back	B
pain	I
,	O
arthralgia	B
,	O
hypertension	B
,	O
and	O
diarrhea	B
.	O
	
Discontinue	O
PROMACTA	O
if	O
antiviral	O
therapy	O
is	O
discontinued	O
.	O
	
Serious	O
adverse	O
reactions	O
In	O
Studies	O
1	O
and	O
2	O
,	O
serious	O
adverse	O
reactions	O
,	O
regardless	O
of	O
causality	O
,	O
were	O
reported	O
in	O
31	O
%	O
of	O
patients	O
receiving	O
ADCETRIS	O
.	O
	
Patients	O
should	O
be	O
instructed	O
to	O
report	O
any	O
symptoms	O
suggestive	O
of	O
endophthalmitis	O
or	O
retinal	O
detachment	O
without	O
delay	O
and	O
should	O
be	O
managed	O
appropriately	O
[	O
seeDosage	O
and	O
Administration	O
(	O
2.7	O
)	O
andPatient	O
Counseling	O
Information	O
(	O
17	O
)	O
]	O
.	O
	
Discontinue	O
XALKORI	O
in	O
patients	O
with	O
new	O
onset	O
of	O
severe	O
visual	O
loss	O
(	O
best	O
corrected	O
vision	O
less	O
than	O
20/200	O
in	O
one	O
or	O
both	O
eyes	O
)	O
.	O
	
Immune	O
System	O
Disorders	O
:	O
Hypersensitivity	B
manifesting	O
as	O
bullous	B
rash	I
.	O
	
Assessment	O
of	O
BMD	O
should	O
be	O
considered	O
for	O
HIV-1	O
infected	O
patients	O
who	O
have	O
a	O
history	O
of	O
pathologic	O
bone	O
fracture	O
or	O
other	O
risk	O
factors	O
for	O
osteoporosis	O
or	O
bone	O
loss	O
.	O
	
Careful	O
medical	O
history	O
is	O
necessary	O
because	O
CDAD	O
has	O
been	O
reported	O
to	O
occur	O
more	O
than	O
2	O
months	O
after	O
the	O
administration	O
of	O
antibacterial	O
agents	O
.	O
	
There	O
is	O
no	O
established	O
way	O
to	O
reverse	O
the	O
anticoagulant	O
effect	O
of	O
apixaban	O
,	O
which	O
can	O
be	O
expected	O
to	O
persist	O
for	O
at	O
least	O
24	O
hours	O
after	O
the	O
last	O
dose	O
,	O
i.e.	O
,	O
for	O
about	O
two	O
drug	O
half-lives	O
.	O
	
ATEs	O
are	O
defined	O
as	O
nonfatal	O
stroke	O
,	O
nonfatal	O
myocardial	O
infarction	O
,	O
or	O
vascular	O
death	O
(	O
including	O
deaths	O
of	O
unknown	O
cause	O
)	O
.	O
	
Electrocardiogram	O
(	O
ECG	O
)	O
measurements	O
were	O
taken	O
at	O
various	O
time	O
points	O
during	O
the	O
SAPHRIS	O
clinical	O
trial	O
program	O
(	O
5	O
mg	O
or	O
10	O
mg	O
twice	O
daily	O
doses	O
)	O
.	O
	
Proper	O
aseptic	O
injection	O
technique	O
must	O
always	O
be	O
used	O
when	O
administering	O
EYLEA	O
.	O
	
Table	O
5	O
presents	O
adverse	O
reactions	O
from	O
Trial	O
2	O
,	O
a	O
multicenter	O
,	O
open-label	O
,	O
randomized	O
trial	O
of	O
162	O
patients	O
with	O
BRAF	O
V600E	O
or	O
V600K	O
mutation-positive	O
melanoma	O
receiving	O
TAFINLAR	O
150	O
mg	O
twice	O
daily	O
in	O
combination	O
with	O
trametinib	O
2	O
mg	O
orally	O
once	O
daily	O
(	O
n	O
=	O
55	O
)	O
,	O
TAFINLAR	O
150	O
mg	O
orally	O
twice	O
daily	O
in	O
combination	O
with	O
trametinib	O
1	O
mg	O
once	O
daily	O
(	O
n	O
=	O
54	O
)	O
,	O
and	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
150	O
mg	O
orally	O
twice	O
daily	O
(	O
n	O
=	O
53	O
)	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.2	O
)	O
]	O
.	O
	
*	O
If	O
you	O
have	O
high	O
blood	O
pressure	O
,	O
high	O
cholesterol	O
(	O
fat	O
in	O
the	O
blood	O
)	O
,	O
diabetes	O
,	O
are	O
overweight	O
,	O
or	O
if	O
you	O
use	O
tobacco	O
,	O
you	O
may	O
have	O
higher	O
chances	O
of	O
getting	O
heart	O
disease	O
.	O
	
5.2	O
Hepatotoxicity	O
PROMACTA	O
can	O
cause	O
liver	B
enzyme	I
elevations	I
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
In	O
total	O
,	O
536	O
(	O
approximately	O
75	O
%	O
)	O
patients	O
increased	O
their	O
dose	O
to	O
200	O
mg	O
and	O
5	O
(	O
less	O
than	O
1	O
%	O
)	O
patients	O
reduced	O
their	O
dose	O
to	O
50	O
mg.	O
Table	O
2	O
presents	O
the	O
adverse	O
reactions	O
reported	O
when	O
STENDRA	O
was	O
taken	O
as	O
recommended	O
(	O
on	O
an	O
as-needed	O
basis	O
)	O
in	O
this	O
open-label	O
extension	O
trial	O
.	O
	
Monitor	O
patients	O
with	O
clinically	O
significant	O
neutropenia	O
for	O
fever	O
or	O
other	O
symptoms	O
or	O
signs	O
of	O
infection	O
and	O
treat	O
promptly	O
if	O
such	O
symptoms	O
or	O
signs	O
occur	O
.	O
	
For	O
patients	O
at	O
highest	O
risk	O
for	O
NSF	O
,	O
do	O
not	O
exceed	O
the	O
recommended	O
EOVIST	O
dose	O
and	O
allow	O
a	O
sufficient	O
period	O
of	O
time	O
for	O
elimination	O
of	O
the	O
drug	O
from	O
the	O
body	O
prior	O
to	O
any	O
re-administration	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
(	O
5.2	O
)	O
*	O
Increased	B
susceptibility	I
to	I
infection	I
and	O
the	O
possible	O
development	O
of	O
malignancies	B
may	O
result	O
from	O
immunosuppression	O
.	O
	
Across	O
clinical	O
trials	O
of	O
TAFINLAR	O
administered	O
in	O
combination	O
with	O
trametinib	O
(	O
N	O
=	O
202	O
)	O
,	O
8	O
%	O
of	O
patients	O
developed	O
evidence	O
of	O
cardiomyopathy	B
(	O
decrease	B
in	I
LVEF	I
below	O
institutional	O
lower	O
limits	O
of	O
normal	O
with	O
an	O
absolute	B
decrease	I
in	I
LVEF	I
>	O
=10	O
%	O
below	O
baseline	O
)	O
.	O
	
In	O
the	O
AMPLIFY	O
study	O
,	O
ELIQUIS	O
was	O
statistically	O
superior	O
to	O
enoxaparin/warfarin	O
in	O
the	O
primary	O
safety	O
endpoint	O
of	O
major	O
bleeding	B
(	O
relative	O
risk	O
0.31	O
,	O
95	O
%	O
CI	O
[	O
0.17	O
,	O
0.55	O
]	O
,	O
P-value	O
<	O
0.0001	O
)	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Piramal	O
at	O
1-855-545-5245	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
One	O
(	O
n=122	O
)	O
or	O
2	O
(	O
n=	O
18	O
)	O
doses	O
of	O
VORAXAZE	O
were	O
administered	O
intravenously	O
;	O
the	O
number	O
of	O
doses	O
was	O
not	O
specified	O
for	O
1	O
patient	O
.	O
	
Closely	O
monitor	O
patients	O
for	O
fever	O
.	O
	
Keep	O
out	O
of	O
reach	O
of	O
children	O
.	O
	
5.2	O
Hypersensitivity	O
Reactions	O
Hypersensitivity	B
reactions	I
,	O
including	O
anaphylaxis	B
and	O
allergic	B
contact	I
dermatitis	I
,	O
have	O
been	O
reported	O
post-marketing	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
FANAPT	O
should	O
be	O
avoided	O
in	O
patients	O
with	O
histories	O
of	O
significant	O
cardiovascular	O
illness	O
,	O
e.g.	O
,	O
QT	O
prolongation	O
,	O
recent	O
acute	O
myocardial	O
infarction	O
,	O
uncompensated	O
heart	O
failure	O
,	O
or	O
cardiac	O
arrhythmia	O
.	O
	
These	O
findings	O
were	O
consistent	O
with	O
data	O
from	O
an	O
earlier	O
144-week	O
trial	O
of	O
treatment-naive	O
subjects	O
receiving	O
tenofovir	O
DF	O
+	O
lamivudine	O
+	O
efavirenz	O
.	O
	
Adverse	O
reactions	O
similar	O
in	O
nature	O
and	O
frequency	O
were	O
observed	O
to	O
those	O
seen	O
in	O
the	O
controlled	O
phase	O
of	O
the	O
trials	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Mortality	B
:	O
There	O
were	O
more	O
deaths	B
reported	O
with	O
BENLYSTA	O
than	O
with	O
placebo	O
during	O
the	O
controlled	O
period	O
of	O
clinical	O
trials	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
SUPINE	B
HYPERTENSION	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
Additional	O
hypersensitivity	B
reactions	I
observed	O
in	O
infantile-onset	O
Pompe	O
disease	O
patients	O
treated	O
in	O
other	O
clinical	O
trials	O
and	O
expanded	O
access	O
programs	O
with	O
alglucosidase	O
alfa	O
included	O
livedo	B
reticularis	I
,	O
irritability	B
,	O
retching	B
,	O
increased	B
lacrimation	I
,	O
ventricular	B
extrasystoles	I
,	O
nodal	B
rhythm	I
,	O
rales	B
,	O
respiratory	B
tract	I
irritation	I
,	O
and	O
cold	B
sweat	I
.	O
	
5.3	O
Clostridium	O
difficile	O
-associated	O
Diarrhea	O
Clostridium	B
difficile	I
-associated	I
diarrhea	I
(	O
CDAD	B
)	O
has	O
been	O
reported	O
for	O
nearly	O
all	O
systemic	O
antibacterial	O
agents	O
,	O
including	O
ZERBAXA	O
,	O
and	O
may	O
range	O
in	O
severity	O
from	O
mild	O
diarrhea	B
to	O
fatal	B
colitis	B
.	O
	
Additional	O
delayed-onset	O
reactions	O
occurring	O
in	O
alglucosidase	O
alfa-treated	O
patients	O
included	O
fatigue	B
,	O
myalgia	B
,	O
and	O
nausea	B
.	O
	
Monitor	O
glucose	O
regularly	O
in	O
patients	O
at	O
risk	O
for	O
diabetes	O
.	O
	
In	O
both	O
indications	O
,	O
about	O
25	O
%	O
of	O
the	O
subjects	O
were	O
65	O
years	O
of	O
age	O
or	O
older	O
.	O
	
Consider	O
uric	O
acid	O
lowering	O
drugs	O
in	O
patients	O
at	O
risk	O
for	O
TLS	O
.	O
	
*	O
Do	O
not	O
take	O
additional	O
estrogen	O
products	O
while	O
you	O
are	O
taking	O
DUAVEE	O
.	O
	
*	O
Using	O
estrogens	O
may	O
increase	O
your	O
chances	O
of	O
getting	O
strokes	O
or	O
blood	O
clots	O
.	O
	
Estrogens	O
should	O
be	O
prescribed	O
at	O
the	O
lowest	O
effective	O
doses	O
and	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
treatment	O
goals	O
and	O
risks	O
for	O
the	O
individual	O
woman	O
.	O
	
Two	O
patients	O
died	B
of	O
herpetic	B
infections	I
during	O
controlled	O
trials	O
.	O
	
The	O
patient	O
should	O
be	O
carefully	O
monitored	O
,	O
since	O
recurrences	O
of	O
NMS	O
have	O
been	O
reported	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
clinical	O
trials	O
of	O
DALVANCE	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
rates	O
observed	O
in	O
practice	O
.	O
	
Table	O
1	O
summarizes	O
all	O
adverse	O
reactions	O
,	O
regardless	O
of	O
causality	O
,	O
occurring	O
in	O
>	O
=	O
1	O
%	O
of	O
patients	O
with	O
postherpetic	O
neuralgia	O
in	O
the	O
Qutenza	O
group	O
for	O
which	O
the	O
incidence	O
was	O
greater	O
than	O
in	O
the	O
control	O
group	O
.	O
	
XALKORI	O
was	O
discontinued	O
for	O
adverse	O
reactions	O
in	O
15	O
%	O
of	O
patients	O
.	O
	
5.2	O
Impairment	O
in	O
Renal	O
Function	O
INVOKANA	O
increases	B
serum	I
creatinine	I
and	O
decreases	B
eGFR	I
.	O
	
Since	O
patients	O
with	O
COPD	O
often	O
have	O
multiple	O
risk	O
factors	O
for	O
reduced	O
BMD	O
,	O
assessment	O
of	O
BMD	O
is	O
recommended	O
prior	O
to	O
initiating	O
BREO	O
ELLIPTA	O
and	O
periodically	O
thereafter	O
.	O
	
(	O
5.3	O
)	O
*	O
Neuropsychiatric	B
symptoms	I
:	O
Monitor	O
for	O
confusional	O
state	O
,	O
psychotic	O
symptoms	O
,	O
and	O
hallucinations	O
.	O
	
5.8	O
Seizure	O
Cases	O
of	O
seizure	B
have	O
been	O
reported	O
in	O
pre-marketing	O
clinical	O
studies	O
with	O
PRISTIQ	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
Contact	O
AstraZeneca	O
at	O
1-800-236-9933	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
(	O
5.4	O
)	O
*	O
lipid	B
metabolic	I
effects	I
:	O
Monitor	O
prediabetic	O
and	O
diabetic	O
women	O
taking	O
Natazia	O
.	O
	
Monitor	O
complete	O
blood	O
counts	O
prior	O
to	O
each	O
dose	O
;	O
increase	O
the	O
frequency	O
of	O
monitoring	O
in	O
patients	O
who	O
develop	O
Grade	O
3	O
or	O
4	O
cytopenias	O
.	O
	
The	O
racial	O
and	O
ethnic	O
distribution	O
was	O
Caucasian	O
(	O
83	O
%	O
)	O
,	O
Black	O
(	O
5	O
%	O
)	O
,	O
Asian	O
(	O
2	O
%	O
)	O
,	O
and	O
other	O
(	O
5	O
%	O
)	O
.	O
	
(	O
5.1	O
)	O
*	O
Fatal	B
and/or	O
serious	O
and	O
severe	O
diarrhea	B
or	O
colitis	B
occurred	O
in	O
14	O
%	O
of	O
Zydelig-treated	O
patients	O
.	O
	
6.2	O
Post	O
Marketing	O
Experience	O
The	O
following	O
additional	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
ZYTIGA	O
.	O
	
eOn-treatment	O
analysis	O
based	O
on	O
the	O
safety	O
population	O
,	O
compared	O
to	O
ITT	O
analysis	O
presented	O
in	O
Section	O
14	O
Clinical	O
Studies	O
.	O
	
(	O
5.6	O
)	O
*	O
Headache	B
:	O
Evaluate	O
significant	O
change	O
in	O
headaches	O
and	O
discontinue	O
Natazia	O
if	O
indicated	O
.	O
	
Permanently	O
discontinue	O
ZYKADIA	O
in	O
patients	O
diagnosed	O
with	O
treatment-related	O
ILD/pneumonitis	O
.	O
	
Major	O
Neuropsychiatric	B
Symptoms	I
in	O
Placebo-Controlled	O
Epilepsy	O
Trials	O
Adverse	O
Reaction	O
Number	O
(	O
%	O
)	O
with	O
Adverse	O
Reaction	O
Number	O
(	O
%	O
)	O
Discontinuing	O
POTIGA	O
(	O
n	O
=	O
813	O
)	O
Placebo	O
(	O
n	O
=	O
427	O
)	O
POTIGA	O
(	O
n	O
=	O
813	O
)	O
Placebo	O
(	O
n	O
=	O
427	O
)	O
Confusional	B
state	I
75	O
(	O
9	O
%	O
)	O
11	O
(	O
3	O
%	O
)	O
32	O
(	O
4	O
%	O
)	O
4	O
(	O
<	O
1	O
%	O
)	O
Psychosis	B
9	O
(	O
1	O
%	O
)	O
0	O
6	O
(	O
<	O
1	O
%	O
)	O
0	O
Hallucinationsa	O
14	O
(	O
2	O
%	O
)	O
2	O
(	O
<	O
1	O
%	O
)	O
6	O
(	O
<	O
1	O
%	O
)	O
0	O
a	O
Hallucinations	B
includes	O
mixed	B
hallucinations	I
.	O
	
The	O
contribution	O
of	O
the	O
underlying	O
disease	O
and/or	O
prior	O
corticosteroid	O
treatment	O
to	O
the	O
risk	O
is	O
also	O
not	O
known	O
.	O
	
Discoloration	B
of	I
the	I
palate	I
has	O
also	O
been	O
reported	O
.	O
	
However	O
,	O
based	O
on	O
its	O
mechanism	O
of	O
action	O
and	O
findings	O
in	O
animals	O
,	O
ADCETRIS	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
Injection-site	O
Reactions	O
In	O
the	O
placebo-controlled	O
studies	O
,	O
injection-site	B
rash	I
)	O
were	O
reported	O
in	O
0.5	O
%	O
of	O
TRULICITY-treated	O
patients	O
and	O
in	O
0.0	O
%	O
of	O
placebo-treated	O
patients	O
.	O
	
Injection	O
into	O
these	O
structures	O
may	O
result	O
in	O
possible	O
permanent	B
injury	I
such	O
as	O
corporal	B
rupture	I
(	O
penile	B
fracture	I
)	O
.	O
	
Urinary	B
retention	I
was	O
reported	O
as	O
an	O
adverse	O
event	O
in	O
29	O
of	O
1,365	O
(	O
approximately	O
2	O
%	O
)	O
patients	O
treated	O
with	O
POTIGA	O
in	O
the	O
open-label	O
and	O
placebo-controlled	O
epilepsy	O
database	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Cardiac	O
disorders	O
:	O
Angina	B
pectoris	I
,	O
arrhythmias	B
,	O
atrial	B
fibrillation	I
,	O
cardiac	B
failure	I
,	O
hypertensive	B
heart	I
disease	I
,	O
myocardial	B
infarction	I
,	O
myocardial	B
ischemia	I
,	O
pericardial	B
effusion	I
,	O
pericarditis	B
,	O
stroke	B
and	O
transient	B
ischemic	I
attack	I
.	O
	
Baseline	O
renal	O
function	O
was	O
normal	O
or	O
mildly	O
impaired	O
in	O
92	O
%	O
of	O
patients	O
and	O
moderately	O
impaired	O
in	O
8	O
%	O
of	O
patients	O
(	O
mean	O
eGFR	O
86	O
mL/min/1.73	O
m	O
2	O
)	O
.	O
	
Proteinuria	O
At	O
Month	O
1	O
after	O
transplantation	O
in	O
Studies	O
1	O
and	O
2	O
,	O
the	O
frequency	O
of	O
2+	O
proteinuria	B
on	O
urine	O
dipstick	O
in	O
patients	O
treated	O
with	O
the	O
NULOJIX	O
recommended	O
regimen	O
was	O
33	O
%	O
(	O
130/390	O
)	O
and	O
28	O
%	O
(	O
107/384	O
)	O
in	O
patients	O
treated	O
with	O
the	O
cyclosporine	O
control	O
regimen	O
.	O
	
5.3	O
Infections	O
In	O
patients	O
receiving	O
BLINCYTO	O
in	O
clinical	O
trials	O
,	O
serious	O
infections	B
such	O
as	O
sepsis	B
,	O
pneumonia	B
,	O
bacteremia	B
,	O
opportunistic	B
infections	I
,	O
and	O
catheter-site	B
infections	I
were	O
observed	O
in	O
approximately	O
25	O
%	O
of	O
patients	O
,	O
some	O
of	O
which	O
were	O
life-threatening	O
or	O
fatal	B
.	O
	
There	O
were	O
no	O
elevations	B
in	I
transaminases	I
>	O
=	O
3	O
times	O
the	O
ULN	O
with	O
concomitant	O
elevations	B
in	I
total	I
bilirubin	I
>	O
2	O
times	O
the	O
ULN	O
.	O
	
Pooled	O
analyses	O
of	O
199	O
placebo-controlled	O
clinical	O
trials	O
(	O
mono-	O
and	O
adjunctive	O
therapy	O
)	O
of	O
11	O
different	O
AEDs	O
showed	O
that	O
patients	O
randomized	O
to	O
one	O
of	O
the	O
AEDs	O
had	O
approximately	O
twice	O
the	O
risk	O
(	O
adjusted	O
Relative	O
Risk	O
1.8	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
1.2	O
,	O
2.7	O
)	O
of	O
suicidal	B
thinking	I
compared	O
to	O
patients	O
randomized	O
to	O
placebo	O
.	O
	
TABLE	O
3	O
:	O
Changes	O
in	O
Lipids	O
in	O
Adult	O
Patients	O
N*	O
=	O
Number	O
of	O
subjects	O
who	O
had	O
assessments	O
at	O
both	O
Baseline	O
and	O
Endpoint	O
.	O
	
The	O
incidence	O
of	O
all-cause	O
mortality	B
was	O
0.0	O
%	O
in	O
the	O
DUAVEE	O
group	O
and	O
0.2	O
%	O
in	O
the	O
placebo	O
group	O
.	O
	
(	O
5.8	O
)	O
*	O
Infusion	B
Reactions	I
:	O
Pre-medicate	O
with	O
dexamethasone	O
.	O
	
There	O
is	O
no	O
general	O
agreement	O
about	O
specific	O
pharmacological	O
treatment	O
regimens	O
for	O
NMS	O
.	O
	
ZERBAXA	O
was	O
evaluated	O
in	O
Phase	O
3	O
comparator-controlled	O
clinical	O
trials	O
of	O
cIAI	O
and	O
cUTI	O
,	O
which	O
included	O
a	O
total	O
of	O
1015	O
patients	O
treated	O
with	O
ZERBAXA	O
and	O
1032	O
patients	O
treated	O
with	O
comparator	O
(	O
levofloxacin	O
750	O
mg	O
daily	O
in	O
cUTI	O
or	O
meropenem	O
1	O
g	O
every	O
8	O
hours	O
in	O
cIAI	O
)	O
for	O
up	O
to	O
14	O
days	O
.	O
	
Additional	O
adverse	O
drug	O
reactions	O
observed	O
with	O
STRIBILD	O
included	O
suicidal	B
ideation	I
and	O
suicide	B
attempt	I
(	O
0.3	O
%	O
)	O
,	O
all	O
in	O
subjects	O
with	O
a	O
pre-existing	O
history	O
of	O
depression	O
or	O
psychiatric	O
illness	O
.	O
	
(	O
5.1	O
)	O
*	O
Patients	O
with	O
underlying	O
hepatitis	O
B	O
or	O
C	O
may	O
be	O
at	O
increased	O
risk	O
for	O
worsening	O
or	O
development	O
of	O
transaminase	B
elevations	I
with	O
use	O
of	O
TIVICAY	O
.	O
	
Patients	O
were	O
treated	O
with	O
FIRAZYR	O
30	O
mg	O
and	O
could	O
receive	O
up	O
to	O
3	O
doses	O
of	O
FIRAZYR	O
30	O
mg	O
administered	O
at	O
least	O
6	O
hours	O
apart	O
for	O
each	O
attack	O
.	O
	
5.6	O
Risk	O
of	O
Serious	O
Adverse	O
Reactions	O
in	O
Patients	O
with	O
Complete	O
Gastrointestinal	O
Obstruction	O
No	O
studies	O
have	O
been	O
conducted	O
in	O
patients	O
with	O
complete	O
gastrointestinal	O
obstruction	O
or	O
in	O
patients	O
who	O
have	O
surgery	O
for	O
correction	O
of	O
complete	O
bowel	O
obstruction	O
.	O
	
Deaths	B
as	O
a	O
complication	O
of	O
severe	O
dysphagia	B
have	O
been	O
reported	O
after	O
treatment	O
with	O
botulinum	O
toxin	O
.	O
	
Patients	O
were	O
aged	O
1	O
to	O
18	O
years	O
with	O
a	O
median	O
duration	O
of	O
treatment	O
of	O
437	O
days	O
(	O
range	O
13	O
to	O
466	O
days	O
)	O
.	O
	
Instances	O
of	O
suicidal	B
behavior	I
have	O
been	O
observed	O
in	O
0.1	O
%	O
(	O
1/1308	O
)	O
of	O
subjects	O
while	O
receiving	O
OTEZLA	O
,	O
compared	O
to	O
0.2	O
%	O
(	O
1/506	O
)	O
in	O
placebo-treated	O
subjects	O
.	O
	
Premedicate	O
with	O
corticosteroids	O
and	O
H2	O
antagonists	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
SUICIDAL	B
THOUGHTS	I
WARNING	O
:	O
SUICIDAL	B
THOUGHTS	I
Antidepressants	O
increased	O
the	O
risk	O
of	O
suicidal	B
thoughts	I
in	O
children	O
,	O
adolescents	O
,	O
and	O
young	O
adults	O
in	O
short-term	O
studies	O
.	O
	
(	O
5.4	O
)	O
*	O
Renal	B
failure	I
:	O
Cases	O
of	O
renal	B
failure	I
(	O
including	O
acute	B
renal	I
failure	I
)	O
,	O
some	O
with	O
a	O
fatal	B
outcome	O
,	O
have	O
been	O
observed	O
.	O
	
EXCERPT	O
:	O
Advanced	O
HR+	O
BC	O
,	O
advanced	O
PNET	O
,	O
advanced	O
RCC	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=30	O
%	O
)	O
include	O
stomatitis	B
,	O
infections	B
,	O
rash	B
,	O
fatigue	B
,	O
diarrhea	B
,	O
edema	B
,	O
abdominal	B
pain	I
,	O
nausea	B
,	O
fever	B
,	O
asthenia	B
,	O
cough	B
,	O
headache	B
and	O
decreased	B
appetite	I
.	O
	
*	O
Carcinogenicity	O
of	O
albiglutide	O
could	O
not	O
be	O
assessed	O
in	O
rodents	O
,	O
but	O
other	O
glucagon-like	O
peptide-1	O
(	O
GLP-1	O
)	O
receptor	O
agonists	O
have	O
caused	O
thyroid	B
C-cell	I
tumors	I
in	O
rodents	O
at	O
clinically	O
relevant	O
exposures	O
.	O
	
Withhold	O
trametinib	O
for	O
up	O
to	O
3	O
weeks	O
for	O
Grade	O
3	O
hemorrhagic	O
events	O
;	O
if	O
improved	O
,	O
resume	O
at	O
a	O
lower	O
dose	O
level	O
.	O
	
Table	O
5	O
:	O
Bleeding	B
Results	O
in	O
the	O
AMPLIFY	O
Study	O
ELIQUISN=2676n	O
(	O
%	O
)	O
Enoxaparin/WarfarinN=2689n	O
(	O
%	O
)	O
Relative	O
Risk	O
(	O
95	O
%	O
CI	O
)	O
*	O
CRNM	B
=	O
clinically	B
relevant	I
nonmajor	I
bleeding.Events	O
associated	O
with	O
each	O
endpoint	O
were	O
counted	O
once	O
per	O
subject	O
,	O
but	O
subjects	O
may	O
have	O
contributed	O
events	O
to	O
multiple	O
endpoints	O
.	O
	
No	O
definite	O
causality	O
assessment	O
or	O
benefit	O
risk	O
assessment	O
could	O
be	O
made	O
for	O
these	O
events	O
due	O
to	O
the	O
presence	O
of	O
confounding	O
factors	O
and	O
lack	O
of	O
randomization	O
of	O
ESA	O
use	O
.	O
	
Cardiovascular	O
Safety	O
Cardiovascular	B
events	I
and	O
deaths	B
were	O
adjudicated	O
to	O
one	O
of	O
the	O
pre-defined	O
endpoints	O
from	O
the	O
Anti-Platelet	O
Trialists	O
'	O
Collaborations	O
(	O
APTC	O
)	O
(	O
cardiovascular	B
death	I
,	O
non-fatal	O
myocardial	B
infarction	I
,	O
and	O
non-fatal	O
stroke	B
)	O
in	O
the	O
randomized	O
controlled	O
and	O
long-term	O
extension	O
studies	O
.	O
	
*	O
Monitor	O
all	O
patients	O
for	O
active	O
TB	O
during	O
treatment	O
,	O
even	O
if	O
initial	O
latent	O
TB	O
test	O
is	O
negative	O
(	O
5.1	O
)	O
*	O
Lymphoma	B
and	O
other	O
malignancies	B
,	O
some	O
fatal	B
,	O
have	O
been	O
reported	O
in	O
children	O
and	O
adolescent	O
patients	O
treated	O
with	O
TNF	O
blockers	O
,	O
of	O
which	O
CIMZIA	O
is	O
a	O
member	O
(	O
5.2	O
)	O
.	O
	
*	O
Adrenocortical	B
Insufficiency	I
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Table	O
1	O
lists	O
selected	O
adverse	O
reactions	O
occurring	O
in	O
more	O
than	O
2	O
%	O
of	O
patients	O
treated	O
with	O
DALVANCE	O
in	O
clinical	O
trials	O
.	O
	
Observe	O
patients	O
closely	O
for	O
hypersensitivity	O
reactions	O
,	O
especially	O
during	O
the	O
first	O
and	O
second	O
infusions	O
.	O
	
*	O
Keep	O
DUAVEE	O
in	O
the	O
blister	O
until	O
you	O
are	O
ready	O
to	O
take	O
it	O
to	O
protect	O
the	O
tablet	O
from	O
moisture	O
.	O
	
Advise	O
patients	O
of	O
signs	O
and	O
symptoms	O
of	O
blood	O
loss	O
and	O
to	O
report	O
them	O
immediately	O
or	O
go	O
to	O
an	O
emergency	O
room	O
.	O
	
Permanently	O
discontinue	O
for	O
life-threatening	O
bradycardia	O
due	O
to	O
XALKORI	O
;	O
however	O
,	O
if	O
associated	O
with	O
concomitant	O
medications	O
known	O
to	O
cause	O
bradycardia	O
or	O
hypotension	O
,	O
hold	O
XALKORI	O
until	O
recovery	O
to	O
asymptomatic	O
bradycardia	O
or	O
to	O
a	O
heart	O
rate	O
of	O
60	O
bpm	O
or	O
above	O
,	O
and	O
if	O
concomitant	O
medications	O
can	O
be	O
adjusted	O
or	O
discontinued	O
,	O
restart	O
XALKORI	O
at	O
250	O
mg	O
once	O
daily	O
with	O
frequent	O
monitoring	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
If	O
hepatic	O
injury	O
is	O
suspected	O
,	O
promptly	O
discontinue	O
MULTAQ	O
and	O
test	O
serum	O
enzymes	O
,	O
aspartate	O
aminotransferase	O
(	O
AST	O
)	O
,	O
alanine	O
aminotransferase	O
(	O
ALT	O
)	O
and	O
alkaline	O
phosphatase	O
,	O
as	O
well	O
as	O
serum	O
bilirubin	O
,	O
to	O
establish	O
whether	O
there	O
is	O
liver	O
injury	O
.	O
	
There	O
were	O
no	O
reports	O
of	O
Torsade	B
de	I
Pointes	I
or	O
any	O
other	O
adverse	O
reactions	O
associated	O
with	O
delayed	B
ventricular	I
repolarization	I
.	O
	
If	O
ribavirin	O
is	O
permanently	O
discontinued	O
for	O
management	O
of	O
anemia	O
,	O
then	O
peginterferon	O
alfa	O
and	O
VICTRELIS	O
must	O
also	O
be	O
discontinued	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
(	O
5.3	O
)	O
5.1	O
Endophthalmitis	O
and	O
Retinal	O
Detachments	O
Intravitreal	O
injections	O
,	O
including	O
those	O
with	O
EYLEA	O
,	O
have	O
been	O
associated	O
with	O
endophthalmitis	B
and	O
retinal	B
detachments	I
[	O
seeAdverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Significantly	O
elevated	O
serum	O
calcitonin	O
may	O
indicate	O
MTC	O
and	O
patients	O
with	O
MTC	O
usually	O
have	O
calcitonin	O
values	O
>	O
50	O
ng/L	O
.	O
	
Incidence	O
of	O
Laboratory	O
Abnormalities	O
Increased	O
From	O
Baseline	O
Occurring	O
at	O
a	O
Higher	O
Incidence	O
in	O
Patients	O
Treated	O
With	O
TAFINLAR	O
in	O
Trial	O
1	O
[	O
Between-Arm	O
Difference	O
of	O
>	O
=5	O
%	O
(	O
All	O
Grades	O
)	O
or	O
>	O
=2	O
%	O
(	O
Grades	O
3	O
or	O
4	O
)	O
]	O
Test	O
TAFINLAR	O
N	O
=	O
187	O
DTIC	O
N	O
=	O
59	O
All	O
Grades	O
(	O
%	O
)	O
Grades	O
3	O
and	O
4	O
(	O
%	O
)	O
All	O
Grades	O
(	O
%	O
)	O
Grades	O
3	O
and	O
4	O
(	O
%	O
)	O
Hyperglycemia	B
50	O
6	O
43	O
0	O
Hypophosphatemia	B
37	O
6a	O
14	O
2	O
Increased	B
alkaline	I
phosphatase	I
19	O
0	O
14	O
2	O
Hyponatremia	B
8	O
2	O
3	O
0	O
a	O
Grade	O
4	O
laboratory	O
abnormality	O
limited	O
to	O
hypophosphatemia	B
(	O
n	O
=	O
1	O
)	O
.	O
	
5.5	O
Severe	O
Visual	O
Loss	O
Across	O
all	O
clinical	O
trials	O
,	O
the	O
incidence	O
of	O
Grade	O
4	O
visual	B
field	I
defect	I
with	O
vision	B
loss	I
was	O
0.2	O
%	O
(	O
4/1669	O
)	O
.	O
	
Patients	O
with	O
histoplasmosis	B
,	O
rather	O
than	O
localized	O
disease	O
.	O
	
Immune	O
System	O
Disorder	O
:	O
hypersensitivity	B
.	O
	
Table1	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
RISK	O
FOR	O
HEPATIC	B
DECOMPENSATION	I
IN	O
PATIENTS	O
WITH	O
CHRONIC	O
HEPATITIS	O
C	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
6.2	O
Post	O
Marketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post-approval	O
use	O
of	O
ADCETRIS	O
.	O
	
The	O
following	O
serious	O
and	O
otherwise	O
important	O
adverse	O
drug	O
reactions	O
(	O
ADRs	O
)	O
are	O
discussed	O
in	O
detail	O
in	O
another	O
section	O
of	O
the	O
labeling	O
:	O
*	O
Anemia	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
Neutropenia	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Pancytopenia	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
Hypersensitivity	B
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
(	O
more	O
than	O
35	O
%	O
of	O
subjects	O
regardless	O
of	O
investigator	O
's	O
causality	O
assessment	O
)	O
in	O
adult	O
subjects	O
were	O
fatigue	B
,	O
anemia	B
,	O
nausea	B
,	O
headache	B
,	O
and	O
dysgeusia	B
when	O
VICTRELIS	O
was	O
used	O
in	O
combination	O
with	O
PegIntron	O
and	O
REBETOL	O
.	O
	
In	O
this	O
extension	O
trial	O
,	O
all	O
eligible	O
patients	O
were	O
initially	O
assigned	O
to	O
STENDRA	O
100	O
mg.	O
At	O
any	O
point	O
during	O
the	O
trial	O
,	O
patients	O
could	O
request	O
to	O
have	O
their	O
dose	O
of	O
STENDRA	O
increased	O
to	O
200	O
mg	O
or	O
decreased	O
to	O
50	O
mg	O
based	O
on	O
their	O
individual	O
response	O
to	O
treatment	O
.	O
	
(	O
5.3	O
)	O
*	O
Progressive	B
Multifocal	I
Leukoencephalopathy	I
(	O
PML	B
)	O
:	O
increased	O
risk	O
;	O
consider	O
in	O
the	O
diagnosis	O
of	O
patients	O
reporting	O
new	O
or	O
worsening	O
neurological	O
,	O
cognitive	O
,	O
or	O
behavioral	O
signs	O
and	O
symptoms	O
.	O
	
Major	O
15	O
(	O
0.6	O
)	O
49	O
(	O
1.8	O
)	O
0.31	O
(	O
0.17	O
,	O
0.55	O
)	O
p	O
<	O
0.0001	O
CRNM*	O
103	O
(	O
3.9	O
)	O
215	O
(	O
8.0	O
)	O
Major	O
+	O
CRNM	B
115	O
(	O
4.3	O
)	O
261	O
(	O
9.7	O
)	O
Minor	O
313	O
(	O
11.7	O
)	O
505	O
(	O
18.8	O
)	O
All	O
402	O
(	O
15.0	O
)	O
676	O
(	O
25.1	O
)	O
Adverse	O
reactions	O
occurring	O
in	O
>	O
=1	O
%	O
of	O
patients	O
in	O
the	O
AMPLIFY	O
study	O
are	O
listed	O
in	O
Table	O
6	O
.	O
	
(	O
4	O
,	O
5.1	O
)	O
*	O
Only	O
physicians	O
experienced	O
in	O
immunosuppressive	O
therapy	O
and	O
management	O
of	O
kidney	O
transplant	O
patients	O
should	O
prescribe	O
NULOJIX	O
.	O
	
Withhold	O
TAFINLAR	O
for	O
Grade	O
3	O
hemorrhagic	O
events	O
;	O
if	O
improved	O
resume	O
at	O
a	O
lower	O
dose	O
level	O
.	O
	
Reduction	O
of	O
Risk	O
of	O
Stroke	O
and	O
Systemic	O
Embolism	O
in	O
Non-valvular	O
Atrial	O
Fibrillation	O
Reduce	O
the	O
dose	O
of	O
PRADAXA	O
to	O
75	O
mg	O
twice	O
daily	O
when	O
dronedarone	O
or	O
systemic	O
ketoconazole	O
is	O
coadministered	O
with	O
PRADAXA	O
in	O
patients	O
with	O
moderate	O
renal	O
impairment	O
(	O
CrCl	O
30-50	O
mL/min	O
)	O
.	O
	
Monitor	O
patients	O
for	O
symptoms	O
of	O
neuropathy	O
,	O
such	O
as	O
hypoesthesia	O
,	O
hyperesthesia	O
,	O
paresthesia	O
,	O
discomfort	O
,	O
a	O
burning	O
sensation	O
,	O
neuropathic	O
pain	O
,	O
or	O
weakness	O
.	O
	
If	O
accidental	O
exposure	O
occurs	O
,	O
the	O
area	O
should	O
be	O
flushed	O
with	O
water	O
and	O
the	O
patient	O
should	O
seek	O
medical	O
care	O
as	O
soon	O
as	O
possible	O
.	O
	
WARNING	O
:	O
RISK	O
OF	O
THYROID	B
C-CELL	I
TUMORS	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
Adverse	O
reactions	O
occurring	O
in	O
at	O
least	O
1	O
%	O
of	O
ULORIC-treated	O
patients	O
,	O
and	O
at	O
least	O
0.5	O
%	O
greater	O
than	O
placebo	O
,	O
are	O
liver	B
function	I
abnormalities	I
,	O
nausea	B
,	O
arthralgia	B
,	O
and	O
rash	B
.	O
	
CAPS	O
Study	O
1	O
investigated	O
the	O
safety	O
of	O
ILARIS	O
in	O
an	O
8-week	O
,	O
open-label	O
period	O
(	O
Part	O
1	O
)	O
,	O
followed	O
by	O
a	O
24-week	O
,	O
randomized	O
withdrawal	O
period	O
(	O
Part	O
2	O
)	O
,	O
followed	O
by	O
a	O
16-week	O
,	O
open-label	O
period	O
(	O
Part	O
3	O
)	O
.	O
	
The	O
criterion	O
for	O
allowing	O
patients	O
to	O
receive	O
a	O
second	O
glucarpidase	O
dose	O
was	O
not	O
specified	O
in	O
the	O
protocol	O
.	O
	
Safety	O
was	O
also	O
evaluated	O
in	O
99	O
patients	O
(	O
51	O
male	O
,	O
48	O
females	O
)	O
with	O
Pompe	O
disease	O
in	O
an	O
ongoing	O
,	O
open-label	O
,	O
prospective	O
study	O
in	O
patients	O
12	O
months	O
of	O
age	O
and	O
older	O
who	O
were	O
previously	O
treated	O
with	O
the	O
160	O
L	O
scale	O
of	O
alglucosidase	O
alfa	O
and	O
switched	O
to	O
the	O
4000	O
L	O
scale	O
of	O
alglucosidase	O
alfa	O
.	O
	
5.6	O
Hepatic	O
Impairment	O
Toviaz	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
severe	O
hepatic	O
impairment	O
and	O
therefore	O
is	O
not	O
recommended	O
for	O
use	O
in	O
this	O
patient	O
population	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.7	O
)	O
and	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
Monitor	O
supine	O
blood	O
pressure	O
prior	O
to	O
and	O
during	O
treatment	O
and	O
more	O
frequently	O
when	O
increasing	O
doses	O
.	O
	
The	O
median	O
duration	O
of	O
blinded	O
study	O
treatment	O
was	O
48	O
weeks	O
(	O
range	O
2	O
to	O
115	O
weeks	O
)	O
for	O
patients	O
receiving	O
AFINITOR	O
and	O
45	O
weeks	O
(	O
range	O
9	O
to	O
115	O
weeks	O
)	O
for	O
those	O
receiving	O
placebo	O
.	O
	
Clinical	O
status	O
,	O
including	O
liver	O
aminotransferases	O
,	O
should	O
be	O
monitored	O
and	O
appropriate	O
therapy	O
initiated	O
.	O
	
6.6	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
AFINITOR	O
.	O
	
Study	O
1	O
excluded	O
the	O
use	O
of	O
concomitant	O
medications	O
that	O
may	O
lower	O
the	O
seizure	O
threshold	O
,	O
whereas	O
Study	O
2	O
permitted	O
the	O
use	O
of	O
these	O
medications	O
.	O
	
Avoid	O
use	O
of	O
GBCAs	O
among	O
these	O
patients	O
unless	O
the	O
diagnostic	O
information	O
is	O
essential	O
and	O
not	O
available	O
with	O
non-contrast	O
MRI	O
or	O
other	O
modalities	O
.	O
	
6.3	O
Immunogenicity	O
As	O
with	O
all	O
therapeutic	O
proteins	O
,	O
there	O
is	O
a	O
potential	O
for	O
immunogenicity	O
.	O
	
5.3	O
Tumor	O
Lysis	O
Syndrome	O
Cases	O
of	O
tumor	B
lysis	I
syndrome	I
(	O
TLS	B
)	O
,	O
including	O
fatal	B
outcomes	O
,	O
have	O
been	O
reported	O
in	O
patients	O
who	O
received	O
Kyprolis	O
.	O
	
Cases	O
of	O
chronic	B
leukemia	I
have	O
been	O
reported	O
with	O
post-marketing	O
TNF-blocker	O
use	O
in	O
rheumatoid	O
arthritis	O
and	O
other	O
indications	O
.	O
	
Most	O
adverse	O
reactions	O
were	O
mild	O
or	O
moderate	O
in	O
severity	O
and	O
transient	O
in	O
nature	O
.	O
	
PML	B
is	O
an	O
opportunistic	B
viral	I
infection	I
of	I
the	I
brain	I
caused	O
by	O
the	O
JC	B
virus	I
(	O
JCV	B
)	O
that	O
typically	O
only	O
occurs	O
in	O
patients	O
who	O
are	O
immunocompromised	O
,	O
and	O
that	O
usually	O
leads	O
to	O
death	B
or	O
severe	O
disability	B
.	O
	
Adverse	O
reactions	O
reported	O
in	O
>	O
=	O
2	O
%	O
of	O
postmenopausal	O
women	O
with	O
osteoporosis	O
and	O
more	O
frequently	O
in	O
the	O
Prolia-treated	O
women	O
than	O
in	O
the	O
placebo-treated	O
women	O
are	O
shown	O
in	O
the	O
table	O
below	O
.	O
	
(	O
4	O
,	O
5.1	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Do	O
not	O
initiate	O
in	O
acutely	O
deteriorating	O
COPD	O
patients	O
(	O
5.2	O
)	O
*	O
Do	O
not	O
use	O
for	O
relief	O
of	O
acute	O
symptoms	O
.	O
	
(	O
5.5	O
)	O
*	O
Use	O
with	O
caution	O
in	O
patients	O
with	O
cardiovascular	O
or	O
convulsive	O
disorders	O
,	O
thyrotoxicosis	O
or	O
sensitivity	O
to	O
sympathomimetic	O
drugs	O
.	O
	
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
in	O
patients	O
treated	O
with	O
DALVANCE	O
were	O
nausea	B
(	O
5.5	O
%	O
)	O
,	O
headache	B
(	O
4.7	O
%	O
)	O
,	O
and	O
diarrhea	B
(	O
4.4	O
%	O
)	O
.	O
	
5.3	O
Unintended	O
Skin	O
Exposure	O
If	O
skin	O
not	O
intended	O
to	O
be	O
treated	O
comes	O
in	O
contact	O
with	O
Qutenza	O
,	O
apply	O
Cleansing	O
Gel	O
for	O
one	O
minute	O
and	O
wipe	O
off	O
with	O
dry	O
gauze	O
.	O
	
(	O
5.7	O
)	O
*	O
Embryo-fetal	B
toxicity	I
:	O
Fetal	B
harm	I
can	O
occur	O
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
Pediatric	O
Patients	O
:	O
Data	O
from	O
the	O
short-term	O
,	O
placebo-controlled	O
bipolar	O
mania	O
trial	O
are	O
presented	O
in	O
Table	O
4	O
.	O
	
Elevations	B
of	I
alanine	I
aminotransferase	I
to	O
>	O
=	O
3	O
times	O
the	O
ULN	O
occurred	O
in	O
a	O
small	O
number	O
of	O
patients	O
treated	O
with	O
both	O
TECFIDERA	O
and	O
placebo	O
and	O
were	O
balanced	O
between	O
groups	O
.	O
	
Neutralizing	O
antibody	O
titers	O
were	O
not	O
determined	O
in	O
the	O
patients	O
.	O
	
(	O
5.1	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Urinary	B
retention	I
:	O
Patients	O
should	O
be	O
carefully	O
monitored	O
for	O
urologic	O
symptoms	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
common	O
reported	O
adverse	O
reaction	O
was	O
headache	B
,	O
occurring	O
in	O
2	O
%	O
of	O
patients	O
,	O
followed	O
by	O
musculoskeletal	B
pain	I
,	O
blood	B
pressure	I
increased	I
,	O
fatigue	B
,	O
nausea	B
,	O
and	O
injection	B
site	I
reaction	I
,	O
all	O
occurring	O
in	O
<	O
1	O
%	O
of	O
patients	O
(	O
6	O
)	O
.	O
	
Therefore	O
,	O
close	O
monitoring	O
is	O
warranted	O
in	O
patients	O
with	O
a	O
change	O
in	O
vision	O
or	O
with	O
a	O
history	O
of	O
increased	O
intraocular	O
pressure	O
,	O
glaucoma	O
,	O
and/or	O
cataracts	O
.	O
	
This	O
patient	O
had	O
pretreatment	O
calcitonin	O
levels	O
approximately	O
8	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
.	O
	
Of	O
the	O
64	O
dulaglutide-treated	O
patients	O
that	O
developed	O
dulaglutide	O
ADAs	O
,	O
34	O
patients	O
(	O
0.9	O
%	O
of	O
the	O
overall	O
population	O
)	O
had	O
dulaglutide-neutralizing	O
antibodies	O
,	O
and	O
36	O
patients	O
(	O
0.9	O
%	O
of	O
the	O
overall	O
population	O
)	O
developed	O
antibodies	O
against	O
native	O
GLP-1	O
.	O
	
(	O
5.2	O
)	O
*	O
Hypersensitivity	B
reactions	I
,	O
including	O
anaphylaxis	B
:	O
Healthcare	O
providers	O
should	O
be	O
prepared	O
to	O
address	O
hypersensitivity	O
reactions	O
,	O
including	O
anaphylaxis	O
,	O
following	O
XIAFLEX	O
injections	O
.	O
	
Eleven	O
of	O
the	O
13	O
fractures	B
were	O
reported	O
within	O
the	O
first	O
52	O
weeks	O
.	O
	
The	O
data	O
described	O
below	O
reflect	O
the	O
exposure	O
to	O
CIMZIA	O
in	O
2,367	O
RA	O
patients	O
,	O
including	O
2,030	O
exposed	O
for	O
at	O
least	O
6	O
months	O
,	O
1,663	O
exposed	O
for	O
at	O
least	O
one	O
year	O
and	O
282	O
for	O
at	O
least	O
2	O
years	O
;	O
and	O
1,774	O
in	O
adequate	O
and	O
well-controlled	O
studies	O
.	O
	
Approximately	O
10	O
%	O
of	O
patients	O
in	O
long-term	O
clinical	O
trials	O
developed	O
skin	B
discoloration	I
,	O
generally	O
after	O
2	O
or	O
more	O
years	O
of	O
treatment	O
and	O
at	O
higher	O
doses	O
(	O
900	O
mg	O
or	O
greater	O
)	O
of	O
POTIGA	O
.	O
	
The	O
risk	O
of	O
VTE	B
is	O
highest	O
during	O
the	O
first	O
year	O
of	O
use	O
.	O
	
Because	O
of	O
the	O
risks	O
of	O
corporal	B
rupture	I
or	O
other	O
serious	O
penile	B
injury	I
,	O
XIAFLEX	O
is	O
available	O
for	O
the	O
treatment	O
of	O
Peyronie	O
's	O
disease	O
only	O
through	O
a	O
restricted	O
program	O
under	O
a	O
Risk	O
Evaluation	O
and	O
Mitigation	O
Strategy	O
(	O
REMS	O
)	O
called	O
the	O
XIAFLEX	O
REMS	O
Program	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
5.5	O
Dizziness	O
and	O
Somnolence	O
POTIGA	O
causes	O
dose-related	O
increases	O
in	O
dizziness	B
and	O
somnolence	B
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
d	O
Includes	O
:	O
contusion	B
,	O
ecchymoses	B
,	O
penile	B
hemorrhage	I
,	O
and	O
injection	B
site	I
hemorrhage	I
.	O
	
The	O
median	O
duration	O
of	O
treatment	O
with	O
ZYTIGA	O
was	O
13.8	O
months	O
.	O
	
The	O
incidence	O
of	O
rash	B
was	O
higher	O
in	O
women	O
compared	O
to	O
men	O
in	O
the	O
INTELENCE	O
(	O
r	O
)	O
arm	O
in	O
the	O
Phase	O
3	O
trials	O
(	O
rash	B
>	O
=	O
Grade	O
2	O
was	O
reported	O
in	O
9/60	O
[	O
15.0	O
%	O
]	O
women	O
versus	O
51/539	O
[	O
9.5	O
%	O
]	O
men	O
;	O
discontinuations	O
due	O
to	O
rash	B
were	O
reported	O
in	O
3/60	O
[	O
5.0	O
%	O
]	O
women	O
versus	O
10/539	O
[	O
1.9	O
%	O
]	O
men	O
)	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Patients	O
can	O
have	O
more	O
than	O
one	O
site	O
of	O
bleeding	B
.	O
	
Skin	O
:	O
case	O
of	O
severe	O
skin	B
reactions	I
,	O
including	O
Stevens-Johnson	B
syndrome	I
,	O
toxic	B
epidermal	I
necrolysis	I
,	O
erythema	B
multiforme	I
,	O
and	O
new	O
or	O
worsening	O
psoriasis	B
)	O
have	O
been	O
identified	O
during	O
post-approval	O
use	O
of	O
TNF	O
blockers	O
.	O
	
After	O
resumption	O
of	O
treatment	O
at	O
a	O
lower	O
dose	O
,	O
26	O
%	O
of	O
patients	O
had	O
recurrence	B
of	I
ALT	I
and	I
AST	I
elevations	I
.	O
	
Based	O
on	O
patient	O
diaries	O
from	O
three	O
clinical	O
trials	O
evaluating	O
the	O
safety	O
and	O
efficacy	O
of	O
Natazia	O
for	O
contraception	O
,	O
10-23	O
%	O
of	O
women	O
experienced	O
intracyclic	B
bleeding	I
per	O
cycle	O
.	O
	
Withhold	O
YERVOY	O
dosing	O
for	O
moderate	O
enterocolitis	O
;	O
administer	O
anti-diarrheal	O
treatment	O
and	O
,	O
if	O
persistent	O
for	O
more	O
than	O
1	O
week	O
,	O
initiate	O
systemic	O
corticosteroids	O
at	O
a	O
dose	O
of	O
0.5	O
mg/kg/day	O
prednisone	O
or	O
equivalent	O
.	O
	
Severe	O
hypoglycemia	B
occurred	O
in	O
2.4	O
%	O
and	O
3.4	O
%	O
of	O
patients	O
when	O
TRULICITY	O
0.75	O
mg	O
and	O
1.5	O
mg	O
,	O
respectively	O
,	O
was	O
co-administered	O
with	O
prandial	O
insulin	O
.	O
	
Infections	O
The	O
incidence	O
of	O
infections	B
in	O
controlled	O
studies	O
in	O
Crohn	O
's	O
disease	O
was	O
38	O
%	O
for	O
CIMZIA-treated	O
patients	O
and	O
30	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
Do	O
not	O
administer	O
COMETRIQ	O
to	O
patients	O
with	O
a	O
recent	O
history	O
of	O
hemorrhage	O
or	O
hemoptysis	O
.	O
	
Pool	O
of	O
Placebo-	O
and	O
Active-Controlled	O
Trials	O
The	O
occurrence	O
of	O
adverse	O
reactions	O
was	O
also	O
evaluated	O
in	O
a	O
larger	O
pool	O
of	O
patients	O
with	O
type	O
2	O
diabetes	O
participating	O
in	O
6	O
placebo-	O
and	O
active-controlled	O
trials	O
evaluating	O
the	O
use	O
of	O
TRULICITY	O
as	O
monotherapy	O
and	O
add-on	O
therapy	O
to	O
oral	O
medications	O
or	O
insulin	O
.	O
	
Risk	O
of	O
Acute	B
Respiratory	I
Complications	I
:	O
Patients	O
with	O
acute	O
febrile	O
or	O
respiratory	O
illness	O
may	O
be	O
at	O
higher	O
risk	O
of	O
life-threatening	O
complications	O
from	O
hypersensitivity	B
reactions	I
.	O
	
Reduced	B
fetal	I
weights	I
were	O
observed	O
at	O
lower	O
exposures	O
.	O
	
The	O
incidence	O
of	O
antibody	O
formation	O
is	O
highly	O
dependent	O
on	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
assay	O
.	O
	
(	O
5.14	O
)	O
5.1	O
Increased	O
Mortality	O
in	O
Elderly	O
Patients	O
with	O
Dementia-Related	O
Psychosis	O
Elderly	O
patients	O
with	O
dementia-related	O
psychosis	O
treated	O
with	O
antipsychotic	O
drugs	O
are	O
at	O
an	O
increased	O
risk	O
of	O
death	B
.	O
	
Monitor	O
ALT	O
,	O
aspartate	O
aminotransferase	O
(	O
AST	O
)	O
and	O
bilirubin	O
before	O
initiation	O
of	O
and	O
periodically	O
throughout	O
treatment	O
with	O
INLYTA	O
.	O
	
In	O
studies	O
of	O
ACE	O
inhibitors	O
in	O
patients	O
with	O
unilateral	O
or	O
bilateral	O
renal	O
artery	O
stenosis	O
,	O
increases	B
in	I
serum	I
creatinine	I
have	O
been	O
reported	O
.	O
	
Amyvid	O
scan	O
results	O
are	O
indicative	O
of	O
the	O
brain	O
neuritic	O
amyloid	O
plaque	O
content	O
only	O
at	O
the	O
time	O
of	O
image	O
acquisition	O
and	O
a	O
negative	O
scan	O
result	O
does	O
not	O
preclude	O
the	O
development	O
of	O
brain	O
amyloid	O
in	O
the	O
future	O
.	O
	
*	O
Fat	B
Redistribution	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
The	O
majority	O
of	O
patients	O
were	O
able	O
to	O
be	O
rechallenged	O
with	O
alglucosidase	O
alfa	O
using	O
lower	O
doses	O
and/or	O
pretreatment	O
with	O
anti-inflammatory	O
drugs	O
and/or	O
corticosteroids	O
and	O
were	O
able	O
to	O
continue	O
treatment	O
under	O
close	O
clinical	O
supervision	O
.	O
	
Among	O
these	O
patients	O
,	O
63	O
%	O
had	O
a	O
history	O
of	O
hypertension	O
,	O
51	O
%	O
had	O
a	O
history	O
of	O
dyslipidemia	O
,	O
25	O
%	O
had	O
a	O
history	O
of	O
myocardial	O
infarction	O
,	O
8	O
%	O
had	O
a	O
history	O
of	O
unstable	O
angina	O
and	O
7	O
%	O
had	O
a	O
history	O
of	O
congestive	O
heart	O
failure	O
.	O
	
There	O
were	O
no	O
reports	O
of	O
prolactin	B
elevations	I
>	O
=4	O
times	O
ULN	O
(	O
at	O
Endpoint	O
)	O
for	O
patients	O
treated	O
with	O
SAPHRIS	O
or	O
placebo	O
.	O
	
The	O
population	O
was	O
45-77	O
years	O
of	O
age	O
,	O
63	O
%	O
male	O
,	O
100	O
%	O
white	O
,	O
and	O
were	O
treatment	O
naive	O
.	O
	
Grade	O
3	O
or	O
4	O
stomatitis	B
was	O
reported	O
in	O
4	O
%	O
-9	O
%	O
of	O
patients	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
,	O
6.2	O
,	O
6.3	O
,	O
6.4	O
,	O
6.5	O
)	O
]	O
.	O
	
S	O
On-treatment	O
analysis	O
based	O
on	O
the	O
safety	O
population	O
,	O
compared	O
to	O
ITT	O
analysis	O
presented	O
in	O
Section	O
14	O
.	O
	
The	O
mean	O
age	O
of	O
patients	O
treated	O
with	O
TANZEUM	O
was	O
55	O
years	O
,	O
1.5	O
%	O
of	O
the	O
population	O
in	O
these	O
studies	O
was	O
75	O
years	O
or	O
older	O
and	O
51	O
%	O
of	O
participants	O
were	O
male	O
.	O
	
The	O
incidence	O
of	O
urinary	B
tract	I
infections	I
in	O
male	O
patients	O
randomized	O
to	O
placebo	O
,	O
JARDIANCE	O
10	O
mg	O
,	O
and	O
JARDIANCE	O
25	O
mg	O
was	O
3.2	O
%	O
,	O
3.6	O
%	O
,	O
and	O
4.1	O
%	O
,	O
respectively	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
and	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.5	O
)	O
]	O
.	O
	
5.9	O
Hyperglycemia	O
Hyperglycemia	B
can	O
occur	O
when	O
TAFINLAR	O
is	O
administered	O
as	O
a	O
single	O
agent	O
or	O
when	O
used	O
in	O
combination	O
with	O
trametinib	O
.	O
	
Renal	O
function	O
of	O
patients	O
should	O
be	O
monitored	O
particularly	O
where	O
patients	O
have	O
additional	O
risk	O
factors	O
that	O
may	O
further	O
impair	O
renal	O
function	O
.	O
	
d	O
Includes	O
the	O
following	O
terms	O
:	O
abdominal	B
pain	I
,	O
abdominal	B
pain	I
upper	I
,	O
abdominal	B
pain	I
lower	I
,	O
and	O
abdominal	B
discomfort	I
.	O
	
During	O
clinical	O
trials	O
with	O
SAPHRIS	O
,	O
including	O
long-term	O
trials	O
without	O
comparison	O
to	O
placebo	O
,	O
the	O
incidence	O
of	O
adverse	O
reactions	O
suggestive	O
of	O
body	B
temperature	I
increases	I
(	O
pyrexia	B
and	O
feeling	B
hot	I
)	O
was	O
<	O
=1	O
%	O
.	O
	
These	O
patients	O
may	O
have	O
an	O
increased	O
risk	O
for	O
a	O
hypersensitivity	O
reaction	O
to	O
Gadavist	O
.	O
	
In	O
addition	O
,	O
mammography	O
examinations	O
should	O
be	O
scheduled	O
based	O
on	O
patient	O
age	O
,	O
risk	O
factors	O
,	O
and	O
prior	O
mammogram	O
results	O
.	O
	
When	O
vasodilators	O
are	O
taken	O
in	O
combination	O
,	O
blood-pressure-lowering	O
effects	O
of	O
each	O
individual	O
compound	O
may	O
be	O
increased	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Avoid	O
use	O
in	O
patients	O
with	O
known	O
QT	O
prolongation	O
,	O
those	O
with	O
hypokalemia	O
or	O
hypomagnesemia	O
,	O
and	O
those	O
taking	O
other	O
drugs	O
that	O
prolong	O
the	O
QT	O
interval	O
.	O
	
The	O
potential	O
risk	O
of	O
using	O
a	O
TNF	O
blocker	O
in	O
combination	O
with	O
azathioprine	O
or	O
6-MP	O
should	O
be	O
carefully	O
considered	O
.	O
	
Renal	O
and	O
Urinary	O
Disorders	O
:	O
tubulointerstitial	B
nephritis	I
.	O
	
The	O
concomitant	O
use	O
of	O
PRISTIQ	O
with	O
MAOIs	O
intended	O
to	O
treat	O
psychiatric	O
disorders	O
is	O
contraindicated	O
.	O
	
No	O
Grade	O
4	O
infusion-related	B
reactions	I
were	O
reported	O
.	O
	
Another	O
patient	O
developed	O
severe	O
inflammatory	B
arthropathy	I
in	O
association	O
with	O
pyrexia	B
and	O
elevated	B
erythrocyte	I
sedimentation	I
rate	I
.	O
	
Ventricular	B
arrhythmias	I
and	O
bradycardia	B
,	O
resulting	O
in	O
cardiac	B
arrest	I
or	O
death	B
,	O
or	O
requiring	O
cardiac	O
resuscitation	O
or	O
defibrillation	O
have	O
been	O
observed	O
in	O
infantile-onset	O
Pompe	O
disease	O
patients	O
with	O
cardiac	O
hypertrophy	O
during	O
general	O
anesthesia	O
for	O
central	O
venous	O
catheter	O
placement	O
.	O
	
Blood	O
and	O
lymphatic	O
system	O
disorders	O
:	O
Agranulocytosis	B
.	O
	
All	O
women	O
should	O
receive	O
yearly	O
breast	O
examinations	O
by	O
a	O
healthcare	O
provider	O
and	O
perform	O
monthly	O
breast	O
self-examinations	O
.	O
	
Whether	O
any	O
of	O
the	O
symptoms	O
described	O
above	O
represent	O
such	O
a	O
conversion	O
is	O
unknown	O
.	O
	
5.4	O
New	O
Onset	O
or	O
Worsening	O
Heart	O
Failure	O
worsening	B
of	I
heart	I
failure	I
has	O
been	O
reported	O
during	O
treatment	O
with	O
MULTAQ	O
in	O
the	O
postmarketing	O
setting	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reaction	O
occurring	O
in	O
approximately	O
25	O
%	O
of	O
patients	O
was	O
a	O
mild	O
taste	B
following	I
instillation	I
.	O
	
The	O
potential	O
role	O
of	O
TNF	O
blocker	O
therapy	O
in	O
the	O
development	O
of	O
malignancies	O
in	O
adults	O
is	O
not	O
known	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
the	O
incidence	O
of	O
antibodies	O
to	O
SIMPONI	O
ARIA	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
In	O
the	O
controlled	O
phase	O
of	O
Trial	O
1	O
,	O
through	O
Week	O
24	O
,	O
ALT	B
elevations	I
>	O
=	O
5	O
*	O
ULN	O
occurred	O
in	O
0.8	O
%	O
of	O
SIMPONI	O
ARIA-treated	O
patients	O
and	O
0	O
%	O
of	O
control-treated	O
patients	O
and	O
ALT	B
elevations	I
>	O
=	O
3	O
*	O
ULN	O
occurred	O
in	O
2.3	O
%	O
of	O
SIMPONI	O
ARIA-treated	O
patients	O
and	O
2.5	O
%	O
of	O
control-treated	O
patients	O
.	O
	
5.2	O
Cardiovascular	O
Death	O
and	O
Heart	O
Failure	O
in	O
Permanent	O
AF	O
MULTAQ	O
doubles	O
the	O
risk	O
of	O
cardiovascular	B
death	I
)	O
and	O
heart	B
failure	I
events	I
in	O
patients	O
with	O
permanent	O
AF	O
.	O
	
*	O
Administer	O
Gadavist	O
only	O
in	O
situations	O
where	O
trained	O
personnel	O
and	O
therapies	O
are	O
promptly	O
available	O
for	O
the	O
treatment	O
of	O
hypersensitivity	O
reactions	O
,	O
including	O
personnel	O
trained	O
in	O
resuscitation	O
.	O
	
*	O
Elevated	B
Blood	I
Pressure	I
:	O
Control	O
hypertension	O
before	O
initiating	O
treatment	O
.	O
	
Impairment	B
in	I
Renal	I
Function	I
Use	O
of	O
JARDIANCE	O
was	O
associated	O
with	O
increases	B
in	I
serum	I
creatinine	I
and	O
decreases	B
in	I
eGFR	I
(	O
see	O
Table	O
2	O
)	O
.	O
	
A	O
causal	O
relationship	O
of	O
ILARIS	O
to	O
these	O
events	O
can	O
not	O
be	O
excluded	O
.	O
	
Available	O
data	O
from	O
controlled	O
clinical	O
trials	O
suggest	O
that	O
LABA	O
increase	O
the	O
risk	O
of	O
asthma-related	O
hospitalization	O
in	O
pediatric	O
and	O
adolescent	O
patients	O
.	O
	
*	O
Monitor	O
for	O
worsening	O
and	O
emergence	O
of	O
suicidal	O
thoughts	O
and	O
behaviors	O
(	O
5.1	O
)	O
.	O
	
5.8	O
Fetal	O
Risk	O
Based	O
on	O
animal	O
studies	O
,	O
GILENYA	O
may	O
cause	O
fetal	B
harm	I
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
from	O
clinical	O
trials	O
and/or	O
post-marketing	O
surveillance	O
.	O
	
The	O
long-term	O
effects	O
of	O
antibodies	O
to	O
KALBITOR	O
are	O
not	O
known	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
1	O
%	O
)	O
with	O
VORAXAZE	O
are	O
paraesthesias	B
,	O
flushing	B
,	O
nausea	B
and/or	O
vomiting	B
,	O
hypotension	B
,	O
and	O
headache	B
.	O
	
A	O
routine	O
oral	O
exam	O
should	O
be	O
performed	O
by	O
the	O
prescriber	O
prior	O
to	O
initiation	O
of	O
Prolia	O
treatment	O
.	O
	
GILENYA	O
has	O
not	O
been	O
tested	O
in	O
MS	O
patients	O
with	O
diabetes	O
mellitus	O
.	O
	
In	O
this	O
pool	O
,	O
a	O
total	O
of	O
2,116	O
patients	O
with	O
type	O
2	O
diabetes	O
were	O
treated	O
with	O
TANZEUM	O
for	O
a	O
mean	O
duration	O
of	O
75	O
weeks	O
.	O
	
Severe	O
Hypertension	O
The	O
adverse	O
events	O
for	O
patients	O
with	O
severe	O
hypertension	O
are	O
based	O
on	O
an	O
uncontrolled	O
study	O
in	O
patients	O
with	O
severe	O
hypertension	O
(	O
VELOCITY	O
,	O
n=126	O
)	O
.	O
	
Obesity	O
and	O
prolonged	O
nucleoside	O
exposure	O
may	O
be	O
risk	O
factors	O
.	O
	
Once	O
asthma	O
control	O
is	O
achieved	O
and	O
maintained	O
,	O
assess	O
the	O
patient	O
at	O
regular	O
intervals	O
and	O
step	O
down	O
therapy	O
(	O
e.g.	O
,	O
discontinue	O
BREO	O
ELLIPTA	O
)	O
if	O
possible	O
without	O
loss	O
of	O
asthma	O
control	O
and	O
maintain	O
the	O
patient	O
on	O
a	O
long-term	O
asthma	O
control	O
medication	O
,	O
such	O
as	O
an	O
ICS	O
.	O
	
The	O
mean	O
duration	O
of	O
diabetes	O
was	O
seven	O
years	O
,	O
the	O
mean	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
was	O
31	O
kg/m	O
2	O
(	O
51	O
%	O
of	O
patients	O
had	O
a	O
BMI	O
>	O
=30	O
kg/m	O
2	O
)	O
,	O
and	O
the	O
mean	O
age	O
was	O
57	O
years	O
(	O
24	O
%	O
of	O
patients	O
>	O
=65	O
years	O
of	O
age	O
)	O
.	O
	
In	O
patients	O
with	O
confirmed	O
PML	O
,	O
consider	O
stopping	O
immunosuppressant	O
therapy	O
,	O
including	O
BENLYSTA	O
.	O
	
(	O
2.3,5.1	O
)	O
*	O
Bullous	O
and	O
Exfoliative	O
Skin	B
Disorders	I
:	I
Severe	I
bullous	I
,	I
blistering	I
,	I
and	I
exfoliating	I
lesions	I
occurred	O
in	O
0.15	O
%	O
of	O
patients	O
.	O
	
Following	O
resolution	O
of	O
transaminase	O
elevations	O
,	O
consider	O
the	O
benefits	O
and	O
risks	O
of	O
resuming	O
KALYDECO	O
dosing	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
and	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
12-Month	O
Trial	O
Long-term	O
safety	O
data	O
is	O
based	O
on	O
a	O
12-month	O
trial	O
that	O
evaluated	O
the	O
safety	O
of	O
BREO	O
ELLIPTA	O
100/25	O
once	O
daily	O
(	O
n	O
=	O
201	O
)	O
,	O
BREO	O
ELLIPTA	O
200/25	O
once	O
daily	O
(	O
n	O
=	O
202	O
)	O
,	O
and	O
fluticasone	O
propionate	O
500	O
mcg	O
twice	O
daily	O
(	O
n	O
=	O
100	O
)	O
in	O
adolescent	O
and	O
adult	O
subjects	O
with	O
asthma	O
(	O
Trial	O
4	O
)	O
.	O
	
*	O
Effects	O
on	O
serum	O
liver	O
biochemistries	O
in	O
patients	O
with	O
hepatitis	O
B	O
or	O
C	O
co-infection	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Less	O
Common	O
Adverse	O
Reactions	O
The	O
following	O
adverse	O
reactions	O
were	O
reported	O
less	O
frequently	O
(	O
<	O
5	O
%	O
)	O
.	O
	
The	O
infusion	O
rate	O
may	O
be	O
slowed	O
or	O
interrupted	O
if	O
the	O
patient	O
develops	O
an	O
infusion	O
reaction	O
.	O
	
(	O
5.3	O
)	O
*	O
Candida	B
albicans	I
infection	I
of	I
the	I
mouth	I
may	O
occur	O
.	O
	
Discontinuation	O
due	O
to	O
any	O
adverse	O
event	O
occurred	O
in	O
26	O
%	O
in	O
the	O
KRd	O
arm	O
versus	O
25	O
%	O
in	O
the	O
Rd	O
arm	O
.	O
	
The	O
dosage	O
of	O
POTIGA	O
should	O
be	O
reduced	O
over	O
a	O
period	O
of	O
at	O
least	O
3	O
weeks	O
,	O
unless	O
safety	O
concerns	O
require	O
abrupt	O
withdrawal	O
.	O
	
5.12	O
Hepatic	O
Impairment	O
The	O
systemic	O
exposure	O
to	O
axitinib	O
was	O
higher	O
in	O
subjects	O
with	O
moderate	O
hepatic	O
impairment	O
(	O
Child-Pugh	O
class	O
B	O
)	O
compared	O
to	O
subjects	O
with	O
normal	O
hepatic	O
function	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=10	O
%	O
)	O
observed	O
across	O
pre-marketing	O
clinical	O
trials	O
were	O
similar	O
in	O
type	O
and	O
frequency	O
as	O
those	O
observed	O
in	O
the	O
placebo-controlled	O
trial	O
(	O
see	O
Table1	O
)	O
.	O
	
Monitor	O
with	O
periodic	O
liver	O
testing	O
.	O
	
Anyone	O
considering	O
prescribing	O
POTIGA	O
or	O
any	O
other	O
AED	O
must	O
balance	O
this	O
risk	O
with	O
the	O
risk	O
of	O
untreated	O
illness	O
.	O
	
Baseline	O
Follow	O
Up	O
Renal	O
Function	O
Status	O
n	O
Normaln	O
(	O
%	O
)	O
Mildn	O
(	O
%	O
)	O
Mild	O
to	O
Moderaten	O
(	O
%	O
)	O
Moderate	O
to	O
Severen	O
(	O
%	O
)	O
Severen	O
(	O
%	O
)	O
Kidney	B
Failuren	O
(	O
%	O
)	O
Notes	O
:	O
Grading	O
is	O
based	O
on	O
Modification	O
in	O
Diet	O
in	O
Renal	O
Disease	O
method	O
(	O
MDRD	O
)	O
.KDIGO	O
Classification	O
by	O
eGFR	O
:	O
Normal	O
:	O
greater	O
than	O
or	O
equal	O
to	O
90	O
,	O
Mild	O
:	O
60	O
to	O
less	O
than	O
90	O
,	O
Mild	O
to	O
Moderate	O
:	O
45	O
to	O
less	O
than	O
60	O
,	O
Moderate	O
to	O
Severe	O
:	O
30	O
to	O
less	O
than	O
45	O
,	O
Severe	O
:	O
15	O
to	O
less	O
than	O
30	O
,	O
Kidney	O
Failure	O
:	O
less	O
than	O
15	O
ml/min/1.73	O
m	O
2	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Accredo	O
Health	O
Group	O
Inc.	O
at	O
1-888-454-8860	O
,	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Baseline	O
renal	O
function	O
was	O
normal	O
or	O
mildly	O
impaired	O
(	O
mean	O
eGFR	O
81	O
mL/min/1.73	O
m	O
2	O
)	O
.	O
	
Additionally	O
,	O
the	O
observed	O
incidence	O
of	O
a	O
positive	O
antibody	O
(	O
including	O
neutralizing	O
antibody	O
)	O
test	O
result	O
may	O
be	O
influenced	O
by	O
several	O
factors	O
,	O
including	O
assay	O
methodology	O
,	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
In	O
clinical	O
trials	O
with	O
Vimizim	O
,	O
44	O
of	O
235	O
(	O
18.7	O
%	O
)	O
patients	O
experienced	O
hypersensitivity	B
reactions	O
,	O
including	O
anaphylaxis	B
.	O
	
Symptoms	O
have	O
included	O
hypotension	B
,	O
dyspnea	B
,	O
throat	B
tightness	I
,	O
upper	B
airway	I
edema	I
,	O
pruritus	B
,	O
and	O
urticaria	B
.	O
	
Administration	O
of	O
TECFIDERA	O
with	O
food	O
may	O
reduce	O
the	O
incidence	O
of	O
flushing	B
.	O
	
[	O
See	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Reports	O
include	O
cases	O
of	O
pulmonary	B
TB	I
.	O
	
Patients	O
with	O
abnormal	O
coagulation	O
(	O
except	O
for	O
patients	O
taking	O
low-dose	O
aspirin	O
,	O
e.g.	O
,	O
up	O
to	O
150	O
mg	O
per	O
day	O
)	O
were	O
excluded	O
from	O
participating	O
in	O
these	O
studies	O
.	O
	
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
occurring	O
in	O
>	O
=20	O
%	O
of	O
patients	O
treated	O
with	O
the	O
recommended	O
dose	O
and	O
frequency	O
of	O
NULOJIX	O
were	O
anemia	B
,	O
diarrhea	B
,	O
urinary	B
tract	I
infection	I
,	O
peripheral	B
edema	I
,	O
constipation	B
,	O
hypertension	B
,	O
pyrexia	B
,	O
graft	B
dysfunction	I
,	O
cough	B
,	O
nausea	B
,	O
vomiting	B
,	O
headache	B
,	O
hypokalemia	B
,	O
hyperkalemia	B
,	O
and	O
leukopenia	B
.	O
	
*	O
POTIGA	O
can	O
cause	O
retinal	B
abnormalities	I
,	O
which	O
are	O
known	O
to	O
result	O
in	O
damage	B
to	I
the	I
photoreceptors	I
and	O
vision	B
loss	I
.	O
	
Do	O
not	O
use	O
BREO	O
ELLIPTA	O
for	O
patients	O
whose	O
asthma	O
is	O
adequately	O
controlled	O
on	O
low-	O
or	O
medium-dose	O
inhaled	O
corticosteroids	O
.	O
	
There	O
were	O
four	O
suicides	B
in	O
drug	O
treated	O
patients	O
in	O
the	O
trials	O
and	O
none	O
in	O
placebo	O
treated	O
patients	O
,	O
but	O
the	O
number	O
is	O
too	O
small	O
to	O
allow	O
any	O
conclusion	O
about	O
drug	O
effect	O
on	O
suicide	B
.	O
	
5.6	O
Carbohydrate	O
and	O
Lipid	O
Metabolic	O
Effects	O
Carefully	O
monitor	O
prediabetic	O
and	O
diabetic	O
women	O
who	O
are	O
taking	O
Natazia	O
.	O
	
In	O
the	O
lung	O
cancer	O
study	O
,	O
80	O
%	O
of	O
patients	O
were	O
male	O
,	O
the	O
median	O
age	O
was	O
58	O
years	O
,	O
and	O
95	O
%	O
of	O
patients	O
were	O
Caucasian	O
.	O
	
5.2	O
Infections	O
Serious	O
and	O
sometimes	O
fatal	B
infections	B
,	O
including	O
pneumonia	B
and	O
sepsis	B
,	O
have	O
occurred	O
with	O
Beleodaq	O
.	O
	
5.4	O
QT	O
Interval	O
Prolongation	O
QTc	B
interval	I
prolongation	I
,	O
which	O
may	O
lead	O
to	O
an	O
increased	O
risk	O
for	O
ventricular	B
tachyarrhythmias	I
(	O
e.g.	O
,	O
Torsade	B
de	I
pointes	I
)	O
or	O
sudden	B
death	I
,	O
occurred	O
in	O
patients	O
treated	O
with	O
ZYKADIA	O
in	O
clinical	O
trials	O
.	O
	
Steroid	O
hormones	O
may	O
be	O
poorly	O
metabolized	O
in	O
patients	O
with	O
impaired	O
liver	O
function	O
.	O
	
Monitor	O
liver	O
function	O
tests	O
(	O
hepatic	O
transaminase	O
and	O
bilirubin	O
levels	O
)	O
and	O
assess	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
before	O
each	O
dose	O
of	O
YERVOY	O
.	O
	
Monitor	O
blood	O
counts	O
at	O
least	O
every	O
two	O
weeks	O
for	O
the	O
first	O
3	O
months	O
of	O
therapy	O
,	O
and	O
at	O
least	O
weekly	O
in	O
patients	O
while	O
neutrophil	O
counts	O
are	O
less	O
than	O
1.0	O
Gi/L	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
Control	O
hypertension	O
and	O
correct	O
hypokalemia	O
before	O
and	O
during	O
treatment	O
with	O
ZYTIGA	O
.	O
	
(	O
5.8	O
)	O
5.1	O
Hepatotoxicity	O
Fatal	B
and/or	O
serious	O
hepatotoxicity	B
occurred	O
in	O
14	O
%	O
of	O
patients	O
treated	O
with	O
Zydelig	O
.	O
	
In	O
Study	O
RA-III	O
,	O
too	O
few	O
patients	O
developed	O
antibodies	O
to	O
allow	O
for	O
meaningful	O
analysis	O
of	O
ACR20	O
response	O
by	O
antibody	O
status	O
.	O
	
The	O
safety	O
of	O
two	O
concurrent	O
injections	O
of	O
XIAFLEX	O
0.58	O
mg	O
into	O
Dupuytren	O
's	O
cords	O
in	O
the	O
same	O
hand	O
was	O
evaluated	O
in	O
a	O
historically-controlled	O
,	O
open-label	O
multi-center	O
trial	O
in	O
715	O
adult	O
subjects	O
with	O
Dupuytren	O
's	O
contracture	O
(	O
Study	O
3	O
)	O
.	O
	
Consider	O
the	O
benefits	O
and	O
risks	O
before	O
neuraxial	O
intervention	O
in	O
patients	O
who	O
are	O
or	O
who	O
need	O
to	O
be	O
anticoagulated	O
(	O
5.3	O
)	O
.	O
	
If	O
retinal	O
pigmentary	O
abnormalities	O
or	O
vision	O
changes	O
are	O
detected	O
,	O
POTIGA	O
should	O
be	O
discontinued	O
unless	O
no	O
other	O
suitable	O
treatment	O
options	O
are	O
available	O
and	O
the	O
benefits	O
of	O
treatment	O
outweigh	O
the	O
potential	O
risk	O
of	O
vision	O
loss	O
.	O
	
In	O
this	O
study	O
,	O
159	O
patients	O
received	O
XEOMIN	O
(	O
78	O
were	O
randomized	O
to	O
receive	O
a	O
total	O
dose	O
of	O
120	O
Units	O
,	O
and	O
81	O
were	O
randomized	O
to	O
receive	O
a	O
total	O
dose	O
of	O
240	O
Units	O
)	O
.	O
	
Discontinuation	O
of	O
therapy	O
due	O
to	O
adverse	O
reactions	O
occurred	O
in	O
18	O
%	O
of	O
patients	O
treated	O
with	O
BLINCYTO	O
.	O
	
[	O
See	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
,	O
5.2	O
,	O
5.3	O
,	O
5.4	O
,	O
5.5	O
)	O
.	O
]	O
	
Discontinue	O
COMETRIQ	O
in	O
patients	O
who	O
experience	O
a	O
perforation	O
or	O
a	O
fistula	O
.	O
	
Approximately	O
86	O
%	O
of	O
the	O
population	O
studied	O
was	O
Caucasian	O
,	O
and	O
0.8	O
%	O
of	O
the	O
population	O
was	O
aged	O
65	O
years	O
or	O
older	O
.	O
	
Infections	B
were	O
more	O
frequently	O
reported	O
in	O
females	O
than	O
in	O
males	O
(	O
see	O
Table	O
1	O
)	O
.	O
	
5.5	O
Severe	O
and	O
Disabling	O
Arthralgia	O
There	O
have	O
been	O
postmarketing	O
reports	O
of	O
severe	O
and	O
disabling	O
arthralgia	B
in	O
patients	O
taking	O
DPP-4	O
inhibitors	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Same	O
Active	O
Ingredient	O
:	O
Patients	O
receiving	O
Prolia	O
should	O
not	O
receive	O
XGEVA	O
(	O
r	O
)	O
(	O
5.1	O
)	O
*	O
Hypersensitivity	B
including	O
anaphylactic	B
reactions	I
may	O
occur	O
.	O
	
5.3	O
Hypocalcemia	O
and	O
Mineral	O
Metabolism	O
Hypocalcemia	B
may	I
be	I
exacerbated	I
by	O
the	O
use	O
of	O
Prolia	O
.	O
	
In	O
premarketing	O
clinical	O
trials	O
,	O
18	O
of	O
235	O
(	O
7.7	O
%	O
)	O
patients	O
treated	O
with	O
Vimizim	O
experienced	O
signs	O
and	O
symptoms	O
consistent	O
with	O
anaphylaxis	B
.	O
	
It	O
is	O
important	O
to	O
exclude	O
cases	O
where	O
the	O
clinical	O
presentation	O
includes	O
both	O
serious	O
medical	O
illness	O
(	O
e.g	O
.	O
	
In	O
this	O
pool	O
,	O
INVOKANA	O
was	O
also	O
associated	O
with	O
the	O
adverse	O
reactions	O
of	O
fatigue	B
(	O
1.7	O
%	O
with	O
comparator	O
,	O
2.2	O
%	O
with	O
INVOKANA	O
100	O
mg	O
,	O
and	O
2.0	O
%	O
with	O
INVOKANA	O
300	O
mg	O
)	O
and	O
loss	B
of	I
strength	I
(	O
i.e.	O
,	O
asthenia	B
)	O
(	O
0.6	O
%	O
with	O
comparator	O
,	O
0.7	O
%	O
with	O
INVOKANA	O
100	O
mg	O
,	O
and	O
1.1	O
%	O
with	O
INVOKANA	O
300	O
mg	O
)	O
.	O
	
The	O
median	O
time	O
to	O
onset	O
of	O
increased	B
ALT	I
was	O
30	O
and	O
33	O
days	O
,	O
respectively	O
,	O
and	O
the	O
median	O
duration	O
for	O
each	O
was	O
21	O
days	O
.	O
	
5.6	O
Depression	O
In	O
the	O
controlled	O
clinical	O
trials	O
,	O
psychiatric	B
events	I
were	O
reported	O
more	O
frequently	O
with	O
BENLYSTA	O
(	O
16	O
%	O
)	O
than	O
with	O
placebo	O
(	O
12	O
%	O
)	O
,	O
related	O
primarily	O
to	O
depression-related	O
events	O
(	O
6.3	O
%	O
BENLYSTA	O
and	O
4.7	O
%	O
placebo	O
)	O
,	O
insomnia	B
(	O
6.0	O
%	O
BENLYSTA	O
and	O
5.3	O
%	O
placebo	O
)	O
,	O
and	O
anxiety	B
(	O
3.9	O
%	O
BENLYSTA	O
and	O
2.8	O
%	O
placebo	O
)	O
.	O
	
Management	O
of	O
cardiac	O
failure	O
may	O
require	O
permanent	O
discontinuation	O
of	O
INLYTA	O
.	O
	
Monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
pneumonia	O
.	O
	
Grade	O
3/4	O
venous	B
thromboembolic	I
events	I
were	O
reported	O
in	O
9/359	O
patients	O
(	O
3	O
%	O
)	O
receiving	O
INLYTA	O
(	O
including	O
pulmonary	B
embolism	I
,	O
deep	B
vein	I
thrombosis	I
,	O
retinal	B
vein	I
occlusion	I
and	O
retinal	B
vein	I
thrombosis	I
)	O
and	O
2/355	O
patients	O
(	O
1	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
The	O
increase	O
may	O
be	O
larger	O
when	O
coadministered	O
with	O
chlorthalidone	O
or	O
hydrochlorothiazide	O
.	O
	
XEOMIN	O
treated	O
subjects	O
were	O
24	O
to	O
74	O
years	O
old	O
,	O
and	O
were	O
predominantly	O
female	O
(	O
88	O
%	O
)	O
.	O
	
Withhold	O
GILOTRIF	O
for	O
acute	O
onset	O
or	O
worsening	O
of	O
pulmonary	O
symptoms	O
.	O
	
5.3	O
Gastrointestinal-Related	O
Adverse	O
Reactions	O
in	O
Opioid-Tolerant	O
Patients	O
Patients	O
recently	O
exposed	O
to	O
opioids	O
are	O
expected	O
to	O
be	O
more	O
sensitive	O
to	O
the	O
effects	O
of	O
mu-opioid	O
receptor	O
antagonists	O
,	O
such	O
as	O
ENTEREG	O
.	O
	
Asthma-related	O
hospitalizations	O
occurred	O
in	O
10	O
subjects	O
(	O
1	O
%	O
)	O
treated	O
with	O
BREO	O
ELLIPTA	O
100/25	O
compared	O
with	O
7	O
subjects	O
(	O
0.7	O
%	O
)	O
treated	O
with	O
fluticasone	O
furoate	O
100	O
mcg	O
.	O
	
Do	O
not	O
use	O
if	O
the	O
blister	O
package	O
has	O
been	O
open	O
for	O
more	O
than	O
60	O
days	O
.	O
	
The	O
reactions	O
listed	O
are	O
those	O
that	O
could	O
be	O
of	O
clinical	O
importance	O
,	O
as	O
well	O
as	O
reactions	O
that	O
are	O
plausibly	O
drug-related	O
on	O
pharmacologic	O
or	O
other	O
grounds	O
.	O
	
Over	O
the	O
course	O
of	O
a	O
typical	O
10-week	O
controlled	O
trial	O
,	O
the	O
rate	O
of	O
death	B
in	O
drug-treated	O
patients	O
was	O
about	O
4.5	O
%	O
,	O
compared	O
to	O
a	O
rate	O
of	O
about	O
2.6	O
%	O
in	O
the	O
placebo	O
group	O
.	O
	
The	O
types	O
of	O
adverse	O
events	O
that	O
led	O
to	O
discontinuation	O
were	O
similar	O
for	O
the	O
FANAPT-	O
and	O
placebo-treated	O
patients	O
.	O
	
Manifestations	O
included	O
hypotension	B
,	O
angioedema	B
,	O
urticaria	B
or	O
other	O
rash	B
,	O
pruritus	B
,	O
and	O
dyspnea	B
.	O
	
In	O
open	O
label	O
extension	O
trials	O
in	O
MS	O
patients	O
,	O
the	O
incidence	O
of	O
seizures	B
during	O
treatment	O
with	O
dalfampridine	O
15	O
mg	O
twice	O
daily	O
(	O
1.7/100PY	O
)	O
was	O
over	O
4	O
times	O
higher	O
than	O
the	O
incidence	O
during	O
treatment	O
with	O
10	O
mg	O
twice	O
daily	O
(	O
0.4/100PY	O
)	O
.	O
	
The	O
fatal	B
case	O
of	O
PML	B
was	O
reported	O
in	O
a	O
patient	O
receiving	O
higher	O
than	O
recommended	O
doses	O
of	O
NULOJIX	O
and	O
MMF	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
Major	O
327	O
(	O
2.13	O
)	O
462	O
(	O
3.09	O
)	O
0.69	O
(	O
0.60	O
,	O
0.80	O
)	O
<	O
0.0001	O
Intracranial	O
(	O
ICH	B
)	O
?	O
	
Beta-blocker	O
use	O
for	O
this	O
purpose	O
is	O
not	O
recommended	O
.	O
	
Increased	B
Urination	I
In	O
the	O
pool	O
of	O
five	O
placebo-controlled	O
clinical	O
trials	O
,	O
adverse	O
reactions	O
of	O
increased	B
urination	I
(	O
e.g.	O
,	O
polyuria	B
,	O
pollakiuria	B
,	O
and	O
nocturia	B
)	O
occurred	O
more	O
frequently	O
on	O
JARDIANCE	O
than	O
on	O
placebo	O
(	O
see	O
Table	O
1	O
)	O
.	O
	
Consider	O
discontinuing	O
Prolia	O
if	O
severe	O
symptoms	O
develop	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Clinical	B
Worsening/Suicide	O
Risk	B
:	O
Monitor	O
for	O
clinical	O
worsening	O
and	O
suicide	O
risk	O
(	O
5.1	O
)	O
.	O
	
Generally	O
,	O
the	O
observed	O
infections	B
responded	O
to	O
standard	O
therapy	O
.	O
	
5.12	O
Potential	O
for	O
Cognitive	O
and	O
Motor	O
Impairment	O
Somnolence	B
was	O
reported	O
in	O
patients	O
treated	O
with	O
SAPHRIS	O
.	O
	
Patients	O
experiencing	O
these	O
symptoms	O
should	O
be	O
advised	O
to	O
stop	O
taking	O
STENDRA	O
and	O
seek	O
prompt	O
medical	O
attention	O
.	O
	
Autoimmune	O
Disorders	O
and	O
Autoantibodies	O
The	O
use	O
of	O
TNF-blockers	O
,	O
of	O
which	O
SIMPONI	O
ARIA	O
is	O
a	O
member	O
,	O
has	O
been	O
associated	O
with	O
the	O
formation	B
of	I
autoantibodies	I
and	O
,	O
rarely	O
,	O
with	O
the	O
development	O
of	O
a	O
lupus-like	B
syndrome	I
.	O
	
(	O
5.2	O
)	O
*	O
QT	O
prolonging	O
drugs	O
,	O
including	O
quinine	O
and	O
quinidine	O
,	O
should	O
be	O
used	O
cautiously	O
following	O
Coartem	O
Tablets	O
.	O
	
5.4	O
Risk	O
of	O
Cardiac	O
Arrhythmia	O
and	O
Sudden	O
Cardiac	O
Death	O
During	O
General	O
Anesthesia	O
for	O
Central	O
Venous	O
Catheter	O
Placement	O
Administration	O
of	O
general	O
anesthesia	O
can	O
be	O
complicated	O
by	O
the	O
presence	O
of	O
severe	O
cardiac	O
and	O
skeletal	O
(	O
including	O
respiratory	O
)	O
muscle	O
weakness	O
.	O
	
(	O
4	O
,	O
5.1	O
)	O
In	O
patients	O
with	O
permanent	O
atrial	O
fibrillation	O
,	O
MULTAQ	O
doubles	O
the	O
risk	O
of	O
death	B
,	O
stroke	B
and	O
hospitalization	O
for	O
heart	B
failure	I
.	O
	
*	O
Bone	B
Effects	I
of	O
Tenofovir	O
DF	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
.	O
	
Some	O
of	O
these	O
reactions	O
occurred	O
after	O
the	O
first	O
administration	O
of	O
CIMZIA	O
.	O
	
These	O
patients	O
may	O
have	O
an	O
increased	O
risk	O
for	O
a	O
hypersensitivity	B
reaction	I
to	O
EOVIST	O
.	O
	
During	O
the	O
entire	O
course	O
of	O
treatment	O
,	O
the	O
proportion	O
of	O
subjects	O
who	O
discontinued	O
treatment	O
due	O
to	O
adverse	O
reactions	O
was	O
13	O
%	O
for	O
subjects	O
receiving	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
and	O
12	O
%	O
for	O
subjects	O
receiving	O
PegIntron/REBETOL	O
alone	O
.	O
	
At	O
Week	O
20	O
in	O
Trial	O
1	O
,	O
17	O
%	O
of	O
SIMPONI	O
ARIA-treated	O
patients	O
and	O
13	O
%	O
of	O
control	O
patients	O
were	O
newly	B
ANA-positive	I
(	O
at	O
titers	O
of	O
1:160	O
or	O
greater	O
)	O
.	O
	
In	O
patients	O
who	O
report	O
upper	O
abdominal	O
or	O
shoulder	O
pain	O
after	O
receiving	O
GRANIX	O
,	O
discontinue	O
GRANIX	O
and	O
evaluate	O
for	O
an	O
enlarged	O
spleen	O
or	O
splenic	O
rupture	O
.	O
	
Neutralizing	O
antibodies	O
were	O
detected	O
in	O
11	O
of	O
the	O
25	O
patients	O
who	O
tested	O
positive	O
for	O
anti-glucarpidase	O
binding	O
antibodies	O
.	O
	
DAMPA	O
(	O
4-deoxy-4-amino-N	O
10	O
-methylpteroic	O
acid	O
)	O
is	O
an	O
inactive	O
metabolite	O
of	O
methotrexate	O
resulting	O
from	O
treatment	O
with	O
VORAXAZE	O
.	O
	
In	O
addition	O
to	O
diarrhea	B
and	O
nausea	B
(	O
see	O
Table	O
1	O
)	O
,	O
the	O
following	O
gastrointestinal	B
adverse	I
reactions	I
also	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
TANZEUM	O
:	O
vomiting	B
(	O
2.6	O
%	O
versus	O
4.2	O
%	O
for	O
placebo	O
versus	O
TANZEUM	O
)	O
,	O
gastroesophageal	B
reflux	I
disease	I
(	O
1.9	O
%	O
versus	O
3.5	O
%	O
for	O
placebo	O
versus	O
TANZEUM	O
)	O
,	O
and	O
dyspepsia	B
(	O
2.8	O
%	O
versus	O
3.4	O
%	O
for	O
placebo	O
versus	O
TANZEUM	O
)	O
.	O
	
Signs	O
and	O
symptoms	O
have	O
included	O
respiratory	B
compromise	I
,	O
urticaria	B
,	O
and	O
angioedema	B
of	I
the	I
throat	I
.	O
	
In	O
Trial	O
2	O
,	O
the	O
incidence	O
of	O
basal	B
cell	I
carcinoma	I
was	O
increased	O
in	O
patients	O
receiving	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
:	O
9	O
%	O
(	O
5/55	O
)	O
of	O
patients	O
receiving	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
compared	O
with	O
2	O
%	O
(	O
1/53	O
)	O
of	O
patients	O
receiving	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
The	O
common	O
adverse	O
reactions	O
for	O
Cleviprex	O
in	O
severe	O
hypertension	O
included	O
headache	B
(	O
6.3	O
%	O
)	O
,	O
nausea	B
(	O
4.8	O
%	O
)	O
,	O
and	O
vomiting	B
(	O
3.2	O
%	O
)	O
.	O
	
If	O
a	O
patient	O
develops	O
symptoms	O
suggestive	O
of	O
a	O
lupus-like	O
syndrome	O
following	O
treatment	O
with	O
CIMZIA	O
,	O
discontinue	O
treatment	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Adequately	O
supplement	O
all	O
patients	O
with	O
calcium	O
and	O
vitamin	O
D	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
,	O
Contraindications	O
(	O
4.1	O
)	O
,	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
,	O
and	O
Patient	O
Counseling	O
Information	O
(	O
17.3	O
)	O
]	O
.	O
	
Demographic	O
Differences	O
in	O
Adverse	O
Reactions	O
in	O
Clinical	O
Trials	O
An	O
examination	O
of	O
population	O
subgroups	O
in	O
the	O
4	O
placebo-controlled	O
,	O
4-	O
or	O
6-week	O
,	O
fixed-	O
or	O
flexible-dose	O
studies	O
did	O
not	O
reveal	O
any	O
evidence	O
of	O
differences	O
in	O
safety	O
on	O
the	O
basis	O
of	O
age	O
,	O
gender	O
or	O
race	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
The	O
most	O
common	O
Grade	O
3/4	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
2	O
%	O
)	O
were	O
stomatitis	B
,	O
infections	B
,	O
hyperglycemia	B
,	O
fatigue	B
,	O
dyspnea	B
,	O
pneumonitis	B
,	O
and	O
diarrhea	B
.	O
	
Particular	O
caution	O
should	O
be	O
exercised	O
when	O
administering	O
nucleoside	O
analogs	O
to	O
any	O
patient	O
with	O
known	O
risk	O
factors	O
for	O
liver	O
disease	O
;	O
however	O
,	O
cases	O
have	O
also	O
been	O
reported	O
in	O
patients	O
with	O
no	O
known	O
risk	O
factors	O
.	O
	
Permanently	O
discontinue	O
YERVOY	O
for	O
clinically	O
significant	O
or	O
severe	O
immune-mediated	O
adverse	O
reactions	O
.	O
	
*	O
Take	O
DUAVEE	O
exactly	O
as	O
your	O
healthcare	O
provider	O
tells	O
you	O
to	O
take	O
it	O
.	O
	
In	O
addition	O
,	O
one	O
case	O
of	O
hyperparathyroidism	B
has	O
been	O
reported	O
.	O
	
Further	O
information	O
is	O
available	O
at	O
www.ENTEREGREMS.com	O
or	O
1-800-278-0340	O
.	O
	
Extreme	O
care	O
should	O
be	O
exercised	O
,	O
with	O
appropriate	O
resuscitation	O
measures	O
available	O
,	O
if	O
the	O
decision	O
is	O
made	O
to	O
re-administer	O
the	O
product	O
[	O
seeAdverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
(	O
5.2	O
)	O
*	O
Do	O
not	O
use	O
in	O
combination	O
with	O
an	O
additional	O
medicine	O
containing	O
a	O
LABA	O
because	O
of	O
risk	O
of	O
overdose	O
.	O
	
The	O
most	O
common	O
serious	O
adverse	O
events	O
reported	O
in	O
the	O
KRd	O
arm	O
as	O
compared	O
with	O
the	O
Rd	O
arm	O
were	O
pneumonia	B
(	O
14	O
%	O
versus	O
11	O
%	O
)	O
,	O
respiratory	B
tract	I
infection	I
(	O
4	O
%	O
versus	O
1.5	O
%	O
)	O
,	O
pyrexia	B
(	O
4	O
%	O
versus	O
2	O
%	O
)	O
,	O
and	O
pulmonary	B
embolism	I
(	O
3	O
%	O
versus	O
2	O
%	O
)	O
.	O
	
Glabellar	O
Lines	O
In	O
placebo-controlled	O
clinical	O
trials	O
of	O
DYSPORT	O
(	O
r	O
)	O
,	O
the	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=2	O
%	O
)	O
following	O
injection	O
of	O
DYSPORT	O
(	O
r	O
)	O
were	O
nasopharyngitis	B
,	O
headache	B
,	O
injection	B
site	I
pain	I
,	O
injection	B
site	I
reaction	I
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
eyelid	B
edema	I
,	O
eyelid	B
ptosis	I
,	O
sinusitis	B
,	O
and	O
nausea	B
.	O
	
See	O
Table	O
6	O
for	O
steps	O
to	O
prevent	O
or	O
manage	O
these	O
possible	O
and	O
known	O
significant	O
drug	O
interactions	O
,	O
including	O
dosing	O
recommendations	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.5	O
)	O
]	O
.	O
	
(	O
5.2	O
)	O
*	O
Neuroleptic	B
Malignant	I
Syndrome	I
:	O
Manage	O
with	O
immediate	O
discontinuation	O
and	O
close	O
monitoring	O
.	O
	
Of	O
these	O
reports	O
,	O
1	O
patient	O
in	O
the	O
placebo	O
group	O
and	O
all	O
8	O
patients	O
in	O
the	O
Prolia	O
group	O
had	O
serious	O
events	O
,	O
including	O
one	O
death	B
in	O
the	O
Prolia	O
group	O
.	O
	
Pool	O
of	O
Placebo-Controlled	O
Trials	O
evaluating	O
JARDIANCE	O
10	O
and	O
25	O
mg	O
The	O
data	O
in	O
Table	O
1	O
are	O
derived	O
from	O
a	O
pool	O
of	O
four	O
24-week	O
placebo-controlled	O
trials	O
and	O
18-week	O
data	O
from	O
a	O
placebo-controlled	O
trial	O
with	O
insulin	O
.	O
	
[	O
see	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
5.7	O
Withdrawal	O
of	O
AEDs	O
As	O
with	O
all	O
antiepileptic	O
drugs	O
,	O
APTIOM	O
should	O
be	O
withdrawn	O
gradually	O
because	O
of	O
the	O
risk	O
of	O
increased	O
seizure	O
frequency	O
and	O
status	O
epilepticus	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
antibodies	O
to	O
denosumab	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
The	O
time	O
to	O
onset	O
of	O
symptoms	O
following	O
initiation	O
of	O
drug	O
therapy	O
varied	O
from	O
one	O
day	O
to	O
years	O
.	O
	
The	O
most	O
common	O
non-hematologic	O
Grade	O
3	O
or	O
4	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
)	O
were	O
fatigue	B
(	O
11	O
%	O
)	O
,	O
febrile	B
neutropenia	I
(	O
6	O
%	O
)	O
,	O
and	O
pneumonia	B
,	O
hypokalemia	B
and	O
dehydration	B
,	O
each	O
reported	O
in	O
5	O
%	O
of	O
patients	O
.	O
	
The	O
majority	O
of	O
cases	O
occurred	O
in	O
countries	O
with	O
high	O
endemic	O
rates	O
of	O
TB	B
.	O
	
5.2	O
Hemorrhage	O
Serious	O
and	O
sometimes	O
fatal	B
hemorrhage	B
occurred	O
with	O
COMETRIQ	O
.	O
	
Long-standing	B
hyperprolactinemia	I
when	O
associated	O
with	O
hypogonadism	B
may	O
lead	O
to	O
decreased	B
bone	I
density	I
in	O
both	O
female	O
and	O
male	O
patients	O
.	O
	
Cervical	O
Dystonia	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
a	O
single	O
intramuscular	O
dose	O
of	O
XEOMIN	O
in	O
a	O
placebo-controlled	O
,	O
Phase	O
3	O
trial	O
in	O
patients	O
with	O
cervical	O
dystonia	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Hypotension	B
:	O
Before	O
initiating	O
FARXIGA	O
,	O
assess	O
volume	O
status	O
and	O
correct	O
hypovolemia	O
in	O
the	O
elderly	O
,	O
in	O
patients	O
with	O
renal	O
impairment	O
or	O
low	O
systolic	O
blood	O
pressure	O
,	O
and	O
in	O
patients	O
on	O
diuretics	O
.	O
	
Approximately	O
70	O
%	O
of	O
patients	O
were	O
male	O
;	O
67	O
%	O
were	O
white	O
,	O
11	O
%	O
were	O
black	O
,	O
and	O
22	O
%	O
other	O
races	O
.	O
	
5.12	O
Embryo-fetal	O
Toxicity	O
COMETRIQ	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
Chloasma	B
may	O
occasionally	O
occur	O
,	O
especially	O
in	O
women	O
with	O
a	O
history	O
of	O
chloasma	O
gravidarum	O
.	O
	
Patients	O
in	O
the	O
treatment	O
studies	O
who	O
rolled	O
over	O
into	O
the	O
RE-SONATE	O
study	O
had	O
combined	O
treatment	O
duration	O
up	O
to	O
9	O
months	O
,	O
with	O
mean	O
exposure	O
of	O
165	O
days	O
.	O
	
5.8	O
Embryo-fetal	O
Toxicity	O
Based	O
on	O
findings	O
in	O
animals	O
,	O
Zydelig	O
may	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
Long-term	B
cumulative	I
radiation	I
exposure	I
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
cancer	B
.	O
	
Common	O
Adverse	O
Reactions	O
Clinical	O
ADRs	O
of	O
moderate	O
intensity	O
or	O
greater	O
(	O
greater	O
than	O
or	O
equal	O
to	O
Grade	O
2	O
)	O
and	O
reported	O
in	O
at	O
least	O
2	O
%	O
of	O
subjects	O
treated	O
with	O
INTELENCE	O
(	O
r	O
)	O
and	O
occurring	O
at	O
a	O
higher	O
rate	O
compared	O
to	O
placebo	O
(	O
excess	O
of	O
1	O
%	O
)	O
are	O
presented	O
in	O
Table	O
1	O
.	O
	
To	O
reduce	O
this	O
risk	O
,	O
consider	O
coverage	O
with	O
another	O
anticoagulant	O
if	O
PRADAXA	O
is	O
discontinued	O
for	O
a	O
reason	O
other	O
than	O
pathological	O
bleeding	O
or	O
completion	O
of	O
a	O
course	O
of	O
therapy	O
(	O
2.4	O
,	O
2.5	O
,	O
2.6	O
,	O
5.1	O
)	O
.	O
	
5.4	O
Local	O
Effects	O
of	O
Inhaled	O
Corticosteroids	O
In	O
clinical	O
trials	O
,	O
the	O
development	O
of	O
localized	O
infections	B
of	I
the	I
mouth	I
and	I
pharynx	I
with	I
Candida	I
albicans	I
has	O
occurred	O
in	O
subjects	O
treated	O
with	O
BREO	O
ELLIPTA	O
.	O
	
Endometrial	O
biopsies	O
performed	O
in	O
a	O
subset	O
of	O
subjects	O
in	O
a	O
Phase	O
3	O
Natazia	O
clinical	O
trial	O
did	O
not	O
reveal	O
any	O
unexpected	O
or	O
concerning	O
findings	O
for	O
subjects	O
taking	O
COCs	O
.	O
	
The	O
majority	O
of	O
the	O
1,222	O
patients	O
were	O
women	O
(	O
82	O
%	O
)	O
with	O
a	O
median	O
age	O
of	O
58	O
years	O
(	O
range	O
:	O
26	O
to	O
91	O
years	O
)	O
.	O
	
In	O
clinical	O
trials	O
,	O
somnolence	B
or	O
sedation	B
was	O
reported	O
at	O
all	O
effective	O
doses	O
and	O
was	O
dose-related	O
.	O
	
Women	O
of	O
childbearing	O
potential	O
should	O
be	O
advised	O
to	O
avoid	O
pregnancy	O
while	O
receiving	O
Beleodaq	O
.	O
	
Discontinue	O
COMETRIQ	O
in	O
patients	O
who	O
develop	O
an	O
acute	O
myocardial	O
infarction	O
or	O
any	O
other	O
clinically	O
significant	O
arterial	O
thromboembolic	O
complication	O
.	O
	
Therefore	O
NULOJIX	O
is	O
recommended	O
for	O
use	O
only	O
in	O
patients	O
who	O
are	O
EBV	O
seropositive	O
[	O
see	O
Boxed	O
Warning	O
and	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
Increase	O
in	O
Low-Density	O
Lipoprotein	O
Cholesterol	O
In	O
the	O
pool	O
of	O
13	O
placebo-controlled	O
studies	O
,	O
changes	B
from	I
baseline	I
in	I
mean	I
lipid	I
values	I
were	O
reported	O
in	O
FARXIGA-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients	O
.	O
	
Serious	O
infections	B
included	O
tuberculosis	B
,	O
pneumonia	B
,	O
cellulitis	B
,	O
and	O
pyelonephritis	B
.	O
	
Hemodialysis	O
can	O
remove	O
dabigatran	O
;	O
however	O
the	O
clinical	O
experience	O
supporting	O
the	O
use	O
of	O
hemodialysis	O
as	O
a	O
treatment	O
for	O
bleeding	O
is	O
limited	O
[	O
see	O
Overdosage	O
(	O
10	O
)	O
]	O
.	O
	
(	O
5.3	O
)	O
*	O
Genital	B
mycotic	I
infections	I
:	O
Monitor	O
and	O
treat	O
if	O
indicated	O
.	O
	
Blepharospasm	O
:	O
The	O
most	O
commonly	O
observed	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
of	O
patients	O
and	O
>	O
placebo	O
)	O
are	O
eyelid	B
ptosis	I
,	O
dry	B
eye	I
,	O
dry	B
mouth	I
,	O
diarrhea	B
,	O
headache	B
,	O
visual	B
impairment	I
,	O
dyspnea	B
,	O
nasopharyngitis	B
,	O
and	O
respiratory	B
tract	I
infection	I
(	O
6.1	O
)	O
.	O
	
Pre-treatment	O
with	O
antihistamines	O
with	O
or	O
without	O
antipyretics	O
is	O
recommended	O
prior	O
to	O
the	O
start	O
of	O
infusion	O
(	O
5.1	O
)	O
.	O
	
Grade	O
3	O
or	O
4	O
increased	B
bilirubin	I
occurred	O
in	O
3	O
%	O
of	O
patients	O
.	O
	
Patients	O
,	O
their	O
caregivers	O
,	O
and	O
families	O
should	O
be	O
informed	O
that	O
AEDs	O
increase	O
the	O
risk	O
of	O
suicidal	O
thoughts	O
and	O
behavior	O
and	O
should	O
be	O
advised	O
of	O
the	O
need	O
to	O
be	O
alert	O
for	O
the	O
emergence	O
or	O
worsening	O
of	O
the	O
signs	O
and	O
symptoms	O
of	O
depression	O
;	O
any	O
unusual	O
changes	O
in	O
mood	O
or	O
behavior	O
;	O
or	O
the	O
emergence	O
of	O
suicidal	O
thoughts	O
,	O
behavior	O
,	O
or	O
thoughts	O
about	O
self-harm	O
.	O
	
No	O
evidence	O
of	O
altered	O
pharmacokinetic	O
profile	O
,	O
toxicity	B
profile	O
,	O
or	O
clinical	O
response	O
was	O
associated	O
with	O
binding	O
antibody	O
development	O
.	O
	
Anaphylaxis	B
and	O
hypersensitivity	B
reactions	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
SAPHRIS	O
is	O
not	O
approved	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
dementia-related	O
psychosis	O
[	O
see	O
alsoBoxed	O
Warningand	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Similar	O
events	O
have	O
been	O
reported	O
with	O
GILENYA	O
0.5	O
mg	O
in	O
the	O
postmarketing	O
setting	O
although	O
a	O
causal	O
relationship	O
has	O
not	O
been	O
established	O
.	O
	
EPS-related	B
events	I
include	O
:	O
bradykinesia	B
,	O
dyskinesia	B
,	O
dystonia	B
,	O
oromandibular	B
dystonia	I
,	O
muscle	B
contractions	I
involuntary	I
,	O
muscle	B
twitching	I
,	O
musculoskeletal	B
stiffness	I
,	O
parkinsonism	B
,	O
protrusion	B
tongue	I
,	O
resting	B
tremor	I
,	O
and	O
tremor	B
.	O
	
The	O
most	O
common	O
adverse	O
reaction	O
leading	O
to	O
treatment	O
discontinuation	O
was	O
seizure	B
,	O
which	O
occurred	O
in	O
0.9	O
%	O
of	O
the	O
XTANDI-treated	O
patients	O
compared	O
to	O
none	O
(	O
0	O
%	O
)	O
of	O
the	O
placebo-treated	O
patients	O
.	O
	
Eosinophilia	B
is	O
often	O
present	O
.	O
	
These	O
adverse	O
events	O
were	O
related	O
to	O
cardiac	B
disorders	I
in	O
10	O
(	O
2	O
%	O
)	O
patients	O
,	O
infections	B
in	O
8	O
(	O
1	O
%	O
)	O
patients	O
,	O
renal	B
disorders	I
in	O
4	O
(	O
<	O
1	O
%	O
)	O
patients	O
,	O
and	O
other	O
adverse	O
events	O
in	O
8	O
(	O
1	O
%	O
)	O
patients	O
.	O
	
*	O
Administer	O
DOTAREM	O
only	O
in	O
situations	O
where	O
trained	O
personnel	O
and	O
therapies	O
are	O
promptly	O
available	O
for	O
the	O
treatment	O
of	O
hypersensitivity	O
reactions	O
,	O
including	O
personnel	O
trained	O
in	O
resuscitation	O
.	O
	
Because	O
of	O
its	O
mechanism	O
of	O
action	O
,	O
BENLYSTA	O
may	O
interfere	O
with	O
the	O
response	O
to	O
immunizations	O
.	O
	
Because	O
these	O
reactions	O
were	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
*	O
Psoriatic	O
Arthritis	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
)	O
are	O
diarrhea	B
,	O
nausea	B
,	O
and	O
headache	B
(	O
6.1	O
)	O
*	O
Psoriasis	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
)	O
are	O
diarrhea	B
,	O
nausea	B
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
and	O
headache	B
,	O
including	O
tension	B
headache	I
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Celgene	O
Corporation	O
at	O
1-888-423-5436	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trial	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
Of	O
these	O
discontinuations	O
,	O
8	O
in	O
the	O
STRIBILD	O
group	O
and	O
1	O
in	O
the	O
ATV	O
+	O
RTV	O
+	O
TRUVADA	O
group	O
occurred	O
during	O
the	O
first	O
48	O
weeks	O
.	O
	
Monitor	O
patients	O
for	O
clinical	O
signs	O
and	O
symptoms	O
of	O
hypophysitis	O
,	O
adrenal	O
insufficiency	O
(	O
including	O
adrenal	O
crisis	O
)	O
,	O
and	O
hyper-	O
or	O
hypothyroidism	O
.	O
	
6.3	O
Postmarketing	O
Experience	O
In	O
addition	O
to	O
adverse	O
reactions	O
reported	O
from	O
clinical	O
trials	O
,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
postapproval	O
use	O
of	O
BREO	O
ELLIPTA	O
.	O
	
The	O
safety	O
and	O
effectiveness	O
of	O
HORIZANT	O
in	O
patients	O
with	O
epilepsy	O
have	O
not	O
been	O
studied	O
.	O
	
(	O
5.3	O
)	O
*	O
For	O
48	O
hours	O
after	O
VORAXAZE	O
administration	O
,	O
determine	O
the	O
leucovorin	O
dose	O
based	O
on	O
the	O
patient	O
's	O
pre-VORAXAZE	O
methotrexate	O
concentration	O
.	O
	
Permanently	O
discontinue	O
TAFINLAR	O
for	O
RAS	O
mutation-positive	O
non-cutaneous	O
malignancies	O
.	O
	
Figure	O
1	O
:	O
Major	O
Bleeding	B
Hazard	O
Ratios	O
by	O
Baseline	O
Characteristics	O
-	O
ARISTOTLE	O
Study	O
Note	O
:	O
The	O
figure	O
above	O
presents	O
effects	O
in	O
various	O
subgroups	O
,	O
all	O
of	O
which	O
are	O
baseline	O
characteristics	O
and	O
all	O
of	O
which	O
were	O
pre-specified	O
,	O
if	O
not	O
the	O
groupings	O
.	O
	
Corticosteroid	O
utilization	O
should	O
be	O
consistent	O
with	O
the	O
NULOJIX	O
clinical	O
trial	O
experience	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
and	O
Clinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
For	O
patients	O
requiring	O
invasive	O
dental	O
procedures	O
,	O
clinical	O
judgment	O
of	O
the	O
treating	O
physician	O
and/or	O
oral	O
surgeon	O
should	O
guide	O
the	O
management	O
plan	O
of	O
each	O
patient	O
based	O
on	O
individual	O
benefit-risk	O
assessment	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
Adverse	O
reactions	O
have	O
been	O
identified	O
during	O
postapproval	O
use	O
of	O
ULORIC	O
.	O
	
Almost	O
all	O
of	O
these	O
patients	O
had	O
received	O
treatment	O
with	O
the	O
immunosuppressants	O
azathioprine	O
and/or	O
6-mercaptopurine	O
(	O
6-MP	O
)	O
concomitantly	O
with	O
a	O
TNF	O
blocker	O
at	O
or	O
prior	O
to	O
diagnosis	O
.	O
	
5.6	O
Alpha-Blockers	O
and	O
Other	O
Antihypertensives	O
Physicians	O
should	O
discuss	O
with	O
patients	O
the	O
potential	O
for	O
STENDRA	O
to	O
augment	O
the	O
blood	O
pressure-lowering	O
effect	O
of	O
alpha-blockers	O
and	O
other	O
antihypertensive	O
medications	O
[	O
seeDrug	O
Interactions	O
(	O
7.1	O
)	O
andClinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
Table	O
6	O
presents	O
the	O
most	O
common	O
adverse	O
drug	O
reactions	O
(	O
experienced	O
by	O
greater	O
than	O
or	O
equal	O
to	O
3	O
%	O
of	O
pediatric	O
patients	O
6	O
years	O
and	O
older	O
receiving	O
PROMACTA	O
)	O
across	O
the	O
two	O
placebo-controlled	O
trials	O
,	O
with	O
a	O
higher	O
incidence	O
for	O
PROMACTA	O
versus	O
placebo	O
.	O
	
Across	O
clinical	O
trials	O
of	O
TAFINLAR	O
(	O
N	O
=	O
586	O
)	O
,	O
the	O
incidence	O
of	O
cuSCC	B
was	O
11	O
%	O
.	O
	
5.8	O
Combination	O
with	O
Other	O
PDE5	O
Inhibitors	O
or	O
Erectile	O
Dysfunction	O
Therapies	O
The	O
safety	O
and	O
efficacy	O
of	O
combinations	O
of	O
STENDRA	O
with	O
other	O
treatments	O
for	O
ED	O
has	O
not	O
been	O
studied	O
.	O
	
In	O
short-term	O
,	O
placebo-controlled	O
bipolar	O
mania	O
adult	O
trials	O
of	O
therapeutic	O
doses	O
(	O
5-10	O
mg	O
twice	O
daily	O
)	O
,	O
somnolence	B
was	O
reported	O
in	O
24	O
%	O
(	O
90/379	O
)	O
of	O
patients	O
on	O
SAPHRIS	O
compared	O
to	O
6	O
%	O
(	O
13/203	O
)	O
of	O
placebo	O
patients	O
.	O
	
Such	O
an	O
event	O
may	O
be	O
a	O
sign	O
of	O
non-arteritic	B
anterior	I
ischemic	I
optic	I
neuropathy	I
(	O
NAION	B
)	O
,	O
a	O
rare	O
condition	O
and	O
a	O
cause	O
of	O
decreased	B
vision	I
including	O
permanent	B
loss	I
of	I
vision	I
that	O
has	O
been	O
reported	O
rarely	O
postmarketing	O
in	O
temporal	O
association	O
with	O
the	O
use	O
of	O
all	O
PDE5	O
inhibitors	O
.	O
	
In	O
the	O
WHI	O
estrogen-alone	O
substudy	O
,	O
after	O
an	O
average	O
follow-up	O
of	O
7.1	O
years	O
,	O
daily	O
conjugated	O
estrogen	O
(	O
0.625	O
mg	O
)	O
-alone	O
was	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
invasive	B
breast	I
cancer	I
(	O
relative	O
risk	O
[	O
RR	O
]	O
0.80	O
)	O
.	O
	
5.13	O
Body	O
Temperature	O
Regulation	O
Disruption	B
of	I
the	I
body	I
's	I
ability	I
to	I
reduce	I
core	I
body	I
temperature	I
has	O
been	O
attributed	O
to	O
antipsychotic	O
agents	O
.	O
	
MULTAQ	O
is	O
contraindicated	O
in	O
patients	O
in	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
who	O
will	O
not	O
or	O
can	O
not	O
be	O
cardioverted	O
into	O
normal	O
sinus	O
rhythm	O
.	O
	
ULORIC	O
should	O
not	O
be	O
restarted	O
in	O
these	O
patients	O
without	O
another	O
explanation	O
for	O
the	O
liver	O
test	O
abnormalities	O
.	O
	
If	O
peginterferon	O
alfa	O
is	O
permanently	O
discontinued	O
,	O
then	O
ribavirin	O
and	O
VICTRELIS	O
must	O
also	O
be	O
discontinued	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
No	O
adverse	O
reactions	O
representing	O
hemolytic	B
anemia	I
were	O
reported	O
in	O
any	O
treatment	O
group	O
.	O
	
The	O
median	O
time	O
to	O
first	O
cuSCC	B
was	O
9	O
weeks	O
(	O
range	O
:	O
1	O
to	O
53	O
weeks	O
)	O
.	O
	
Pediatric	O
Patients	O
:	O
The	O
data	O
described	O
below	O
reflect	O
median	O
exposure	O
to	O
PROMACTA	O
of	O
91	O
days	O
for	O
82	O
pediatric	O
patients	O
(	O
aged	O
6	O
to	O
17	O
years	O
)	O
with	O
chronic	O
ITP	O
,	O
of	O
whom	O
52	O
%	O
were	O
female	O
,	O
across	O
the	O
randomized	O
phase	O
of	O
two	O
placebo-controlled	O
trials	O
.	O
	
In	O
these	O
patients	O
,	O
renal	O
biopsy	O
was	O
consistent	O
with	O
immune	B
complex	I
deposition	I
.	O
	
(	O
5.6	O
)	O
5.1	O
Need	O
for	O
Aseptic	O
Technique	O
Use	O
aseptic	O
technique	O
and	O
discard	O
any	O
unused	O
product	O
within	O
12	O
hours	O
of	O
stopper	O
puncture	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
5.8	O
Immunizations	O
The	O
use	O
of	O
live	O
vaccines	O
should	O
be	O
avoided	O
during	O
treatment	O
with	O
NULOJIX	O
,	O
including	O
but	O
not	O
limited	O
to	O
the	O
following	O
:	O
intranasal	O
influenza	O
,	O
measles	O
,	O
mumps	O
,	O
rubella	O
,	O
oral	O
polio	O
,	O
BCG	O
,	O
yellow	O
fever	O
,	O
varicella	O
,	O
and	O
TY21a	O
typhoid	O
vaccines	O
.	O
	
In	O
Trial	O
2	O
,	O
the	O
incidence	O
of	O
Grade	O
3	O
hyperglycemia	B
based	O
on	O
laboratory	O
values	O
was	O
5	O
%	O
(	O
3/55	O
)	O
in	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
compared	O
with	O
2	O
%	O
(	O
1/53	O
)	O
in	O
patients	O
treated	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
[	O
see	O
Contraindications	O
(	O
4	O
)	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
,	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
EXCERPT	O
:	O
WARNING	O
:	O
ANAPHYLAXIS	B
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Anaphylaxis	B
has	O
been	O
reported	O
after	O
administration	O
of	O
KALBITOR	O
(	O
r	O
)	O
.	O
	
Monitor	O
patients	O
receiving	O
the	O
combination	O
closely	O
for	O
signs	O
or	O
symptoms	O
of	O
non-cutaneous	O
malignancies	O
.	O
	
In	O
the	O
randomized	O
,	O
placebo-controlled	O
portion	O
of	O
SJIA	O
Study	O
2	O
,	O
high	B
ALT	I
greater	O
than	O
or	O
equal	O
to	O
3	O
times	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
were	O
reported	O
in	O
2	O
(	O
4.1	O
%	O
)	O
ILARIS-treated	O
patients	O
and	O
1	O
(	O
2.0	O
%	O
)	O
placebo	O
patient	O
.	O
	
For	O
advanced	O
HR+	O
BC	O
,	O
advanced	O
PNET	O
,	O
advanced	O
RCC	O
,	O
and	O
renal	O
angiomyolipoma	O
with	O
TSC	O
patients	O
with	O
severe	O
hepatic	B
impairment	I
(	O
Child-Pugh	O
class	O
C	O
)	O
,	O
AFINITOR	O
may	O
be	O
used	O
at	O
a	O
reduced	O
dose	O
if	O
the	O
desired	O
benefit	O
outweighs	O
the	O
risk	O
.	O
	
[	O
See	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
.	O
]	O
	
ILARIS	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
a	O
positive	O
tuberculosis	O
screen	O
,	O
and	O
the	O
safety	O
of	O
ILARIS	O
in	O
individuals	O
with	O
latent	O
tuberculosis	O
infection	O
is	O
unknown	O
.	O
	
In	O
Study	O
1	O
,	O
all	O
patients	O
were	O
evaluated	O
for	O
LVEF	O
at	O
screening	O
and	O
every	O
9	O
weeks	O
thereafter	O
in	O
the	O
GILOTRIF-treated	O
group	O
and	O
as	O
needed	O
in	O
the	O
pemetrexed/cisplatin	O
group	O
.	O
	
*	O
Eye	O
disorders	O
:	O
infrequent	O
:	O
diplopia	B
,	O
vision	B
blurred	I
*	O
Gastrointestinal	O
disorders	O
:	O
infrequent	O
:	O
gastroesophageal	B
reflux	I
disease	I
*	O
Injury	O
,	O
Poisoning	O
,	O
and	O
Procedural	O
Complications	O
:	O
infrequent	O
:	O
fall	B
*	O
Skin	O
and	O
subcutaneous	O
tissue	O
disorders	O
:	O
infrequent	O
:	O
photosensitivity	B
reaction	I
*	O
Renal	O
and	O
urinary	O
disorders	O
:	O
infrequent	O
:	O
enuresis	B
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post-approval	O
use	O
of	O
SAPHRIS	O
.	O
	
Physicians	O
should	O
exercise	O
caution	O
when	O
considering	O
the	O
use	O
of	O
BENLYSTA	O
in	O
patients	O
with	O
chronic	O
infections	O
.	O
	
*	O
Increased	O
incidence	O
of	O
myocardial	B
infarction	I
was	O
seen	O
in	O
a	O
clinical	O
trial	O
of	O
patients	O
taking	O
alvimopan	O
for	O
long-term	O
use	O
.	O
	
(	O
5.8	O
)	O
5.1	O
Lactic	O
Acidosis/Severe	O
Hepatomegaly	O
with	O
Steatosis	O
Lactic	B
acidosis	I
and	O
severe	O
hepatomegaly	B
with	O
steatosis	B
,	O
including	O
fatal	B
cases	O
,	O
have	O
been	O
reported	O
with	O
the	O
use	O
of	O
nucleoside	O
analogs	O
,	O
including	O
tenofovir	O
DF	O
,	O
a	O
component	O
of	O
STRIBILD	O
,	O
in	O
combination	O
with	O
other	O
antiretrovirals	O
.	O
	
The	O
most	O
frequent	O
adverse	O
reactions	O
,	O
reported	O
in	O
at	O
least	O
10	O
%	O
of	O
patients	O
,	O
that	O
led	O
to	O
dose	O
reductions	O
or	O
interruptions	O
were	O
:	O
increased	B
ALT	I
(	O
29	O
%	O
)	O
,	O
nausea	B
(	O
20	O
%	O
)	O
,	O
increased	B
AST	I
(	O
16	O
%	O
)	O
,	O
diarrhea	B
(	O
16	O
%	O
)	O
,	O
and	O
vomiting	B
(	O
16	O
%	O
)	O
.	O
	
5.8	O
Concomitant	O
Use	O
with	O
Other	O
Biologic	O
Therapies	O
or	O
Intravenous	O
Cyclophosphamide	O
BENLYSTA	O
has	O
not	O
been	O
studied	O
in	O
combination	O
with	O
other	O
biologic	O
therapies	O
,	O
including	O
B-cell	O
targeted	O
therapies	O
,	O
or	O
intravenous	O
cyclophosphamide	O
.	O
	
(	O
5.7	O
)	O
*	O
Women	O
of	O
childbearing	O
potential	O
should	O
use	O
effective	O
contraception	O
during	O
and	O
for	O
2	O
months	O
after	O
stopping	O
GILENYA	O
.	O
	
Lymphomas	O
Cases	O
of	O
lymphoma	B
have	O
occurred	O
in	O
premarketing	O
clinical	O
trials	O
and	O
in	O
the	O
postmarketing	O
setting	O
.	O
	
Deaths	B
due	O
to	O
adverse	O
events	O
within	O
30	O
days	O
of	O
the	O
last	O
dose	O
of	O
Kyprolis	O
occurred	O
in	O
30/598	O
(	O
5	O
%	O
)	O
patients	O
receiving	O
Kyprolis	O
monotherapy	O
.	O
	
*	O
Immune	B
Reconstitution	I
Syndrome	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
Immune-mediated	B
enterocolitis	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Among	O
these	O
patients	O
,	O
2	O
patients	O
discontinued	O
INVOKANA	O
.	O
	
5.3	O
Neuroleptic	O
Malignant	O
Syndrome	O
A	O
potentially	O
fatal	B
symptom	O
complex	O
sometimes	O
referred	O
to	O
as	O
Neuroleptic	B
Malignant	I
Syndrome	I
(	O
NMS	B
)	O
has	O
been	O
reported	O
in	O
association	O
with	O
administration	O
of	O
antipsychotic	O
drugs	O
,	O
including	O
SAPHRIS	O
.	O
	
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
described	O
below	O
and	O
elsewhere	O
in	O
the	O
labeling	O
:	O
.	O
	
None	O
of	O
the	O
patients	O
tested	O
positive	O
for	O
neutralizing	O
antibodies	O
,	O
as	O
was	O
assessed	O
using	O
a	O
chemiluminescent	O
cell-based	O
in	O
vitro	O
biological	O
assay	O
.	O
	
No	O
data	O
are	O
available	O
on	O
the	O
response	O
to	O
live	O
vaccinations	O
or	O
the	O
secondary	O
transmission	O
of	O
infection	O
by	O
live	O
vaccines	O
in	O
patients	O
receiving	O
CIMZIA	O
.	O
	
Table	O
2	O
identifies	O
the	O
shift	O
from	O
baseline	O
to	O
lowest	O
observed	O
estimated	O
glomerular	O
filtration	O
rate	O
(	O
eGFR	O
)	O
during	O
BOSULIF	O
therapy	O
for	O
patients	O
in	O
the	O
global	O
Ph+	O
Leukemia	O
studies	O
.	O
	
(	O
5.11	O
)	O
*	O
Potential	O
for	O
Motor	B
Impairment	I
:	O
Use	O
caution	O
when	O
operating	O
machinery	O
.	O
	
Consider	O
DPP-4	O
inhibitors	O
as	O
a	O
possible	O
cause	O
for	O
severe	O
joint	O
pain	O
and	O
discontinue	O
drug	O
if	O
appropriate	O
.	O
	
.	O
	
In	O
addition	O
,	O
the	O
following	O
clinical	O
trials	O
have	O
also	O
been	O
conducted	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12	O
)	O
and	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
:	O
*	O
An	O
8-week	O
crossover	O
design	O
trial	O
(	O
Trial	O
4	O
)	O
involving	O
39	O
patients	O
between	O
the	O
ages	O
of	O
6	O
and	O
57	O
years	O
with	O
a	O
G1244E	O
,	O
G1349D	O
,	O
G178R	O
,	O
G551S	O
,	O
G970R	O
,	O
S1251N	O
,	O
S1255P	O
,	O
S549N	O
,	O
or	O
S549R	O
mutation	O
in	O
the	O
CFTR	O
gene	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
leading	O
to	O
discontinuation	O
in	O
NULOJIX-treated	O
patients	O
were	O
cytomegalovirus	B
infection	I
(	O
1.5	O
%	O
)	O
and	O
complications	B
of	I
transplanted	I
kidney	I
(	O
1.5	O
%	O
)	O
.	O
	
Glabellar	O
Lines	O
:	O
The	O
most	O
commonly	O
observed	O
adverse	O
reaction	O
(	O
>	O
1	O
%	O
of	O
patients	O
and	O
>	O
placebo	O
)	O
is	O
headache	B
(	O
6.1	O
)	O
.	O
	
It	O
is	O
not	O
possible	O
to	O
determine	O
whether	O
POTIGA	O
caused	O
this	O
decreased	B
visual	I
acuity	I
.	O
	
Some	O
patients	O
with	O
retinal	B
abnormalities	I
have	O
been	O
found	O
to	O
have	O
abnormal	B
visual	I
acuity	I
.	O
	
Patients	O
should	O
be	O
cautioned	O
about	O
operating	O
hazardous	O
machinery	O
,	O
including	O
automobiles	O
,	O
until	O
they	O
are	O
reasonably	O
certain	O
that	O
therapy	O
with	O
FANAPT	O
does	O
not	O
affect	O
them	O
adversely	O
.	O
	
(	O
5.7	O
)	O
5.1	O
Hypotension	O
FARXIGA	O
causes	O
intravascular	B
volume	I
contraction	I
.	O
	
Table	O
2	O
:	O
Summary	O
of	O
PTLD	B
Reported	O
in	O
Studies	O
1	O
,	O
2	O
,	O
and	O
3	O
Through	O
Three	O
Years	O
of	O
Treatment	O
NULOJIX	O
Non-Recommended	O
Regimen*	O
(	O
N=477	O
)	O
NULOJIX	O
Recommended	O
Regimen	O
(	O
N=472	O
)	O
Cyclosporine	O
(	O
N=476	O
)	O
Trial	O
EBV	O
Positive	O
(	O
n=406	O
)	O
EBV	O
Negative	O
(	O
n=43	O
)	O
EBV	O
Unknown	O
(	O
n=28	O
)	O
EBV	O
Positive	O
(	O
n=404	O
)	O
EBV	O
Negative	O
(	O
n=48	O
)	O
EBV	O
Unknown	O
(	O
n=20	O
)	O
EBV	O
Positive	O
(	O
n=399	O
)	O
EBV	O
Negative	O
(	O
n=57	O
)	O
EBV	O
Unknown	O
(	O
n=20	O
)	O
*	O
Regimen	O
with	O
higher	O
cumulative	O
dose	O
and	O
more	O
frequent	O
dosing	O
than	O
the	O
recommended	O
NULOJIX	O
regimen	O
.	O
	
Adverse	O
reactions	O
for	O
FIRAZYR	O
were	O
similar	O
in	O
nature	O
and	O
frequency	O
to	O
those	O
reported	O
in	O
Table	O
1	O
.	O
	
In	O
clinical	O
trials	O
,	O
HALAVEN	O
has	O
been	O
administered	O
to	O
1,222	O
patients	O
with	O
multiple	O
tumor	O
types	O
,	O
including	O
240	O
patients	O
exposed	O
to	O
HALAVEN	O
for	O
6	O
months	O
or	O
longer	O
.	O
	
Obtain	O
a	O
complete	O
blood	O
cell	O
(	O
CBC	O
)	O
count	O
,	O
including	O
a	O
white	O
blood	O
cell	O
(	O
WBC	O
)	O
count	O
corrected	O
for	O
the	O
presence	O
of	O
nucleated	O
red	O
blood	O
cells	O
,	O
an	O
absolute	O
neutrophil	O
count	O
(	O
ANC	O
)	O
,	O
and	O
a	O
platelet	O
count	O
daily	O
until	O
recovery	O
(	O
ANC	O
>	O
=	O
1.5	O
x	O
10	O
9	O
/L	O
)	O
.	O
	
When	O
beginning	O
treatment	O
with	O
BREO	O
ELLIPTA	O
,	O
patients	O
who	O
have	O
been	O
taking	O
oral	O
or	O
inhaled	O
,	O
short-acting	O
beta2-agonists	O
on	O
a	O
regular	O
basis	O
(	O
e.g.	O
,	O
4	O
times	O
a	O
day	O
)	O
should	O
be	O
instructed	O
to	O
discontinue	O
the	O
regular	O
use	O
of	O
these	O
drugs	O
and	O
to	O
use	O
them	O
only	O
for	O
symptomatic	O
relief	O
of	O
acute	O
respiratory	O
symptoms	O
.	O
	
5.4	O
Intestinal	O
Perforation	O
Fatal	B
and	O
serious	O
intestinal	B
perforation	I
occurred	O
in	O
Zydelig-treated	O
patients	O
.	O
	
(	O
5.2	O
)	O
*	O
Fatal	B
and	O
serious	O
pneumonitis	B
can	O
occur	O
in	O
Zydelig-treated	O
patients	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
other	O
clinical	O
trials	O
of	O
the	O
same	O
or	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
5.3	O
Risks	O
for	O
Benzyl	O
Alcohol	O
Toxicity	O
in	O
Infants	O
AdreView	O
contains	O
benzyl	O
alcohol	O
at	O
a	O
concentration	O
of	O
10.3	O
mg/mL	O
.	O
	
In	O
Study	O
1	O
,	O
sinus	B
bradycardia	I
,	O
defined	O
as	O
a	O
heart	B
rate	I
of	I
less	I
than	I
50	I
beats	I
per	I
minute	I
,	O
was	O
noted	O
as	O
a	O
new	O
finding	O
in	O
1	O
%	O
of	O
255	O
patients	O
.	O
	
(	O
5.6	O
)	O
5.1	O
Hypersensitivity	O
Reactions	O
Hypersensitivity	B
reactions	I
have	O
been	O
reported	O
following	O
AdreView	O
administration	O
.	O
	
Adverse	O
Reactions	O
Occurring	O
in	O
>	O
=5.0	O
%	O
of	O
Subjects	O
Who	O
Received	O
Two	O
Concurrent	O
Injections	O
of	O
XIAFLEX	O
in	O
Study	O
3	O
Adverse	O
Reaction	O
XIAFLEXN=715	O
Subjects	O
with	O
>	O
=1	O
adverse	O
reaction	O
95	O
%	O
Edema	B
peripheral	I
77	O
%	O
Contusion	B
59	O
%	O
Pain	B
in	I
extremity	I
51	O
%	O
Laceration	B
22	O
%	O
Pruritus	B
15	O
%	O
Injection	B
site	I
pain	I
14	O
%	O
Lymphadenopathy	B
13	O
%	O
Blood	B
blister	I
12	O
%	O
Injection	B
site	I
hematoma	I
8	O
%	O
Axillary	B
pain	I
7	O
%	O
Injection	B
site	I
hemorrhage	I
6	O
%	O
Injection	B
site	I
swelling	I
5	O
%	O
Ecchymosis	B
5	O
%	O
Safety	O
of	O
Retreatment	O
of	O
Recurrent	O
Contractures	O
An	O
observational	O
,	O
open	O
label	O
study	O
was	O
conducted	O
in	O
subjects	O
who	O
had	O
participated	O
in	O
XIAFLEX	O
clinical	O
trials	O
for	O
Dupuytren	O
's	O
contracture	O
(	O
Study	O
4	O
)	O
.	O
	
*	O
In	O
other	O
XIAFLEX-treated	O
patients	O
(	O
9	O
of	O
1044	O
;	O
0.9	O
%	O
)	O
,	O
a	O
combination	O
of	O
penile	B
ecchymoses	I
,	O
sudden	O
penile	B
detumescence	I
,	O
and/or	O
a	O
penile	B
``	O
popping	B
''	O
sound	B
was	O
reported	O
,	O
and	O
in	O
these	O
cases	O
,	O
a	O
diagnosis	O
of	O
corporal	B
rupture	I
can	O
not	O
be	O
excluded	O
.	O
	
When	O
possible	O
,	O
avoid	O
use	O
of	O
ZYKADIA	O
in	O
patients	O
with	O
congenital	O
long	O
QT	O
syndrome	O
.	O
	
(	O
2.2	O
,	O
5.3	O
)	O
*	O
Tumor	B
lysis	I
syndrome	I
:	O
Monitor	O
patients	O
with	O
advanced	O
stage	O
disease	O
and/or	O
high	O
tumor	O
burden	O
and	O
take	O
appropriate	O
precautions	O
.	O
	
At	O
baseline	O
,	O
the	O
population	O
had	O
diabetes	O
for	O
an	O
average	O
of	O
8.2	O
years	O
and	O
had	O
a	O
mean	O
HbA1c	O
of	O
7.6-8.5	O
%	O
.	O
	
Serious	O
infections	B
observed	O
included	O
viral	B
infections	I
,	O
pneumonia	B
,	O
and	O
pyelonephritis	B
.	O
	
If	O
anaphylaxis	O
or	O
severe	O
hypersensitivity	O
reactions	O
occur	O
,	O
immediately	O
stop	O
the	O
infusion	O
and	O
initiate	O
appropriate	O
medical	O
treatment	O
.	O
	
The	O
percentage	O
of	O
patients	O
who	O
withdrew	O
from	O
the	O
study	O
due	O
to	O
adverse	O
events	O
was	O
0	O
%	O
and	O
2.5	O
%	O
for	O
the	O
placebo	O
and	O
Prolia	O
groups	O
,	O
respectively	O
.	O
	
Similar	O
proportions	O
of	O
patients	O
developed	O
protective	O
levels	O
of	O
anti-vaccine	O
antibodies	O
between	O
CIMZIA	O
and	O
placebo	O
treatment	O
groups	O
;	O
however	O
patients	O
receiving	O
CIMZIA	O
and	O
concomitant	O
methotrexate	O
had	O
a	O
lower	O
humoral	O
response	O
compared	O
with	O
patients	O
receiving	O
CIMZIA	O
alone	O
.	O
	
In	O
these	O
trials	O
,	O
which	O
had	O
a	O
median	O
treatment	O
duration	O
of	O
12	O
weeks	O
,	O
the	O
estimated	O
incidence	O
of	O
suicidal	B
behavior	I
among	O
27,863	O
AED-treated	O
patients	O
was	O
0.43	O
%	O
compared	O
with	O
0.24	O
%	O
among	O
16,029	O
placebo-treated	O
patients	O
,	O
representing	O
an	O
increase	O
of	O
approximately	O
1	O
case	O
of	O
suicidal	B
thinking	I
for	O
every	O
530	O
patients	O
treated	O
.	O
	
JARDIANCE	O
was	O
used	O
as	O
monotherapy	O
in	O
one	O
trial	O
and	O
as	O
add-on	O
therapy	O
in	O
four	O
trials	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
In	O
clinical	O
studies	O
,	O
treatment	O
with	O
INVOKANA	O
was	O
associated	O
with	O
a	O
dose-dependent	O
increase	O
in	O
the	O
incidence	O
of	O
volume	B
depletion-related	I
adverse	I
reactions	I
(	O
e.g.	O
,	O
hypotension	B
,	O
postural	B
dizziness	I
,	O
orthostatic	B
hypotension	I
,	O
syncope	B
,	O
and	O
dehydration	B
)	O
.	O
	
Grade	O
3/4	O
hemorrhagic	B
events	I
were	O
reported	O
in	O
5/359	O
(	O
1	O
%	O
)	O
patients	O
receiving	O
INLYTA	O
(	O
including	O
cerebral	B
hemorrhage	I
,	O
hematuria	B
,	O
hemoptysis	B
,	O
lower	B
gastrointestinal	I
hemorrhage	I
,	O
and	O
melena	B
)	O
and	O
11/355	O
(	O
3	O
%	O
)	O
patients	O
receiving	O
sorafenib	O
.	O
	
Moderate	O
endocrinopathy	B
(	O
requiring	O
hormone	O
replacement	O
or	O
medical	O
intervention	O
;	O
Grade	O
2	O
)	O
occurred	O
in	O
12	O
(	O
2.3	O
%	O
)	O
patients	O
and	O
consisted	O
of	O
hypothyroidism	B
,	O
adrenal	B
insufficiency	I
,	O
hypopituitarism	B
,	O
and	O
1	O
case	O
each	O
of	O
hyperthyroidism	B
and	O
Cushing	B
's	I
syndrome	I
.	O
	
(	O
6.5	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Novartis	O
Pharmaceuticals	O
Corporation	O
at	O
1-888-669-6682	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Initiate	O
systemic	O
corticosteroids	O
at	O
a	O
dose	O
of	O
1	O
to	O
2	O
mg/kg/day	O
prednisone	O
or	O
equivalent	O
for	O
severe	O
immune-mediated	O
adverse	O
reactions	O
.	O
	
Reactions	O
are	O
further	O
categorized	O
by	O
MedDRA	O
system	O
organ	O
class	O
and	O
listed	O
in	O
order	O
of	O
decreasing	O
frequency	O
according	O
to	O
the	O
following	O
definitions	O
:	O
those	O
occurring	O
in	O
at	O
least	O
1/100	O
patients	O
(	O
frequent	O
)	O
(	O
only	O
those	O
not	O
already	O
listed	O
in	O
the	O
tabulated	O
results	O
from	O
placebo-controlled	O
trials	O
appear	O
in	O
this	O
listing	O
)	O
;	O
those	O
occurring	O
in	O
1/100	O
to	O
1/1000	O
patients	O
(	O
infrequent	O
)	O
;	O
and	O
those	O
occurring	O
in	O
fewer	O
than	O
1/1000	O
patients	O
(	O
rare	O
)	O
.	O
	
Thrombotic	B
events	I
included	O
five	O
patients	O
with	O
pulmonary	B
embolus	I
in	O
the	O
everolimus	O
arm	O
and	O
one	O
in	O
the	O
placebo	O
arm	O
as	O
well	O
as	O
three	O
patients	O
with	O
thrombosis	B
in	O
the	O
everolimus	O
arm	O
and	O
two	O
in	O
the	O
placebo	O
arm	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Angioedema	B
of	I
the	I
face	I
has	O
been	O
reported	O
with	O
fesoterodine	O
.	O
	
Consider	O
interrupting	O
therapy	O
with	O
BENLYSTA	O
in	O
patients	O
who	O
develop	O
a	O
new	O
infection	O
while	O
undergoing	O
treatment	O
with	O
BENLYSTA	O
and	O
monitor	O
these	O
patients	O
closely	O
.	O
	
Advise	O
families	O
and	O
caregivers	O
of	O
the	O
need	O
for	O
close	O
observation	O
and	O
communication	O
with	O
the	O
prescriber	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
The	O
mean	O
age	O
was	O
63	O
years	O
,	O
80	O
%	O
were	O
male	O
and	O
20	O
%	O
were	O
female	O
,	O
and	O
100	O
%	O
were	O
white	O
.	O
	
All	O
had	O
grade	O
4	O
neutropenia	B
and	O
one	O
had	O
febrile	B
neutropenia	I
.	O
	
Discontinuation	O
of	O
Prolia	O
therapy	O
should	O
be	O
considered	O
based	O
on	O
individual	O
benefit-risk	O
assessment	O
.	O
	
Careful	O
monitoring	O
and	O
appropriate	O
dose	O
adjustments	O
for	O
adverse	O
reactions	O
are	O
recommended	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
,	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.5	O
)	O
]	O
.	O
	
The	O
evaluation	O
of	O
adverse	O
reactions	O
in	O
patients	O
treated	O
with	O
VORAXAZE	O
is	O
confounded	O
by	O
the	O
population	O
in	O
which	O
it	O
was	O
studied	O
,	O
patients	O
with	O
toxic	O
plasma	O
methotrexate	O
levels	O
due	O
to	O
impaired	O
renal	O
function	O
.	O
	
Total	B
bilirubin	I
greater	I
than	I
or	I
equal	I
to	I
1.5	I
x	I
ULN	I
was	O
reported	O
in	O
76	O
%	O
and	O
50	O
%	O
of	O
patients	O
receiving	O
PROMACTA	O
and	O
placebo	O
,	O
respectively	O
.	O
	
Appropriate	O
medical	O
support	O
and	O
monitoring	O
measures	O
should	O
be	O
readily	O
available	O
during	O
alglucosidase	O
alfa	O
infusion	O
,	O
and	O
some	O
patients	O
may	O
require	O
prolonged	O
observation	O
times	O
that	O
should	O
be	O
individualized	O
based	O
on	O
the	O
needs	O
of	O
the	O
patient	O
.	O
	
Interstitial	B
infiltration	I
and/or	I
inflammation	I
were	I
observed	I
on	I
radiographs	I
and	I
computed	I
tomographic	I
imaging	I
of	I
the	I
chest	I
.	O
	
There	O
may	O
be	O
circumstances	O
when	O
it	O
is	O
necessary	O
to	O
initiate	O
treatment	O
with	O
a	O
MAOI	O
such	O
as	O
linezolid	O
or	O
intravenous	O
methylene	O
blue	O
in	O
a	O
patient	O
taking	O
PRISTIQ	O
.	O
	
Serious	O
adverse	O
events	O
were	O
reported	O
in	O
11	O
%	O
of	O
subjects	O
receiving	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
and	O
in	O
8	O
%	O
of	O
subjects	O
receiving	O
PegIntron/REBETOL	O
.	O
	
Because	O
IL-1	O
blockade	O
may	O
interfere	O
with	O
immune	O
response	O
to	O
infections	O
,	O
it	O
is	O
recommended	O
that	O
prior	O
to	O
initiation	O
of	O
therapy	O
with	O
ILARIS	O
,	O
adult	O
and	O
pediatric	O
patients	O
receive	O
all	O
recommended	O
vaccinations	O
,	O
as	O
appropriate	O
,	O
including	O
pneumococcal	O
vaccine	O
and	O
inactivated	O
influenza	O
vaccine	O
.	O
	
Somnolence	B
led	O
to	O
discontinuation	O
in	O
0	O
%	O
,	O
3	O
%	O
,	O
1	O
%	O
,	O
and	O
2	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
,	O
and	O
SAPHRIS	O
2.5	O
mg	O
twice	O
daily	O
,	O
5	O
mg	O
twice	O
daily	O
,	O
and	O
10	O
mg	O
twice	O
daily	O
,	O
respectively	O
.	O
	
Gastrointestinal	O
Disorders	O
:	O
Stomatitis	B
,	O
pancreatitis	B
.	O
	
Because	O
these	O
events	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
Patients	O
typically	O
reported	O
cough	B
and	O
dyspnea	B
.	O
	
Patients	O
improved	O
following	O
treatment	O
interruption	O
.	O
	
Major	O
45	O
(	O
1.41	O
)	O
29	O
(	O
0.92	O
)	O
1.54	O
(	O
0.96	O
,	O
2.45	O
)	O
0.07	O
Fatal	B
5	O
(	O
0.16	O
)	O
5	O
(	O
0.16	O
)	O
0.99	O
(	O
0.23	O
,	O
4.29	O
)	O
-	O
Intracranial	O
11	O
(	O
0.34	O
)	O
11	O
(	O
0.35	O
)	O
0.99	O
(	O
0.39	O
,	O
2.51	O
)	O
-	O
ARISTOTLE	O
Major	O
Bleeding	B
Forest	O
Plot	O
Other	O
Adverse	O
Reactions	O
Hypersensitivity	B
reactions	I
(	O
including	O
drug	B
hypersensitivity	I
,	O
such	O
as	O
skin	B
rash	I
,	O
and	O
anaphylactic	B
reactions	I
,	O
such	O
as	O
allergic	B
edema	I
)	O
and	O
syncope	B
were	O
reported	O
in	O
<	O
1	O
%	O
of	O
patients	O
receiving	O
ELIQUIS	O
.	O
	
Neutralizing	O
antibodies	O
to	O
ecallantide	O
were	O
determined	O
in	O
vitro	O
to	O
be	O
present	O
in	O
8.8	O
%	O
of	O
patients	O
and	O
were	O
not	O
associated	O
with	O
loss	O
of	O
efficacy	O
.	O
	
Adverse	O
reactions	O
related	O
to	O
toxic	O
methotrexate	O
levels	O
due	O
to	O
prolonged	O
methotrexate	O
clearance	O
include	O
myelosuppression	O
,	O
mucositis	O
,	O
acute	O
hepatitis	O
,	O
and	O
renal	O
dysfunction	O
and	O
failure	O
.	O
	
There	O
was	O
considerable	O
variation	O
in	O
risk	O
of	O
suicidality	B
among	O
drugs	O
,	O
but	O
a	O
tendency	O
toward	O
an	O
increase	O
in	O
the	O
younger	O
patients	O
for	O
almost	O
all	O
drugs	O
studied	O
.	O
	
(	O
5.5	O
)	O
*	O
Activation	B
of	I
Mania	I
:	O
Use	O
cautiously	O
in	O
patients	O
with	O
Bipolar	O
Disorder	O
.	O
	
5.5	O
Capillary	O
Leak	O
Syndrome	O
Capillary	B
leak	I
syndrome	I
(	O
CLS	B
)	O
can	O
occur	O
in	O
patients	O
receiving	O
human	O
granulocyte	O
colony-stimulating	O
factors	O
and	O
is	O
characterized	O
by	O
hypotension	B
,	O
hypoalbuminemia	B
,	O
edema	B
and	O
hemoconcentration	B
.	O
	
Withhold	O
TAFINLAR	O
,	O
and	O
trametinib	O
if	O
used	O
in	O
combination	O
,	O
for	O
any	O
serious	O
febrile	O
reaction	O
or	O
fever	O
complicated	O
by	O
hypotension	O
,	O
rigors	O
or	O
chills	O
,	O
dehydration	O
,	O
or	O
renal	O
failure	O
and	O
evaluate	O
for	O
signs	O
and	O
symptoms	O
of	O
infection	O
.	O
	
When	O
possible	O
,	O
optimal	O
glucose	O
and	O
lipid	O
control	O
should	O
be	O
achieved	O
before	O
starting	O
a	O
patient	O
on	O
AFINITOR	O
.	O
	
These	O
trials	O
were	O
comprised	O
of	O
374	O
patients	O
of	O
whom	O
249	O
and	O
125	O
received	O
0.58	O
mg	O
of	O
XIAFLEX	O
and	O
placebo	O
,	O
respectively	O
.	O
	
Systemic	O
and	O
local	O
corticosteroid	O
use	O
may	O
result	O
in	O
the	O
following	O
:	O
*	O
Candida	B
albicans	I
infection	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
Increased	O
risk	O
of	O
pneumonia	B
in	O
COPD	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
*	O
Immunosuppression	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
*	O
Hypercorticism	B
and	O
adrenal	B
suppression	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.8	O
)	O
]	O
*	O
Reduction	B
in	I
bone	I
mineral	I
density	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.13	O
)	O
]	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
PRISTIQ	O
is	O
not	O
approved	O
for	O
use	O
in	O
pediatric	O
patients	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.4	O
)	O
]	O
.	O
	
Withhold	O
or	O
discontinue	O
GILOTRIF	O
for	O
confirmed	O
ulcerative	O
keratitis	O
.	O
	
6.2	O
Post-marketing	O
Experience	O
The	O
following	O
events	O
have	O
been	O
reported	O
in	O
association	O
with	O
fesoterodine	O
use	O
in	O
worldwide	O
post-marketing	O
experience	O
:	O
Eye	O
disorders	O
:	O
Blurred	B
vision	I
;	O
Cardiac	O
disorders	O
:	O
Palpitations	B
;	O
General	O
disorders	O
and	O
administrative	O
site	O
conditions	O
:	O
Hypersensitivity	B
reactions	I
,	O
including	O
angioedema	B
with	O
airway	B
obstruction	I
,	O
face	B
edema	I
;	O
Central	O
nervous	O
system	O
disorders	O
:	O
Dizziness	B
,	O
headache	B
,	O
somnolence	B
;	O
Skin	O
and	O
subcutaneous	O
tissue	O
disorders	O
:	O
Urticaria	B
,	O
pruritus	B
Because	O
these	O
spontaneously	O
reported	O
events	O
are	O
from	O
the	O
worldwide	O
post-marketing	O
experience	O
,	O
the	O
frequency	O
of	O
events	O
and	O
the	O
role	O
of	O
fesoterodine	O
in	O
their	O
causation	O
can	O
not	O
be	O
reliably	O
determined	O
.	O
	
Dosing	O
should	O
be	O
interrupted	O
in	O
patients	O
with	O
ALT	O
or	O
AST	O
of	O
greater	O
than	O
5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
.	O
	
The	O
mean	O
change	O
from	O
baseline	O
observed	O
for	O
selected	O
lipid	O
values	O
is	O
presented	O
in	O
Table	O
4	O
.	O
	
Progressive	O
Multifocal	O
Leukoencephalopathy	O
(	O
PML	O
)	O
Cases	O
of	O
JC	B
virus-associated	O
PML	B
resulting	O
in	O
neurological	B
deficits	I
,	O
including	O
fatal	B
cases	O
,	O
have	O
been	O
reported	O
in	O
patients	O
with	O
SLE	O
receiving	O
immunosuppressants	O
,	O
including	O
BENLYSTA	O
.	O
	
The	O
most	O
common	O
reasons	O
for	O
discontinuation	O
of	O
therapy	O
with	O
MULTAQ	O
were	O
gastrointestinal	B
disorders	I
(	O
3.2	O
%	O
versus	O
1.8	O
%	O
in	O
the	O
placebo	O
group	O
)	O
and	O
QT	B
prolongation	I
(	O
1.5	O
%	O
versus	O
0.5	O
%	O
in	O
the	O
placebo	O
group	O
)	O
.	O
	
Somnolence/sedation	O
led	O
to	O
withdrawal	O
in	O
2	O
%	O
of	O
patients	O
receiving	O
600	O
mg	O
of	O
HORIZANT	O
per	O
day	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
that	O
led	O
to	O
discontinuation	O
in	O
pediatric	O
patients	O
treated	O
with	O
SAPHRIS	O
(	O
rates	O
at	O
least	O
2	O
%	O
in	O
any	O
SAPHRIS	O
arm	O
and	O
at	O
least	O
twice	O
the	O
placebo	O
rate	O
)	O
were	O
somnolence	B
(	O
3	O
%	O
in	O
the	O
2.5mg	O
twice	O
daily	O
group	O
,	O
1	O
%	O
in	O
the	O
5mg	O
twice	O
daily	O
group	O
,	O
and	O
2	O
%	O
in	O
the	O
10mg	O
twice	O
daily	O
group	O
)	O
,	O
abdominal	B
pain	I
(	O
2	O
%	O
in	O
the	O
10mg	O
twice	O
daily	O
group	O
)	O
,	O
and	O
nausea	B
(	O
2	O
%	O
in	O
the	O
10mg	O
twice	O
daily	O
group	O
)	O
No	O
placebo-treated	O
patients	O
dropped	O
out	O
for	O
these	O
events	O
.	O
	
[	O
seeDosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
*	O
DUAVEE	O
comes	O
in	O
a	O
blister	O
package	O
.	O
	
Discontinue	O
ERWINAZE	O
for	O
a	O
thrombotic	O
or	O
hemorrhagic	O
event	O
until	O
symptoms	O
resolve	O
;	O
after	O
resolution	O
,	O
treatment	O
with	O
ERWINAZE	O
may	O
be	O
resumed	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Other	O
adverse	O
reactions	O
occurring	O
more	O
frequently	O
on	O
INVOKANA	O
than	O
on	O
comparator	O
were	O
:	O
Volume	O
Depletion-Related	O
Adverse	O
Reactions	O
INVOKANA	O
results	O
in	O
an	O
osmotic	B
diuresis	I
,	O
which	O
may	O
lead	O
to	O
reductions	B
in	I
intravascular	I
volume	I
.	O
	
When	O
beginning	O
ARCAPTA	O
NEOHALER	O
,	O
patients	O
who	O
have	O
been	O
taking	O
inhaled	O
,	O
short-acting	O
beta2-agonists	O
on	O
a	O
regular	O
basis	O
(	O
e.g.	O
,	O
four	O
times	O
a	O
day	O
)	O
should	O
be	O
instructed	O
to	O
discontinue	O
the	O
regular	O
use	O
of	O
these	O
drugs	O
and	O
use	O
them	O
only	O
for	O
symptomatic	O
relief	O
of	O
acute	O
respiratory	O
symptoms	O
.	O
	
Pooled	O
analyses	O
of	O
199	O
placebo-controlled	O
clinical	O
trials	O
(	O
mono-	O
and	O
adjunctive-therapy	O
)	O
of	O
11	O
different	O
AEDs	O
showed	O
that	O
patients	O
randomized	O
to	O
one	O
of	O
the	O
AEDs	O
had	O
approximately	O
twice	O
the	O
risk	O
(	O
adjusted	O
relative	O
risk	O
1.8	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
1.2	O
,	O
2.7	O
)	O
of	O
suicidal	B
thinking	I
compared	O
with	O
patients	O
randomized	O
to	O
placebo	O
.	O
	
Therefore	O
,	O
avoid	O
the	O
use	O
of	O
strong	O
CYP3A4	O
inhibitors	O
for	O
more	O
than	O
14	O
consecutive	O
days	O
while	O
on	O
SIRTURO	O
,	O
unless	O
the	O
benefit	O
of	O
treatment	O
with	O
the	O
drug	O
combination	O
outweighs	O
the	O
risk	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
]	O
.	O
	
DRESS	B
may	O
be	O
fatal	B
or	O
life-threatening	O
.	O
	
Bleeding	B
events	O
of	O
any	O
grade	O
,	O
including	O
bruising	B
and	O
petechiae	B
,	O
occurred	O
in	O
approximately	O
half	O
of	O
patients	O
treated	O
with	O
IMBRUVICA	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Bleeding	B
:	O
PRADAXA	O
can	O
cause	O
serious	O
and	O
fatal	B
bleeding	B
(	O
5.2	O
)	O
*	O
Bioprosthetic	O
heart	O
valves	O
:	O
PRADAXA	O
use	O
not	O
recommended	O
(	O
5.4	O
)	O
5.1	O
Increased	O
Risk	O
of	O
Thrombotic	O
Events	O
after	O
Premature	O
Discontinuation	O
Premature	O
discontinuation	O
of	O
any	O
oral	O
anticoagulant	O
,	O
including	O
PRADAXA	O
,	O
in	O
the	O
absence	O
of	O
adequate	O
alternative	O
anticoagulation	O
increases	O
the	O
risk	O
of	O
thrombotic	O
events	O
.	O
	
PRADAXA	O
's	O
anticoagulant	O
activity	O
and	O
half-life	O
are	O
increased	O
in	O
patients	O
with	O
renal	O
impairment	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
incidence	O
of	O
antibodies	O
to	O
YERVOY	O
with	O
the	O
incidences	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
The	O
majority	O
of	O
these	O
events	O
were	O
infections	B
.	O
	
Eight	O
of	O
79	O
(	O
10.1	O
%	O
)	O
patients	O
in	O
the	O
SIRTURO	O
group	O
and	O
16	O
of	O
81	O
(	O
19.8	O
%	O
)	O
patients	O
in	O
the	O
placebo	O
treatment	O
group	O
were	O
HIV-infected	O
.	O
	
(	O
5.1	O
)	O
*	O
Measure	O
the	O
absolute	O
neutrophil	O
count	O
(	O
ANC	O
)	O
before	O
starting	O
Ferriprox	O
and	O
monitor	O
the	O
ANC	O
weekly	O
on	O
therapy	O
.	O
	
Clinically	O
significant	O
cardiovascular	O
effects	O
and	O
fatalities	B
have	O
been	O
reported	O
in	O
association	O
with	O
excessive	O
use	O
of	O
inhaled	O
sympathomimetic	O
drugs	O
.	O
	
BREO	O
ELLIPTA	O
should	O
not	O
be	O
used	O
for	O
the	O
relief	O
of	O
acute	O
symptoms	O
,	O
i.e.	O
,	O
as	O
rescue	O
therapy	O
for	O
the	O
treatment	O
of	O
acute	O
episodes	O
of	O
bronchospasm	O
.	O
	
Concurrent	O
elevations	B
in	I
ALT	I
greater	O
than	O
3	O
times	O
the	O
ULN	O
and	O
total	B
bilirubin	I
greater	I
than	I
2	I
times	I
the	I
ULN	I
,	O
with	O
normal	O
alkaline	O
phosphatase	O
,	O
occurred	O
in	O
less	O
than	O
1	O
%	O
of	O
patients	O
in	O
clinical	O
studies	O
.	O
	
Agranulocytosis	B
and	O
neutropenia	B
usually	O
resolve	O
upon	O
discontinuation	O
of	O
Ferriprox	O
,	O
but	O
there	O
have	O
been	O
reports	O
of	O
agranulocytosis	B
leading	O
to	O
death	B
.	O
	
Monitor	O
weekly	O
for	O
liver	O
toxicity	O
if	O
the	O
ALT	O
or	O
AST	O
rises	O
above	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
until	O
resolved	O
.	O
	
(	O
5.13	O
)	O
*	O
Close	O
monitoring	O
for	O
glaucoma	O
and	O
cataracts	O
is	O
warranted	O
.	O
	
Patients	O
should	O
be	O
closely	O
monitored	O
for	O
signs	O
or	O
symptoms	O
of	O
SJS/TEN	O
,	O
especially	O
during	O
the	O
first	O
8	O
weeks	O
of	O
treatment	O
initiation	O
or	O
when	O
re-introducing	O
therapy	O
.	O
	
5.4	O
Genital	O
Mycotic	O
Infections	O
FARXIGA	O
increases	O
the	O
risk	O
of	O
genital	B
mycotic	I
infections	I
.	O
	
Withdrawal	O
symptoms	O
occurred	O
following	O
abrupt	O
discontinuation	O
of	O
ONFI	O
;	O
the	O
risk	O
of	O
withdrawal	O
symptoms	O
is	O
greater	O
with	O
higher	O
doses	O
.	O
	
Clinical	O
Myocardial	O
Infarction	O
Events	O
In	O
the	O
active-controlled	O
VTE	O
studies	O
,	O
a	O
higher	O
rate	O
of	O
clinical	O
myocardial	B
infarction	I
was	O
reported	O
in	O
patients	O
who	O
received	O
PRADAXA	O
[	O
20	O
(	O
0.66	O
per	O
100	O
patient-years	O
)	O
]	O
than	O
in	O
those	O
who	O
received	O
warfarin	O
[	O
5	O
(	O
0.17	O
per	O
100	O
patient-years	O
)	O
]	O
.	O
	
An	O
increase	O
in	O
frequency	O
or	O
severity	O
of	O
migraine	B
during	O
COC	O
use	O
(	O
which	O
may	O
be	O
prodromal	O
of	O
a	O
cerebrovascular	B
event	I
)	O
may	O
be	O
a	O
reason	O
for	O
immediate	O
discontinuation	O
of	O
the	O
COC	O
.	O
	
5.3	O
Excessive	O
Use	O
of	O
BREO	O
ELLIPTA	O
and	O
Use	O
with	O
Other	O
Long-Acting	O
Beta2-Agonists	O
BREO	O
ELLIPTA	O
should	O
not	O
be	O
used	O
more	O
often	O
than	O
recommended	O
,	O
at	O
higher	O
doses	O
than	O
recommended	O
,	O
or	O
in	O
conjunction	O
with	O
other	O
medicines	O
containing	O
LABA	O
,	O
as	O
an	O
overdose	O
may	O
result	O
.	O
	
Table	O
3	O
shows	O
the	O
incidence	O
of	O
adverse	O
reactions	O
that	O
were	O
reported	O
in	O
greater	O
than	O
or	O
equal	O
to	O
5	O
%	O
of	O
XIAFLEX-treated	O
patients	O
and	O
at	O
a	O
frequency	O
greater	O
than	O
placebo-treated	O
patients	O
after	O
up	O
to	O
3	O
injections	O
in	O
the	O
pooled	O
placebo-controlled	O
trials	O
through	O
Day	O
90	O
(	O
Studies	O
1	O
and	O
2	O
)	O
.	O
	
Anti-blinatumomab	O
antibody	O
formation	O
may	O
affect	O
pharmacokinetics	O
of	O
BLINCYTO	O
.	O
	
Hypersensitivity	B
reactions	I
related	O
to	O
BLINCYTO	O
treatment	O
were	O
hypersensitivity	B
(	O
1	O
%	O
)	O
and	O
bronchospasm	B
(	O
<	O
1	O
%	O
)	O
.	O
	
For	O
some	O
TNF	O
blockers	O
,	O
more	O
cases	O
of	O
malignancies	B
have	O
been	O
observed	O
among	O
patients	O
receiving	O
those	O
TNF	O
blockers	O
compared	O
to	O
control	O
patients	O
.	O
	
5.3	O
XIAFLEX	O
REMS	O
Program	O
Because	O
of	O
the	O
risks	O
of	O
corporal	O
rupture	O
(	O
penile	O
fracture	O
)	O
or	O
other	O
serious	O
penile	O
injury	O
in	O
the	O
treatment	O
of	O
Peyronie	O
's	O
disease	O
,	O
XIAFLEX	O
is	O
available	O
only	O
through	O
the	O
XIAFLEX	O
REMS	O
Program	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Adverse	O
Reactions	O
Leading	O
to	O
Study	O
Discontinuation	O
:	O
11.4	O
%	O
of	O
the	O
women	O
discontinued	O
from	O
the	O
clinical	O
trials	O
due	O
to	O
an	O
adverse	O
reaction	O
;	O
the	O
most	O
frequent	O
adverse	O
reactions	O
leading	O
to	O
discontinuation	O
were	O
menstrual	B
disorder	I
(	O
metrorrhagia	B
,	O
menorrhagia	B
,	O
menstruation	B
irregular	I
,	O
genital	B
hemorrhage	I
,	O
vaginal	B
hemorrhage	I
,	O
dysfunctional	B
uterine	I
bleeding	I
)	O
(	O
2.3	O
%	O
)	O
;	O
mood	B
changes	I
(	O
depression	B
,	O
mood	B
swings	I
,	O
mood	B
altered	I
,	O
depressed	B
mood	I
,	O
dysthymic	B
disorder	I
,	O
crying	B
)	O
(	O
1.2	O
%	O
)	O
;	O
acne	B
(	O
1.1	O
%	O
)	O
,	O
headache	B
(	O
including	O
migraines	B
)	O
(	O
1.1	O
%	O
)	O
,	O
and	O
weight	B
increased	I
(	O
0.7	O
%	O
)	O
.	O
	
Patients	O
using	O
supplemental	O
oxygen	O
or	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
during	O
sleep	O
should	O
have	O
these	O
treatments	O
readily	O
available	O
during	O
infusion	O
in	O
the	O
event	O
of	O
an	O
acute	O
reaction	O
,	O
or	O
extreme	O
drowsiness/sleep	O
induced	O
by	O
antihistamine	O
use	O
.	O
	
Given	O
the	O
potential	O
for	O
delay	O
in	O
lymphocyte	O
recovery	O
after	O
discontinuation	O
of	O
TECFIDERA	O
,	O
consider	O
following	O
lymphocyte	O
counts	O
until	O
lymphopenia	O
is	O
resolved	O
.	O
	
Renal	B
cysts	I
occurred	O
in	O
8	O
(	O
5	O
%	O
)	O
patients	O
treated	O
with	O
XALKORI	O
and	O
1	O
(	O
1	O
%	O
)	O
patient	O
treated	O
with	O
chemotherapy	O
in	O
Study	O
1	O
.	O
	
Interrupt	O
,	O
dose	O
reduce	O
or	O
discontinue	O
BOSULIF	O
as	O
necessary	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
occurring	O
in	O
at	O
least	O
10	O
%	O
of	O
patients	O
,	O
using	O
the	O
NCI	O
CTC	O
Version	O
4	O
,	O
are	O
shown	O
in	O
Table	O
3	O
.	O
	
6.1	O
Clinical	O
Study	O
Experience	O
The	O
data	O
from	O
clinical	O
studies	O
reflect	O
exposure	O
to	O
DaTscan	O
in	O
942	O
subjects	O
with	O
a	O
mean	O
age	O
of	O
66	O
years	O
(	O
range	O
25	O
to	O
90	O
years	O
)	O
.	O
	
Common	O
Adverse	O
Reactions	O
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
(	O
occurring	O
in	O
more	O
than	O
5	O
%	O
of	O
patients	O
who	O
received	O
500	O
Units	O
of	O
DYSPORT	O
(	O
r	O
)	O
in	O
the	O
placebo	O
controlled	O
clinical	O
trials	O
)	O
in	O
cervical	O
dystonia	O
patients	O
were	O
:	O
muscular	B
weakness	I
,	O
dysphagia	B
,	O
dry	B
mouth	I
,	O
injection	B
site	I
discomfort	I
,	O
fatigue	B
,	O
headache	B
,	O
neck	B
pain	I
,	O
musculoskeletal	B
pain	I
,	O
dysphonia	B
,	O
injection	B
site	I
pain	I
,	O
and	O
eye	B
disorders	I
(	O
consisting	O
of	O
blurred	B
vision	I
,	O
diplopia	B
,	O
and	O
reduced	B
visual	I
acuity	I
)	O
.	O
	
Severe	O
reactions	O
are	O
generally	O
managed	O
with	O
infusion	O
interruption	O
,	O
administration	O
of	O
antihistamines	O
,	O
corticosteroids	O
,	O
intravenous	O
fluids	O
,	O
and/or	O
oxygen	O
,	O
when	O
clinically	O
indicated	O
.	O
	
DUAVEE	O
may	O
also	O
affect	O
how	O
your	O
other	O
medicines	O
work	O
.	O
	
In	O
a	O
3-week	O
,	O
placebo-controlled	O
pediatric	O
trial	O
with	O
bipolar	O
I	O
disorder	O
,	O
the	O
incidences	O
of	O
EPS-related	B
events	I
,	O
excluding	O
events	O
related	O
to	O
akathisia	B
,	O
were	O
4	O
%	O
,	O
3	O
%	O
,	O
and	O
5	O
%	O
for	O
patients	O
treated	O
with	O
SAPHRIS	O
2.5	O
mg	O
,	O
5	O
mg	O
,	O
and	O
10	O
mg	O
twice	O
daily	O
,	O
respectively	O
,	O
as	O
compared	O
to	O
3	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
(	O
5.1	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Correct	O
volume	O
or	O
salt	O
depletion	O
prior	O
to	O
administration	O
of	O
Edarbi	O
.	O
	
Do	O
not	O
take	O
DUAVEE	O
if	O
you	O
:	O
*	O
currently	O
have	O
or	O
have	O
had	O
blood	O
clots	O
*	O
are	O
allergic	O
to	O
estrogens	O
or	O
bazedoxifene	O
,	O
the	O
active	O
ingredients	O
in	O
DUAVEE	O
,	O
or	O
any	O
of	O
its	O
ingredients	O
.	O
	
These	O
patients	O
may	O
have	O
an	O
increased	O
risk	O
for	O
a	O
hypersensitivity	B
reaction	I
to	O
DOTAREM	O
.	O
	
For	O
those	O
patients	O
who	O
reported	O
dry	B
mouth	I
,	O
most	O
had	O
their	O
first	O
occurrence	O
of	O
the	O
event	O
within	O
the	O
first	O
month	O
of	O
treatment	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Elevated	B
transaminases	I
)	O
:	O
Transaminases	O
(	O
ALT	O
and	O
AST	O
)	O
should	O
be	O
assessed	O
prior	O
to	O
initiating	O
KALYDECO	O
,	O
every	O
3	O
months	O
during	O
the	O
first	O
year	O
of	O
treatment	O
,	O
and	O
annually	O
thereafter	O
.	O
	
Risk	O
by	O
Indication	O
for	O
Antiepileptic	O
Drugs	O
in	O
the	O
Pooled	O
Analysis	O
Indication	O
PlaceboPatients	O
WithEvents	O
Per1,000	O
Patients	O
Drug	O
PatientsWith	O
Events	O
Per1,000	O
Patients	O
Relative	O
Risk	O
:	O
Incidence	O
of	O
Eventsin	O
DrugPatients/Incidencein	O
Placebo	O
Patients	O
Risk	O
Difference	O
:	O
Additional	O
DrugPatients	O
WithEvents	O
Per	O
1,000Patients	O
Epilepsy	O
1.0	O
3.4	O
3.5	O
2.4	O
Psychiatric	O
5.7	O
8.5	O
1.5	O
2.9	O
Other	O
1.0	O
1.8	O
1.9	O
0.9	O
Total	O
2.4	O
4.3	O
1.8	O
1.9	O
The	O
relative	O
risk	O
for	O
suicidal	B
thoughts	I
was	O
higher	O
in	O
clinical	O
trials	O
for	O
epilepsy	O
than	O
in	O
clinical	O
trials	O
for	O
psychiatric	O
or	O
other	O
conditions	O
,	O
but	O
the	O
absolute	O
risk	O
differences	O
were	O
similar	O
for	O
the	O
epilepsy	O
and	O
psychiatric	O
indications	O
.	O
	
5.6	O
Liver	O
Transplant	O
Use	O
of	O
NULOJIX	O
in	O
liver	O
transplant	O
patients	O
is	O
not	O
recommended	O
[	O
see	O
Boxed	O
Warning	O
]	O
.	O
	
Only	O
Study	O
1	O
included	O
a	O
placebo	O
group	O
,	O
allowing	O
comparison	O
of	O
adverse	O
reaction	O
rates	O
on	O
ONFI	O
at	O
several	O
doses	O
to	O
placebo	O
.	O
	
Discontinuation	O
due	O
to	O
GI	B
adverse	I
reactions	I
occurred	O
in	O
2	O
%	O
of	O
individuals	O
on	O
TANZEUM	O
or	O
placebo	O
.	O
	
Advise	O
all	O
patients	O
to	O
seek	O
immediate	O
medical	O
attention	O
if	O
they	O
develop	O
signs	O
and	O
symptoms	O
suggestive	O
of	O
blood	O
dyscrasias	O
or	O
infection	O
(	O
e.g.	O
,	O
persistent	O
fever	O
,	O
bruising	O
,	O
bleeding	O
,	O
pallor	O
)	O
while	O
on	O
CIMZIA	O
.	O
	
Treatment	O
with	O
medications	O
that	O
work	O
through	O
inhibition	O
of	O
IL-1	O
has	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
serious	O
infections	B
.	O
	
Perform	O
dermatologic	O
evaluations	O
prior	O
to	O
initiation	O
of	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
or	O
in	O
combination	O
with	O
trametinib	O
,	O
every	O
2	O
months	O
while	O
on	O
therapy	O
,	O
and	O
for	O
up	O
to	O
6	O
months	O
following	O
discontinuation	O
of	O
TAFINLAR	O
.	O
	
5.6	O
Interference	O
with	O
Visualization	O
of	O
Liver	O
Lesions	O
Severe	O
renal	O
or	O
hepatic	O
failure	O
may	O
impair	O
EOVIST	O
imaging	O
performance	O
.	O
	
Physicians	O
should	O
consider	O
whether	O
their	O
patients	O
with	O
underlying	O
NAION	O
risk	O
factors	O
could	O
be	O
adversely	O
affected	O
by	O
use	O
of	O
PDE5	O
inhibitors	O
.	O
	
Table	O
5	O
presents	O
the	O
most	O
common	O
treatment-related	O
adverse	O
reactions	O
(	O
experienced	O
by	O
greater	O
than	O
or	O
equal	O
to	O
3	O
%	O
of	O
patients	O
receiving	O
PROMACTA	O
)	O
from	O
the	O
extension	O
trial	O
.	O
	
In	O
a	O
3-week	O
,	O
placebo-controlled	O
,	O
bipolar	O
I	O
pediatric	O
trial	O
,	O
the	O
incidence	O
of	O
somnolence	B
(	O
including	O
sedation	B
and	O
hypersomnia	B
)	O
for	O
placebo	O
,	O
SAPHRIS	O
2.5	O
mg	O
twice	O
daily	O
,	O
5	O
mg	O
twice	O
daily	O
,	O
and	O
10	O
mg	O
twice	O
daily	O
,	O
was	O
12	O
%	O
(	O
12/101	O
)	O
,	O
46	O
%	O
(	O
48/104	O
)	O
,	O
53	O
%	O
(	O
52/99	O
)	O
,	O
and	O
49	O
%	O
(	O
49/99	O
)	O
,	O
respectively	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
unknown	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
casual	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
5.5	O
Development	O
of	O
Drug-Resistant	O
Bacteria	O
Prescribing	O
DALVANCE	O
in	O
the	O
absence	O
of	O
a	O
proven	O
or	O
strongly	O
suspected	O
bacterial	O
infection	O
is	O
unlikely	O
to	O
provide	O
benefit	O
to	O
the	O
patient	O
and	O
increases	O
the	O
risk	O
of	O
the	O
development	O
of	O
drug-resistant	O
bacteria	O
.	O
	
Malignancies	B
,	O
some	O
fatal	B
,	O
have	O
been	O
reported	O
among	O
children	O
,	O
adolescents	O
,	O
and	O
young	O
adults	O
who	O
received	O
treatment	O
with	O
TNF-blocking	O
agents	O
(	O
initiation	O
of	O
therapy	O
<	O
=	O
18	O
years	O
of	O
age	O
)	O
,	O
of	O
which	O
CIMZIA	O
is	O
a	O
member	O
.	O
	
5.4	O
Effects	O
on	O
Eye	O
Physicians	O
should	O
advise	O
patients	O
to	O
stop	O
use	O
of	O
all	O
PDE5	O
inhibitors	O
,	O
including	O
STENDRA	O
,	O
and	O
seek	O
medical	O
attention	O
in	O
the	O
event	O
of	O
a	O
sudden	O
loss	O
of	O
vision	O
in	O
one	O
or	O
both	O
eyes	O
.	O
	
Obtain	O
a	O
liver	O
test	O
panel	O
(	O
serum	O
alanine	O
aminotransferase	O
[	O
ALT	O
]	O
,	O
aspartate	O
aminotransferase	O
[	O
AST	O
]	O
,	O
alkaline	O
phosphatase	O
,	O
and	O
total	O
bilirubin	O
)	O
as	O
a	O
baseline	O
before	O
initiating	O
ULORIC	O
.	O
	
STENDRA	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
anatomical	O
deformation	O
of	O
the	O
penis	O
(	O
such	O
as	O
angulation	O
,	O
cavernosal	O
fibrosis	O
,	O
or	O
Peyronie	O
's	O
disease	O
)	O
,	O
or	O
in	O
patients	O
who	O
have	O
conditions	O
which	O
may	O
predispose	O
them	O
to	O
priapism	O
(	O
such	O
as	O
sickle	O
cell	O
anemia	O
,	O
multiple	O
myeloma	O
,	O
or	O
leukemia	O
)	O
.	O
	
Adequate	O
diagnostic	O
measures	O
,	O
including	O
directed	O
or	O
random	O
endometrial	O
sampling	O
when	O
indicated	O
,	O
should	O
be	O
undertaken	O
to	O
rule	O
out	O
malignancy	O
in	O
postmenopausal	O
women	O
with	O
undiagnosed	O
persistent	O
or	O
recurring	O
abnormal	O
genital	O
bleeding	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=20	O
%	O
)	O
,	O
regardless	O
of	O
causality	O
,	O
were	O
neutropenia	B
,	O
peripheral	B
sensory	I
neuropathy	I
,	O
fatigue	B
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
nausea	B
,	O
diarrhea	B
,	O
anemia	B
,	O
pyrexia	B
,	O
thrombocytopenia	B
,	O
rash	B
,	O
abdominal	B
pain	I
,	O
cough	B
,	O
and	O
vomiting	B
.	O
	
The	O
increase	O
in	O
VTE	B
risk	O
was	O
demonstrated	O
during	O
the	O
first	O
2	O
years	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.5	O
)	O
]	O
.	O
	
Somnolence	B
(	O
including	O
sedation	B
)	O
led	O
to	O
discontinuation	O
in	O
0.6	O
%	O
(	O
12/1953	O
)	O
of	O
patients	O
in	O
short-term	O
,	O
placebo-controlled	O
trials	O
.	O
	
5.4	O
Immunizations	O
Live	O
vaccines	O
should	O
not	O
be	O
given	O
concurrently	O
with	O
ILARIS	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.2	O
)	O
]	O
.	O
	
From	O
this	O
information	O
,	O
it	O
is	O
not	O
possible	O
to	O
determine	O
whether	O
these	O
events	O
are	O
related	O
directly	O
to	O
the	O
use	O
of	O
PDE5	O
inhibitors	O
or	O
to	O
other	O
factors	O
[	O
seeAdverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
While	O
taking	O
AFINITOR	O
,	O
be	O
vigilant	O
for	O
signs	O
and	O
symptoms	O
of	O
infection	O
;	O
if	O
a	O
diagnosis	O
of	O
an	O
infection	O
is	O
made	O
,	O
institute	O
appropriate	O
treatment	O
promptly	O
and	O
consider	O
interruption	O
or	O
discontinuation	O
of	O
AFINITOR	O
.	O
	
Other	O
Adverse	O
Reactions	O
Hypoglycemia	O
The	O
proportion	O
of	O
patients	O
experiencing	O
at	O
least	O
one	O
documented	O
symptomatic	O
hypoglycemic	B
episode	I
on	O
TANZEUM	O
and	O
the	O
proportion	O
of	O
patients	O
experiencing	O
at	O
least	O
one	O
severe	O
hypoglycemic	B
episode	I
on	O
TANZEUM	O
in	O
clinical	O
trials	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
is	O
shown	O
in	O
Table	O
2	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Interleukin-1	O
blockade	O
may	O
interfere	O
with	O
immune	O
response	O
to	O
infections	O
.	O
	
Pooled	O
analyses	O
of	O
short-term	O
placebo-controlled	O
studies	O
of	O
antidepressant	O
drugs	O
(	O
SSRIs	O
and	O
others	O
)	O
showed	O
that	O
these	O
drugs	O
increase	O
the	O
risk	O
of	O
suicidal	B
thinking	I
(	O
suicidality	B
)	O
in	O
children	O
,	O
adolescents	O
,	O
and	O
young	O
adults	O
(	O
ages	O
18	O
to	O
24	O
)	O
with	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
and	O
other	O
psychiatric	O
disorders	O
.	O
	
5.6	O
Respiratory	O
Effects	O
Dose-dependent	O
reductions	B
in	I
forced	I
expiratory	I
volume	I
over	I
1	I
second	I
)	O
were	O
observed	O
in	O
patients	O
treated	O
with	O
GILENYA	O
as	O
early	O
as	O
1	O
month	O
after	O
treatment	O
initiation	O
.	O
	
Consider	O
discontinuation	O
of	O
CIMZIA	O
therapy	O
in	O
patients	O
with	O
confirmed	O
significant	O
hematologic	O
abnormalities	O
.	O
	
The	O
incidence	O
of	O
adverse	O
reactions	O
below	O
is	O
based	O
upon	O
2	O
placebo-controlled	O
,	O
clinical	O
trials	O
(	O
EDEMA3	O
(	O
r	O
)	O
and	O
EDEMA4	O
(	O
r	O
)	O
)	O
in	O
a	O
total	O
of	O
143	O
unique	O
patients	O
with	O
HAE	O
.	O
	
Through	O
48	O
weeks	O
,	O
the	O
rates	O
of	O
adverse	O
events	O
leading	O
to	O
discontinuation	O
were	O
2	O
%	O
in	O
subjects	O
receiving	O
TIVICAY	O
and	O
4	O
%	O
in	O
subjects	O
receiving	O
darunavir/ritonavir	O
.	O
	
Anyone	O
considering	O
prescribing	O
HORIZANT	O
must	O
balance	O
the	O
risk	O
of	O
suicidal	O
thoughts	O
or	O
behavior	O
with	O
the	O
risk	O
of	O
untreated	O
illness	O
.	O
	
The	O
rates	O
of	O
treatment-emergent	O
adverse	O
events	O
resulting	O
in	O
permanent	O
discontinuation	O
were	O
24	O
%	O
and	O
5	O
%	O
for	O
the	O
AFINITOR	O
plus	O
exemestane	O
and	O
placebo	O
plus	O
exemestane	O
treatment	O
groups	O
,	O
respectively	O
.	O
	
These	O
events	O
were	O
observed	O
primarily	O
in	O
subjects	O
with	O
a	O
pre-existing	O
history	O
of	O
depression	O
or	O
other	O
psychiatric	O
illness	O
.	O
	
Two	O
of	O
the	O
four	O
subjects	O
had	O
renal	O
impairment	O
(	O
i.e	O
.	O
	
Alternatives	O
to	O
NSAIDs	O
should	O
be	O
considered	O
,	O
if	O
needed	O
,	O
in	O
patients	O
at	O
risk	O
for	O
renal	O
dysfunction	O
.	O
	
Some	O
of	O
these	O
reactions	O
occurred	O
after	O
the	O
first	O
administration	O
of	O
golimumab	O
.	O
	
Falls	O
and	O
Fall-related	O
Injuries	O
In	O
the	O
two	O
randomized	O
clinical	O
trials	O
,	O
falls	B
including	O
fall-related	B
injuries	I
,	O
occurred	O
in	O
9	O
%	O
of	O
patients	O
treated	O
with	O
XTANDI	O
compared	O
to	O
4	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
.	O
	
Although	O
cobicistat	O
(	O
a	O
component	O
of	O
STRIBILD	O
)	O
may	O
cause	O
modest	O
increases	B
in	I
serum	I
creatinine	I
and	O
modest	O
declines	B
in	I
estimated	I
creatinine	I
clearance	I
without	O
affecting	O
renal	O
glomerular	O
function	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
,	O
patients	O
who	O
experience	O
a	O
confirmed	O
increase	O
in	O
serum	O
creatinine	O
of	O
greater	O
than	O
0.4	O
mg	O
per	O
dL	O
from	O
baseline	O
should	O
be	O
closely	O
monitored	O
for	O
renal	O
safety	O
.	O
	
In	O
clinical	O
trials	O
with	O
INLYTA	O
,	O
arterial	B
thromboembolic	I
events	I
(	O
including	O
transient	B
ischemic	I
attack	I
,	O
cerebrovascular	B
accident	I
,	O
myocardial	B
infarction	I
,	O
and	O
retinal	B
artery	I
occlusion	I
)	O
were	O
reported	O
in	O
17/715	O
patients	O
(	O
2	O
%	O
)	O
,	O
with	O
two	O
deaths	B
secondary	O
to	O
cerebrovascular	B
accident	I
.	O
	
6.3	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
the	O
postmarketing	O
use	O
of	O
EDARBI	O
.	O
	
In	O
short-term	O
,	O
placebo-controlled	O
schizophrenia	O
adult	O
trials	O
,	O
the	O
mean	O
increase	B
in	I
transaminase	I
levels	I
for	O
SAPHRIS-treated	O
patients	O
was	O
1.6	O
units/L	O
compared	O
to	O
a	O
decrease	O
of	O
0.4	O
units/L	O
for	O
placebo-treated	O
patients	O
.	O
	
Do	O
not	O
take	O
DUAVEE	O
if	O
the	O
test	O
is	O
positive	O
and	O
talk	O
to	O
your	O
healthcare	O
provider	O
.	O
	
No	O
discernible	O
pattern	O
between	O
death	B
and	O
sputum	O
culture	O
conversion	O
,	O
relapse	O
,	O
sensitivity	O
to	O
other	O
drugs	O
used	O
to	O
treat	O
tuberculosis	O
,	O
HIV	O
status	O
,	O
or	O
severity	O
of	O
disease	O
could	O
be	O
observed	O
.	O
	
There	O
were	O
4	O
suicides	B
in	O
drug-treated	O
patients	O
in	O
the	O
trials	O
and	O
none	O
in	O
placebo-treated	O
patients	O
,	O
but	O
the	O
number	O
is	O
too	O
small	O
to	O
allow	O
any	O
conclusion	O
about	O
drug	O
effect	O
on	O
suicide	B
.	O
	
The	O
patient	O
recovered	O
fully	O
following	O
discontinuation	O
of	O
BOSULIF	O
.	O
	
Renal	B
cysts	I
occurred	O
in	O
8	O
(	O
5	O
%	O
)	O
patients	O
treated	O
with	O
XALKORI	O
and	O
1	O
(	O
1	O
%	O
)	O
patient	O
treated	O
with	O
chemotherapy	O
in	O
Study	O
2	O
.	O
	
IMBRUVICA	O
may	O
increase	O
the	O
risk	O
of	O
hemorrhage	B
in	O
patients	O
receiving	O
antiplatelet	O
or	O
anticoagulant	O
therapies	O
.	O
	
Evaluation	O
of	O
airway	O
patency	O
should	O
be	O
considered	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
Vimizim	O
.	O
	
NESINA	O
should	O
not	O
be	O
restarted	O
in	O
these	O
patients	O
without	O
another	O
explanation	O
for	O
the	O
liver	O
test	O
abnormalities	O
.	O
	
In	O
Studies	O
1	O
and	O
2	O
,	O
Grade	O
3	O
syncope	B
occurred	O
in	O
2.0	O
%	O
of	O
XALKORI-treated	O
patients	O
and	O
in	O
0.6	O
%	O
of	O
the	O
chemotherapy-treated	O
patients	O
.	O
	
If	O
a	O
patient	O
develops	O
any	O
of	O
these	O
reactions	O
after	O
treatment	O
with	O
APTIOM	O
,	O
the	O
drug	O
should	O
be	O
discontinued	O
.	O
	
Discontinue	O
COMETRIQ	O
in	O
patients	O
who	O
develop	O
nephrotic	O
syndrome	O
.	O
	
Administer	O
systemic	O
high-dose	O
corticosteroids	O
for	O
severe	O
,	O
persistent	O
,	O
or	O
recurring	O
immune-mediated	O
reactions	O
.	O
	
Advise	O
patients	O
regarding	O
good	O
oral	O
hygiene	O
practices	O
.	O
	
Across	O
the	O
treatment	O
arms	O
,	O
the	O
mean	O
age	O
of	O
patients	O
was	O
56	O
years	O
,	O
1	O
%	O
were	O
75	O
years	O
or	O
older	O
and	O
53	O
%	O
were	O
male	O
.	O
	
Infliximab	O
was	O
administered	O
to	O
5	O
of	O
the	O
62	O
patients	O
(	O
8	O
%	O
)	O
with	O
moderate	O
,	O
severe	O
,	O
or	O
life-threatening	O
immune-mediated	B
enterocolitis	I
following	O
inadequate	O
response	O
to	O
corticosteroids	O
.	O
	
No	O
association	O
was	O
seen	O
between	O
antibody	O
development	O
and	O
development	O
of	O
adverse	O
events	O
.	O
	
5.3	O
Avoidance	O
of	O
Contact	O
Lenses	O
Patients	O
should	O
not	O
wear	O
contact	O
lenses	O
if	O
they	O
have	O
signs	O
or	O
symptoms	O
of	O
bacterial	O
conjunctivitis	O
or	O
during	O
the	O
course	O
of	O
therapy	O
with	O
Besivance	O
.	O
	
Most	O
of	O
the	O
adverse	O
reactions	O
appear	O
to	O
be	O
dose	O
related	O
(	O
especially	O
those	O
classified	O
as	O
psychiatric	O
and	O
nervous	O
system	O
symptoms	O
)	O
,	O
including	O
dizziness	B
,	O
somnolence	B
,	O
confusional	B
state	I
,	O
tremor	B
,	O
abnormal	B
coordination	I
,	O
memory	B
impairment	I
,	O
blurred	B
vision	I
,	O
gait	B
disturbance	I
,	O
aphasia	B
,	O
balance	B
disorder	I
,	O
constipation	B
,	O
dysuria	B
,	O
and	O
chromaturia	B
.	O
	
Measure	O
serum	O
transaminases	O
(	O
ALT	O
and	O
AST	O
)	O
and	O
bilirubin	O
levels	O
prior	O
to	O
starting	O
treatment	O
with	O
ZYTIGA	O
,	O
every	O
two	O
weeks	O
for	O
the	O
first	O
three	O
months	O
of	O
treatment	O
and	O
monthly	O
thereafter	O
.	O
	
Management	O
of	O
hyperammonemia	O
due	O
to	O
NAGS	O
deficiency	O
should	O
be	O
done	O
in	O
coordination	O
with	O
medical	O
personnel	O
experienced	O
in	O
metabolic	O
disorders	O
.	O
	
6.3	O
Postmarketing	O
Experience	O
The	O
following	O
events	O
have	O
been	O
identified	O
during	O
postmarketing	O
use	O
of	O
INTELENCE	O
(	O
r	O
)	O
.	O
	
As	O
with	O
all	O
antiepileptic	O
drugs	O
,	O
ONFI	O
should	O
be	O
withdrawn	O
gradually	O
to	O
minimize	O
the	O
risk	O
of	O
precipitating	O
seizures	O
,	O
seizure	O
exacerbation	O
,	O
or	O
status	O
epilepticus	O
.	O
	
5.7	O
Headache	O
If	O
a	O
woman	O
taking	O
Natazia	O
develops	O
new	O
headaches	B
that	I
are	I
recurrent	I
,	O
or	O
severe	O
,	O
evaluate	O
the	O
cause	O
and	O
discontinue	O
Natazia	O
if	O
indicated	O
.	O
	
One	O
treatment-related	O
death	B
associated	O
with	O
hepatic	B
failure	I
was	O
reported	O
in	O
the	O
trial	O
.	O
	
6.2	O
Clinical	O
Studies	O
Experience	O
in	O
Patients	O
with	O
Peyronie	O
's	O
Disease	O
Because	O
clinical	O
studies	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
studies	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Immune	O
System	O
Disorders	O
:	O
Severe	O
hypersensitivity	B
reactions	O
including	O
DRESS	B
and	O
cases	O
of	O
hepatic	B
failure	I
have	O
been	O
reported	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
A	O
treatment-related	O
death	B
from	O
ventricular	B
fibrillation	I
was	O
reported	O
in	O
another	O
monotherapy	O
clinical	O
trial	O
with	O
Beleodaq	O
.	O
	
(	O
5.14	O
)	O
*	O
Use	O
with	O
caution	O
in	O
patients	O
with	O
convulsive	O
disorders	O
,	O
thyrotoxicosis	O
,	O
diabetes	O
mellitus	O
,	O
and	O
ketoacidosis	O
.	O
	
Patients	O
with	O
a	O
history	O
of	O
genital	O
mycotic	O
infections	O
were	O
more	O
likely	O
to	O
develop	O
genital	B
mycotic	I
infections	I
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
The	O
other	O
most	O
common	O
reactions	O
were	O
flushing	B
(	O
0.3	O
%	O
)	O
and	O
headache	B
(	O
0.4	O
%	O
)	O
.	O
	
The	O
most	O
frequently	O
reported	O
adverse	O
drug	O
reactions	O
(	O
>	O
=	O
25	O
%	O
)	O
in	O
the	O
XIAFLEX	O
clinical	O
trials	O
in	O
patients	O
with	O
Dupuytren	O
's	O
contracture	O
included	O
edema	B
peripheral	I
(	O
mostly	O
swelling	B
of	I
the	I
injected	I
hand	I
)	O
,	O
contusion	B
,	O
injection	B
site	I
hemorrhage	I
,	O
injection	B
site	I
reaction	I
,	O
and	O
pain	B
in	I
the	I
treated	I
extremity	I
.	O
	
Ensure	O
safe	O
handling	O
to	O
protect	O
patients	O
and	O
health	O
care	O
workers	O
from	O
unintentional	O
radiation	O
exposure	O
(	O
5.2	O
)	O
.	O
	
Table	O
4	O
Bleeding	B
Events	O
in	O
RE-MEDY	O
Treated	O
Patients	O
Note	O
:	O
MBE	B
can	O
belong	O
to	O
more	O
than	O
one	O
criterion	O
.	O
	
Promptly	O
measure	O
serum	O
total	O
bilirubin	O
,	O
AST	O
,	O
and	O
ALT	O
if	O
clinical	O
symptoms	O
or	O
signs	O
suggestive	O
of	O
hepatotoxicity	O
develop	O
.	O
	
In	O
the	O
short-term	O
trials	O
,	O
FANAPT	O
was	O
associated	O
with	O
modest	O
levels	O
of	O
prolactin	B
elevation	I
compared	O
to	O
greater	O
prolactin	B
elevations	I
observed	O
with	O
some	O
other	O
antipsychotic	O
agents	O
.	O
	
Hypoglycemia	B
was	O
more	O
frequent	O
when	O
FARXIGA	O
was	O
added	O
to	O
sulfonylurea	O
or	O
insulin	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
Possible	O
risk	O
factors	O
for	O
leukopenia/neutropenia	O
include	O
preexisting	O
low	O
white	O
blood	O
cell	O
count	O
(	O
WBC	O
)	O
and	O
history	O
of	O
drug	O
induced	O
leukopenia/neutropenia	O
.	O
	
Further	O
information	O
is	O
available	O
at	O
www.XIAFLEXREMS.com	O
or	O
1-877-313-1235	O
.	O
	
Anaphylaxis	B
was	O
reported	O
in	O
a	O
post-marketing	O
clinical	O
trial	O
(	O
Study	O
3	O
)	O
in	O
one	O
patient	O
who	O
had	O
previous	O
exposure	O
to	O
XIAFLEX	O
for	O
the	O
treatment	O
of	O
Dupuytren	O
's	O
contracture	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
To	O
minimize	O
the	O
risk	O
of	O
contamination	O
,	O
do	O
not	O
touch	O
dropper	O
tip	O
to	O
any	O
surface	O
.	O
	
Patients	O
eligible	O
for	O
Trial	O
6	O
were	O
those	O
with	O
the	O
G551D	O
,	O
G1244E	O
,	O
G1349D	O
,	O
G178R	O
,	O
G551S	O
,	O
G970R	O
,	O
S1251N	O
,	O
S1255P	O
,	O
S549N	O
,	O
or	O
S549R	O
mutation	O
in	O
the	O
CFTR	O
gene	O
.	O
	
Monitor	O
patients	O
frequently	O
for	O
signs	O
and	O
symptoms	O
of	O
neurological	O
impairment	O
(	O
e.g.	O
,	O
numbness	O
or	O
weakness	O
of	O
the	O
legs	O
,	O
bowel	O
,	O
or	O
bladder	O
dysfunction	O
)	O
.	O
	
Local	B
cystic	I
invasion	I
beyond	I
the	I
kidney	I
occurred	O
,	O
in	O
some	O
cases	O
with	O
imaging	O
characteristics	O
suggestive	O
of	O
abscess	B
formation	O
.	O
	
Discontinue	O
SIRTURO	O
and	O
all	O
other	O
QT	O
prolonging	O
drugs	O
if	O
the	O
patient	O
develops	O
:	O
*	O
Clinically	O
significant	O
ventricular	O
arrhythmia	O
*	O
A	O
QTcF	O
interval	O
of	O
greater	O
than	O
500	O
ms	O
(	O
confirmed	O
by	O
repeat	O
ECG	O
)	O
If	O
syncope	O
occurs	O
,	O
obtain	O
an	O
ECG	O
to	O
detect	O
QT	O
prolongation	O
.	O
	
5.5	O
Drug	O
Reaction	O
With	O
Eosinophilia	O
and	O
Systemic	O
Symptoms	O
(	O
DRESS	O
)	O
/Multiorgan	O
Hypersensitivity	O
Drug	B
Reaction	I
with	I
Eosinophilia	I
and	I
Systemic	I
Symptoms	I
(	O
DRESS	B
)	O
,	O
also	O
known	O
as	O
multiorgan	B
hypersensitivity	I
,	O
has	O
been	O
reported	O
in	O
patients	O
taking	O
antiepileptic	O
drugs	O
,	O
including	O
gabapentin	O
.	O
	
(	O
2	O
,	O
5.1	O
)	O
*	O
Infections	B
:	O
GILENYA	O
may	O
increase	O
the	O
risk	O
of	O
infections	B
.	O
	
During	O
the	O
clinical	O
studies	O
,	O
two	O
patients	O
(	O
<	O
1	O
%	O
)	O
experienced	O
adverse	O
reactions	O
leading	O
to	O
withdrawal	O
.	O
	
In	O
clinical	O
trials	O
,	O
no	O
serious	O
adverse	O
reactions	O
were	O
reported	O
.	O
	
Other	O
Findings	O
:	O
Oral	B
hypoesthesia	I
and/or	O
oral	B
paresthesia	I
may	O
occur	O
directly	O
after	O
administration	O
of	O
SAPHRIS	O
and	O
usually	O
resolves	O
within	O
1	O
hour	O
.	O
	
Correct	O
volume	O
or	O
salt	O
depletion	O
prior	O
to	O
administration	O
of	O
Edarbi	O
,	O
or	O
start	O
treatment	O
at	O
40	O
mg	O
.	O
	
EXCERPT	O
:	O
*	O
Postmenopausal	O
osteoporosis	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
5	O
%	O
and	O
more	O
common	O
than	O
placebo	O
)	O
were	O
:	O
back	B
pain	I
,	O
pain	B
in	I
extremity	I
,	O
hypercholesterolemia	B
,	O
musculoskeletal	B
pain	I
,	O
and	O
cystitis	B
.	O
	
The	O
adverse	O
reactions	O
below	O
reflect	O
exposure	O
to	O
XEOMIN	O
with	O
glabellar	O
lines	O
in	O
placebo-controlled	O
studies	O
.	O
	
The	O
GBCA-associated	O
NSF	B
risk	O
appears	O
highest	O
for	O
patients	O
with	O
chronic	O
,	O
severe	O
kidney	O
disease	O
(	O
GFR	O
<	O
30	O
mL/min/1.73m	O
2	O
)	O
as	O
well	O
as	O
patients	O
with	O
acute	O
kidney	O
injury	O
.	O
	
More	O
than	O
two-thirds	O
of	O
patients	O
were	O
from	O
Asia	O
(	O
GILOTRIF	O
70	O
%	O
;	O
pemetrexed/cisplatin	O
72	O
%	O
)	O
.	O
	
5.4	O
Hypersensitivity	O
Reactions	O
,	O
including	O
Anaphylaxis	O
Acute	B
hypersensitivity	I
reactions	I
,	O
including	O
anaphylaxis	B
and	O
death	B
,	O
have	O
been	O
reported	O
in	O
association	O
with	O
BENLYSTA	O
.	O
	
The	O
most	O
commonly	O
reported	O
adverse	O
event	O
in	O
patients	O
treated	O
with	O
Toviaz	O
was	O
dry	B
mouth	I
.	O
	
The	O
rates	O
of	O
treatment-emergent	O
adverse	O
events	O
resulting	O
in	O
permanent	O
discontinuation	O
were	O
20	O
%	O
and	O
6	O
%	O
for	O
the	O
AFINITOR	O
and	O
placebo	O
treatment	O
groups	O
,	O
respectively	O
.	O
	
Common	O
and	O
Drug-Related	O
Adverse	O
Reactions	O
in	O
Clinical	O
Trials	O
Based	O
on	O
the	O
pooled	O
data	O
from	O
4	O
placebo-controlled	O
,	O
4-	O
or	O
6-week	O
,	O
fixed-	O
or	O
flexible-dose	O
studies	O
,	O
the	O
following	O
adverse	O
reactions	O
occurred	O
in	O
>	O
=5	O
%	O
incidence	O
in	O
the	O
patients	O
treated	O
with	O
FANAPT	O
and	O
at	O
least	O
twice	O
the	O
placebo	O
rate	O
for	O
at	O
least	O
1	O
dose	O
:	O
dizziness	B
,	O
dry	B
mouth	I
,	O
fatigue	B
,	O
nasal	B
congestion	I
,	O
somnolence	B
,	O
tachycardia	B
,	O
orthostatic	B
hypotension	I
,	O
and	O
weight	B
increased	I
.	O
	
In	O
patients	O
with	O
a	O
history	O
of	O
transaminase	O
elevations	O
,	O
more	O
frequent	O
monitoring	O
of	O
liver	O
function	O
tests	O
should	O
be	O
considered	O
.	O
	
For	O
mild	O
to	O
moderate	O
dermatitis	O
,	O
such	O
as	O
localized	O
rash	O
and	O
pruritus	O
,	O
treat	O
symptomatically	O
.	O
	
Serious	O
infections	B
occurred	O
in	O
6.0	O
%	O
of	O
patients	O
treated	O
with	O
BENLYSTA	O
and	O
in	O
5.2	O
%	O
of	O
patients	O
who	O
received	O
placebo	O
.	O
	
(	O
5.2	O
)	O
*	O
Continue	O
therapy	O
with	O
leucovorin	O
until	O
the	O
methotrexate	O
concentration	O
has	O
been	O
maintained	O
below	O
the	O
leucovorin	O
treatment	O
threshold	O
for	O
a	O
minimum	O
of	O
3	O
days	O
.	O
	
(	O
6.1	O
)	O
*	O
Asthma	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
2	O
%	O
)	O
are	O
nasopharyngitis	B
,	O
oral	B
candidiasis	I
,	O
headache	B
,	O
influenza	B
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
bronchitis	B
,	O
sinusitis	B
,	O
oropharyngeal	B
pain	I
,	O
dysphonia	B
,	O
and	O
cough	B
.	O
	
Defined	O
as	O
clinically	O
overt	O
bleeding	B
accompanied	O
by	O
one	O
or	O
more	O
of	O
the	O
following	O
:	O
a	O
decrease	B
in	I
hemoglobin	I
of	O
>	O
=2	O
g/dL	O
,	O
a	O
transfusion	O
of	O
2	O
or	O
more	O
units	O
of	O
packed	O
red	O
blood	O
cells	O
,	O
compartment	B
syndrome	I
or	O
with	O
fatal	B
outcome	I
.	O
	
Do	O
not	O
administer	O
GRANIX	O
to	O
patients	O
with	O
a	O
history	O
of	O
serious	O
allergic	O
reactions	O
to	O
filgrastim	O
or	O
pegfilgrastim	O
.	O
	
Withhold	O
TAFINLAR	O
for	O
fever	O
of	O
101.3oF	O
or	O
higher	O
.	O
	
Thus	O
,	O
the	O
ability	O
to	O
differentiate	O
the	O
adverse	O
event	O
profile	O
between	O
treatments	O
is	O
limited	O
.	O
	
Additional	O
Adverse	O
Reactions	O
Other	O
adverse	O
reactions	O
known	O
to	O
occur	O
following	O
administration	O
of	O
human	O
granulocyte	O
colony-stimulating	O
factors	O
include	O
myalgia	B
,	O
headache	B
,	O
vomiting	B
,	O
Sweet	B
's	I
syndrome	I
(	O
acute	B
febrile	I
neutrophilic	I
dermatosis	I
)	O
,	O
cutaneous	B
vasculitis	I
and	O
thrombocytopenia	B
.	O
	
Table	O
1	O
Age	O
Range	O
Drug-Placebo	O
Difference	O
in	O
Number	O
of	O
Cases	O
of	O
Suicidality	B
per	O
1,000	O
Patients	O
Treated	O
Increases	O
Compared	O
to	O
Placebo	O
<	O
18	O
14	O
additional	O
cases	O
18	O
to	O
24	O
5	O
additional	O
cases	O
Decreases	O
Compared	O
to	O
Placebo	O
25	O
to	O
64	O
1	O
fewer	O
case	O
>	O
=65	O
6	O
fewer	O
cases	O
No	O
suicides	B
occurred	O
in	O
any	O
of	O
the	O
pediatric	O
studies	O
.	O
	
Pneumocystis	B
jiroveci	I
pneumonia	I
,	O
some	O
with	O
a	O
fatal	B
outcome	O
,	O
has	O
been	O
reported	O
in	O
patients	O
who	O
received	O
everolimus	O
.	O
	
Patients	O
with	O
osteosarcoma	O
were	O
eligible	O
for	O
these	O
studies	O
if	O
the	O
plasma	O
methotrexate	O
concentration	O
was	O
greater	O
than	O
50	O
mumol/L	O
at	O
24	O
hours	O
,	O
greater	O
that	O
5	O
mumol/L	O
at	O
48	O
hours	O
,	O
or	O
greater	O
than	O
2	O
standard	O
deviations	O
above	O
the	O
mean	O
methotrexate	O
elimination	O
curve	O
at	O
least	O
12	O
hours	O
after	O
methotrexate	O
administration	O
and	O
there	O
was	O
a	O
2-fold	O
or	O
greater	O
increase	O
in	O
serum	O
creatinine	O
above	O
baseline	O
.	O
	
6.1	O
Clinical	O
Trial	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
the	O
adverse	O
reaction	O
rates	O
observed	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
other	O
trials	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
Injection	B
site	I
pruritus	I
also	O
contributed	O
to	O
the	O
frequently	O
reported	O
reactions	O
.	O
	
Thirty-three	O
patients	O
receiving	O
DIFICID	O
(	O
5.9	O
%	O
)	O
withdrew	O
from	O
trials	O
as	O
a	O
result	O
of	O
adverse	O
reactions	O
(	O
AR	O
)	O
.	O
	
(	O
5.11	O
,	O
8.1	O
)	O
EXCERPT	O
:	O
5.1	O
New	O
Primary	O
Malignancies	O
New	O
primary	B
malignancies	I
,	I
cutaneous	I
,	O
can	O
occur	O
when	O
TAFINLAR	O
is	O
administered	O
as	O
a	O
single	O
agent	O
or	O
when	O
used	O
in	O
combination	O
with	O
trametinib	O
.	O
	
Ensure	O
safe	O
handling	O
to	O
protect	O
patients	O
and	O
health	O
care	O
workers	O
from	O
unintentional	O
radiation	O
exposure	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
]	O
.	O
	
Infections	O
and	O
Infestations	O
:	O
Cellulitis	B
,	O
folliculitis	B
,	O
paronychia	B
,	O
rash	B
pustular	I
.	O
	
Among	O
299	O
patients	O
with	O
chronic	O
ITP	O
who	O
received	O
PROMACTA	O
in	O
the	O
single-arm	O
extension	O
trial	O
,	O
the	O
adverse	O
reactions	O
occurred	O
in	O
a	O
pattern	O
similar	O
to	O
that	O
seen	O
in	O
the	O
placebo-controlled	O
trials	O
.	O
	
The	O
results	O
suggest	O
an	O
approximate	O
2-fold	O
increase	O
in	O
the	O
risk	O
of	O
NAION	B
within	O
5	O
half-lives	O
of	O
PDE5	O
inhibitor	O
use	O
.	O
	
If	O
not	O
treated	O
immediately	O
,	O
penile	O
tissue	O
damage	O
and	O
permanent	O
loss	O
of	O
potency	O
could	O
result	O
.	O
	
Extensive	O
brain	O
atrophy	O
may	O
limit	O
the	O
ability	O
to	O
distinguish	O
grey	O
and	O
white	O
matter	O
on	O
a	O
Vizamyl	O
scan	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.5	O
)	O
]	O
.	O
	
Median	O
duration	O
of	O
treatment	O
was	O
9	O
cycles	O
(	O
range	O
,	O
1-16	O
)	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
(	O
5.2	O
)	O
*	O
Hemorrhage	B
:	O
Major	O
hemorrhagic	B
events	I
can	O
occur	O
in	O
patients	O
receiving	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
.	O
	
These	O
risk	O
differences	O
(	O
drug-placebo	O
difference	O
in	O
the	O
number	O
of	O
cases	O
of	O
suicidality	B
per	O
1,000	O
patients	O
treated	O
)	O
are	O
provided	O
in	O
Table	O
1	O
.	O
	
In	O
both	O
studies	O
,	O
patients	O
received	O
XTANDI	O
160	O
mg	O
orally	O
once	O
daily	O
in	O
the	O
active	O
treatment	O
arm	O
or	O
placebo	O
in	O
the	O
control	O
arm	O
.	O
	
Genital	B
mycotic	I
infections	I
occurred	O
more	O
frequently	O
in	O
female	O
than	O
male	O
patients	O
(	O
see	O
Table	O
1	O
)	O
.	O
	
(	O
5.1	O
)	O
*	O
Measurement	O
of	O
methotrexate	O
using	O
immunoassays	O
is	O
unreliable	O
for	O
samples	O
collected	O
within	O
48	O
hours	O
following	O
VORAXAZE	O
administration	O
.	O
	
Do	O
not	O
give	O
JEVTANA	O
if	O
neutrophil	O
counts	O
are	O
<	O
=1,500	O
cells/mm3	O
.	O
	
In	O
2	O
of	O
the	O
trials	O
(	O
Trial	O
1	O
and	O
Trial	O
3	O
)	O
,	O
treatment	O
was	O
given	O
for	O
48	O
weeks	O
,	O
while	O
in	O
the	O
other	O
trial	O
(	O
Trial	O
2	O
)	O
treatment	O
was	O
given	O
for	O
72	O
weeks	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
In	O
these	O
trials	O
,	O
patients	O
were	O
treated	O
with	O
up	O
to	O
3	O
injections	O
of	O
0.58	O
mg	O
of	O
XIAFLEX	O
or	O
placebo	O
with	O
approximately	O
4-week	O
intervals	O
between	O
injections	O
and	O
the	O
patients	O
had	O
finger	O
extension	O
procedures	O
the	O
day	O
after	O
injection	O
,	O
if	O
needed	O
,	O
to	O
facilitate	O
disruption	O
of	O
the	O
cord	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
5.8	O
Serious	O
Skin	O
Toxicity	O
Serious	O
skin	B
toxicity	I
can	O
occur	O
when	O
TAFINLAR	O
is	O
used	O
in	O
combination	O
with	O
trametinib	O
and	O
with	O
trametinib	O
as	O
a	O
single	O
agent	O
[	O
refer	O
to	O
Full	O
Prescribing	O
Information	O
for	O
trametinib	O
]	O
.	O
	
?	O
	
Patients	O
who	O
develop	O
increased	O
transaminase	O
levels	O
should	O
be	O
closely	O
monitored	O
until	O
the	O
abnormalities	O
resolve	O
.	O
	
(	O
2.3,5.5	O
)	O
*	O
Embryofetal	B
toxicity	I
:	O
Can	O
cause	O
fetal	B
harm	I
.	O
	
Dose	O
delay	O
or	O
reduction	O
was	O
necessary	O
in	O
61	O
%	O
of	O
everolimus	O
patients	O
and	O
29	O
%	O
of	O
placebo	O
patients	O
.	O
	
Baseline	O
and	O
follow-up	O
examinations	O
are	O
recommended	O
in	O
pediatric	O
patients	O
initiating	O
KALYDECO	O
treatment	O
.	O
	
*	O
Lactic	B
acidosis	I
and	O
severe	O
hepatomegaly	B
with	O
steatosis	B
,	O
including	O
fatal	B
cases	O
,	O
have	O
been	O
reported	O
with	O
the	O
use	O
of	O
nucleoside	O
analogs	O
,	O
including	O
tenofovir	O
disoproxil	O
fumarate	O
(	O
DF	O
)	O
,	O
a	O
component	O
of	O
STRIBILD	O
.	O
	
Currently	O
available	O
data	O
are	O
inadequate	O
to	O
determine	O
whether	O
concurrent	O
use	O
of	O
inhaled	O
corticosteroids	O
(	O
ICS	O
)	O
or	O
other	O
long-term	O
asthma	O
control	O
drugs	O
mitigates	O
the	O
increased	O
risk	O
of	O
asthma-related	O
death	B
from	O
LABA	O
.	O
	
Patients	O
should	O
be	O
informed	O
of	O
the	O
signs	O
and	O
symptoms	O
of	O
an	O
acute	O
hypersensitivity	O
reaction	O
and	O
be	O
instructed	O
to	O
seek	O
immediate	O
medical	O
care	O
should	O
a	O
reaction	O
occur	O
.	O
	
Grade	O
3	O
proteinuria	B
was	O
reported	O
in	O
11/359	O
patients	O
(	O
3	O
%	O
)	O
receiving	O
INLYTA	O
and	O
6/355	O
patients	O
(	O
2	O
%	O
)	O
receiving	O
sorafenib	O
[	O
seeAdverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
The	O
mechanism	O
of	O
action	O
of	O
BENLYSTA	O
could	O
increase	O
the	O
risk	O
for	O
the	O
development	O
of	O
malignancies	B
.	O
	
(	O
5.8	O
)	O
*	O
If	O
paradoxical	O
bronchospasm	O
occurs	O
,	O
discontinue	O
BREO	O
ELLIPTA	O
and	O
institute	O
alternative	O
therapy	O
.	O
	
Caution	O
should	O
be	O
exercised	O
when	O
using	O
TNF-blockers	O
,	O
including	O
SIMPONI	O
ARIA	O
,	O
in	O
patients	O
who	O
have	O
or	O
have	O
had	O
significant	O
cytopenias	O
.	O
	
Pancreatitis	B
has	O
been	O
reported	O
in	O
clinical	O
trials	O
(	O
6.1	O
)	O
*	O
Male	O
Osteoporosis	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
5	O
%	O
and	O
more	O
common	O
than	O
placebo	O
)	O
were	O
:	O
back	B
pain	I
,	O
arthralgia	B
,	O
and	O
nasopharyngitis	B
(	O
6.1	O
)	O
*	O
Bone	O
loss	O
due	O
to	O
hormone	O
ablation	O
for	O
cancer	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
=	O
10	O
%	O
and	O
more	O
common	O
than	O
placebo	O
)	O
were	O
:	O
arthralgia	B
and	O
back	B
pain	I
.	O
	
In	O
SPRING-2	O
,	O
822	O
subjects	O
were	O
randomized	O
and	O
received	O
at	O
least	O
1	O
dose	O
of	O
either	O
TIVICAY	O
50	O
mg	O
once	O
daily	O
or	O
raltegravir	O
400	O
mg	O
twice	O
daily	O
,	O
both	O
in	O
combination	O
with	O
fixed-dose	O
dual	O
nucleoside	O
reverse	O
transcriptase	O
inhibitor	O
(	O
NRTI	O
)	O
treatment	O
(	O
either	O
abacavir	O
sulfate	O
and	O
lamivudine	O
[	O
EPZICOM	O
(	O
r	O
)	O
]	O
or	O
emtricitabine/tenofovir	O
[	O
TRUVADA	O
(	O
r	O
)	O
]	O
)	O
.	O
	
In	O
a	O
randomized	O
trial	O
comparing	O
Kyprolis	O
as	O
a	O
single	O
agent	O
versus	O
corticosteroids	O
with	O
optional	O
oral	O
cyclophosphamide	O
for	O
patients	O
with	O
relapsed	O
and	O
refractory	O
multiple	O
myeloma	O
,	O
mortality	B
was	O
higher	O
in	O
the	O
patients	O
treated	O
with	O
Kyprolis	O
in	O
comparison	O
to	O
the	O
control	O
arm	O
in	O
the	O
subgroup	O
of	O
48	O
patients	O
>	O
=75	O
years	O
of	O
age	O
.	O
	
In	O
the	O
short-term	O
,	O
placebo-controlled	O
schizophrenia	O
adult	O
trials	O
,	O
the	O
incidence	O
of	O
reported	O
EPS-related	B
events	I
,	O
excluding	O
events	O
related	O
to	O
akathisia	B
,	O
for	O
SAPHRIS-treated	O
patients	O
was	O
10	O
%	O
versus	O
7	O
%	O
for	O
placebo	O
;	O
and	O
the	O
incidence	O
of	O
akathisia-related	O
events	O
for	O
SAPHRIS-treated	O
patients	O
was	O
6	O
%	O
versus	O
3	O
%	O
for	O
placebo	O
.	O
	
The	O
median	O
duration	O
of	O
treatment	O
was	O
17.5	O
months	O
with	O
XTANDI	O
and	O
4.6	O
months	O
with	O
placebo	O
.	O
	
A	O
recent	O
CBC	O
should	O
be	O
available	O
before	O
initiating	O
treatment	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Spectrum	O
Pharmaceuticals	O
,	O
Inc.	O
at	O
1-888-292-9617	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
Beleodaq	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
The	O
majority	O
of	O
renal	B
cysts	I
.	O
	
If	O
traumatic	O
puncture	O
occurs	O
,	O
delay	O
the	O
administration	O
of	O
ELIQUIS	O
for	O
48	O
hours	O
.	O
	
Patients	O
received	O
INVOKANA	O
100	O
mg	O
(	O
N=3092	O
)	O
,	O
INVOKANA	O
300	O
mg	O
(	O
N=3085	O
)	O
or	O
comparator	O
(	O
N=3262	O
)	O
once	O
daily	O
.	O
	
TECFIDERA	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
pre-existing	O
low	O
lymphocyte	O
counts	O
.	O
	
Anaphylaxis	B
and	O
angioedema	B
associated	O
with	O
laryngeal	B
edema	I
can	O
be	O
fatal	B
.	O
	
Of	O
34	O
patients	O
enrolled	O
,	O
32	O
had	O
the	O
G551D	O
mutation	O
and	O
2	O
had	O
the	O
S549N	O
mutation	O
.	O
	
Withhold	O
COMETRIQ	O
in	O
patients	O
who	O
develop	O
intolerable	O
Grade	O
2	O
PPES	O
or	O
Grade	O
3-4	O
PPES	O
until	O
improvement	O
to	O
Grade	O
1	O
;	O
resume	O
COMETRIQ	O
at	O
a	O
reduced	O
dose	O
.	O
	
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
The	O
infections	B
consisted	O
primarily	O
of	O
upper	B
respiratory	I
tract	I
infections	I
,	O
herpes	B
infections	I
,	O
urinary	B
tract	I
infections	I
,	O
and	O
lower	B
respiratory	I
tract	I
infections	I
.	O
	
Hypoglycemia	O
The	O
frequency	O
of	O
hypoglycemia	B
by	O
study	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
is	O
shown	O
in	O
Table	O
5	O
.	O
	
Baseline	O
estimated	O
renal	O
function	O
was	O
normal	O
or	O
mildly	O
impaired	O
(	O
eGFR	O
>	O
=60	O
ml/min/1.73	O
m2	O
)	O
in	O
95.7	O
%	O
of	O
the	O
TRULICITY	O
population	O
.	O
	
Resume	O
COMETRIQ	O
therapy	O
after	O
surgery	O
based	O
on	O
clinical	O
judgment	O
of	O
adequate	O
wound	O
healing	O
.	O
	
Laboratory	O
Tests	O
Increase	O
in	O
Hematocrit	O
In	O
the	O
pool	O
of	O
13	O
placebo-controlled	O
studies	O
,	O
increases	B
from	I
baseline	I
in	I
mean	I
hematocrit	I
values	I
were	O
observed	O
in	O
FARXIGA-treated	O
patients	O
starting	O
at	O
Week	O
1	O
and	O
continuing	O
up	O
to	O
Week	O
16	O
,	O
when	O
the	O
maximum	O
mean	O
difference	O
from	O
baseline	O
was	O
observed	O
.	O
	
The	O
data	O
described	O
below	O
represent	O
adverse	O
reactions	O
observed	O
from	O
the	O
two	O
placebo-controlled	O
trials	O
,	O
consisting	O
of	O
77	O
patients	O
who	O
received	O
FIRAZYR	O
at	O
a	O
dose	O
of	O
30	O
mg	O
SC	O
,	O
and	O
75	O
who	O
received	O
placebo	O
.	O
	
Avoid	O
using	O
ZYKADIA	O
in	O
combination	O
with	O
other	O
agents	O
known	O
to	O
cause	O
bradycardia	O
(	O
e.g.	O
,	O
beta-blockers	O
,	O
non-dihydropyridine	O
calcium	O
channel	O
blockers	O
,	O
clonidine	O
,	O
and	O
digoxin	O
)	O
to	O
the	O
extent	O
possible	O
.	O
	
Musculoskeletal	O
and	O
Connective	O
Tissue	O
Disorders	O
:	O
rhabdomyolysis	B
Skin	O
and	O
Subcutaneous	O
Tissue	O
Disorders	O
:	O
Fatal	B
cases	O
of	O
toxic	B
epidermal	I
necrolysis	I
have	O
been	O
reported	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
The	O
use	O
of	O
clinical	O
information	O
in	O
the	O
interpretation	O
of	O
Neuraceq	O
images	O
has	O
not	O
been	O
evaluated	O
and	O
may	O
lead	O
to	O
errors	O
.	O
	
5.3	O
Withdrawal	O
Symptoms	O
Abrupt	O
discontinuation	O
of	O
ONFI	O
should	O
be	O
avoided	O
.	O
	
(	O
5.3	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
5.1	O
Hyperammonemia	O
Any	O
episode	O
of	O
acute	O
symptomatic	O
hyperammonemia	O
should	O
be	O
treated	O
as	O
a	O
life-threatening	O
emergency	O
.	O
	
Data	O
are	O
not	O
available	O
to	O
determine	O
whether	O
the	O
rate	O
of	O
death	B
in	O
patients	O
with	O
COPD	O
is	O
increased	O
by	O
LABA	O
.	O
	
In	O
all	O
three	O
studies	O
a	O
placebo	O
(	O
Cycle	O
1	O
of	O
the	O
breast	O
cancer	O
study	O
only	O
)	O
or	O
a	O
non-US-approved	O
filgrastim	O
product	O
were	O
used	O
as	O
controls	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Thrombocytopenia	B
,	O
leukopenia	B
(	O
neutropenia	B
and	O
lymphopenia	B
)	O
,	O
and	O
anemia	B
:	O
Monitor	O
blood	O
counts	O
and	O
modify	O
dosage	O
for	O
hematologic	O
toxicities	O
.	O
	
The	O
majority	O
of	O
these	O
cases	O
were	O
mild	O
to	O
moderate	O
and	O
occurred	O
during	O
the	O
first	O
year	O
of	O
exposure	O
.	O
	
5.9	O
Reversible	O
Posterior	O
Leukoencephalopathy	O
Syndrome	O
Reversible	B
Posterior	I
Leukoencephalopathy	I
Syndrome	I
(	O
RPLS	B
)	O
,	O
a	O
syndrome	O
of	O
subcortical	B
vasogenic	I
edema	I
diagnosed	O
by	O
characteristic	O
finding	O
on	O
MRI	O
,	O
occurred	O
in	O
one	O
(	O
<	O
1	O
%	O
)	O
patient	O
.	O
	
5.5	O
Risk	O
of	O
bleeding	O
in	O
Patients	O
with	O
Abnormal	O
Coagulation	O
In	O
the	O
XIAFLEX	O
trials	O
in	O
Dupuytren	O
's	O
contracture	O
(	O
Studies	O
1	O
and	O
2	O
)	O
,	O
70	O
%	O
and	O
38	O
%	O
of	O
XIAFLEX-treated	O
patients	O
developed	O
an	O
ecchymosis/contusion	O
or	O
an	O
injection	B
site	I
hemorrhage	I
,	O
respectively	O
(	O
see	O
Table	O
3	O
)	O
.	O
	
5.3	O
Hypoglycemia	O
with	O
Concomitant	O
Use	O
with	O
Insulin	O
and	O
Insulin	O
Secretagogues	O
Insulin	O
and	O
insulin	O
secretagogues	O
are	O
known	O
to	O
cause	O
hypoglycemia	O
.	O
	
The	O
safety	O
of	O
COMETRIQ	O
was	O
evaluated	O
in	O
330	O
patients	O
with	O
progressive	O
metastatic	O
medullary	O
thyroid	O
cancer	O
randomized	O
to	O
receive	O
140	O
mg	O
COMETRIQ	O
(	O
n	O
=	O
214	O
)	O
or	O
placebo	O
(	O
n	O
=	O
109	O
)	O
administered	O
daily	O
until	O
disease	O
progression	O
or	O
intolerable	O
toxicity	O
in	O
a	O
randomized	O
,	O
doubleblind	O
,	O
controlled	O
trial	O
.	O
	
Patients	O
with	O
a	O
prior	O
DRESS	O
reaction	O
with	O
either	O
oxcarbazepine	O
or	O
APTIOM	O
should	O
not	O
be	O
treated	O
with	O
APTIOM	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
Monitor	O
patients	O
for	O
pulmonary	O
symptoms	O
indicative	O
of	O
ILD/pneumonitis	O
.	O
	
If	O
pancreatitis	O
is	O
suspected	O
,	O
NESINA	O
should	O
promptly	O
be	O
discontinued	O
and	O
appropriate	O
management	O
should	O
be	O
initiated	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Wyeth	O
Pharmaceuticals	O
Inc.	O
,	O
a	O
subsidiary	O
of	O
Pfizer	O
Inc.	O
,	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
(	O
5.2	O
)	O
*	O
Remove	O
contact	O
lenses	O
prior	O
to	O
instillation	O
of	O
BEPREVE	O
.	O
	
These	O
metabolic	B
changes	I
include	O
hyperglycemia	B
,	O
dyslipidemia	B
,	O
and	O
weight	B
gain	I
.	O
	
This	O
case	O
represented	O
1	O
out	O
of	O
1209	O
patients	O
in	O
BOSULIF	O
clinical	O
trials	O
.	O
	
Do	O
not	O
start	O
in	O
patients	O
with	O
active	O
infections	O
.	O
	
Discontinuations	O
due	O
to	O
adverse	O
events	O
were	O
reported	O
for	O
6	O
%	O
of	O
XTANDI-treated	O
patients	O
and	O
6	O
%	O
of	O
placebo-treated	O
patients	O
.	O
	
Similar	O
results	O
may	O
be	O
anticipated	O
in	O
patients	O
treated	O
with	O
Edarbi	O
[	O
seeDrug	O
Interactions	O
(	O
7	O
)	O
,	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
,	O
andClinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
Adverse	O
reactions	O
reported	O
in	O
less	O
than	O
1	O
%	O
of	O
subjects	O
were	O
:	O
facial	B
paresis	I
(	O
brow	B
ptosis	I
)	O
,	O
muscle	B
disorder	I
(	O
elevation	B
of	I
eyebrow	I
)	O
,	O
injection	B
site	I
pain	I
,	O
and	O
eyelid	B
edema	I
.	O
	
In	O
some	O
patients	O
,	O
heart	B
rate	I
decrease	I
during	O
the	O
second	O
period	O
is	O
more	O
pronounced	O
than	O
the	O
decrease	O
observed	O
in	O
the	O
first	O
6	O
hours	O
.	O
	
6Includes	O
the	O
preferred	O
terms	O
somnolence	B
,	O
sedation	B
,	O
and	O
hypersomnia	B
.	O
	
Discontinue	O
INLYTA	O
if	O
hypertension	O
is	O
severe	O
and	O
persistent	O
despite	O
anti-hypertensive	O
therapy	O
and	O
dose	O
reduction	O
of	O
INLYTA	O
,	O
and	O
discontinuation	O
should	O
be	O
considered	O
if	O
there	O
is	O
evidence	O
of	O
hypertensive	O
crisis	O
.	O
	
While	O
these	O
symptoms	O
can	O
occur	O
at	O
low	O
doses	O
,	O
they	O
occur	O
more	O
frequently	O
and	O
with	O
greater	O
severity	O
with	O
high	O
potency	O
and	O
at	O
higher	O
doses	O
of	O
first	O
generation	O
antipsychotic	O
drugs	O
.	O
	
The	O
information	O
presented	O
in	O
these	O
sections	O
was	O
derived	O
from	O
pooled	O
data	O
from	O
4	O
placebo-controlled	O
,	O
4-	O
or	O
6-week	O
,	O
fixed-	O
or	O
flexible-dose	O
studies	O
in	O
patients	O
who	O
received	O
FANAPT	O
at	O
daily	O
doses	O
within	O
a	O
range	O
of	O
10	O
to	O
24	O
mg	O
(	O
n=874	O
)	O
.	O
	
Patients	O
treated	O
with	O
OTEZLA	O
should	O
have	O
their	O
weight	O
monitored	O
regularly	O
.	O
	
In	O
the	O
controlled	O
clinical	O
trials	O
,	O
malignancies	B
(	O
including	O
non-melanoma	B
skin	I
cancers	I
)	O
were	O
reported	O
in	O
0.4	O
%	O
of	O
patients	O
receiving	O
BENLYSTA	O
and	O
0.4	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
Magnetic	O
resonance	O
imaging	O
is	O
necessary	O
to	O
confirm	O
the	O
diagnosis	O
of	O
RPLS	O
.	O
	
5.2	O
Somnolence/Sedation	O
and	O
Dizziness	O
HORIZANT	O
causes	O
somnolence/sedation	O
and	O
dizziness	B
(	O
see	O
Tables	O
4	O
and	O
5	O
)	O
.	O
	
Stop	O
treatment	O
with	O
INLYTA	O
at	O
least	O
24	O
hours	O
prior	O
to	O
scheduled	O
surgery	O
.	O
	
Diarrhea	B
,	O
headache	B
,	O
and	O
nausea	B
were	O
the	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
.	O
	
The	O
overall	O
incidence	O
of	O
bone	B
pain	I
in	O
Cycle	O
1	O
of	O
treatment	O
was	O
3.4	O
%	O
(	O
3.4	O
%	O
GRANIX	O
,	O
1.4	O
%	O
placebo	O
,	O
7.5	O
%	O
non-US-approved	O
filgrastim	O
product	O
)	O
.	O
	
5.14	O
Exacerbation	O
of	O
Other	O
Conditions	O
Estrogens	O
may	O
cause	O
an	O
exacerbation	O
of	O
asthma	O
,	O
diabetes	O
mellitus	O
,	O
epilepsy	O
,	O
migraine	O
or	O
porphyria	O
,	O
systemic	O
lupus	O
erythematosus	O
,	O
and	O
hepatic	O
hemangiomas	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
women	O
with	O
these	O
conditions	O
.	O
	
Treatment	O
of	O
latent	O
tuberculosis	O
infection	O
should	O
be	O
initiated	O
prior	O
to	O
NULOJIX	O
use	O
.	O
	
Atypical	B
femoral	I
fractures	I
most	O
commonly	O
occur	O
with	O
minimal	O
or	O
no	O
trauma	O
to	O
the	O
affected	O
area	O
.	O
	
5.5	O
Other	O
Serious	O
Infections	O
Patients	O
receiving	O
immunosuppressants	O
,	O
including	O
NULOJIX	O
,	O
are	O
at	O
increased	O
risk	O
of	O
developing	O
protozoal	B
infections	I
,	O
including	O
opportunistic	B
infections	I
.	O
	
(	O
5.2	O
)	O
*	O
Neutropenia	B
-	O
The	O
addition	O
of	O
VICTRELIS	O
to	O
peginterferon	O
alfa	O
and	O
ribavirin	O
may	O
result	O
in	O
worsening	B
of	I
neutropenia	I
associated	O
with	O
peginterferon	O
alfa	O
and	O
ribavirin	O
therapy	O
alone	O
.	O
	
In	O
children	O
,	O
the	O
adverse	O
reactions	O
were	O
pyrexia	B
,	O
cough	B
,	O
vomiting	B
,	O
anorexia	B
,	O
and	O
headache	B
.	O
	
Therefore	O
,	O
PDE5	O
inhibitors	O
,	O
including	O
STENDRA	O
,	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients	O
and	O
only	O
when	O
the	O
anticipated	O
benefits	O
outweigh	O
the	O
risks	O
.	O
	
Rates	O
in	O
clinical	O
studies	O
for	O
CIMZIA	O
can	O
not	O
be	O
compared	O
to	O
the	O
rates	O
of	O
clinical	O
trials	O
of	O
other	O
TNF	O
blockers	O
and	O
may	O
not	O
predict	O
the	O
rates	O
observed	O
when	O
CIMZIA	O
is	O
used	O
in	O
a	O
broader	O
patient	O
population	O
.	O
	
The	O
majority	O
of	O
the	O
TB	B
cases	O
occurred	O
in	O
countries	O
with	O
a	O
high	O
incidence	O
rate	O
of	O
TB	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Vizamyl	O
scan	O
results	O
are	O
indicative	O
of	O
the	O
brain	O
neuritic	O
amyloid	O
plaque	O
content	O
only	O
at	O
the	O
time	O
of	O
image	O
acquisition	O
and	O
a	O
negative	O
scan	O
result	O
does	O
not	O
preclude	O
the	O
development	O
of	O
brain	O
amyloid	O
in	O
the	O
future	O
.	O
	
(	O
5.5	O
,	O
2.3	O
)	O
*	O
Ocular	B
Toxicities	I
:	O
Perform	O
ophthalmologic	O
evaluation	O
for	O
any	O
visual	O
disturbances	O
.	O
	
The	O
following	O
serious	O
adverse	O
reactions	O
of	O
trametinib	O
as	O
a	O
single	O
agent	O
,	O
which	O
may	O
occur	O
when	O
TAFINLAR	O
is	O
used	O
in	O
combination	O
with	O
trametinib	O
,	O
are	O
not	O
described	O
in	O
the	O
Full	O
Prescribing	O
Information	O
for	O
TAFINLAR	O
:	O
*	O
Retinal	B
vein	I
occlusion	I
*	O
Interstitial	B
lung	I
disease	I
*	O
New	O
primary	B
malignancies	I
,	I
cutaneous	I
,	O
can	O
occur	O
when	O
TAFINLAR	O
is	O
administered	O
as	O
a	O
single	O
agent	O
or	O
in	O
combination	O
with	O
trametinib	O
.	O
	
5.2	O
Cardiovascular	O
Events	O
In	O
the	O
randomized	O
controlled	O
studies	O
,	O
there	O
was	O
a	O
higher	O
rate	O
of	O
cardiovascular	B
thromboembolic	I
events	I
(	O
cardiovascular	B
deaths	I
,	O
non-fatal	O
myocardial	B
infarctions	I
,	O
and	O
non-fatal	O
strokes	B
)	O
in	O
patients	O
treated	O
with	O
ULORIC	O
(	O
0.74	O
per	O
100	O
P-Y	O
[	O
95	O
%	O
Confidence	O
Interval	O
(	O
CI	O
)	O
0.36-1.37	O
]	O
)	O
than	O
allopurinol	O
(	O
0.60	O
per	O
100	O
P-Y	O
[	O
95	O
%	O
CI	O
0.16-1.53	O
]	O
)	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
A	O
dental	O
examination	O
with	O
appropriate	O
preventive	O
dentistry	O
is	O
recommended	O
prior	O
to	O
treatment	O
with	O
Prolia	O
in	O
patients	O
with	O
risk	O
factors	O
for	O
ONJ	O
such	O
as	O
invasive	O
dental	O
procedures	O
(	O
e.g	O
.	O
	
A	O
higher	O
risk	O
of	O
serious	O
infections	B
was	O
also	O
observed	O
in	O
combination	O
use	O
of	O
TNF	O
blockers	O
with	O
abatacept	O
and	O
rituximab	O
.	O
	
AMPYRA	O
has	O
not	O
been	O
evaluated	O
in	O
patients	O
with	O
a	O
history	O
of	O
seizures	O
or	O
with	O
evidence	O
of	O
epileptiform	O
activity	O
on	O
an	O
EEG	O
,	O
as	O
these	O
patients	O
were	O
excluded	O
from	O
clinical	O
trials	O
.	O
	
In	O
a	O
pooled	O
analysis	O
of	O
randomized	O
double-blind	O
oncology	O
clinical	O
trials	O
,	O
the	O
incidence	O
of	O
angioedema	B
in	O
patients	O
taking	O
everolimus	O
with	O
an	O
ACE	O
inhibitor	O
was	O
6.8	O
%	O
compared	O
to	O
1.3	O
%	O
in	O
the	O
control	O
arm	O
with	O
an	O
ACE	O
inhibitor	O
.	O
	
Most	O
patients	O
who	O
developed	O
IgG	O
antibodies	O
did	O
so	O
within	O
the	O
first	O
3	O
months	O
of	O
exposure	O
(	O
median	O
time	O
to	O
seroconversion	O
was	O
4	O
weeks	O
)	O
.	O
	
Nervous	O
System	O
Disorders	O
Tremor	B
.	O
	
The	O
detection	O
of	O
antibody	O
formation	O
is	O
highly	O
dependent	O
on	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
assay	O
.	O
	
Limited	O
data	O
suggest	O
that	O
patients	O
with	O
a	O
history	O
of	O
multiple	O
drug	O
allergies	O
or	O
significant	O
hypersensitivity	O
may	O
be	O
at	O
increased	O
risk	O
.	O
	
Tell	O
your	O
healthcare	O
provider	O
if	O
you	O
have	O
any	O
side	O
effects	O
that	O
bother	O
you	O
or	O
do	O
not	O
go	O
away	O
.	O
	
(	O
5.3	O
)	O
*	O
Not	O
recommended	O
in	O
patients	O
with	O
severe	O
hepatic	O
impairment	O
.	O
	
If	O
the	O
recommended	O
dose	O
is	O
exceeded	O
,	O
the	O
dose	O
should	O
be	O
reduced	O
to	O
600	O
mg	O
daily	O
for	O
1	O
week	O
prior	O
to	O
discontinuation	O
to	O
minimize	O
the	O
potential	O
of	O
withdrawal	O
seizure	O
.	O
	
In	O
short-term	O
,	O
placebo-controlled	O
bipolar	O
adult	O
mania	O
trials	O
,	O
the	O
mean	O
increase	B
in	I
transaminase	I
levels	I
for	O
SAPHRIS-treated	O
patients	O
was	O
8.9	O
units/L	O
compared	O
to	O
a	O
decrease	O
of	O
4.9	O
units/L	O
in	O
placebo-treated	O
patients	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Anaphylaxis	B
and	O
Hypersensitivity	B
Reactions	I
:	O
Life-threatening	O
anaphylaxis	B
and	O
hypersensitivity	B
reactions	I
have	O
been	O
observed	O
in	O
some	O
patients	O
during	O
and	O
after	O
treatment	O
with	O
alglucosidase	O
alfa	O
.	O
	
Screen	O
patients	O
for	O
acute	O
kidney	O
injury	O
and	O
other	O
conditions	O
that	O
may	O
reduce	O
renal	O
function	O
.	O
	
Because	O
of	O
physiological	O
diurnal	O
variation	O
,	O
there	O
is	O
a	O
second	O
period	O
of	O
heart	B
rate	I
decrease	I
within	O
24	O
hours	O
after	O
the	O
first	O
dose	O
.	O
	
Headache	B
was	O
the	O
most	O
common	O
adverse	O
reaction	O
,	O
reported	O
for	O
57	O
subjects	O
(	O
7.1	O
%	O
)	O
,	O
followed	O
by	O
injection	B
site	I
hematoma	I
in	O
8	O
subjects	O
(	O
1.0	O
%	O
)	O
.	O
	
STRIBILD	O
should	O
be	O
discontinued	O
if	O
estimated	O
creatinine	O
clearance	O
declines	O
below	O
50	O
mL	O
per	O
minute	O
as	O
dose	O
interval	O
adjustment	O
required	O
for	O
emtricitabine	O
and	O
tenofovir	O
DF	O
can	O
not	O
be	O
achieved	O
with	O
the	O
fixed-dose	O
combination	O
tablet	O
.	O
	
Monitor	O
for	O
infection	O
during	O
treatment	O
and	O
for	O
2	O
months	O
after	O
discontinuation	O
.	O
	
In	O
the	O
546	O
patients	O
from	O
the	O
safety	O
population	O
,	O
the	O
incidence	O
of	O
ALT	B
elevation	I
was	O
17	O
%	O
and	O
AST	B
elevation	I
was	O
14	O
%	O
.	O
	
Renal	O
Cysts	O
Renal	B
cysts	I
were	O
experienced	O
by	O
50	O
(	O
3	O
%	O
)	O
of	O
1669	O
patients	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
described	O
in	O
more	O
detail	O
in	O
other	O
sections	O
of	O
the	O
prescribing	O
information	O
.	O
	
Interrupt	O
or	O
discontinue	O
BLINCYTO	O
as	O
recommended	O
.	O
	
Additional	O
Adverse	O
Reactions	O
Observed	O
during	O
All	O
Phase	O
2	O
and	O
3	O
Clinical	O
Trials	O
Following	O
is	O
a	O
list	O
of	O
adverse	O
reactions	O
reported	O
by	O
patients	O
treated	O
with	O
POTIGA	O
during	O
all	O
clinical	O
trials	O
:	O
rash	B
,	O
nystagmus	B
,	O
dyspnea	B
,	O
leukopenia	B
,	O
muscle	B
spasms	I
,	O
alopecia	B
,	O
nephrolithiasis	B
,	O
syncope	B
,	O
neutropenia	B
,	O
thrombocytopenia	B
,	O
euphoric	B
mood	I
,	O
renal	B
colic	I
,	O
coma	B
,	O
encephalopathy	B
.	O
	
TRULICITY	O
0.75	O
mg	O
and	O
1.5	O
mg	O
resulted	O
in	O
a	O
mean	O
increase	B
in	I
heart	I
rate	I
)	O
of	O
2-4	O
beats	O
per	O
minute	O
(	O
bpm	O
)	O
.	O
	
Baseline	O
estimated	O
renal	O
function	O
was	O
normal	O
or	O
mildly	O
impaired	O
(	O
eGFR	O
>	O
=60mL/min/1.73	O
m	O
2	O
)	O
in	O
96.0	O
%	O
of	O
the	O
pooled	O
study	O
populations	O
.	O
	
Immunogenicity	O
Patients	O
were	O
tested	O
at	O
multiple	O
time	O
points	O
for	O
antibodies	O
to	O
certolizumab	O
pegol	O
during	O
Studies	O
CD1	O
and	O
CD2	O
.	O
	
An	O
increase	B
in	I
blood	I
pressure	I
has	O
been	O
reported	O
in	O
women	O
taking	O
COCs	O
,	O
and	O
this	O
increase	O
is	O
more	O
likely	O
in	O
older	O
women	O
and	O
with	O
extended	O
duration	O
of	O
use	O
.	O
	
5.6	O
Bladder	O
Cancer	O
Across	O
22	O
clinical	O
studies	O
,	O
newly	O
diagnosed	O
cases	O
of	O
bladder	B
cancer	I
were	O
reported	O
in	O
10/6045	O
patients	O
(	O
0.17	O
%	O
)	O
treated	O
with	O
FARXIGA	O
and	O
1/3512	O
patient	O
(	O
0.03	O
%	O
)	O
treated	O
with	O
placebo/comparator	O
.	O
	
Dosage	O
Modifications	O
due	O
to	O
Adverse	O
Reactions	O
In	O
the	O
trial	O
,	O
dosage	O
adjustments	O
due	O
to	O
adverse	O
reactions	O
occurred	O
in	O
12	O
%	O
of	O
Beleodaq-treated	O
patients	O
.	O
	
Dyspepsia	B
(	O
including	O
abdominal	B
pain	I
upper	I
,	O
abdominal	B
pain	I
,	O
abdominal	B
discomfort	I
,	O
and	O
epigastric	B
discomfort	I
)	O
occurred	O
in	O
patients	O
on	O
PRADAXA	O
in	O
7.5	O
%	O
vs.	O
5.5	O
%	O
on	O
warfarin	O
,	O
and	O
gastritis-like	O
symptoms	O
(	O
including	O
gastritis	B
,	O
GERD	B
,	O
esophagitis	B
,	O
erosive	B
gastritis	I
and	O
gastric	B
hemorrhage	I
)	O
occurred	O
at	O
3.0	O
%	O
vs.	O
1.7	O
%	O
,	O
respectively	O
.	O
	
No	O
trial	O
adequate	O
to	O
determine	O
whether	O
the	O
rate	O
of	O
asthma-related	O
death	B
is	O
increased	O
in	O
subjects	O
treated	O
with	O
BREO	O
ELLIPTA	O
has	O
been	O
conducted	O
.	O
	
In	O
patients	O
with	O
prior	O
history	O
of	O
bladder	O
cancer	O
,	O
the	O
benefits	O
of	O
glycemic	O
control	O
versus	O
unknown	O
risks	O
for	O
cancer	O
recurrence	O
with	O
FARXIGA	O
should	O
be	O
considered	O
.	O
	
A	O
small	O
proportion	O
of	O
women	O
will	O
have	O
adverse	B
lipid	I
changes	I
while	O
on	O
COCs	O
.	O
	
Advise	O
women	O
of	O
potential	O
risk	O
to	O
a	O
fetus	O
and	O
to	O
avoid	O
pregnancy	O
while	O
taking	O
Zydelig	O
.	O
	
ECG	O
monitoring	O
is	O
recommended	O
if	O
therapy	O
is	O
initiated	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
,	O
bradyarrhythmias	O
,	O
drugs	O
known	O
to	O
prolong	O
the	O
QT	O
interval	O
,	O
including	O
Class	O
Ia	O
and	O
III	O
antiarrhythmics	O
,	O
and	O
electrolyte	O
abnormalities	O
.	O
	
Withhold	O
HALAVEN	O
in	O
patients	O
who	O
experience	O
Grade	O
3	O
or	O
4	O
peripheral	O
neuropathy	O
until	O
resolution	O
to	O
Grade	O
2	O
or	O
less	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
If	O
this	O
drug	O
is	O
used	O
during	O
pregnancy	O
,	O
or	O
if	O
a	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
this	O
drug	O
,	O
she	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
5.7	O
Neutropenia	O
Treatment-emergent	O
Grade	O
3	O
or	O
4	O
neutropenia	B
occurred	O
in	O
31	O
%	O
of	O
Zydelig-treated	O
patients	O
across	O
clinical	O
trials	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Grade	O
2	O
or	O
higher	O
laboratory	O
abnormalities	B
that	I
represent	I
a	I
worsening	I
from	I
baseline	I
of	I
AST	I
occurred	O
in	O
27.8	O
%	O
,	O
25.0	O
%	O
and	O
7.1	O
%	O
respectively	O
,	O
of	O
INTELENCE	O
(	O
r	O
)	O
-treated	O
co-infected	O
subjects	O
as	O
compared	O
to	O
6.7	O
%	O
,	O
7.5	O
%	O
and	O
1.8	O
%	O
of	O
non-co-infected	O
INTELENCE	O
(	O
r	O
)	O
-treated	O
subjects	O
.	O
	
5.5	O
Increases	O
in	O
Low-Density	O
Lipoprotein	O
Cholesterol	O
(	O
LDL-C	O
)	O
Increases	B
in	I
LDL-C	I
occur	O
with	O
FARXIGA	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Monitor	O
fasting	O
serum	O
glucose	O
prior	O
to	O
the	O
start	O
of	O
ZYKADIA	O
treatment	O
and	O
periodically	O
thereafter	O
as	O
clinically	O
indicated	O
.	O
	
Co-administration	O
of	O
a	O
corticosteroid	O
suppresses	O
adrenocorticotropic	O
hormone	O
(	O
ACTH	O
)	O
drive	O
,	O
resulting	O
in	O
a	O
reduction	O
in	O
the	O
incidence	O
and	O
severity	O
of	O
these	O
adverse	O
reactions	O
.	O
	
COCs	O
may	O
decrease	B
glucose	I
tolerance	I
in	O
a	O
dose-related	O
fashion	O
.	O
	
When	O
plasma	O
ammonia	O
level	O
is	O
normalized	O
,	O
dietary	O
protein	O
intake	O
can	O
usually	O
be	O
reintroduced	O
.	O
	
Reported	O
infections	O
include	O
:	O
*	O
Active	B
tuberculosis	I
,	O
including	O
reactivation	B
of	I
latent	I
tuberculosis	I
.	O
	
A	O
28-week	O
,	O
placebo-controlled	O
,	O
US	O
trial	O
that	O
compared	O
the	O
safety	O
of	O
another	O
LABA	O
(	O
salmeterol	O
)	O
with	O
placebo	O
,	O
each	O
added	O
to	O
usual	O
asthma	O
therapy	O
,	O
showed	O
an	O
increase	O
in	O
asthma-related	O
deaths	B
in	O
subjects	O
receiving	O
salmeterol	O
(	O
13/13,176	O
in	O
subjects	O
treated	O
with	O
salmeterol	O
vs.	O
3/13,179	O
in	O
subjects	O
treated	O
with	O
placebo	O
;	O
relative	O
risk	O
:	O
4.37	O
[	O
95	O
%	O
CI	O
:	O
1.25	O
,	O
15.34	O
]	O
)	O
.	O
	
Discontinue	O
COMETRIQ	O
for	O
severe	O
hypertension	O
that	O
can	O
not	O
be	O
controlled	O
with	O
anti-hypertensive	O
therapy	O
.	O
	
These	O
adverse	O
reactions	O
were	O
not	O
present	O
at	O
baseline	O
,	O
occurred	O
more	O
commonly	O
on	O
TRULICITY	O
than	O
on	O
placebo	O
,	O
and	O
occurred	O
in	O
at	O
least	O
5	O
%	O
of	O
patients	O
treated	O
with	O
TRULICITY	O
.	O
	
[	O
See	O
Clinical	O
Studies	O
(	O
14	O
)	O
.	O
]	O
	
Six	O
of	O
the	O
8	O
cases	O
presented	O
with	O
CNS	O
involvement	O
.	O
	
In	O
a	O
short-term	O
placebo-controlled	O
trial	O
(	O
4-weeks	O
)	O
,	O
the	O
mean	O
change	O
from	O
baseline	O
to	O
endpoint	O
in	O
plasma	B
prolactin	I
levels	I
for	I
the	I
FANAPT	I
24	I
mg/day-treated	I
group	I
was	I
an	I
increase	I
of	O
2.6	O
ng/mL	O
compared	O
to	O
a	O
decrease	O
of	O
6.3	O
ng/mL	O
in	O
the	O
placebo-group	O
.	O
	
Pre-existing	O
hypocalcemia	O
must	O
be	O
corrected	O
prior	O
to	O
initiating	O
therapy	O
with	O
Prolia	O
.	O
	
The	O
finding	O
of	O
increased	O
risk	O
with	O
AEDs	O
of	O
varying	O
mechanism	O
of	O
action	O
and	O
across	O
a	O
range	O
of	O
indications	O
suggests	O
that	O
the	O
risk	O
applies	O
to	O
all	O
AEDs	O
used	O
for	O
any	O
indication	O
.	O
	
In	O
these	O
trials	O
6	O
%	O
of	O
patients	O
on	O
POTIGA	O
and	O
1.2	O
%	O
on	O
placebo	O
discontinued	O
treatment	O
because	O
of	O
dizziness	B
;	O
3	O
%	O
of	O
patients	O
on	O
POTIGA	O
and	O
<	O
1.0	O
%	O
on	O
placebo	O
discontinued	O
because	O
of	O
somnolence	B
.	O
	
Most	O
cases	O
of	O
transaminase	B
elevations	I
occurred	O
early	O
in	O
treatment	O
;	O
of	O
patients	O
who	O
experienced	O
transaminase	B
elevations	I
of	O
any	O
grade	O
,	O
more	O
than	O
80	O
%	O
experienced	O
their	O
first	O
event	O
within	O
the	O
first	O
3	O
months	O
.	O
	
If	O
such	O
effects	O
occur	O
,	O
ARCAPTA	O
NEOHALER	O
may	O
need	O
to	O
be	O
discontinued	O
.	O
	
DUAVEE	O
is	O
not	O
for	O
pregnant	O
women	O
.	O
	
(	O
5.2	O
)	O
*	O
Progressive	B
multifocal	I
leukoencephalopathy	I
(	O
PML	B
)	O
;	O
Withhold	O
GILENYA	O
at	O
the	O
first	O
sign	O
or	O
symptom	O
suggestive	O
of	O
PML	O
.	O
	
If	O
anaphylaxis	O
or	O
severe	O
hypersensitivity	O
reactions	O
occur	O
,	O
immediately	O
discontinue	O
infusion	O
and	O
initiate	O
appropriate	O
medical	O
treatment	O
(	O
5.1	O
)	O
.	O
	
In	O
a	O
52-week	O
,	O
double-blind	O
,	O
comparator-controlled	O
trial	O
that	O
included	O
primarily	O
adult	O
patients	O
with	O
schizophrenia	O
,	O
the	O
mean	O
increase	B
from	I
baseline	I
of	I
ALT	I
was	O
1.7	O
units/L	O
.	O
	
An	O
elevated	O
risk	O
of	O
acute	B
dystonia	I
is	O
observed	O
in	O
males	O
and	O
younger	O
age	O
groups	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
,	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.4	O
)	O
,	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
Your	O
healthcare	O
provider	O
will	O
let	O
you	O
know	O
if	O
you	O
need	O
to	O
stop	O
taking	O
DUAVEE	O
.	O
	
Gastrointestinal	O
Disorders	O
:	O
Abdominal	B
pain	I
,	O
abdominal	B
discomfort	I
,	O
flatulence	B
,	O
upper	B
abdominal	I
pain	I
,	O
vomiting	B
.	O
	
Monitor	O
CLcr	O
,	O
urine	O
glucose	O
,	O
and	O
urine	O
protein	O
in	O
all	O
patients	O
.	O
	
The	O
only	O
treatment-emergent	O
ADR	O
of	O
moderate	O
to	O
severe	O
intensity	O
with	O
at	O
least	O
2	O
%	O
frequency	O
in	O
either	O
treatment	O
group	O
was	O
diarrhea	B
,	O
2	O
%	O
(	O
6	O
of	O
354	O
)	O
in	O
subjects	O
receiving	O
TIVICAY	O
50	O
mg	O
once	O
daily	O
+	O
background	O
regimen	O
and	O
1	O
%	O
(	O
5	O
of	O
361	O
)	O
in	O
subjects	O
receiving	O
raltegravir	O
400	O
mg	O
twice	O
daily	O
+	O
background	O
regimen	O
.	O
	
Withhold	O
YERVOY	O
dosing	O
in	O
patients	O
with	O
moderate	O
neuropathy	O
(	O
not	O
interfering	O
with	O
daily	O
activities	O
)	O
.	O
	
The	O
extent	O
to	O
which	O
the	O
findings	O
of	O
increased	O
mortality	O
in	O
observational	O
studies	O
may	O
be	O
attributed	O
to	O
the	O
antipsychotic	O
drug	O
as	O
opposed	O
to	O
some	O
characteristic	O
(	O
s	O
)	O
of	O
the	O
patients	O
is	O
not	O
clear	O
.	O
	
Patients	O
should	O
be	O
monitored	O
during	O
and	O
for	O
an	O
appropriate	O
period	O
of	O
time	O
after	O
administration	O
of	O
BENLYSTA	O
.	O
	
Anaphylaxis	B
was	O
observed	O
in	O
0.6	O
%	O
(	O
9/1,458	O
)	O
of	O
patients	O
receiving	O
BENLYSTA	O
and	O
0.4	O
%	O
(	O
3/675	O
)	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
Whether	O
the	O
impairment	O
is	O
related	O
to	O
somnolence	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
or	O
other	O
effects	O
of	O
HORIZANT	O
is	O
unknown	O
.	O
	
Therefore	O
,	O
the	O
use	O
of	O
CIMZIA	O
in	O
combination	O
with	O
other	O
biological	O
DMARDs	O
is	O
not	O
recommended	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
]	O
.	O
	
The	O
most	O
common	O
(	O
>	O
=	O
10	O
%	O
)	O
grade	O
1-4	O
adverse	O
reactions	O
were	O
anemia	B
,	O
leukopenia	B
,	O
neutropenia	B
,	O
thrombocytopenia	B
,	O
diarrhea	B
,	O
fatigue	B
,	O
nausea	B
,	O
vomiting	B
,	O
constipation	B
,	O
asthenia	B
,	O
abdominal	B
pain	I
,	O
hematuria	B
,	O
back	B
pain	I
,	O
anorexia	B
,	O
peripheral	B
neuropathy	I
,	O
pyrexia	B
,	O
dyspnea	B
,	O
dysguesia	B
,	O
cough	B
,	O
arthralgia	B
,	O
and	O
alopecia	B
.	O
	
*	O
Interstitial	B
Lung	I
Disease	I
and	O
Eosinophilic	B
Pneumonia	I
:	O
Can	O
occur	O
(	O
5.10	O
)	O
.	O
	
Use	O
of	O
DUAVEE	O
in	O
patients	O
with	O
renal	O
impairment	O
is	O
not	O
recommended	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
Leukocytosis	O
In	O
clinical	O
studies	O
,	O
leukocytosis	B
(	O
WBC	B
counts	I
>	I
100,000	I
x	I
10	I
6	I
/L	I
)	O
was	O
observed	O
in	O
less	O
than	O
1	O
%	O
patients	O
with	O
non-myeloid	O
malignancies	O
receiving	O
GRANIX	O
.	O
	
Recent	O
(	O
i.e.	O
,	O
within	O
last	O
6	O
months	O
)	O
transaminase	O
and	O
bilirubin	O
levels	O
should	O
be	O
available	O
before	O
initiation	O
of	O
GILENYA	O
therapy	O
.	O
	
In	O
patients	O
who	O
develop	O
serious	O
infections	O
while	O
on	O
Prolia	O
,	O
prescribers	O
should	O
assess	O
the	O
need	O
for	O
continued	O
Prolia	O
therapy	O
.	O
	
Patients	O
should	O
discontinue	O
use	O
of	O
any	O
product	O
containing	O
4-aminopyridine	O
prior	O
to	O
initiating	O
treatment	O
with	O
AMPYRA	O
in	O
order	O
to	O
reduce	O
the	O
potential	O
for	O
dose-related	O
adverse	O
reactions	O
.	O
	
In	O
the	O
group	O
treated	O
with	O
TANZEUM	O
,	O
investigators	O
graded	O
the	O
severity	O
of	O
GI	B
reactions	I
as	O
``	O
mild	O
''	O
in	O
56	O
%	O
of	O
cases	O
,	O
``	O
moderate	O
''	O
in	O
37	O
%	O
of	O
cases	O
,	O
and	O
``	O
severe	O
''	O
in	O
7	O
%	O
of	O
cases	O
.	O
	
5.12	O
Embryo-fetal	O
Toxicity	O
Based	O
on	O
the	O
mechanism	O
of	O
action	O
,	O
AFINITOR	O
can	O
cause	O
fetal	B
harm	I
.	O
	
Recurrence	O
of	O
liver	B
transaminase	I
elevations	I
occurred	O
with	O
rechallenge	O
in	O
some	O
patients	O
.	O
	
Before	O
therapy	O
with	O
Teflaro	O
is	O
instituted	O
,	O
careful	O
inquiry	O
about	O
previous	O
hypersensitivity	O
reactions	O
to	O
other	O
cephalosporins	O
,	O
penicillins	O
,	O
or	O
carbapenems	O
should	O
be	O
made	O
.	O
	
Extreme	O
care	O
must	O
be	O
taken	O
to	O
avoid	O
pregnancy	O
in	O
female	O
patients	O
and	O
in	O
female	O
partners	O
of	O
male	O
patients	O
.	O
	
Observe	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
hypersensitivity	O
reactions	O
during	O
and	O
following	O
Gadavist	O
administration	O
.	O
	
(	O
5.6	O
,	O
2.3	O
)	O
*	O
Serious	O
Febrile	B
Reactions	I
:	O
Incidence	O
and	O
severity	O
of	O
pyrexia	B
are	O
increased	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
.	O
	
Advise	O
females	O
of	O
reproductive	O
potential	O
of	O
potential	O
risk	O
to	O
a	O
fetus	O
.	O
	
Drugs	O
that	O
have	O
a	O
mixed	O
effect	O
on	O
CYP3A4	O
,	O
especially	O
antiretroviral	O
drugs	O
such	O
as	O
HIV	O
protease	O
inhibitors	O
and	O
non-nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
,	O
and	O
those	O
that	O
have	O
an	O
effect	O
on	O
the	O
QT	O
interval	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
taking	O
Coartem	O
Tablets	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.3	O
,	O
7.7	O
)	O
]	O
.	O
	
Maintain	O
clinical	O
supervision	O
if	O
this	O
product	O
is	O
to	O
be	O
given	O
to	O
a	O
penicillin-	O
or	O
other	O
beta-lactam-allergic	O
patient	O
,	O
because	O
cross	O
sensitivity	O
among	O
beta-lactam	O
antibacterial	O
agents	O
has	O
been	O
clearly	O
established	O
.	O
	
5.3	O
Acute	O
Kidney	O
Injury	O
In	O
patients	O
with	O
chronic	O
renal	O
impairment	O
,	O
acute	B
kidney	I
injury	I
sometimes	O
requiring	O
dialysis	O
has	O
been	O
observed	O
with	O
the	O
use	O
of	O
some	O
GBCAs	O
.	O
	
Table	O
4	O
presents	O
the	O
most	O
common	O
adverse	O
drug	O
reactions	O
(	O
experienced	O
by	O
greater	O
than	O
or	O
equal	O
to	O
3	O
%	O
of	O
patients	O
receiving	O
PROMACTA	O
)	O
from	O
the	O
three	O
placebo-controlled	O
trials	O
,	O
with	O
a	O
higher	O
incidence	O
in	O
PROMACTA	O
versus	O
placebo	O
.	O
	
The	O
median	O
time	O
to	O
onset	O
of	O
skin	B
toxicity	I
in	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
was	O
37	O
days	O
(	O
range	O
:	O
1	O
to	O
225	O
days	O
)	O
and	O
median	O
time	O
to	O
resolution	O
of	O
skin	B
toxicity	I
was	O
33	O
days	O
(	O
range	O
:	O
3	O
to	O
421	O
days	O
)	O
.	O
	
Table	O
1	O
shows	O
adverse	O
reactions	O
occurring	O
in	O
>	O
=3	O
%	O
of	O
KALBITOR-treated	O
patients	O
that	O
also	O
occurred	O
at	O
a	O
higher	O
rate	O
than	O
in	O
the	O
placebo-treated	O
patients	O
in	O
the	O
two	O
controlled	O
trials	O
(	O
EDEMA3	O
and	O
EDEMA4	O
)	O
of	O
the	O
30	O
mg	O
subcutaneous	O
dose	O
.	O
	
Constipation	B
also	O
contributed	O
to	O
the	O
frequently	O
reported	O
reactions	O
.	O
	
Forty-eight	O
percent	O
of	O
patients	O
were	O
white	O
,	O
15	O
%	O
African/African	O
American	O
,	O
9	O
%	O
Asian	O
,	O
and	O
26	O
%	O
were	O
Hispanic/Latino	O
.	O
	
Lipid	O
intake	O
restrictions	O
may	O
be	O
necessary	O
for	O
patients	O
with	O
significant	O
disorders	O
of	O
lipid	O
metabolism	O
.	O
	
Dabrafenib	O
was	O
teratogenic	B
and	O
embryotoxic	B
in	O
rats	O
at	O
doses	O
three	O
times	O
greater	O
than	O
the	O
human	O
exposure	O
at	O
the	O
recommended	O
clinical	O
dose	O
.	O
	
This	O
may	O
be	O
associated	O
with	O
concomitant	O
use	O
of	O
corticosteroids	O
or	O
other	O
immunosuppressive	O
agents	O
.	O
	
*	O
Hyponatremia	B
:	O
Can	O
occur	O
in	O
association	O
with	O
SIADH	O
(	O
5.9	O
)	O
.	O
	
The	O
majority	O
of	O
injection	B
site	I
reactions	I
were	O
judged	O
as	O
``	O
mild	O
''	O
by	O
investigators	O
in	O
both	O
groups	O
(	O
73	O
%	O
for	O
TANZEUM	O
versus	O
94	O
%	O
for	O
placebo	O
)	O
.	O
	
6.4	O
Laboratory	O
Findings	O
Hematology	O
During	O
clinical	O
trials	O
with	O
ILARIS	O
,	O
mean	O
values	O
decreased	B
for	I
white	I
blood	I
cells	I
.	O
	
In	O
Trial	O
2	O
,	O
treatment	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
resulted	O
in	O
an	O
increased	O
incidence	O
and	O
severity	O
of	O
any	O
hemorrhagic	B
event	I
:	O
16	O
%	O
(	O
9/55	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
compared	O
with	O
2	O
%	O
(	O
1/53	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
In	O
the	O
controlled	O
clinical	O
trials	O
,	O
hypersensitivity	B
reactions	I
(	O
occurring	O
on	O
the	O
same	O
day	O
of	O
infusion	O
)	O
were	O
reported	O
in	O
13	O
%	O
(	O
191/1,458	O
)	O
of	O
patients	O
receiving	O
BENLYSTA	O
and	O
11	O
%	O
(	O
76/675	O
)	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
Withhold	O
YERVOY	O
dosing	O
in	O
symptomatic	O
patients	O
.	O
	
(	O
6.1	O
)	O
EXCERPT	O
:	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Teva	O
Pharmaceuticals	O
at	O
1-800-896-5855	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
It	O
is	O
recommended	O
that	O
ALT	O
and	O
AST	O
be	O
assessed	O
prior	O
to	O
initiating	O
KALYDECO	O
,	O
every	O
3	O
months	O
during	O
the	O
first	O
year	O
of	O
treatment	O
,	O
and	O
annually	O
thereafter	O
.	O
	
cutaneous	B
immune-mediated	I
reactions	I
,	O
including	O
proteinuria	B
and	O
nephrotic	B
syndrome	I
secondary	O
to	O
membranous	B
glomerulonephritis	I
,	O
and	O
necrotizing	B
skin	I
lesions	I
have	O
been	O
reported	O
in	O
postmarketing	O
safety	O
experience	O
with	O
alglucosidase	O
alfa	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Consider	O
initiation	O
of	O
systemic	O
corticosteroids	O
at	O
a	O
dose	O
of	O
1	O
to	O
2	O
mg/kg/day	O
prednisone	O
or	O
equivalent	O
for	O
severe	O
neuropathies	O
.	O
	
The	O
stated	O
frequencies	O
of	O
adverse	O
reactions	O
represent	O
the	O
proportions	O
of	O
individuals	O
who	O
experienced	O
a	O
treatment-emergent	O
adverse	O
reaction	O
of	O
the	O
type	O
listed	O
.	O
	
During	O
the	O
24-week	O
,	O
open-label	O
,	O
clinical	O
trial	O
in	O
34	O
patients	O
ages	O
2	O
to	O
less	O
than	O
6	O
years	O
(	O
Trial	O
6	O
)	O
,	O
where	O
patients	O
received	O
either	O
50	O
mg	O
(	O
less	O
than	O
14	O
kg	O
)	O
or	O
75	O
mg	O
(	O
14	O
kg	O
or	O
greater	O
)	O
ivacaftor	O
granules	O
twice	O
daily	O
,	O
the	O
incidence	O
of	O
patients	O
experiencing	O
transaminase	B
elevations	I
(	O
AST	B
)	I
>	I
3	I
*	I
ULN	I
was	O
14.7	O
%	O
(	O
5/34	O
)	O
.	O
	
Table	O
3	O
:	O
Key	O
Laboratory	O
Abnormalities	O
Reported	O
in	O
>	O
=	O
10	O
%	O
of	O
Patients	O
with	O
Advanced	O
HR+	O
BC	O
Grading	O
according	O
to	O
CTCAE	O
Version	O
3.0	O
a	O
Exemestane	O
(	O
25	O
mg/day	O
)	O
b	O
Reflects	O
corresponding	O
adverse	O
drug	O
reaction	O
reports	O
of	O
anemia	B
,	O
leukopenia	B
,	O
lymphopenia	B
,	O
neutropenia	B
,	O
and	O
thrombocytopenia	B
(	O
collectively	O
as	O
pancytopenia	B
)	O
,	O
which	O
occurred	O
at	O
lower	O
frequency	O
.	O
	
5.2	O
Hypersensitivity	O
Reactions	O
anaphylactoid	B
reactions	I
have	O
been	O
reported	O
with	O
DOTAREM	O
,	O
involving	O
cardiovascular	O
,	O
respiratory	O
,	O
and/or	O
cutaneous	O
manifestations	O
.	O
	
One	O
(	O
0.3	O
%	O
)	O
subject	O
who	O
received	O
ATV	O
+	O
RTV	O
+	O
TRUVADA	O
developed	O
laboratory	O
findings	O
consistent	O
with	O
proximal	B
renal	I
tubular	I
dysfunction	I
leading	O
to	O
discontinuation	O
of	O
ATV	O
+	O
RTV	O
+	O
TRUVADA	O
after	O
Week	O
96	O
.	O
	
In	O
controlled	O
clinical	O
trials	O
,	O
adverse	O
reactions	O
of	O
symptomatic	B
bradycardia	I
following	O
the	O
first	O
dose	O
were	O
reported	O
in	O
0.6	O
%	O
of	O
patients	O
receiving	O
GILENYA	O
0.5	O
mg	O
and	O
in	O
0.1	O
%	O
of	O
patients	O
on	O
placebo	O
.	O
	
5.5	O
Acute	O
PE	O
in	O
Hemodynamically	O
Unstable	O
Patients	O
or	O
Patients	O
who	O
Require	O
Thrombolysis	O
or	O
Pulmonary	O
Embolectomy	O
Initiation	O
of	O
ELIQUIS	O
is	O
not	O
recommended	O
as	O
an	O
alternative	O
to	O
unfractionated	O
heparin	O
for	O
the	O
initial	O
treatment	O
of	O
patients	O
with	O
PE	O
who	O
present	O
with	O
hemodynamic	O
instability	O
or	O
who	O
may	O
receive	O
thrombolysis	O
or	O
pulmonary	O
embolectomy	O
.	O
	
(	O
5.6	O
)	O
*	O
Orthostatic	B
Hypotension	I
,	O
Syncope	B
,	O
and	O
Other	O
Hemodynamic	B
Effects	I
:	O
Dizziness	B
,	O
tachycardia	B
or	O
bradycardia	B
,	O
and	O
syncope	B
may	O
occur	O
,	O
especially	O
early	O
in	O
treatment	O
.	O
	
(	O
5.1	O
,	O
5.2	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Cerebrovascular	B
Adverse	I
Events	I
:	O
An	O
increased	O
incidence	O
of	O
cerebrovascular	B
adverse	I
events	I
(	O
e.g.	O
,	O
stroke	B
,	O
transient	B
ischemic	I
attack	I
)	O
has	O
been	O
seen	O
in	O
elderly	O
patients	O
with	O
dementia-related	O
psychoses	O
treated	O
with	O
atypical	O
antipsychotic	O
drugs	O
.	O
	
Seventeen	O
patients	O
(	O
1.0	O
%	O
)	O
required	O
permanent	O
discontinuation	O
due	O
to	O
elevated	B
transaminases	I
.	O
	
In	O
a	O
trial	O
carried	O
out	O
in	O
patients	O
with	O
moderate	O
renal	O
impairment	O
with	O
a	O
baseline	O
eGFR	O
of	O
30	O
to	O
less	O
than	O
50	O
mL/min/1.73	O
m	O
2	O
(	O
mean	O
baseline	O
eGFR	O
39	O
mL/min/1.73	O
m	O
2	O
)	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.3	O
)	O
]	O
,	O
the	O
proportion	O
of	O
patients	O
who	O
experienced	O
at	O
least	O
one	O
event	O
of	O
significant	O
renal	B
function	I
decline	I
,	O
defined	O
as	O
an	O
eGFR	B
30	I
%	I
lower	I
than	I
baseline	I
,	O
was	O
6.9	O
%	O
with	O
placebo	O
,	O
18	O
%	O
with	O
INVOKANA	O
100	O
mg	O
,	O
and	O
22.5	O
%	O
with	O
INVOKANA	O
300	O
mg.	O
At	O
the	O
end	O
of	O
treatment	O
,	O
4.6	O
%	O
with	O
placebo	O
,	O
3.4	O
%	O
with	O
INVOKANA	O
100	O
mg	O
,	O
and	O
2.2	O
%	O
with	O
INVOKANA	O
300	O
mg	O
had	O
a	O
significant	O
renal	B
function	I
decline	I
.	O
	
Monitor	O
symptoms	O
(	O
such	O
as	O
fatigue	O
,	O
anorexia	O
,	O
nausea	O
,	O
jaundice	O
,	O
dark	O
urine	O
,	O
liver	O
tenderness	O
and	O
hepatomegaly	O
)	O
and	O
laboratory	O
tests	O
(	O
ALT	O
,	O
AST	O
,	O
alkaline	O
phosphatase	O
,	O
and	O
bilirubin	O
)	O
at	O
baseline	O
,	O
monthly	O
while	O
on	O
treatment	O
,	O
and	O
as	O
needed	O
.	O
	
These	O
cases	O
of	O
anaphylaxis	B
occurred	O
as	O
early	O
as	O
30	O
minutes	O
from	O
the	O
start	O
of	O
infusion	O
and	O
up	O
to	O
three	O
hours	O
after	O
infusion	O
.	O
	
Measurement	O
of	O
serum	O
sodium	O
and	O
chloride	O
levels	O
should	O
be	O
considered	O
during	O
maintenance	O
treatment	O
with	O
APTIOM	O
,	O
particularly	O
if	O
the	O
patient	O
is	O
receiving	O
other	O
medications	O
known	O
to	O
decrease	O
serum	O
sodium	O
levels	O
and	O
should	O
be	O
performed	O
if	O
symptoms	O
of	O
hyponatremia	O
develop	O
(	O
e.g.	O
,	O
nausea/vomiting	O
,	O
malaise	O
,	O
headache	O
,	O
lethargy	O
,	O
confusion	O
,	O
irritability	O
,	O
muscle	O
weakness/spasms	O
,	O
obtundation	O
,	O
or	O
increase	O
in	O
seizure	O
frequency	O
or	O
severity	O
)	O
.	O
	
Four	O
weeks	O
after	O
stopping	O
TECFIDERA	O
,	O
mean	O
lymphocyte	O
counts	O
increased	O
but	O
did	O
not	O
return	O
to	O
baseline	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Shire	O
Human	O
Genetic	O
Therapies	O
at	O
the	O
OnePath	O
(	O
r	O
)	O
phone	O
#	O
1-866-888-0660	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
The	O
safety	O
of	O
icatibant	O
was	O
evaluated	O
in	O
three	O
controlled	O
trials	O
that	O
included	O
223	O
patients	O
who	O
received	O
FIRAZYR	O
30	O
mg	O
(	O
n=113	O
)	O
,	O
placebo	O
(	O
n=75	O
)	O
,	O
or	O
comparator	O
(	O
n=38	O
)	O
.	O
	
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
studies	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
studies	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Genital	B
mycotic	I
infections	I
were	O
reported	O
in	O
0.9	O
%	O
of	O
patients	O
on	O
placebo	O
,	O
5.7	O
%	O
on	O
FARXIGA	O
5	O
mg	O
,	O
and	O
4.8	O
%	O
on	O
FARXIGA	O
10	O
mg	O
,	O
in	O
the	O
12-study	O
placebo-controlled	O
pool	O
.	O
	
Severe	O
penile	B
hematoma	I
was	O
also	O
reported	O
as	O
an	O
adverse	O
reaction	O
in	O
39	O
of	O
1044	O
patients	O
(	O
3.7	O
%	O
)	O
in	O
the	O
controlled	O
and	O
uncontrolled	O
clinical	O
trials	O
in	O
Peyronie	O
's	O
disease	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Autoantibodies	O
In	O
clinical	O
studies	O
in	O
Crohn	O
's	O
disease	O
,	O
4	O
%	O
of	O
patients	O
treated	O
with	O
CIMZIA	O
and	O
2	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
that	O
had	O
negative	O
baseline	O
ANA	B
titers	I
developed	I
positive	I
titers	O
during	O
the	O
studies	O
.	O
	
At	O
study	O
baseline	O
,	O
approximately	O
25	O
%	O
had	O
mild	O
,	O
50	O
%	O
had	O
moderate	O
,	O
and	O
25	O
%	O
had	O
severe	O
cervical	O
dystonia	O
.	O
	
Withhold	O
COMETRIQ	O
for	O
hypertension	O
that	O
is	O
not	O
adequately	O
controlled	O
with	O
medical	O
management	O
;	O
when	O
controlled	O
,	O
resume	O
COMETRIQ	O
at	O
a	O
reduced	O
dose	O
.	O
	
Consider	O
alternative	O
contraception	O
for	O
women	O
with	O
uncontrolled	O
dyslipidemia	O
.	O
	
In	O
the	O
majority	O
of	O
cases	O
,	O
rash	B
type	O
,	O
and	O
occurred	O
in	O
the	O
second	O
week	O
of	O
therapy	O
.	O
	
5.6	O
Suicidal	O
Behavior	O
and	O
Ideation	O
Antiepileptic	O
drugs	O
(	O
AEDs	O
)	O
,	O
including	O
ONFI	O
,	O
increase	O
the	O
risk	O
of	O
suicidal	B
thoughts	I
in	O
patients	O
taking	O
these	O
drugs	O
for	O
any	O
indication	O
.	O
	
In	O
patients	O
who	O
develop	O
serious	O
allergic	O
reactions	O
,	O
discontinue	O
Zydelig	O
permanently	O
and	O
institute	O
appropriate	O
supportive	O
measures	O
.	O
	
Monitor	O
liver	O
function	O
tests	O
before	O
treatment	O
and	O
before	O
the	O
start	O
of	O
each	O
cycle	O
.	O
	
Febrile	B
neutropenia	I
has	O
been	O
reported	O
with	O
treatment	O
with	O
ADCETRIS	O
.	O
	
Patients	O
received	O
placebo	O
(	O
N=1393	O
)	O
,	O
FARXIGA	O
5	O
mg	O
(	O
N=1145	O
)	O
,	O
or	O
FARXIGA	O
10	O
mg	O
(	O
N=1193	O
)	O
once	O
daily	O
.	O
	
At	O
one	O
year	O
after	O
transplantation	O
these	O
values	O
were	O
183	O
mg/dL	O
,	O
50	O
mg/dL	O
,	O
102	O
mg/dL	O
,	O
and	O
151	O
mg/dL	O
,	O
respectively	O
,	O
in	O
401	O
patients	O
treated	O
with	O
the	O
NULOJIX	O
recommended	O
regimen	O
and	O
196	O
mg/dL	O
,	O
48	O
mg/dL	O
,	O
108	O
mg/dL	O
,	O
and	O
195	O
mg/dL	O
,	O
respectively	O
,	O
in	O
405	O
patients	O
treated	O
with	O
the	O
cyclosporine	O
control	O
regimen	O
.	O
	
Follow	O
instructions	O
for	O
preparation	O
(	O
including	O
admixing	O
)	O
and	O
administration	O
strictly	O
to	O
minimize	O
medication	O
errors	O
(	O
including	O
underdose	O
and	O
overdose	O
)	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
(	O
2.4	O
)	O
]	O
.	O
	
In	O
other	O
XIAFLEX-treated	O
patients	O
(	O
9	O
of	O
1044	O
;	O
0.9	O
%	O
)	O
,	O
a	O
combination	O
of	O
penile	B
ecchymoses	I
,	O
sudden	O
penile	B
detumescence	I
,	O
and/or	O
a	O
penile	B
``	O
popping	B
''	O
sound	B
was	O
reported	O
,	O
and	O
in	O
these	O
cases	O
,	O
a	O
diagnosis	O
of	O
corporal	B
rupture	I
can	O
not	O
be	O
excluded	O
.	O
	
The	O
information	O
below	O
is	O
derived	O
from	O
a	O
clinical	O
trial	O
database	O
for	O
FANAPT	O
consisting	O
of	O
2070	O
patients	O
exposed	O
to	O
FANAPT	O
at	O
doses	O
of	O
10	O
mg/day	O
or	O
greater	O
,	O
for	O
the	O
treatment	O
of	O
schizophrenia	O
.	O
	
Serious	O
adverse	O
reactions	O
were	O
reported	O
in	O
54	O
(	O
49	O
%	O
)	O
subjects	O
treated	O
with	O
Zydelig	O
+	O
rituximab	O
.	O
	
Serious	O
adverse	O
events	O
that	O
may	O
be	O
associated	O
with	O
CRS	B
included	O
pyrexia	B
,	O
headache	B
,	O
nausea	B
,	O
asthenia	B
,	O
hypotension	B
,	O
increased	B
alanine	I
aminotransferase	I
,	O
increased	B
aspartate	I
aminotransferase	I
,	O
and	O
increased	B
total	I
bilirubin	I
;	O
these	O
events	O
infrequently	O
led	O
to	O
BLINCYTO	O
discontinuation	O
.	O
	
(	O
2.3	O
)	O
,	O
(	O
5.2	O
)	O
5	O
.	O
	
*	O
Macrovascular	O
outcomes	O
:	O
There	O
have	O
been	O
no	O
studies	O
establishing	O
conclusive	O
evidence	O
of	O
macrovascular	O
risk	O
reduction	O
with	O
TRULICITY	O
or	O
any	O
other	O
antidiabetic	O
drug	O
(	O
5.7	O
)	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
RISK	O
OF	O
THYROID	B
C-CELL	I
TUMORS	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
While	O
all	O
atypical	O
antipsychotic	O
drugs	O
have	O
been	O
shown	O
to	O
produce	O
some	O
metabolic	O
changes	O
,	O
each	O
drug	O
in	O
the	O
class	O
has	O
its	O
own	O
specific	O
risk	O
profile	O
.	O
	
In	O
a	O
monotherapy	O
study	O
comparing	O
NESINA	O
to	O
a	O
sulfonylurea	O
in	O
elderly	O
patients	O
,	O
the	O
incidence	O
of	O
hypoglycemia	B
was	O
5.4	O
%	O
with	O
NESINA	O
compared	O
to	O
26	O
%	O
with	O
glipizide	O
(	O
Table	O
2	O
)	O
.	O
	
Patients	O
who	O
experience	O
Grade	O
3	O
or	O
worse	O
allergic-type	O
reactions	O
should	O
not	O
be	O
rechallenged	O
.	O
	
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
ENTEREG	O
12	O
mg	O
in	O
1,793	O
patients	O
in	O
10	O
placebo-controlled	O
studies	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
and	O
at	O
least	O
twice	O
the	O
rate	O
of	O
placebo	O
)	O
reported	O
with	O
acute	O
monotherapy	O
treatment	O
of	O
manic	O
or	O
mixed	O
episodes	O
associated	O
with	O
bipolar	O
I	O
disorder	O
in	O
adults	O
were	O
somnolence	B
,	O
dizziness	B
,	O
extrapyramidal	B
symptoms	I
other	O
than	O
akathisia	B
,	O
and	O
increased	B
weight	I
and	O
during	O
the	O
adjunctive	O
therapy	O
trial	O
in	O
bipolar	O
I	O
disorder	O
in	O
adults	O
were	O
somnolence	B
and	O
oral	B
hypoesthesia	I
.	O
	
The	O
incidence	O
of	O
all-cause	O
mortality	B
was	O
2.3	O
%	O
(	O
n	O
=	O
90	O
)	O
in	O
the	O
placebo	O
group	O
and	O
1.8	O
%	O
(	O
n	O
=	O
70	O
)	O
in	O
the	O
Prolia	O
group	O
.	O
	
(	O
5.1	O
)	O
QT	O
Prolongation	O
*	O
QT	B
prolongation	I
can	O
occur	O
with	O
SIRTURO	O
.	O
	
The	O
safety	O
of	O
SAPHRIS	O
was	O
evaluated	O
in	O
403	O
pediatric	O
patients	O
with	O
bipolar	O
I	O
disorder	O
who	O
participated	O
in	O
a	O
3-week	O
,	O
placebo-controlled	O
,	O
double-blind	O
trial	O
,	O
of	O
whom	O
302	O
patients	O
received	O
SAPHRIS	O
at	O
fixed	O
doses	O
ranging	O
from	O
2.5	O
mg	O
to	O
10	O
mg	O
twice	O
daily	O
.	O
	
Other	O
important	O
considerations	O
in	O
the	O
differential	O
diagnosis	O
include	O
central	O
anticholinergic	O
toxicity	O
,	O
heat	O
stroke	O
,	O
drug	O
fever	O
,	O
and	O
primary	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
pathology	O
.	O
	
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
less	O
than	O
10	O
%	O
of	O
AFINITOR	O
-treated	O
patients	O
:	O
epistaxis	B
(	O
9	O
%	O
)	O
,	O
decreased	B
appetite	I
(	O
6	O
%	O
)	O
,	O
otitis	B
media	I
(	O
6	O
%	O
)	O
,	O
depression	B
(	O
5	O
%	O
)	O
,	O
abnormal	B
taste	I
(	O
5	O
%	O
)	O
,	O
increased	B
blood	I
luteinizing	I
hormone	I
(	I
LH	I
)	I
levels	I
(	O
4	O
%	O
)	O
,	O
increased	B
blood	I
follicle	I
stimulating	I
hormone	I
(	I
FSH	I
)	I
levels	I
(	O
3	O
%	O
)	O
,	O
hypersensitivity	B
(	O
3	O
%	O
)	O
,	O
ovarian	B
cyst	I
(	O
3	O
%	O
)	O
,	O
pneumonitis	B
(	O
1	O
%	O
)	O
,	O
and	O
angioedema	B
(	O
1	O
%	O
)	O
.	O
	
Most	O
patients	O
(	O
>	O
70	O
%	O
)	O
in	O
both	O
trials	O
were	O
enrolled	O
in	O
Eastern	O
Europe	O
and	O
were	O
White	O
.	O
	
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
2	O
%	O
and	O
more	O
common	O
than	O
placebo	O
)	O
are	O
cough	B
,	O
oropharyngeal	B
pain	I
,	O
nasopharyngitis	B
,	O
headache	B
and	O
nausea	B
.	O
	
The	O
safety	O
of	O
DYSPORT	O
(	O
r	O
)	O
for	O
the	O
treatment	O
of	O
hyperhidrosis	O
has	O
not	O
been	O
established	O
.	O
	
Creatinine	B
increases	I
were	O
comparable	O
by	O
background	O
NRTIs	O
and	O
were	O
similar	O
in	O
treatment-experienced	O
subjects	O
.	O
	
(	O
5.13	O
)	O
*	O
Potential	O
for	O
motor	B
impairment	I
:	O
Use	O
caution	O
when	O
operating	O
machinery	O
.	O
	
Use	O
with	O
caution	O
in	O
patients	O
with	O
chronic	O
infections	O
.	O
	
*	O
Oral	B
ulceration	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
Monitor	O
for	O
signs	O
and	O
symptoms	O
of	O
hypotension	O
after	O
initiating	O
therapy	O
and	O
increase	O
monitoring	O
in	O
clinical	O
situations	O
where	O
volume	O
contraction	O
is	O
expected	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.5	O
)	O
]	O
.	O
	
Rehydrate	O
and	O
treat	O
with	O
anti-emetics	O
and	O
anti-diarrheals	O
as	O
needed	O
.	O
	
Promptly	O
evaluate	O
signs	O
and	O
symptoms	O
of	O
blood	O
loss	O
.	O
	
Refer	O
to	O
the	O
prescribing	O
information	O
for	O
peginterferon	O
alfa	O
and	O
ribavirin	O
for	O
pre-treatment	O
,	O
on-treatment	O
and	O
post-treatment	O
laboratory	O
testing	O
recommendations	O
including	O
hematology	O
,	O
biochemistry	O
(	O
including	O
hepatic	O
function	O
tests	O
)	O
,	O
and	O
pregnancy	O
testing	O
requirements	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
important	O
adverse	O
reactions	O
are	O
described	O
elsewhere	O
in	O
labeling	O
:	O
*	O
Anaphylaxis	B
and	O
Angioedema	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
*	O
e	O
Rate	O
of	O
documented	O
symptomatic	O
hypoglycemia	B
for	O
active	O
controls	O
18	O
%	O
(	O
glimepiride	O
)	O
and	O
2	O
%	O
(	O
sitagliptin	O
)	O
.	O
	
Monitor	O
patients	O
for	O
the	O
development	O
of	O
signs	O
and	O
symptoms	O
of	O
tuberculosis	O
including	O
patients	O
who	O
tested	O
negative	O
for	O
latent	O
tuberculosis	O
infection	O
prior	O
to	O
initiating	O
therapy	O
,	O
patients	O
who	O
are	O
on	O
treatment	O
for	O
latent	O
tuberculosis	O
,	O
or	O
patients	O
who	O
were	O
previously	O
treated	O
for	O
tuberculosis	O
infection	O
.	O
	
(	O
5.4	O
)	O
*	O
Elderly	O
patients	O
:	O
Patients	O
>	O
=	O
65	O
years	O
of	O
age	O
were	O
more	O
likely	O
to	O
experience	O
fatal	B
outcomes	O
not	O
related	O
to	O
disease	O
progression	O
and	O
certain	O
adverse	O
reactions	O
,	O
including	O
neutropenia	B
and	O
febrile	B
neutropenia	I
.	O
	
Hepatobiliary	O
disorders	O
:	O
hepatotoxicity	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.8	O
)	O
]	O
.	O
	
(	O
5.2	O
)	O
*	O
ALT	B
elevations	I
with	O
DALVANCE	O
treatment	O
were	O
reported	O
in	O
clinical	O
trials	O
.	O
	
Consultation	O
with	O
a	O
physician	O
with	O
expertise	O
in	O
the	O
treatment	O
of	O
tuberculosis	O
is	O
recommended	O
to	O
aid	O
in	O
the	O
decision	O
of	O
whether	O
initiating	O
anti-tuberculosis	O
therapy	O
is	O
appropriate	O
for	O
an	O
individual	O
patient	O
.	O
	
Skin	O
and	O
subcutaneous	O
tissue	O
disorders	O
:	O
Toxic	B
epidermal	I
necrolysis	I
,	O
including	O
fatal	B
outcomes	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11	O
)	O
]	O
.	O
	
Before	O
prescribing	O
STENDRA	O
,	O
it	O
is	O
important	O
to	O
note	O
the	O
following	O
:	O
EXCERPT	O
:	O
*	O
Patients	O
should	O
not	O
use	O
STENDRA	O
if	O
sexual	O
activity	O
is	O
inadvisable	O
due	O
to	O
cardiovascular	O
status	O
or	O
any	O
other	O
reason	O
(	O
5.1	O
)	O
*	O
Use	O
of	O
STENDRA	O
with	O
alpha-blockers	O
,	O
other	O
antihypertensives	O
,	O
or	O
substantial	O
amounts	O
of	O
alcohol	O
(	O
greater	O
than	O
3	O
units	O
)	O
may	O
lead	O
to	O
hypotension	B
(	O
2.3,5.6,5.7	O
)	O
*	O
Patients	O
should	O
seek	O
emergency	O
treatment	O
if	O
an	O
erection	O
lasts	O
greater	O
than	O
4	O
hours	O
(	O
5.3	O
)	O
*	O
Patients	O
should	O
stop	O
STENDRA	O
and	O
seek	O
medical	O
care	O
if	O
a	O
sudden	O
loss	O
of	O
vision	O
occurs	O
in	O
one	O
or	O
both	O
eyes	O
,	O
which	O
could	O
be	O
a	O
sign	O
of	O
Non	O
Arteritic	O
Ischemic	O
Optic	O
Neuropathy	O
(	O
NAION	O
)	O
.	O
	
Table	O
4	O
presents	O
the	O
adverse	O
reactions	O
occurring	O
in	O
>	O
=	O
2	O
%	O
of	O
subjects	O
treated	O
with	O
STENDRA	O
.	O
	
Hypertoxin-producing	O
strains	O
of	O
C.	O
difficile	O
cause	O
increased	O
morbidity	O
and	O
mortality	O
,	O
as	O
these	O
infections	O
can	O
be	O
refractory	O
to	O
antibacterial	O
therapy	O
and	O
may	O
require	O
colectomy	O
.	O
	
corticosteroids	O
or	O
methotrexate	O
)	O
may	O
be	O
at	O
a	O
greater	O
risk	O
of	O
infection	B
.	O
	
Sixty-two	O
percent	O
of	O
these	O
patients	O
had	O
at	O
least	O
one	O
sample	O
that	O
was	O
positive	O
for	O
the	O
presence	O
of	O
neutralizing	O
antibodies	O
.	O
	
TANZEUM	O
is	O
contraindicated	O
in	O
patients	O
with	O
a	O
personal	O
or	O
family	O
history	O
of	O
MTC	O
or	O
in	O
patients	O
with	O
MEN	O
2	O
.	O
	
In	O
clinical	O
trials	O
with	O
VICTRELIS	O
,	O
the	O
proportion	O
of	O
subjects	O
who	O
experienced	O
hemoglobin	B
values	I
less	I
than	I
10	I
g	I
per	I
dL	I
was	O
higher	O
in	O
subjects	O
treated	O
with	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron	O
(	O
r	O
)	O
/REBETOL	O
(	O
r	O
)	O
than	O
in	O
those	O
treated	O
with	O
PegIntron/REBETOL	O
alone	O
(	O
see	O
Table	O
4	O
)	O
.	O
	
Consider	O
other	O
antidiabetic	O
therapies	O
in	O
patients	O
with	O
a	O
history	O
of	O
pancreatitis	O
.	O
	
Sustained	B
increases	I
in	I
intraocular	I
pressure	I
have	O
also	O
been	O
reported	O
after	O
repeated	O
intravitreal	O
dosing	O
with	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
inhibitors	O
.	O
	
Monitor	O
for	O
signs	O
and	O
symptoms	O
of	O
MI	O
and	O
stroke	O
.	O
	
In	O
Study	O
1	O
and	O
Study	O
2	O
,	O
NULOJIX	O
was	O
studied	O
at	O
the	O
recommended	O
dose	O
and	O
frequency	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
]	O
in	O
a	O
total	O
of	O
401	O
patients	O
compared	O
to	O
a	O
cyclosporine	O
control	O
regimen	O
in	O
a	O
total	O
of	O
405	O
patients	O
.	O
	
5.6	O
Increased	O
Low-Density	O
Lipoprotein	O
Cholesterol	O
(	O
LDL-C	O
)	O
Increases	B
in	I
LDL-C	I
can	O
occur	O
with	O
JARDIANCE	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
*	O
d	O
Event	O
requiring	O
another	O
person	O
to	O
administer	O
a	O
resuscitative	O
action	O
.	O
	
The	O
safety	O
of	O
ILARIS	O
compared	O
to	O
placebo	O
was	O
investigated	O
in	O
two	O
phase	O
3	O
studies	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.2	O
)	O
]	O
.	O
	
Administration	O
of	O
Picato	O
(	O
r	O
)	O
gel	O
is	O
not	O
recommended	O
until	O
the	O
skin	O
is	O
healed	O
from	O
any	O
previous	O
drug	O
or	O
surgical	O
treatment	O
.	O
	
Therefore	O
,	O
the	O
use	O
of	O
ENTEREG	O
is	O
not	O
recommended	O
in	O
this	O
population	O
.	O
	
Overall	O
,	O
55	O
%	O
of	O
the	O
patients	O
were	O
men	O
.	O
	
In	O
treatment-naive	O
subjects	O
,	O
a	O
mean	O
change	O
from	O
baseline	O
of	O
0.15	O
mg	O
per	O
dL	O
(	O
range	O
:	O
-0.32	O
mg	O
per	O
dL	O
to	O
0.65	O
mg	O
per	O
dL	O
)	O
was	O
observed	O
after	O
96	O
weeks	O
of	O
treatment	O
.	O
	
DYSPORT	O
(	O
r	O
)	O
is	O
approved	O
only	O
for	O
intramuscular	O
injection	O
.	O
	
Instances	O
of	O
suicidal	B
ideation	I
have	O
been	O
observed	O
in	O
0.2	O
%	O
(	O
3/1441	O
)	O
of	O
subjects	O
while	O
receiving	O
OTEZLA	O
,	O
compared	O
to	O
none	O
in	O
placebo	O
treated	O
subjects	O
(	O
0/495	O
)	O
.	O
	
5.10	O
Thrombocytopenia	O
Kyprolis	O
causes	O
thrombocytopenia	B
with	O
platelet	B
nadirs	I
observed	O
between	O
Day	O
8	O
and	O
Day	O
15	O
of	O
each	O
28-day	O
cycle	O
with	O
recovery	O
to	O
baseline	O
platelet	O
count	O
usually	O
by	O
the	O
start	O
of	O
the	O
next	O
cycle	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
(	O
5.1	O
)	O
*	O
Somnolence/sedation	O
and	O
dizziness	B
:	O
May	O
impair	B
the	I
patient	I
's	I
ability	I
to	I
operate	I
complex	I
machinery	I
.	O
	
Contact	O
lens	O
use	O
is	O
also	O
a	O
risk	O
factor	O
for	O
keratitis	O
and	O
ulceration	O
.	O
	
Higher	O
than	O
recommended	O
dosing	O
or	O
repeat	O
dosing	O
appear	O
to	O
increase	O
the	O
risk	O
.	O
	
5.2	O
Infections	O
Risk	O
of	O
Infections	O
GILENYA	O
causes	O
a	O
dose-dependent	O
reduction	B
in	I
peripheral	I
lymphocyte	I
count	I
to	O
20	O
%	O
-30	O
%	O
of	O
baseline	O
values	O
because	O
of	O
reversible	O
sequestration	B
of	I
lymphocytes	I
in	I
lymphoid	I
tissues	I
.	O
	
No	O
unconfounded	O
cases	O
of	O
NSF	B
have	O
been	O
reported	O
with	O
DOTAREM	O
.	O
	
For	O
moderate	O
to	O
severe	O
proteinuria	O
,	O
reduce	O
the	O
dose	O
or	O
temporarily	O
interrupt	O
treatment	O
with	O
INLYTA	O
.	O
	
The	O
patients	O
had	O
no	O
other	O
identified	O
systemic	O
medical	O
conditions	O
resulting	O
in	O
compromised	B
immune	I
system	I
function	O
and	O
had	O
not	O
previously	O
been	O
treated	O
with	O
natalizumab	O
,	O
which	O
has	O
a	O
known	O
association	O
with	O
PML	B
.	O
	
It	O
is	O
unknown	O
whether	O
this	O
finding	O
applies	O
to	O
younger	O
postmenopausal	O
women	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
In	O
the	O
absence	O
of	O
comparable	O
data	O
,	O
these	O
risks	O
should	O
be	O
assumed	O
to	O
be	O
similar	O
for	O
other	O
doses	O
of	O
conjugated	O
estrogens	O
and	O
other	O
dosage	O
forms	O
of	O
estrogens	O
.	O
	
Nearly	O
all	O
of	O
the	O
reported	O
TNF-blocker	O
associated	O
cases	O
have	O
occurred	O
in	O
patients	O
with	O
Crohn	O
's	O
disease	O
or	O
ulcerative	O
colitis	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
the	O
incidence	O
of	O
antibodies	O
to	O
ERWINAZE	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
Use	O
with	O
drugs	O
that	O
prolong	O
the	O
QT	O
interval	O
may	O
cause	O
additive	O
QT	B
prolongation	I
.	O
	
(	O
5.2	O
,	O
5.3	O
)	O
*	O
Transient	O
increases	B
in	I
blood	I
pressure	I
may	O
occur	O
in	O
patients	O
during	O
and	O
shortly	O
after	O
the	O
Qutenza	O
treatment	O
.	O
	
The	O
adverse	O
reactions	O
described	O
in	O
this	O
section	O
reflect	O
Gadavist	O
exposure	O
in	O
6,330	O
subjects	O
(	O
including	O
184	O
pediatric	O
patients	O
,	O
ages	O
0	O
to	O
17	O
years	O
)	O
with	O
the	O
majority	O
receiving	O
the	O
recommended	O
dose	O
.	O
	
The	O
safety	O
profile	O
of	O
SAPHRIS	O
in	O
the	O
maintenance	O
treatment	O
of	O
schizophrenia	O
in	O
adults	O
was	O
similar	O
to	O
that	O
seen	O
with	O
acute	O
treatment	O
.	O
	
Decrease	B
of	I
Hemoglobin	I
in	O
Patients	O
with	O
WM	O
(	O
N=63	O
)	O
Percent	O
of	O
Patients	O
(	O
N=63	O
)	O
All	O
Grades	O
(	O
%	O
)	O
Grade	O
3	O
or	O
4	O
(	O
%	O
)	O
Platelets	B
Decreased	I
43	O
13	O
Neutrophils	B
Decreased	I
44	O
19	O
Hemoglobin	B
Decreased	I
13	O
8	O
6	O
.	O
	
The	O
adverse	O
reactions	O
most	O
commonly	O
(	O
>	O
=1	O
%	O
in	O
any	O
APTIOM	O
treatment	O
group	O
,	O
and	O
greater	O
than	O
placebo	O
)	O
leading	O
to	O
discontinuation	O
,	O
in	O
descending	O
order	O
of	O
frequency	O
,	O
were	O
dizziness	B
,	O
nausea	B
,	O
vomiting	B
,	O
ataxia	B
,	O
diplopia	B
,	O
somnolence	B
,	O
headache	B
,	O
blurred	B
vision	I
,	O
vertigo	B
,	O
asthenia	B
,	O
fatigue	B
,	O
rash	B
,	O
dysarthria	B
,	O
and	O
tremor	B
.	O
	
Patients	O
with	O
myelosuppression	B
following	O
treatment	O
with	O
TREANDA	O
are	O
more	O
susceptible	O
to	O
infections	B
.	O
	
These	O
metabolic	O
changes	O
include	O
hyperglycemia	B
,	O
dyslipidemia	B
,	O
and	O
body	B
weight	I
gain	I
[	O
see	O
Patient	O
Counseling	O
Information	O
(	O
17.3	O
)	O
]	O
.	O
	
The	O
rate	O
of	O
progression	O
of	O
retinal	B
abnormalities	I
and	O
the	O
reversibility	O
after	O
drug	O
discontinuation	O
are	O
unknown	O
.	O
	
If	O
significant	O
reductions	O
in	O
BMD	O
are	O
seen	O
and	O
BREO	O
ELLIPTA	O
is	O
still	O
considered	O
medically	O
important	O
for	O
that	O
patient	O
's	O
COPD	O
therapy	O
,	O
use	O
of	O
medicine	O
to	O
treat	O
or	O
prevent	O
osteoporosis	O
should	O
be	O
strongly	O
considered	O
.	O
	
Infusion	B
reactions	I
have	O
occurred	O
with	O
the	O
BLINCYTO	O
infusion	O
and	O
may	O
be	O
clinically	O
indistinguishable	O
from	O
manifestations	O
of	O
CRS	O
.	O
	
If	O
this	O
product	O
is	O
used	O
for	O
10	O
days	O
or	O
longer	O
,	O
intraocular	O
pressure	O
should	O
be	O
monitored	O
.	O
	
Of	O
these	O
,	O
806	O
received	O
FANAPT	O
for	O
at	O
least	O
6	O
months	O
,	O
with	O
463	O
exposed	O
to	O
FANAPT	O
for	O
at	O
least	O
12	O
months	O
.	O
	
*	O
Women	O
over	O
35	O
years	O
old	O
who	O
smoke	O
should	O
not	O
use	O
Natazia	O
.	O
	
6.1	O
Controlled	O
Clinical	O
Trials	O
Experience	O
In	O
three	O
placebo-controlled	O
clinical	O
trials	O
of	O
up	O
to	O
14	O
weeks	O
duration	O
,	O
4	O
%	O
(	O
15/400	O
)	O
of	O
patients	O
treated	O
with	O
AMPYRA	O
10	O
mg	O
twice	O
daily	O
experienced	O
one	O
or	O
more	O
treatment	O
emergent	O
adverse	O
events	O
leading	O
to	O
discontinuation	O
,	O
compared	O
to	O
2	O
%	O
(	O
5/238	O
)	O
of	O
placebo-treated	O
patients	O
.	O
	
Table	O
2	O
shows	O
absolute	O
and	O
relative	O
risk	O
by	O
indication	O
for	O
all	O
evaluated	O
AEDs	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
additional	O
adverse	O
reactions	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
Ferriprox	O
.	O
	
Patients	O
,	O
their	O
caregivers	O
,	O
and	O
families	O
should	O
be	O
informed	O
that	O
AEDs	O
increase	O
the	O
risk	O
of	O
suicidal	O
thoughts	O
and	O
behavior	O
and	O
should	O
be	O
advised	O
of	O
the	O
need	O
to	O
be	O
alert	O
for	O
the	O
emergence	O
or	O
worsening	O
of	O
the	O
signs	O
and	O
symptoms	O
of	O
depression	O
,	O
any	O
unusual	O
changes	O
in	O
mood	O
or	O
behavior	O
,	O
or	O
the	O
emergence	O
of	O
suicidal	O
thoughts	O
,	O
behavior	O
,	O
or	O
thoughts	O
about	O
self-harm	O
.	O
	
(	O
5.1	O
)	O
5.1	O
Severe	O
Skin	O
and	O
Hypersensitivity	O
Reactions	O
Severe	O
,	O
potentially	O
life-threatening	O
,	O
and	O
fatal	B
skin	B
reactions	I
have	O
been	O
reported	O
.	O
	
In	O
case	O
of	O
recurrent	O
events	O
of	O
the	O
same	O
category	O
,	O
the	O
first	O
event	O
was	O
considered	O
.	O
	
(	O
5.13	O
,	O
7.1	O
)	O
5.1	O
Thromboembolic	O
Disorders	O
and	O
Other	O
Vascular	O
Problems	O
Stop	O
Natazia	O
if	O
an	O
arterial	O
or	O
venous	O
thrombotic	O
event	O
(	O
VTE	O
)	O
occurs	O
.	O
	
Cleviprex	O
was	O
infused	O
for	O
<	O
24	O
hours	O
in	O
the	O
majority	O
of	O
patients	O
(	O
n=1199	O
)	O
;	O
it	O
was	O
infused	O
as	O
a	O
continuous	O
infusion	O
in	O
an	O
additional	O
93	O
patients	O
for	O
durations	O
between	O
24	O
and	O
72	O
hours	O
.	O
	
Table	O
3	O
gives	O
the	O
incidence	O
of	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
=2	O
%	O
of	O
subjects	O
with	O
partial-onset	O
seizures	O
in	O
any	O
APTIOM	O
treatment	O
group	O
and	O
for	O
which	O
the	O
incidence	O
was	O
greater	O
than	O
placebo	O
during	O
the	O
controlled	O
clinical	O
trials	O
.	O
	
(	O
6.1	O
)	O
Glabellar	O
Lines	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
(	O
>	O
=2	O
%	O
)	O
are	O
:	O
nasopharyngitis	B
,	O
headache	B
,	O
injection	B
site	I
pain	I
,	O
injection	B
site	I
reaction	I
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
eyelid	B
edema	I
,	O
eyelid	B
ptosis	I
,	O
sinusitis	B
,	O
and	O
nausea	B
.	O
	
5.3	O
Anaphylaxis	O
and	O
Infusion	O
Reactions	O
Infusion	B
reactions	I
to	O
TREANDA	O
have	O
occurred	O
commonly	O
in	O
clinical	O
trials	O
.	O
	
Table	O
7	O
:	O
Non-Hematologic	O
Adverse	O
Reactions	O
in	O
>	O
=	O
10	O
%	O
of	O
Patients	O
with	O
Waldenstrom	O
's	O
Macroglobulinemia	O
(	O
N=63	O
)	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
All	O
Grades	O
(	O
%	O
)	O
Grade	O
3	O
or	O
4	O
(	O
%	O
)	O
The	O
system	O
organ	O
class	O
and	O
individual	O
ADR	O
terms	O
are	O
sorted	O
in	O
descending	O
frequency	O
order	O
.	O
	
Adult	O
Patients	O
:	O
Pooled	O
data	O
from	O
the	O
short-term	O
,	O
placebo-controlled	O
schizophrenia	O
and	O
bipolar	O
mania	O
trials	O
are	O
presented	O
in	O
Table	O
3	O
.	O
	
They	O
represent	O
an	O
evaluation	O
of	O
the	O
adverse	O
reaction	O
data	O
from	O
870	O
patients	O
with	O
Ph+	O
leukemia	O
who	O
received	O
at	O
least	O
1	O
dose	O
of	O
single-agent	O
BOSULIF	O
.	O
	
Only	O
use	O
SIRTURO	O
when	O
an	O
effective	O
treatment	O
regimen	O
can	O
not	O
otherwise	O
be	O
provided	O
[	O
see	O
Indications	O
and	O
Usage	O
(	O
1	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Anaphylaxis	B
was	O
reported	O
in	O
4	O
%	O
of	O
patients	O
with	O
HAE	O
.	O
	
Of	O
these	O
4	O
patients	O
who	O
developed	O
anti-ERWINAZE	O
antibodies	O
,	O
3	O
experienced	O
hypersensitivity	B
reactions	I
(	O
10	O
%	O
,	O
3	O
of	O
30	O
)	O
during	O
the	O
study	O
.	O
	
EXCERPT	O
:	O
Commonly	O
observed	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=5	O
%	O
and	O
at	O
least	O
twice	O
that	O
for	O
placebo	O
)	O
were	O
(	O
6.1	O
)	O
:	O
*	O
Schizophrenia	O
Adults	O
:	O
akathisia	B
,	O
oral	B
hypoesthesia	I
,	O
somnolence	B
.	O
	
*	O
Do	O
not	O
use	O
estrogens	O
to	O
prevent	O
heart	O
disease	O
,	O
heart	O
attacks	O
,	O
strokes	O
or	O
dementia	O
(	O
decline	O
in	O
brain	O
function	O
)	O
.	O
	
Avoid	O
use	O
of	O
GBCAs	O
in	O
these	O
patients	O
unless	O
the	O
diagnostic	O
information	O
is	O
essential	O
and	O
not	O
available	O
with	O
non-contrasted	O
MRI	O
or	O
other	O
modalities	O
.	O
	
Before	O
initiating	O
treatment	O
with	O
GILENYA	O
,	O
a	O
recent	O
CBC	O
(	O
i.e.	O
,	O
within	O
6	O
months	O
or	O
after	O
discontinuation	O
of	O
prior	O
therapy	O
)	O
should	O
be	O
available	O
.	O
	
Patients	O
should	O
be	O
counseled	O
about	O
the	O
possibility	O
of	O
delayed-onset	O
hypersensitivity	O
reactions	O
and	O
given	O
proper	O
follow-up	O
instructions	O
.	O
	
Afatinib	O
was	O
embryotoxic	B
and	O
,	O
in	O
animals	O
with	O
maternal	O
toxicity	O
,	O
led	O
to	O
abortions	B
at	I
late	I
gestational	I
stages	I
in	O
rabbits	O
at	O
doses	O
of	O
5	O
mg/kg	O
(	O
approximately	O
0.2	O
times	O
the	O
human	O
exposure	O
at	O
the	O
recommended	O
dose	O
of	O
40	O
mg	O
daily	O
)	O
or	O
greater	O
.	O
	
5.4	O
Macular	O
Edema	O
Fingolimod	O
increases	O
the	O
risk	O
of	O
macular	B
edema	I
.	O
	
Symptoms	O
of	O
macular	B
edema	I
included	O
blurred	B
vision	I
and	O
decreased	B
visual	I
acuity	I
.	O
	
Changes	O
in	O
Serum	O
Creatinine	O
Dolutegravir	O
has	O
been	O
shown	O
to	O
increase	B
serum	I
creatinine	I
due	O
to	O
inhibition	O
of	O
tubular	O
secretion	O
of	O
creatinine	O
without	O
affecting	O
renal	O
glomerular	O
function	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
In	O
Studies	O
102	O
and	O
103	O
,	O
increases	B
in	I
serum	I
creatinine	I
and	O
decreases	B
in	I
estimated	I
creatinine	I
clearance	I
occurred	O
early	O
in	O
treatment	O
with	O
STRIBILD	O
,	O
after	O
which	O
they	O
stabilized	O
.	O
	
Discontinue	O
trametinib	O
if	O
no	O
improvement	O
after	O
3	O
weeks	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling	O
:	O
*	O
Hepatotoxicity	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Interstitial	B
Lung	I
Disease/Pneumonitis	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
QT	B
Interval	I
Prolongation	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Bradycardia	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
Severe	O
Visual	B
Loss	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=25	O
%	O
)	O
are	O
vision	B
disorders	I
,	O
diarrhea	B
,	O
nausea	B
,	O
vomiting	B
,	O
constipation	B
,	O
edema	B
,	O
elevated	B
transaminases	I
,	O
upper	B
respiratory	I
infection	I
,	O
decreased	B
appetite	I
,	O
and	O
dysgeusia	B
.	O
	
The	O
discontinuation	O
rate	O
due	O
to	O
bleeding	B
events	O
was	O
0.7	O
%	O
in	O
the	O
ELIQUIS-treated	O
patients	O
compared	O
to	O
1.7	O
%	O
in	O
enoxaparin/warfarin-treated	O
patients	O
in	O
the	O
AMPLIFY	O
study	O
.	O
	
(	O
2.3	O
)	O
*	O
JEVTANA	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
Eye	B
disorders	I
,	O
including	O
severe	O
eye	B
pain	I
,	O
chemical	B
conjunctivitis	I
,	O
corneal	B
burn	I
,	O
eyelid	B
edema	I
,	O
eyelid	B
ptosis	I
,	O
periorbital	B
edema	I
can	O
occur	O
after	O
exposure	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
additional	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
postmarketing	O
use	O
of	O
Gadavist	O
.	O
	
Some	O
deaths	B
due	O
to	O
renal	B
failure	I
did	O
not	O
have	O
a	O
clear	O
etiology	O
.	O
	
The	O
concomitant	O
use	O
of	O
a	O
TNF-blocker	O
and	O
abatacept	O
or	O
anakinra	O
was	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
serious	O
infections	O
;	O
therefore	O
,	O
the	O
concomitant	O
use	O
of	O
SIMPONI	O
ARIA	O
and	O
these	O
biologic	O
products	O
is	O
not	O
recommended	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
,	O
5.6	O
)	O
and	O
Drug	O
Interactions	O
(	O
7.2	O
)	O
]	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
the	O
incidence	O
of	O
antibodies	O
to	O
EYLEA	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
Possible	O
risk	O
factors	O
for	O
leukopenia/neutropenia	O
include	O
pre-existing	O
low	O
white	O
blood	O
cell	O
count	O
(	O
WBC	O
)	O
/absolute	O
neutrophil	O
count	O
(	O
ANC	O
)	O
and	O
history	O
of	O
drug	O
induced	O
leukopenia/neutropenia	O
.	O
	
The	O
anti-brentuximab	O
antibodies	O
were	O
directed	O
against	O
the	O
antibody	O
component	O
of	O
brentuximab	O
vedotin	O
in	O
all	O
patients	O
with	O
transiently	O
or	O
persistently	O
positive	O
antibodies	O
.	O
	
For	O
more	O
information	O
,	O
go	O
to	O
www.DUAVEE.com	O
,	O
or	O
call	O
1-800-438-1985	O
.	O
	
Consider	O
lowering	O
sulfonylurea	O
or	O
insulin	O
dosage	O
when	O
starting	O
TANZEUM	O
.	O
	
Table	O
1	O
Adverse	O
Reactions	O
Reaction	O
Rate	O
(	O
%	O
)	O
n	O
=	O
1581	O
Nausea	B
1.1	O
Headache	B
1.1	O
Feeling	B
hot	I
0.8	O
Dizziness	B
0.6	O
Back	B
pain	I
0.6	O
Vomiting	B
0.4	O
Blood	B
pressure	I
increased	I
0.4	O
Injection	B
site	I
reactions	I
)	O
0.4	O
Dysgeusia	B
0.4	O
Paresthesia	B
0.3	O
Flushing	B
0.3	O
Parosmia	B
0.3	O
Pruritus	B
(	I
generalized	I
)	O
0.3	O
Rash	B
0.3	O
Respiratory	B
disorders	I
(	O
dyspnea	B
,	O
respiratory	B
distress	I
)	O
0.2	O
Fatigue	B
0.2	O
Chest	B
pain	I
0.1	O
Vertigo	B
0.1	O
Dry	B
mouth	I
0.1	O
Chills	B
0.1	O
Feeling	B
abnormal	I
0.1	O
Adverse	O
reactions	O
that	O
occurred	O
with	O
a	O
frequency	O
of	O
<	O
0.1	O
%	O
in	O
subjects	O
who	O
received	O
EOVIST	O
include	O
:	O
tremor	B
,	O
akathisia	B
,	O
bundle	B
branch	I
block	I
,	O
palpitation	B
,	O
oral	B
discomfort	I
,	O
salivary	B
hypersecretion	I
,	O
maculopapular	B
rash	I
,	O
hyperhidrosis	B
,	O
discomfort	B
,	O
and	O
malaise	B
.	O
	
Anti-tuberculosis	O
therapy	O
should	O
also	O
be	O
considered	O
prior	O
to	O
initiation	O
of	O
CIMZIA	O
in	O
patients	O
with	O
a	O
past	O
history	O
of	O
latent	O
or	O
active	O
tuberculosis	O
in	O
whom	O
an	O
adequate	O
course	O
of	O
treatment	O
can	O
not	O
be	O
confirmed	O
,	O
and	O
for	O
patients	O
with	O
a	O
negative	O
test	O
for	O
latent	O
tuberculosis	O
but	O
having	O
risk	O
factors	O
for	O
tuberculosis	O
infection	O
.	O
	
This	O
list	O
also	O
includes	O
adverse	O
reactions	O
(	O
less	O
than	O
1	O
%	O
of	O
subjects	O
)	O
associated	O
with	O
organ	O
systems	O
from	O
Warnings	O
and	O
Precautions	O
.	O
	
For	O
patients	O
at	O
highest	O
risk	O
for	O
NSF	O
,	O
do	O
not	O
exceed	O
the	O
recommended	O
Gadavist	O
dose	O
and	O
allow	O
a	O
sufficient	O
period	O
of	O
time	O
for	O
elimination	O
of	O
the	O
drug	O
prior	O
to	O
re-administration	O
.	O
	
(	O
5.2	O
)	O
*	O
Hypoglycemia	B
:	O
Can	O
occur	O
when	O
used	O
in	O
combination	O
with	O
insulin	O
secretagogues	O
(	O
e.g.	O
,	O
sulfonylureas	O
)	O
or	O
insulin	O
.	O
	
Treatment	O
with	O
CIMZIA	O
should	O
not	O
be	O
initiated	O
in	O
patients	O
with	O
an	O
active	O
infection	O
,	O
including	O
clinically	O
important	O
localized	O
infections	O
.	O
	
Treatment	O
with	O
antibacterial	O
agents	O
can	O
alter	O
the	O
normal	O
flora	O
of	O
the	O
colon	O
,	O
and	O
may	O
permit	O
overgrowth	O
of	O
C.	O
difficile	O
.	O
	
Counsel	O
patients	O
regarding	O
the	O
potential	O
risk	O
for	O
MTC	O
with	O
the	O
use	O
of	O
TANZEUM	O
and	O
inform	O
them	O
of	O
symptoms	O
of	O
thyroid	O
tumors	O
(	O
e.g.	O
,	O
a	O
mass	O
in	O
the	O
neck	O
,	O
dysphagia	O
,	O
dyspnea	O
,	O
or	O
persistent	O
hoarseness	O
)	O
.	O
	
The	O
most	O
frequent	O
(	O
>	O
=2	O
%	O
)	O
adverse	O
reactions	O
leading	O
to	O
dose	O
reduction	O
of	O
TAFINLAR	O
were	O
pyrexia	B
(	O
9	O
%	O
)	O
,	O
PPES	B
(	O
3	O
%	O
)	O
,	O
chills	B
(	O
3	O
%	O
)	O
,	O
fatigue	B
(	O
2	O
%	O
)	O
,	O
and	O
headache	B
(	O
2	O
%	O
)	O
.	O
	
*	O
Lymphopenia	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
Hypersensitivity	B
reactions	I
(	O
dyspnea	B
,	O
angioedema	B
,	O
rash	B
,	O
and	O
pruritus	B
)	O
have	O
been	O
reported	O
.	O
	
This	O
information	O
was	O
abstracted	O
and	O
categorized	O
using	O
the	O
National	O
Cancer	O
Institute	O
(	O
NCI	O
)	O
``	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
''	O
(	O
CTCAE	O
)	O
version	O
3	O
scale	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=	O
20	O
%	O
)	O
were	O
pyrexia	B
(	O
62	O
%	O
)	O
,	O
headache	B
(	O
36	O
%	O
)	O
,	O
peripheral	B
edema	I
(	O
25	O
%	O
)	O
,	O
febrile	B
neutropenia	I
(	O
25	O
%	O
)	O
,	O
nausea	B
(	O
25	O
%	O
)	O
,	O
hypokalemia	B
(	O
23	O
%	O
)	O
,	O
and	O
constipation	B
(	O
20	O
%	O
)	O
.	O
	
Across	O
clinical	O
trials	O
of	O
TAFINLAR	O
administered	O
in	O
combination	O
with	O
trametinib	O
(	O
N	O
=	O
202	O
)	O
,	O
the	O
incidence	O
of	O
RPED	B
was	O
1	O
%	O
(	O
2/202	O
)	O
.	O
	
Monitor	O
signs	O
and	O
symptoms	O
.	O
	
patients	O
less	O
than	O
1	O
month	O
of	O
age	O
or	O
preterm	O
infants	O
with	O
a	O
corrected	O
age	O
of	O
less	O
than	O
44	O
weeks	O
)	O
could	O
be	O
at	O
risk	O
for	O
gasping	B
syndrome	I
if	O
treated	O
with	O
ULESFIA	O
(	O
r	O
)	O
Lotion	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.4	O
)	O
]	O
.	O
	
EXCERPT	O
:	O
The	O
most	O
frequent	O
(	O
>	O
=	O
0.2	O
%	O
)	O
adverse	O
reactions	O
in	O
clinical	O
studies	O
were	O
nausea	B
,	O
headache	B
,	O
injection	B
site	I
pain	I
,	O
injection	B
site	I
coldness	I
,	O
and	O
burning	B
sensation	I
.	O
	
5.5	O
End-Stage	O
Renal	O
Disease	O
No	O
studies	O
have	O
been	O
conducted	O
in	O
patients	O
with	O
end-stage	O
renal	O
disease	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
L	O
ong	O
-	O
acting	O
beta	O
2	O
-adrenergic	O
agonists	O
,	O
such	O
as	O
A	O
RCAPTA	O
NEOHALER	O
,	O
increase	O
the	O
risk	O
of	O
asthma-related	O
death	B
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
in	O
Chronic	O
Obstructive	O
Pulmonary	O
Disease	O
The	O
clinical	O
program	O
for	O
BREO	O
ELLIPTA	O
included	O
7,700	O
subjects	O
with	O
COPD	O
in	O
two	O
6-month	O
lung	O
function	O
trials	O
,	O
two	O
12-month	O
exacerbation	O
trials	O
,	O
and	O
6	O
other	O
trials	O
of	O
shorter	O
duration	O
.	O
	
The	O
most	O
commonly	O
observed	O
adverse	O
reactions	O
(	O
>	O
=10	O
%	O
and	O
greater	O
than	O
placebo	O
)	O
in	O
this	O
trial	O
for	O
the	O
1,200	O
mg	O
dose	O
of	O
HORIZANT	O
were	O
dizziness	B
,	O
somnolence	B
,	O
and	O
headache	B
(	O
see	O
Table	O
5	O
)	O
.	O
	
If	O
the	O
diagnosis	O
of	O
TTP/HUS	O
is	O
excluded	O
,	O
Kyprolis	O
may	O
be	O
restarted	O
.	O
	
GILENYA	O
may	O
therefore	O
increase	O
the	O
risk	O
of	O
infections	B
,	O
some	O
serious	O
in	O
nature	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
In	O
controlled	O
trials	O
of	O
other	O
TNF-blockers	O
in	O
patients	O
at	O
higher	O
risk	O
for	O
malignancies	O
(	O
e.g.	O
,	O
patients	O
with	O
COPD	O
,	O
patients	O
with	O
Wegener	O
's	O
granulomatosis	O
treated	O
with	O
concomitant	O
cyclophosphamide	O
)	O
a	O
greater	O
portion	O
of	O
malignancies	B
occurred	O
in	O
the	O
TNF-blocker	O
group	O
compared	O
to	O
the	O
controlled	O
group	O
.	O
	
Your	O
healthcare	O
provider	O
should	O
check	O
any	O
unusual	O
vaginal	O
bleeding	O
to	O
find	O
out	O
the	O
cause	O
.	O
	
(	O
5.1	O
)	O
*	O
Hypersensitivity	B
:	O
anaphylactic	B
reactions	I
with	O
cutaneous	B
manifestations	I
,	O
ranging	O
from	O
mild	O
to	O
severe	O
,	O
including	O
death	B
,	O
have	O
uncommonly	O
occurred	O
.	O
	
Seventy-eight	O
percent	O
of	O
patients	O
(	O
693	O
of	O
893	O
)	O
were	O
able	O
to	O
receive	O
all	O
planned	O
doses	O
to	O
complete	O
their	O
prescribed	O
treatment	O
regimen	O
.	O
	
If	O
hypertension	O
can	O
not	O
be	O
adequately	O
controlled	O
,	O
a	O
risk-benefit	O
decision	O
on	O
continued	O
Kyprolis	O
therapy	O
is	O
needed	O
.	O
	
Discontinue	O
immediately	O
.	O
	
The	O
percentage	O
of	O
patients	O
who	O
withdrew	O
from	O
the	O
study	O
due	O
to	O
adverse	O
events	O
was	O
2.1	O
%	O
and	O
2.4	O
%	O
for	O
the	O
placebo	O
and	O
Prolia	O
groups	O
,	O
respectively	O
.	O
	
Male	B
genital	I
mycotic	I
infections	I
occurred	O
more	O
commonly	O
in	O
uncircumcised	O
males	O
and	O
in	O
males	O
with	O
a	O
prior	O
history	O
of	O
balanitis	O
or	O
balanoposthitis	O
.	O
	
The	O
first	O
dose	O
of	O
ENTEREG	O
was	O
administered	O
30	O
minutes	O
to	O
5	O
hours	O
before	O
the	O
scheduled	O
start	O
of	O
surgery	O
and	O
then	O
twice	O
daily	O
until	O
hospital	O
discharge	O
(	O
or	O
for	O
a	O
maximum	O
of	O
7	O
days	O
of	O
postoperative	O
treatment	O
)	O
.	O
	
In	O
these	O
patients	O
,	O
increases	B
in	I
potassium	I
were	O
more	O
commonly	O
seen	O
in	O
those	O
with	O
elevated	O
potassium	O
at	O
baseline	O
.	O
	
Permanent	O
discontinuation	O
of	O
XALKORI	O
treatment	O
for	O
adverse	O
reactions	O
was	O
8.2	O
%	O
.	O
	
A	O
total	O
of	O
1964	O
patients	O
participated	O
in	O
two	O
12-week	O
,	O
Phase	O
3	O
efficacy	O
and	O
safety	O
studies	O
and	O
subsequent	O
open-label	O
extension	O
studies	O
.	O
	
Table	O
5	O
:	O
Non-Hematologic	O
Adverse	O
Reactions	O
>	O
=	O
10	O
%	O
Reported	O
in	O
Study	O
2	O
IMBRUVICA	O
(	O
N=195	O
)	O
Ofatumumab	O
(	O
N=191	O
)	O
System	O
Organ	O
Class	O
ADR	O
Term	O
All	O
Grades	O
(	O
%	O
)	O
Grade	O
3	O
or	O
4	O
(	O
%	O
)	O
All	O
Grades	O
(	O
%	O
)	O
Grade	O
3	O
or	O
4	O
(	O
%	O
)	O
Subjects	O
with	O
multiple	O
events	O
for	O
a	O
given	O
ADR	O
term	O
are	O
counted	O
once	O
only	O
for	O
each	O
ADR	O
term	O
.	O
	
Adult	O
Patients	O
:	O
Pooled	O
data	O
on	O
mean	O
changes	O
in	O
body	O
weight	O
and	O
the	O
proportion	O
of	O
subjects	O
meeting	O
a	O
weight	B
gain	I
criterion	O
of	O
>	O
=7	O
%	O
of	O
body	O
weight	O
from	O
the	O
short-term	O
,	O
placebo-controlled	O
schizophrenia	O
and	O
bipolar	O
mania	O
trials	O
are	O
presented	O
in	O
Table	O
5	O
.	O
	
PML	O
is	O
an	O
opportunistic	O
viral	O
infection	O
of	O
the	O
brain	O
caused	O
by	O
the	O
JC	O
virus	O
(	O
JCV	O
)	O
that	O
typically	O
only	O
occurs	O
in	O
patients	O
who	O
are	O
immunocompromised	O
,	O
and	O
that	O
usually	O
leads	O
to	O
death	O
or	O
severe	O
disability	O
.	O
	
Do	O
not	O
restart	O
NESINA	O
if	O
liver	O
injury	O
is	O
confirmed	O
and	O
no	O
alternative	O
etiology	O
can	O
be	O
found	O
.	O
	
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
in	O
patients	O
receiving	O
APTIOM	O
at	O
doses	O
of	O
800	O
mg	O
or	O
1200	O
mg	O
(	O
>	O
=4	O
%	O
and	O
>	O
=2	O
%	O
greater	O
than	O
placebo	O
)	O
were	O
dizziness	B
,	O
somnolence	B
,	O
nausea	B
,	O
headache	B
,	O
diplopia	B
,	O
vomiting	B
,	O
fatigue	B
,	O
vertigo	B
,	O
ataxia	B
,	O
blurred	B
vision	I
,	O
and	O
tremor	B
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
5.2	O
Cataracts	O
Use	O
of	O
corticosteroids	O
may	O
result	O
in	O
posterior	B
subcapsular	I
cataract	I
formation	O
.	O
	
Hydronephrosis	B
occurred	O
in	O
2	O
patients	O
,	O
one	O
of	O
whom	O
had	O
associated	O
renal	B
function	I
impairment	I
that	O
resolved	O
upon	O
discontinuation	O
of	O
POTIGA	O
.	O
	
5.2	O
Urinary	O
Retention	O
POTIGA	O
caused	O
urinary	B
retention	I
in	O
clinical	O
trials	O
.	O
	
(	O
5.4	O
)	O
*	O
Patients	O
with	O
abnormal	O
coagulation	O
:	O
Use	O
with	O
caution	O
,	O
including	O
in	O
patients	O
who	O
have	O
received	O
anticoagulant	O
medications	O
other	O
than	O
low-dose	O
aspirin	O
within	O
7	O
days	O
of	O
the	O
injection	O
.	O
	
Table	O
3	O
:	O
Overall	O
Infections	B
and	O
Select	O
Infections	B
with	O
Identified	O
Etiology	O
by	O
Treatment	O
Group	O
following	O
One	O
and	O
Three	O
Years	O
of	O
Treatment	O
in	O
Studies	O
1	O
and	O
2*	O
Up	O
to	O
Year	O
1	O
Up	O
to	O
Year	O
3	O
NULOJIX	O
Recommended	O
Regimen	O
N=401	O
n	O
(	O
%	O
)	O
Cyclosporine	O
N=405	O
n	O
(	O
%	O
)	O
NULOJIX	O
Recommended	O
Regimen	O
N=401	O
n	O
(	O
%	O
)	O
Cyclosporine	O
N=405	O
n	O
(	O
%	O
)	O
*	O
Studies	O
1	O
and	O
2	O
were	O
not	O
designed	O
to	O
support	O
comparative	O
claims	O
for	O
NULOJIX	O
for	O
the	O
adverse	O
reactions	O
reported	O
in	O
this	O
table	O
.	O
	
(	O
2.3	O
)	O
,	O
(	O
5.1	O
)	O
*	O
Neurological	B
toxicities	I
,	O
which	O
may	O
be	O
severe	O
,	O
life-threatening	O
,	O
or	O
fatal	B
,	O
occurred	O
in	O
patients	O
receiving	O
BLINCYTO	O
.	O
	
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Table	O
2	O
and	O
Table	O
3	O
summarize	O
common	O
adverse	O
reactions	O
and	O
laboratory	O
abnormalities	O
reported	O
for	O
Zydelig	O
+	O
rituximab	O
and	O
placebo	O
+	O
rituximab	O
arms	O
.	O
	
Table	O
4	O
:	O
Adverse	O
Reactions	O
Reported	O
by	O
>	O
=10	O
%	O
of	O
Patients	O
Treated	O
with	O
Either	O
the	O
NULOJIX	O
Recommended	O
Regimen	O
or	O
Control	O
in	O
Studies	O
1	O
and	O
2	O
Through	O
Three	O
Years*	O
,	O
Adverse	O
Reaction	O
NULOJIX	O
Recommended	O
Regimen	O
N=401	O
%	O
Cyclosporine	O
N=405	O
%	O
*	O
All	O
randomized	O
and	O
transplanted	O
patients	O
in	O
Studies	O
1	O
and	O
2	O
.	O
	
Prednisone	O
reduction	O
can	O
be	O
accomplished	O
by	O
reducing	O
the	O
daily	O
prednisone	O
dose	O
by	O
2.5	O
mg	O
on	O
a	O
weekly	O
basis	O
during	O
therapy	O
with	O
BREO	O
ELLIPTA	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Acorda	O
Therapeutics	O
at	O
1-800-367-5109	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
If	O
paradoxical	O
bronchospasm	O
occurs	O
following	O
dosing	O
with	O
BREO	O
ELLIPTA	O
,	O
it	O
should	O
be	O
treated	O
immediately	O
with	O
an	O
inhaled	O
,	O
short-acting	O
bronchodilator	O
;	O
BREO	O
ELLIPTA	O
should	O
be	O
discontinued	O
immediately	O
;	O
and	O
alternative	O
therapy	O
should	O
be	O
instituted	O
.	O
	
In	O
4	O
studies	O
FARXIGA	O
was	O
used	O
as	O
monotherapy	O
,	O
and	O
in	O
8	O
studies	O
FARXIGA	O
was	O
used	O
as	O
add-on	O
to	O
background	O
antidiabetic	O
therapy	O
or	O
as	O
combination	O
therapy	O
with	O
metformin	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Tables	O
2	O
and	O
3	O
summarize	O
the	O
common	O
adverse	O
reactions	O
and	O
laboratory	O
abnormalities	O
observed	O
in	O
ZYKADIA-treated	O
patients	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
reported	O
during	O
clinical	O
trials	O
were	O
chromaturia	B
,	O
nausea	B
,	O
vomiting	B
,	O
abdominal	B
pain	I
,	O
alanine	B
aminotransferase	I
increased	I
,	O
arthralgia	B
and	O
neutropenia	B
.	O
	
If	O
feasible	O
,	O
stop	O
Natazia	O
at	O
least	O
4	O
weeks	O
before	O
and	O
through	O
2	O
weeks	O
after	O
major	O
surgery	O
or	O
other	O
surgeries	O
known	O
to	O
have	O
an	O
elevated	O
risk	O
of	O
thromboembolism	O
.	O
	
Less	O
Common	O
Adverse	O
Reactions	O
:	O
The	O
following	O
additional	O
adverse	O
reactions	O
were	O
reported	O
in	O
>	O
=5	O
%	O
to	O
<	O
10	O
%	O
of	O
the	O
HALAVEN-treated	O
group	O
:	O
*	O
Eye	O
Disorders	O
:	O
increased	B
lacrimation	I
*	O
Gastrointestinal	O
Disorders	O
:	O
dyspepsia	B
,	O
abdominal	B
pain	I
,	O
stomatitis	B
,	O
dry	B
mouth	I
*	O
General	O
Disorders	O
and	O
Administration	O
Site	O
Conditions	O
:	O
peripheral	B
edema	I
*	O
Infections	O
and	O
Infestations	O
:	O
upper	B
respiratory	I
tract	I
infection	I
*	O
Metabolism	O
and	O
Nutrition	O
Disorders	O
:	O
hypokalemia	B
*	O
Musculoskeletal	O
and	O
Connective	O
Tissue	O
Disorders	O
:	O
muscle	B
spasms	I
,	O
muscular	B
weakness	I
*	O
Nervous	O
System	O
Disorders	O
:	O
dysgeusia	B
,	O
dizziness	B
*	O
Psychiatric	O
Disorders	O
:	O
insomnia	B
,	O
depression	B
*	O
Skin	O
and	O
Subcutaneous	O
Tissue	O
Disorders	O
:	O
rash	B
6	O
.	O
	
Neutralizing	O
antibodies	O
to	O
AUX-I	O
or	O
AUX-II	O
,	O
were	O
detected	O
in	O
60	O
%	O
and	O
51.8	O
%	O
,	O
respectively	O
,	O
of	O
patients	O
tested	O
.	O
	
(	O
2.2	O
,	O
5.1	O
)	O
*	O
Hepatotoxicity	B
:	O
ZYKADIA	O
can	O
cause	O
hepatotoxicity	B
.	O
	
Avoid	O
the	O
use	O
of	O
ADCETRIS	O
in	O
patients	O
with	O
moderate	O
(	O
Child-Pugh	O
B	O
)	O
or	O
severe	O
(	O
Child-Pugh	O
C	O
)	O
hepatic	O
impairment	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.7	O
)	O
]	O
.	O
	
In	O
Phase	O
3	O
clinical	O
trials	O
,	O
Grade	O
3	O
and	O
4	O
rashes	B
were	O
reported	O
in	O
1.3	O
%	O
of	O
subjects	O
receiving	O
INTELENCE	O
(	O
r	O
)	O
compared	O
to	O
0.2	O
%	O
of	O
placebo	O
subjects	O
.	O
	
During	O
controlled	O
clinical	O
studies	O
,	O
the	O
proportion	O
of	O
patients	O
with	O
serious	O
adverse	O
reactions	O
was	O
10	O
%	O
for	O
CIMZIA	O
and	O
9	O
%	O
for	O
placebo	O
.	O
	
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
)	O
are	O
fatigue	B
,	O
diarrhea	B
,	O
pruritus	B
,	O
rash	B
,	O
and	O
colitis	B
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reaction	O
in	O
adults	O
was	O
diarrhea	B
(	O
2	O
%	O
)	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
have	O
been	O
associated	O
with	O
Zydelig	O
in	O
clinical	O
trials	O
and	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
prescribing	O
information	O
.	O
	
In	O
some	O
cases	O
,	O
disseminated	B
intravascular	I
coagulation	I
(	O
DIC	B
)	O
,	O
capillary	B
leak	I
syndrome	I
(	O
CLS	B
)	O
,	O
and	O
hemophagocytic	B
lymphohistiocytosis/macrophage	O
activation	B
syndrome	I
(	O
HLH/MAS	O
)	O
have	O
been	O
reported	O
in	O
the	O
setting	O
of	O
CRS	B
.	O
	
2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post-approval	O
use	O
of	O
IMBRUVICA	O
.	O
	
The	O
most	O
commonly	O
occurring	O
adverse	O
reactions	O
(	O
>	O
=	O
20	O
%	O
)	O
were	O
thrombocytopenia	B
,	O
diarrhea	B
,	O
neutropenia	B
,	O
anemia	B
,	O
fatigue	B
,	O
musculoskeletal	B
pain	I
,	O
peripheral	B
edema	I
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
nausea	B
,	O
bruising	B
,	O
dyspnea	B
,	O
constipation	B
,	O
rash	B
,	O
abdominal	B
pain	I
,	O
vomiting	B
and	O
decreased	B
appetite	I
(	O
see	O
Tables	O
1	O
and	O
2	O
)	O
.	O
	
Preventive	O
measures	O
include	O
vigorous	O
hydration	O
and	O
close	O
monitoring	O
of	O
blood	O
chemistry	O
,	O
particularly	O
potassium	O
and	O
uric	O
acid	O
levels	O
.	O
	
Dose	O
reductions	O
due	O
to	O
adverse	O
reactions	O
were	O
required	O
in	O
6.4	O
%	O
of	O
XALKORI-treated	O
patients	O
.	O
	
A	O
risk	O
for	O
the	O
development	O
for	O
hepatosplenic	O
T-cell	O
lymphoma	O
in	O
patients	O
treated	O
with	O
TNF-blockers	O
can	O
not	O
be	O
excluded	O
.	O
	
(	O
5.8	O
)	O
*	O
Reversible	B
Posterior	I
Leukoencephalopathy	I
Syndrome	I
(	O
RPLS	B
)	O
has	O
been	O
observed	O
.	O
	
Consider	O
factors	O
that	O
contribute	O
to	O
fracture	O
risk	O
prior	O
to	O
initiating	O
INVOKANA	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Based	O
on	O
effective	O
donor	O
screening	O
and	O
product	O
manufacturing	O
processes	O
,	O
it	O
carries	O
an	O
extremely	O
remote	O
risk	O
for	O
transmission	B
of	I
viral	I
diseases	I
.	O
	
Seventy-seven	O
subjects	O
initiated	O
a	O
lipid-lowering	O
agent	O
post-baseline	O
;	O
their	O
last	O
fasted	O
on-treatment	O
values	O
(	O
prior	O
to	O
starting	O
the	O
agent	O
)	O
were	O
used	O
regardless	O
if	O
they	O
discontinued	O
the	O
agent	O
(	O
SPRING-2	O
:	O
TIVICAY	O
n	O
=	O
9	O
,	O
raltegravir	O
n	O
=	O
13	O
;	O
SINGLE	O
:	O
TIVICAY	O
n	O
=	O
25	O
and	O
ATRIPLA	O
:	O
n	O
=	O
30	O
)	O
.	O
	
Overall	O
,	O
the	O
safety	O
profile	O
in	O
subjects	O
with	O
hepatitis	O
B	O
and/or	O
C	O
virus	O
co-infection	O
was	O
similar	O
to	O
that	O
observed	O
in	O
subjects	O
without	O
hepatitis	O
B	O
or	O
C	O
co-infection	O
,	O
although	O
the	O
rates	O
of	O
ALT	B
abnormalities	I
were	O
higher	O
in	O
the	O
subgroup	O
with	O
hepatitis	O
B	O
and/or	O
C	O
virus	O
co-infection	O
for	O
all	O
treatment	O
groups	O
.	O
	
5.1	O
Increased	O
Risks	O
in	O
Elderly	O
Patients	O
with	O
Dementia-Related	O
Psychosis	O
Increased	O
Mortality	O
Elderly	O
patients	O
with	O
dementia-related	O
psychosis	O
treated	O
with	O
atypical	O
antipsychotic	O
drugs	O
are	O
at	O
an	O
increased	O
risk	O
of	O
death	B
compared	O
to	O
placebo	O
.	O
	
Overall	O
,	O
the	O
mean	O
age	O
of	O
patients	O
in	O
the	O
PHN	O
studies	O
ranged	O
from	O
61	O
to	O
64	O
years	O
of	O
age	O
across	O
dose	O
groups	O
;	O
the	O
majority	O
of	O
patients	O
were	O
male	O
(	O
45	O
%	O
to	O
61	O
%	O
)	O
and	O
Caucasian	O
(	O
80	O
%	O
to	O
98	O
%	O
)	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
in	O
COPD	B
or	O
loss	B
of	I
efficacy	I
.	O
	
(	O
5.7	O
)	O
*	O
Leukopenia	B
,	O
Neutropenia	B
,	O
and	O
Agranulocytosis	B
have	O
been	O
reported	O
with	O
antipsychotics	O
.	O
	
GILOTRIF	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
a	O
history	O
of	O
keratitis	O
,	O
ulcerative	O
keratitis	O
,	O
or	O
severe	O
dry	O
eye	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
resulting	O
in	O
discontinuation	O
of	O
treatment	O
(	O
>	O
=1	O
%	O
of	O
patients	O
receiving	O
BENLYSTA	O
or	O
placebo	O
)	O
were	O
infusion	B
reactions	I
(	O
1.6	O
%	O
BENLYSTA	O
and	O
0.9	O
%	O
placebo	O
)	O
,	O
lupus	B
nephritis	I
(	O
0.7	O
%	O
BENLYSTA	O
and	O
1.2	O
%	O
placebo	O
)	O
,	O
and	O
infections	B
(	O
0.7	O
%	O
BENLYSTA	O
and	O
1.0	O
%	O
placebo	O
)	O
.	O
	
ULESFIA	O
(	O
r	O
)	O
Lotion	O
may	O
cause	O
eye	B
irritation	I
.	O
	
Patients	O
with	O
pre-VORAXAZE	O
methotrexate	O
concentrations	O
>	O
100	O
mumol/L	O
were	O
to	O
receive	O
a	O
second	O
dose	O
of	O
VORAXAZE	O
48	O
hours	O
after	O
the	O
first	O
dose	O
.	O
	
If	O
toxicity	O
recurs	O
at	O
Grade	O
3	O
,	O
consider	O
discontinuation	O
of	O
AFINITOR	O
.	O
	
The	O
incidence	O
of	O
Common	O
Terminology	O
Criteria	O
(	O
CTC	O
)	O
Grade	O
3	O
and	O
4	O
non-infectious	B
pneumonitis	I
was	O
up	O
to	O
4.0	O
%	O
and	O
up	O
to	O
0.2	O
%	O
,	O
respectively	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
,	O
6.2	O
,	O
6.3	O
,	O
6.4	O
,	O
6.5	O
)	O
]	O
.	O
	
Stopping	O
or	O
slowing	O
the	O
infusion	O
may	O
result	O
in	O
cessation	O
of	O
these	O
reactions	O
.	O
	
After	O
initiation	O
of	O
TANZEUM	O
,	O
observe	O
patients	O
carefully	O
for	O
signs	O
and	O
symptoms	O
of	O
pancreatitis	O
(	O
including	O
persistent	O
severe	O
abdominal	O
pain	O
,	O
sometimes	O
radiating	O
to	O
the	O
back	O
and	O
which	O
may	O
or	O
may	O
not	O
be	O
accompanied	O
by	O
vomiting	O
)	O
.	O
	
Patients	O
should	O
be	O
closely	O
monitored	O
for	O
the	O
development	O
of	O
signs	O
and	O
symptoms	O
of	O
infection	O
during	O
and	O
after	O
treatment	O
with	O
CIMZIA	O
,	O
including	O
the	O
possible	O
development	O
of	O
tuberculosis	O
in	O
patients	O
who	O
tested	O
negative	O
for	O
latent	O
tuberculosis	O
infection	O
prior	O
to	O
initiating	O
therapy	O
.	O
	
No	O
comparator-treated	O
subject	O
with	O
normal	O
baseline	O
transaminases	O
had	O
post-baseline	O
ALT	B
elevation	I
greater	O
than	O
10	O
times	O
ULN	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Nephrogenic	B
Systemic	I
Fibrosis	I
has	O
occurred	O
in	O
patients	O
with	O
impaired	O
elimination	O
of	O
GBCAs	O
.	O
	
SAPHRIS	O
should	O
be	O
used	O
cautiously	O
when	O
treating	O
patients	O
who	O
receive	O
treatment	O
with	O
other	O
drugs	O
that	O
can	O
induce	O
hypotension	O
,	O
bradycardia	O
,	O
respiratory	O
or	O
central	O
nervous	O
system	O
depression	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
]	O
.	O
	
6.2	O
Immunogenicity	O
As	O
with	O
all	O
therapeutic	O
proteins	O
,	O
there	O
is	O
a	O
potential	O
for	O
an	O
immune	O
response	O
in	O
patients	O
treated	O
with	O
EYLEA	O
.	O
	
If	O
reactivation	O
occurs	O
,	O
stop	O
SIMPONI	O
ARIA	O
and	O
begin	O
anti-viral	O
therapy	O
(	O
5.1	O
)	O
.	O
	
Inactive	O
Ingredients	O
:	O
calcium	O
phosphate	O
tribasic	O
,	O
hydroxypropyl	O
cellulose	O
,	O
microcrystalline	O
cellulose	O
,	O
powdered	O
cellulose	O
,	O
hypromellose	O
,	O
lactose	O
monohydrate	O
,	O
magnesium	O
stearate	O
,	O
polyethylene	O
glycol	O
,	O
sucrose	O
,	O
ascorbic	O
acid	O
,	O
sucrose	O
palmitic	O
acid	O
ester	O
,	O
hydroxyethylcellulose	O
,	O
titanium	O
dioxide	O
,	O
red	O
iron	O
oxide	O
,	O
yellow	O
iron	O
oxide	O
,	O
black	O
iron	O
oxide	O
,	O
povidone	O
,	O
polydextrose	O
,	O
maltitol	O
,	O
poloxamer	O
188	O
,	O
propylene	O
glycol	O
,	O
isopropyl	O
alcohol	O
.	O
	
Respiratory	O
,	O
thoracic	O
and	O
mediastinal	O
disorders	O
:	O
noninfectious	B
pulmonary	I
toxicity	I
including	O
pneumonitis	B
,	O
interstitial	B
lung	I
disease	I
,	O
and	O
ARDS	B
(	O
some	O
with	O
fatal	B
outcomes	O
)	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.10	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
5.2	O
Management	O
of	O
Immunosuppression	O
Only	O
physicians	O
experienced	O
in	O
management	O
of	O
systemic	O
immunosuppressant	O
therapy	O
in	O
transplantation	O
should	O
prescribe	O
NULOJIX	O
.	O
	
Table	O
4	O
:	O
Incidence	O
(	O
%	O
)	O
of	O
Patients	O
With	O
Lipid	B
Abnormalities	I
of	O
Potential	O
Clinical	O
Significance*	O
PRISTIQ	O
Placebo	O
50	O
mg	O
100	O
mg	O
200	O
mg	O
400	O
mg	O
Total	B
Cholesterol*	I
(	I
Increase	I
of	I
>	I
=	I
50	I
mg/dl	I
and	I
an	I
absolute	I
value	I
of	I
>	I
=	I
261	I
mg/dl	I
)	O
2	O
3	O
4	O
4	O
10	O
LDL	B
Cholesterol*	I
(	I
Increase	I
>	I
=	I
50	I
mg/dl	I
and	I
an	I
absolute	I
value	I
of	I
>	I
=	I
190	I
mg/dl	I
)	O
0	O
1	O
0	O
1	O
2	O
Triglycerides	B
,	I
fasting*	I
(	I
Fasting	I
:	I
>	I
=	I
327	I
mg/dl	I
)	O
3	O
2	O
1	O
4	O
6	O
Proteinuria	O
Proteinuria	B
,	O
greater	O
than	O
or	O
equal	O
to	O
trace	O
,	O
was	O
observed	O
in	O
the	O
pre-marketing	O
fixed-dose	O
controlled	O
studies	O
(	O
see	O
Table	O
5	O
)	O
.	O
	
AFINITOR	O
may	O
be	O
re-introduced	O
at	O
a	O
daily	O
dose	O
approximately	O
50	O
%	O
lower	O
than	O
the	O
dose	O
previously	O
administered	O
depending	O
on	O
the	O
individual	O
clinical	O
circumstances	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
None	O
of	O
these	O
antibodies	O
were	O
shown	O
to	O
neutralize	O
the	O
activity	O
of	O
albiglutide	O
in	O
an	O
in	O
vitro	O
bioassay	O
.	O
	
VORAXAZE	O
was	O
given	O
at	O
a	O
dose	O
of	O
50	O
Units/kg	O
as	O
an	O
intravenous	O
injection	O
over	O
5	O
minutes	O
.	O
	
5.2	O
Eye	O
Irritation	O
Avoid	O
eye	O
exposure	O
.	O
	
Patients	O
who	O
develop	O
radiological	O
changes	O
suggestive	O
of	O
non-infectious	O
pneumonitis	O
and	O
have	O
few	O
or	O
no	O
symptoms	O
may	O
continue	O
AFINITOR	O
therapy	O
without	O
dose	O
alteration	O
.	O
	
Postherpetic	O
Neuralgia	O
:	O
The	O
exposure	O
to	O
HORIZANT	O
in	O
417	O
patients	O
with	O
PHN	O
included	O
207	O
patients	O
exposed	O
for	O
at	O
least	O
3	O
months	O
.	O
	
Patients	O
who	O
have	O
experienced	O
anaphylaxis	O
or	O
hypersensitivity	O
reactions	O
should	O
be	O
treated	O
with	O
caution	O
when	O
they	O
are	O
re-administered	O
alglucosidase	O
alfa	O
.	O
	
Patients	O
received	O
INVOKANA	O
100	O
mg	O
(	O
N=833	O
)	O
,	O
INVOKANA	O
300	O
mg	O
(	O
N=834	O
)	O
or	O
placebo	O
(	O
N=646	O
)	O
once	O
daily	O
.	O
	
To	O
prevent	O
ectropion	O
,	O
botulinum	O
toxin	O
products	O
should	O
not	O
be	O
injected	O
into	O
the	O
medial	O
lower	O
eyelid	O
area	O
.	O
	
5.8	O
Human	O
Albumin	O
and	O
Transmission	O
of	O
Viral	O
Diseases	O
This	O
product	O
contains	O
albumin	O
,	O
a	O
derivative	O
of	O
human	O
blood	O
.	O
	
The	O
effect	O
of	O
FANAPT	O
on	O
the	O
QT	O
interval	O
was	O
augmented	O
by	O
the	O
presence	O
of	O
CYP450	O
2D6	O
or	O
3A4	O
metabolic	O
inhibition	O
(	O
paroxetine	O
20	O
mg	O
once	O
daily	O
and	O
ketoconazole	O
200	O
mg	O
twice	O
daily	O
,	O
respectively	O
)	O
.	O
	
Withhold	O
Kyprolis	O
and	O
evaluate	O
promptly	O
.	O
	
Melanoma	B
has	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
TNF-blocking	O
agents	O
,	O
including	O
the	O
subcutaneous	O
formulation	O
of	O
golimumab	O
.	O
	
For	O
patients	O
at	O
risk	O
for	O
chronically	O
reduced	O
renal	O
function	O
(	O
e.g	O
.	O
	
*	O
Limiting	O
the	O
dose	O
injected	O
into	O
the	O
sternocleidomastoid	O
muscle	O
may	O
decrease	O
the	O
occurrence	O
of	O
dysphagia	O
.	O
	
Increases	O
in	O
Serum	O
Phosphate	O
Dose-related	O
increases	B
in	I
serum	I
phosphate	I
levels	O
were	O
observed	O
with	O
INVOKANA	O
.	O
	
Dose-related	O
increases	B
in	I
non-HDL-C	I
with	O
INVOKANA	O
were	O
observed	O
.	O
	
All	O
but	O
one	O
subject	O
who	O
died	B
of	O
TB	O
had	O
not	O
converted	O
or	O
had	O
relapsed	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Mantle	O
Cell	O
Lymphoma	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
IMBRUVICA	O
in	O
a	O
clinical	O
trial	O
that	O
included	O
111	O
patients	O
with	O
previously	O
treated	O
MCL	O
treated	O
with	O
560	O
mg	O
daily	O
with	O
a	O
median	O
treatment	O
duration	O
of	O
8.3	O
months	O
.	O
	
Adverse	O
Reactions	O
in	O
Placebo-Controlled	O
and	O
Uncontrolled	O
Studies	O
In	O
placebo-controlled	O
and	O
uncontrolled	O
clinical	O
studies	O
,	O
a	O
total	O
of	O
2513	O
patients	O
have	O
received	O
TECFIDERA	O
and	O
been	O
followed	O
for	O
periods	O
up	O
to	O
4	O
years	O
with	O
an	O
overall	O
exposure	O
of	O
4603	O
person-years	O
.	O
	
Infusion-related	B
reactions	I
within	O
one	O
hour	O
of	O
infusion	O
were	O
reported	O
in	O
5	O
%	O
of	O
patients	O
treated	O
with	O
the	O
recommended	O
dose	O
of	O
NULOJIX	O
,	O
similar	O
to	O
the	O
placebo	O
rate	O
.	O
	
Fungal	B
infections	I
were	O
reported	O
in	O
18	O
%	O
of	O
patients	O
receiving	O
NULOJIX	O
compared	O
to	O
22	O
%	O
receiving	O
cyclosporine	O
,	O
primarily	O
due	O
to	O
mucocutaneous	B
fungal	I
infections	I
.	O
	
The	O
best	O
method	O
of	O
detection	O
of	O
these	O
abnormalities	O
and	O
the	O
optimal	O
frequency	O
of	O
periodic	O
ophthalmologic	O
monitoring	O
are	O
unknown	O
.	O
	
The	O
majority	O
of	O
patients	O
in	O
the	O
active	O
group	O
were	O
between	O
the	O
ages	O
of	O
18	O
and	O
64	O
.	O
	
A	O
total	O
of	O
2.2	O
%	O
of	O
HIV-1-infected	O
subjects	O
receiving	O
INTELENCE	O
(	O
r	O
)	O
discontinued	O
from	O
Phase	O
3	O
trials	O
due	O
to	O
rash	B
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Patients	O
who	O
have	O
experienced	O
a	O
prior	O
infusion-related	O
reaction	O
should	O
be	O
premedicated	O
for	O
subsequent	O
infusions	O
.	O
	
Discontinuations	O
resulting	O
from	O
these	O
reactions	O
were	O
more	O
common	O
in	O
the	O
drug-treated	O
group	O
(	O
see	O
Table	O
2	O
)	O
.	O
	
5.3	O
Immune	O
Reconstitution	O
Syndrome	O
Immune	B
reconstitution	I
syndrome	I
has	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
combination	O
antiretroviral	O
therapy	O
,	O
including	O
INTELENCE	O
(	O
r	O
)	O
.	O
	
5.8	O
Leukoencephalopathy	O
Cranial	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
changes	O
showing	O
leukoencephalopathy	B
have	O
been	O
observed	O
in	O
patients	O
receiving	O
BLINCYTO	O
,	O
especially	O
in	O
patients	O
with	O
prior	O
treatment	O
with	O
cranial	O
irradiation	O
and	O
antileukemic	O
chemotherapy	O
(	O
including	O
systemic	O
high-dose	O
methotrexate	O
or	O
intrathecal	O
cytarabine	O
)	O
.	O
	
Hydronephrosis	B
was	O
not	O
reported	O
in	O
placebo	O
patients	O
.	O
	
Table	O
2	O
Investigator	O
Assessment	O
of	O
Maximal	O
Local	B
Skin	I
Reactions	I
in	O
the	O
Treatment	O
Area	O
during	O
the	O
57	O
Days	O
Post	O
Treatment	O
Period	O
(	O
trunk/extremities	O
trials	O
)	O
Trunk	O
and	O
Extremities	O
(	O
n=457	O
)	O
Picato	O
(	O
r	O
)	O
gel	O
,	O
0.05	O
%	O
once	O
daily	O
for	O
2	O
days	O
Skin	B
reactions	I
Any	I
Gradea	I
>	I
Baseline	I
Grade	I
4	I
58	O
(	O
26	O
%	O
)	O
6	O
(	O
3	O
%	O
)	O
2	O
(	O
1	O
%	O
)	O
0	O
(	O
0	O
%	O
)	O
a	O
Mild	O
(	O
grade	O
1	O
)	O
,	O
Moderate	O
(	O
grade	O
2-3	O
)	O
or	O
Severe	O
(	O
grade	O
4	O
)	O
.	O
	
A	O
single	O
event	O
of	O
serum	B
sickness	I
was	O
reported	O
in	O
a	O
patient	O
treated	O
with	O
NESINA	O
25	O
mg.	O
Hypoglycemia	O
Hypoglycemic	B
events	I
were	O
documented	O
based	O
upon	O
a	O
blood	O
glucose	O
value	O
and/or	O
clinical	O
signs	O
and	O
symptoms	O
of	O
hypoglycemia	B
.	O
	
Consider	O
discontinuation	O
for	O
Grade	O
3	O
infusions	O
reactions	O
as	O
clinically	O
appropriate	O
considering	O
individual	O
benefits	O
,	O
risks	O
,	O
and	O
supportive	O
care	O
.	O
	
Adverse	O
reactions	O
observed	O
in	O
these	O
studies	O
were	O
generally	O
similar	O
to	O
those	O
observed	O
and	O
attributed	O
to	O
drug	O
in	O
adjunctive	O
placebo-controlled	O
studies	O
.	O
	
in	O
Placebo	O
and	O
Active-Controlled	O
Studies	O
when	O
NESINA	O
Was	O
Used	O
as	O
Add-On	O
Therapy	O
to	O
Glyburide	O
,	O
Insulin	O
,	O
Metformin	O
,	O
Pioglitazone	O
or	O
Compared	O
to	O
Glipizide	O
Add-On	O
to	O
Glyburide	O
(	O
26	O
Weeks	O
)	O
NESINA	O
25	O
mg+	O
Glyburide	O
Placebo+	O
Glyburide	O
N=198	O
N=99	O
Overall	O
(	O
%	O
)	O
19	O
(	O
9.6	O
)	O
11	O
(	O
11.1	O
)	O
Severe	O
(	O
%	O
)	O
Severe	O
events	O
of	O
hypoglycemia	B
were	O
defined	O
as	O
those	O
events	O
requiring	O
medical	O
assistance	O
or	O
exhibiting	O
depressed	O
level	O
or	O
loss	O
of	O
consciousness	O
or	O
seizure	O
.	O
	
Pain	B
in	I
extremity	I
and	O
musculoskeletal	B
pain	I
have	O
also	O
been	O
reported	O
in	O
clinical	O
trials	O
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Amgen	O
Inc.	O
at	O
1-800-77-AMGEN	O
(	O
1-800-772-6436	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
For	O
those	O
patients	O
who	O
require	O
the	O
use	O
of	O
opioids	O
to	O
treat	O
pain	O
during	O
or	O
following	O
the	O
procedure	O
,	O
their	O
ability	O
to	O
perform	O
potentially	O
hazardous	O
activities	O
such	O
as	O
driving	O
or	O
operating	O
machinery	O
may	O
be	O
affected	O
.	O
	
(	O
2.3	O
,	O
5.3	O
)	O
*	O
Fluid	B
Retention	I
:	O
Monitor	O
patients	O
and	O
manage	O
using	O
standard	O
of	O
care	O
treatment	O
.	O
	
*	O
Immediate	O
medical	O
attention	O
may	O
be	O
required	O
in	O
cases	O
of	O
respiratory	O
,	O
speech	O
or	O
swallowing	O
difficulties	O
(	O
5.1	O
,	O
5.4	O
)	O
.	O
	
5.2	O
Acute	O
Renal	O
Failure	O
Cases	O
of	O
acute	B
renal	I
failure	I
have	O
occurred	O
in	O
patients	O
receiving	O
Kyprolis	O
.	O
	
*	O
Lower	O
lid	O
injections	O
should	O
not	O
be	O
repeated	O
if	O
diplopia	O
occurred	O
with	O
previous	O
botulinum	O
toxin	O
injections	O
.	O
	
(	O
5.4	O
)	O
*	O
Cardiac	B
failure	I
has	O
been	O
observed	O
and	O
can	O
be	O
fatal	B
.	O
	
Monitor	O
for	O
signs	O
and	O
symptoms	O
of	O
TTP/HUS	O
.	O
	
Monotherapy	O
Historical	O
Control	O
Trials	O
In	O
the	O
monotherapy	O
epilepsy	O
trials	O
(	O
Study	O
1	O
and	O
Study	O
2	O
)	O
,	O
13	O
%	O
of	O
patients	O
randomized	O
to	O
receive	O
APTIOM	O
at	O
the	O
recommended	O
doses	O
of	O
1200	O
mg	O
and	O
1600	O
mg	O
once	O
daily	O
discontinued	O
from	O
the	O
trials	O
as	O
a	O
result	O
of	O
an	O
adverse	O
event	O
.	O
	
In	O
Study	O
2	O
all	O
adverse	O
events	O
of	O
all	O
Grades	O
were	O
prospectively	O
collected	O
.	O
	
(	O
5.7	O
)	O
*	O
Stop	O
INLYTA	O
at	O
least	O
24	O
hours	O
prior	O
to	O
scheduled	O
surgery	O
.	O
	
Prescribers	O
should	O
carefully	O
evaluate	O
the	O
risks	O
and	O
benefits	O
of	O
continuing	O
treatment	O
with	O
OTEZLA	O
if	O
such	O
events	O
occur	O
.	O
	
FANAPT	O
is	O
not	O
approved	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
dementia-related	O
psychosis	O
[	O
s	O
ee	O
Boxed	O
Warning	O
]	O
.	O
	
MRI	O
signs	O
may	O
be	O
apparent	O
before	O
clinical	O
symptoms	O
.	O
	
Three	O
of	O
these	O
patients	O
had	O
subsequent	O
tests	O
which	O
were	O
negative	O
.	O
	
The	O
reduction	O
in	O
clinical	O
cure	O
rates	O
was	O
more	O
marked	O
in	O
the	O
ZERBAXA	O
plus	O
metronidazole	O
arm	O
compared	O
to	O
the	O
meropenem	O
arm	O
.	O
	
Monitor	O
for	O
suicidal	O
thoughts	O
or	O
behaviors	O
.	O
	
Thromboprophylaxis	O
is	O
recommended	O
and	O
should	O
be	O
based	O
on	O
an	O
assessment	O
of	O
the	O
patient	O
's	O
underlying	O
risks	O
,	O
treatment	O
regimen	O
,	O
and	O
clinical	O
status	O
.	O
	
Evaluate	O
with	O
cardiac	O
imaging	O
and/or	O
other	O
tests	O
as	O
indicated	O
.	O
	
Atrial	O
Fibrillation/Flutte	O
r	O
In	O
the	O
pool	O
of	O
7	O
placebo-	O
and	O
active-controlled	O
trials	O
,	O
adverse	O
reactions	O
of	O
atrial	B
fibrillation	I
(	O
1.0	O
%	O
)	O
and	O
atrial	B
flutter	I
(	O
0.2	O
%	O
)	O
were	O
reported	O
more	O
frequently	O
for	O
TANZEUM	O
than	O
for	O
all	O
comparators	O
(	O
0.5	O
%	O
and	O
0	O
%	O
,	O
respectively	O
)	O
.	O
	
For	O
cases	O
of	O
Grade	O
4	O
non-infectious	O
pneumonitis	O
,	O
discontinue	O
AFINITOR	O
.	O
	
Table	O
2	O
Adverse	O
Reactions	O
with	O
a	O
Frequency	O
>	O
=0.5	O
%	O
Reported	O
in	O
Clinical	O
Trials	O
(	O
n	O
=	O
978	O
Administrations	O
in	O
872	O
Subjects	O
)	O
Adverse	O
drug	O
reaction	O
n	O
(	O
%	O
)	O
application	B
site	I
erythema	I
17	O
(	O
1.7	O
)	O
Injection	B
site	I
irritation	I
12	O
(	O
1.2	O
)	O
Injection	B
site	I
pain	I
38	O
(	O
3.9	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
Image	O
interpretation	O
errors	O
(	O
especially	O
false	O
positives	O
)	O
have	O
been	O
observed	O
(	O
5.1	O
)	O
.	O
	
Delay	O
or	O
discontinue	O
JEVTANA	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
another	O
section	O
of	O
the	O
label	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5	O
)	O
]	O
:	O
*	O
Non-infectious	B
pneumonitis	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Retinal	B
detachments	I
resulting	O
from	O
trametinib	O
are	O
often	O
bilateral	O
and	O
multifocal	O
,	O
occurring	O
in	O
the	O
macular	O
region	O
of	O
the	O
retina	O
.	O
	
Patients	O
who	O
are	O
EBV	O
seropositive	O
and	O
CMV	O
seronegative	O
may	O
be	O
at	O
increased	O
risk	O
for	O
PTLD	O
compared	O
to	O
patients	O
who	O
are	O
EBV	O
seropositive	O
and	O
CMV	O
seropositive	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Monitor	O
and	O
treat	O
promptly	O
per	O
standard	O
of	O
care	O
until	O
signs	O
and	O
symptoms	O
resolve	O
.	O
	
Women	O
of	O
childbearing	O
potential	O
and	O
men	O
must	O
use	O
at	O
least	O
two	O
forms	O
of	O
effective	O
contraception	O
during	O
treatment	O
and	O
for	O
at	O
least	O
6	O
months	O
after	O
treatment	O
has	O
concluded	O
.	O
	
Cases	O
of	O
other	O
malignancies	B
have	O
been	O
observed	O
among	O
patients	O
receiving	O
TNF-blockers	O
(	O
5.2	O
)	O
.	O
	
Diabetic	O
Macular	O
Edema	O
(	O
DME	O
)	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
EYLEA	O
in	O
578	O
patients	O
with	O
DME	O
treated	O
with	O
the	O
2-mg	O
dose	O
in	O
2	O
double-masked	O
,	O
controlled	O
clinical	O
studies	O
(	O
VIVID	O
and	O
VISTA	O
)	O
from	O
baseline	O
to	O
week	O
52	O
and	O
from	O
baseline	O
to	O
week	O
100	O
[	O
seeClinical	O
Studies	O
(	O
14.4	O
)	O
]	O
.	O
	
5.8	O
Leukopenia	O
,	O
Neutropenia	O
,	O
and	O
Agranulocytosis	O
In	O
clinical	O
trial	O
and	O
postmarketing	O
experience	O
,	O
leukopenia	B
and	O
neutropenia	B
have	O
been	O
reported	O
temporally	O
related	O
to	O
antipsychotic	O
agents	O
,	O
including	O
SAPHRIS	O
.	O
	
If	O
the	O
abnormalities	O
are	O
confirmed	O
,	O
monitor	O
serum	O
liver	O
tests	O
weekly	O
until	O
resolved	O
or	O
stabilized	O
.	O
	
*	O
Heart	B
failure	I
,	O
may	O
occur	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
most	O
serious	O
adverse	O
reactions	O
reported	O
with	O
NULOJIX	O
are	O
:	O
*	O
PTLD	B
,	O
predominantly	O
CNS	B
PTLD	I
,	O
and	O
other	O
malignancies	B
[	O
see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
,	O
5.3	O
)	O
]	O
*	O
Serious	O
infections	B
,	O
including	O
JC	B
virus-associated	O
PML	B
and	O
polyoma	B
virus	I
nephropathy	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
,	O
5.5	O
,	O
5.6	O
)	O
]	O
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
=20	O
%	O
on	O
NULOJIX	O
treatment	O
)	O
are	O
anemia	B
,	O
diarrhea	B
,	O
urinary	B
tract	I
infection	I
,	O
peripheral	B
edema	I
,	O
constipation	B
,	O
hypertension	B
,	O
pyrexia	B
,	O
graft	B
dysfunction	I
,	O
cough	B
,	O
nausea	B
,	O
vomiting	B
,	O
headache	B
,	O
hypokalemia	B
,	O
hyperkalemia	B
,	O
and	O
leukopenia	B
.	O
	
If	O
hypersensitivity	O
reactions	O
occur	O
,	O
discontinue	O
use	O
of	O
TANZEUM	O
;	O
treat	O
promptly	O
per	O
standard	O
of	O
care	O
and	O
monitor	O
until	O
signs	O
and	O
symptoms	O
resolve	O
[	O
see	O
Contraindications	O
(	O
4.2	O
)	O
]	O
.	O
	
CMV	O
prophylaxis	O
is	O
recommended	O
for	O
at	O
least	O
3	O
months	O
after	O
transplantation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
5.7	O
Serious	O
Febrile	O
Reactions	O
Serious	O
febrile	B
reactions	I
and	O
fever	B
of	O
any	O
severity	O
complicated	O
by	O
hypotension	B
,	O
rigors	B
or	O
chills	B
,	O
dehydration	B
,	O
or	O
renal	B
failure	I
,	O
can	O
occur	O
when	O
TAFINLAR	O
is	O
administered	O
as	O
a	O
single	O
agent	O
or	O
when	O
used	O
in	O
combination	O
with	O
trametinib	O
.	O
	
Monitor	O
and	O
treat	O
as	O
appropriate	O
.	O
	
Patients	O
should	O
receive	O
premedication	O
.	O
	
5.2	O
Hypersensitivity	O
Reactions	O
Acute	B
hypersensitivity	I
reactions	I
,	O
including	O
dyspnea	B
,	O
rash	B
pruritus	B
,	O
and	O
angioedema	B
of	I
the	I
mouth	I
have	O
been	O
reported	O
with	O
fidaxomicin	O
.	O
	
In	O
both	O
groups	O
,	O
patients	O
with	O
events	O
were	O
generally	O
male	O
,	O
older	O
,	O
and	O
had	O
underlying	O
renal	O
impairment	O
or	O
cardiac	O
disease	O
(	O
e.g.	O
,	O
history	O
of	O
arrhythmia	O
,	O
palpitations	O
,	O
congestive	O
heart	O
failure	O
,	O
cardiomyopathy	O
,	O
etc	O
.	O
	
)	O
.	O
	
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=10	O
%	O
and	O
>	O
=2	O
%	O
placebo	O
)	O
were	O
flushing	B
,	O
abdominal	B
pain	I
,	O
diarrhea	B
,	O
and	O
nausea	B
.	O
	
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
(	O
occurring	O
in	O
at	O
least	O
0.5	O
%	O
of	O
subjects	O
)	O
during	O
Neuraceq	O
clinical	O
trials	O
are	O
shown	O
in	O
Table	O
2	O
.	O
	
Use	O
of	O
a	O
sensitive	O
real-time	O
reverse-transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
assay	O
for	O
monitoring	O
HCV-RNA	O
levels	O
during	O
treatment	O
is	O
recommended	O
.	O
	
In	O
the	O
two	O
clinical	O
trials	O
in	O
infantile-onset	O
patients	O
,	O
the	O
majority	O
of	O
patients	O
(	O
34	O
of	O
38	O
;	O
89	O
%	O
)	O
tested	O
positive	O
for	O
IgG	O
antibodies	O
to	O
alglucosidase	O
alfa	O
.	O
	
Of	O
these	O
patients	O
,	O
there	O
were	O
2	O
respiratory-related	O
deaths	B
in	O
the	O
ARCAPTA	O
NEOHALER	O
300	O
mcg	O
dose	O
group	O
.	O
	
5.4	O
Development	O
of	O
Drug-Resistant	O
Bacteria	O
Prescribing	O
ZERBAXA	O
in	O
the	O
absence	O
of	O
a	O
proven	O
or	O
strongly	O
suspected	O
bacterial	O
infection	O
is	O
unlikely	O
to	O
provide	O
benefit	O
to	O
the	O
patient	O
and	O
risks	O
the	O
development	O
of	O
drug-resistant	O
bacteria	O
.	O
	
The	O
most	O
commonly-reported	O
adverse	O
reactions	O
,	O
occurring	O
in	O
>	O
=5	O
%	O
of	O
patients	O
in	O
clinical	O
trials	O
were	O
nausea	B
,	O
diarrhea	B
,	O
pyrexia	B
,	O
nasopharyngitis	B
,	O
bronchitis	B
,	O
insomnia	B
,	O
pain	B
in	I
extremity	I
,	O
depression	B
,	O
migraine	B
,	O
and	O
pharyngitis	B
.	O
	
Since	O
ENTEREG	O
acts	O
peripherally	O
,	O
clinical	O
signs	O
and	O
symptoms	O
of	O
increased	B
sensitivity	I
would	I
be	I
related	I
to	I
the	I
gastrointestinal	I
tract	I
(	O
e.g.	O
,	O
abdominal	B
pain	I
,	O
nausea	B
and	O
vomiting	B
,	O
diarrhea	B
)	O
.	O
	
Cerebrovascular	O
Adverse	O
Events	O
,	O
Including	O
Stroke	O
In	O
placebo-controlled	O
trials	O
with	O
risperidone	O
,	O
aripiprazole	O
,	O
and	O
olanzapine	O
in	O
elderly	O
patients	O
with	O
dementia	O
,	O
there	O
was	O
a	O
higher	O
incidence	O
of	O
cerebrovascular	B
adverse	I
events	I
(	O
cerebrovascular	B
accidents	I
and	O
transient	B
ischemic	I
attacks	I
)	O
including	O
fatalities	B
compared	O
to	O
placebo-treated	O
patients	O
.	O
	
Monitor	O
thyroid	O
function	O
before	O
initiation	O
of	O
,	O
and	O
periodically	O
throughout	O
,	O
treatment	O
with	O
INLYTA	O
.	O
	
In	O
the	O
EMTP	O
trial	O
,	O
safety	O
data	O
were	O
derived	O
from	O
case	O
report	O
forms	O
that	O
collected	O
adverse	O
event	O
information	O
.	O
	
Discontinue	O
Kyprolis	O
if	O
suspected	O
.	O
	
There	O
is	O
no	O
clinical	O
trial	O
experience	O
with	O
XTANDI	O
in	O
patients	O
who	O
have	O
had	O
a	O
seizure	O
.	O
	
Blepharospasm	O
(	O
5.6	O
)	O
:	O
*	O
Corneal	B
exposure	I
*	O
Injection	O
of	O
XEOMIN	O
into	O
the	O
orbicularis	O
oculi	O
muscle	O
may	O
lead	O
to	O
reduced	B
blinking	I
and	O
corneal	B
exposure	I
.	O
	
NSF	B
may	O
result	O
in	O
fatal	B
or	O
debilitating	O
fibrosis	B
affecting	O
the	O
skin	O
,	O
muscle	O
and	O
internal	O
organs	O
.	O
	
The	O
majority	O
were	O
in	O
adolescent	O
and	O
young	O
adult	O
males	O
.	O
	
TABLE	O
1	O
:	O
Changes	O
in	O
Fasting	O
Glucose	O
in	O
Adult	O
Patients	O
N*	O
=	O
Number	O
of	O
patients	O
who	O
had	O
assessments	O
at	O
both	O
Baseline	O
and	O
Endpoint	O
.	O
	
A	O
total	O
of	O
56	O
%	O
of	O
patients	O
were	O
female	O
and	O
45	O
%	O
of	O
patients	O
were	O
Asian	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
QT	B
prolongation	I
can	O
occur	O
with	O
SIRTURO	O
.	O
	
Patients	O
with	O
uncontrolled	O
or	O
significant	O
cardiovascular	O
disease	O
including	O
QT	O
interval	O
prolongation	O
were	O
excluded	O
by	O
protocol	O
.	O
	
BRAF	O
V600E	O
Unresectable	O
or	O
Metastatic	O
Melanoma	O
:	O
The	O
safety	O
of	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
was	O
evaluated	O
in	O
586	O
patients	O
with	O
BRAF	O
V600	O
mutation-positive	O
unresectable	O
or	O
metastatic	O
melanoma	O
,	O
previously	O
treated	O
or	O
untreated	O
,	O
who	O
received	O
TAFINLAR	O
150	O
mg	O
orally	O
twice	O
daily	O
until	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	O
,	O
including	O
181	O
patients	O
treated	O
for	O
at	O
least	O
6	O
months	O
and	O
86	O
additional	O
patients	O
treated	O
for	O
more	O
than	O
12	O
months	O
.	O
	
Myelosuppression	O
may	O
require	O
dose	O
delays	O
and/or	O
subsequent	O
dose	O
reductions	O
if	O
recovery	O
to	O
the	O
recommended	O
values	O
has	O
not	O
occurred	O
by	O
the	O
first	O
day	O
of	O
the	O
next	O
scheduled	O
cycle	O
.	O
	
No	O
new	O
adverse	O
reactions	O
were	O
reported	O
.	O
	
The	O
median	O
exposure	O
was	O
11.0	O
months	O
for	O
patients	O
treated	O
with	O
GILOTRIF	O
and	O
3.4	O
months	O
for	O
patients	O
treated	O
with	O
pemetrexed/cisplatin	O
.	O
	
Conditions	O
that	O
lower	O
the	O
seizure	O
threshold	O
may	O
be	O
more	O
prevalent	O
in	O
a	O
population	O
of	O
65	O
years	O
or	O
older	O
.	O
	
Renal-related	B
adverse	I
reactions	I
,	O
including	O
renal	B
failure	I
and	O
blood	B
creatinine	I
increase	I
,	O
were	O
more	O
frequent	O
in	O
patients	O
treated	O
with	O
FARXIGA	O
(	O
see	O
Table	O
4	O
)	O
.	O
	
Counsel	O
patients	O
regarding	O
the	O
potential	O
risk	O
of	O
MTC	O
with	O
use	O
of	O
TRULICITY	O
and	O
inform	O
them	O
of	O
symptoms	O
of	O
thyroid	O
tumors	O
(	O
e.g.	O
,	O
mass	O
in	O
the	O
neck	O
,	O
dysphagia	O
,	O
dyspnea	O
,	O
persistent	O
hoarseness	O
)	O
.	O
	
Bacterial	O
,	O
Mycobacterial	O
,	O
Viral	O
,	O
and	O
Fungal	O
Infections	O
Adverse	O
reactions	O
of	O
infectious	B
etiology	I
were	O
reported	O
based	O
on	O
clinical	O
assessment	O
by	O
physicians	O
.	O
	
The	O
most	O
common	O
laboratory	O
abnormalities	O
(	O
incidence	O
>	O
=30	O
%	O
)	O
are	O
neutropenia	B
,	O
hypertriglyceridemia	B
,	O
hyperglycemia	B
,	O
ALT	B
elevations	I
,	O
and	O
AST	B
elevations	I
(	O
6.1	O
)	O
.	O
	
0.3	O
2.8	O
2.7	O
Nausea	B
2.4	O
2.8	O
2.5	O
Influenza	B
2.3	O
2.7	O
2.3	O
Dyslipidemia	B
1.5	O
2.1	O
2.5	O
Constipation	B
1.5	O
2.2	O
1.9	O
Discomfort	B
with	I
urination	I
0.7	O
1.6	O
2.1	O
Pain	B
in	I
extremity	I
1.4	O
2.0	O
1.7	O
Pool	O
of	O
13	O
Placebo-Controlled	O
Studies	O
for	O
FARXIGA	O
10	O
mg	O
The	O
safety	O
and	O
tolerability	O
of	O
FARXIGA	O
10	O
mg	O
was	O
also	O
evaluated	O
in	O
a	O
larger	O
placebo-controlled	O
study	O
pool	O
.	O
	
The	O
following	O
adverse	O
reactions	O
are	O
described	O
in	O
more	O
detail	O
in	O
the	O
Warnings	O
and	O
Precautions	O
section	O
of	O
the	O
label	O
:	O
Seizures	B
,	O
Anaphylaxis	B
,	O
and	O
Urinary	B
Tract	I
Infections	I
.	O
	
The	O
risk	O
did	O
not	O
vary	O
substantially	O
by	O
age	O
(	O
5-100	O
years	O
)	O
in	O
the	O
clinical	O
trials	O
analyzed	O
.	O
	
5.9	O
Drug	O
Interactions	O
with	O
Strong	O
Cytochrome	O
P450	O
3A4	O
Inhibitors	O
Caution	O
should	O
be	O
exercised	O
when	O
considering	O
the	O
coadministration	O
of	O
BREO	O
ELLIPTA	O
with	O
long-term	O
ketoconazole	O
and	O
other	O
known	O
strong	O
CYP3A4	O
inhibitors	O
(	O
e.g.	O
,	O
ritonavir	O
,	O
clarithromycin	O
,	O
conivaptan	O
,	O
indinavir	O
,	O
itraconazole	O
,	O
lopinavir	O
,	O
nefazodone	O
,	O
nelfinavir	O
,	O
saquinavir	O
,	O
telithromycin	O
,	O
troleandomycin	O
,	O
voriconazole	O
)	O
because	O
increased	O
systemic	O
corticosteroid	O
and	O
increased	O
cardiovascular	O
adverse	O
effects	O
may	O
occur	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
,	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
Patients	O
receiving	O
the	O
drug	O
should	O
be	O
managed	O
in	O
facilities	O
equipped	O
and	O
staffed	O
with	O
adequate	O
laboratory	O
and	O
supportive	O
medical	O
resources	O
.	O
	
If	O
an	O
infusion-related	O
reaction	O
occurs	O
,	O
the	O
infusion	O
should	O
be	O
interrupted	O
and	O
appropriate	O
medical	O
management	O
instituted	O
.	O
	
Chronic	O
Immune	O
(	O
Idiopathic	O
)	O
Thrombocytopenia	O
:	O
Adults	O
:	O
In	O
clinical	O
trials	O
,	O
hemorrhage	B
was	O
the	O
most	O
common	O
serious	O
adverse	O
reaction	O
and	O
most	O
hemorrhagic	B
reactions	I
followed	O
discontinuation	O
of	O
PROMACTA	O
.	O
	
Table	O
3	O
shows	O
the	O
number	O
of	O
patients	O
experiencing	O
bleeding	B
events	O
in	O
the	O
pooled	O
analysis	O
of	O
RE-COVER	O
and	O
RE-COVER	O
II	O
studies	O
during	O
the	O
full	O
treatment	O
including	O
parenteral	O
and	O
oral	O
only	O
treatment	O
periods	O
after	O
randomization	O
.	O
	
Table	O
1shows	O
all	O
adverse	O
reactions	O
that	O
occurred	O
with	O
a	O
frequency	O
of	O
greater	O
than	O
or	O
equal	O
to	O
1	O
%	O
in	O
the	O
TUDORZA	O
PRESSAIR	O
group	O
in	O
the	O
two	O
3-month	O
and	O
one	O
6-month	O
placebo-controlled	O
trials	O
where	O
the	O
rates	O
in	O
the	O
TUDORZA	O
PRESSAIR	O
group	O
exceeded	O
placebo	O
.	O
	
The	O
median	O
duration	O
of	O
exposure	O
was	O
6.1	O
months	O
(	O
range	O
0.3	O
to	O
26.4	O
months	O
)	O
.	O
	
The	O
median	O
age	O
of	O
patients	O
treated	O
with	O
Teflaro	O
was	O
54	O
years	O
,	O
ranging	O
between	O
18	O
and	O
99	O
years	O
old	O
.	O
